The epidemiology of cirrhosis and abnormal liver function in the general population of the UK by Fleming, Catherine Mary
Fleming, Catherine Mary (2010) The epidemiology of 
cirrhosis and abnormal liver function in the general 
population of the UK. PhD thesis, University of 
Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/11371/1/FlemingCatherineMary2010.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
  
 
 
 
The epidemiology of cirrhosis and abnormal liver function  
in the general population of the UK 
 
 
 
 
 
Catherine Mary Fleming, MA MSc 
 
 
 
 
 
 
 
Thesis submitted to the University of Nottingham  
for the degree of Doctor of Philosophy 
  
April 2010 
 
2 
Table of contents 
Table of contents ............................................................................................ 2 
Abstract ............................................................................................................ 9 
Acknowledgements ....................................................................................... 15 
List of figures ................................................................................................. 16 
List of tables .................................................................................................. 18 
Abbreviations used ....................................................................................... 20 
1. Introduction ........................................................................................... 21 
1.1. Measuring the burden of disease .....................................22 
1.1.1. Measuring the frequency of disease ............................22 
1.1.1.1. The definition of a disease .........................................23 
1.1.1.2. Defining the population at risk..................................23 
1.1.1.3. Identification of people with disease .......................24 
1.1.2. Measuring the mortality and morbidity associated 
with disease ......................................................................................25 
1.1.3. Measuring the financial and service requirements 
associated with disease ..................................................................26 
1.1.4. Data used to measure the burden of disease ............26 
1.1.4.1. Vital statistics ...............................................................27 
1.1.4.2. Administrative health care data ................................29 
1.1.4.3. Surveys .........................................................................30 
1.1.5. Limitations in the measurement of disease burden ..31 
1.2. The global burden of liver disease ...................................32 
1.2.1. Chronic liver disease.......................................................33 
1.2.2. Viral hepatitis ...................................................................34 
1.2.2.1. Hepatitis B ....................................................................34 
1.2.2.2. Hepatitis C ....................................................................37 
1.2.3. Liver cancer ......................................................................39 
1.3. Liver disease in the UK ......................................................41 
1.3.1. Chronic liver disease.......................................................42 
1.3.2. Viral hepatitis ...................................................................44 
1.3.3. Liver cancer ......................................................................45 
1.3.4. Liver transplant ...............................................................45 
3 
1.4. Rationale behind the studies in this thesis .....................46 
1.4.1. Cirrhosis ............................................................................46 
1.4.1.1. Incidence and prevalence of cirrhosis in the UK ....49 
1.4.1.2. Mortality experience of patients with cirrhosis ......51 
1.4.1.3. Progression with cirrhosis ..........................................54 
1.4.2. Liver function tests .........................................................56 
1.4.2.1. Prevalence of elevated liver function tests .............60 
1.4.2.2. Associations with elevated liver function tests ......62 
1.4.2.3. Mortality associated with liver function tests .........64 
1.5. Thesis objectives .................................................................66 
2. The General Practice Research Database ......................................... 67 
2.1. Introduction to the GPRD ..................................................67 
2.2. Data format of the GPRD ...................................................68 
2.3. Strengths and weaknesses of the GPRD .........................71 
2.3.1. Size ........................................................................................71 
2.3.2. Representative ....................................................................71 
2.3.3. Prospectively collected .......................................................72 
2.3.4. Contemporaneous ...............................................................72 
2.3.5. Validity ..................................................................................72 
2.3.6. Incomplete recording .........................................................73 
2.3.7. Duration of follow-up .........................................................74 
2.3.8. Reproducibility .....................................................................74 
2.4. Data used for chapters 3-5 ...............................................75 
2.4.1. Original data extracted for liver disease grant ..........75 
2.4.2. Data manipulation for date variables ..........................75 
2.4.3. Extraction of data on patients with cirrhosis ..............76 
2.4.4. Definitions used throughout ..........................................80 
2.4.4.1. Death .............................................................................80 
2.4.4.2. Age .................................................................................80 
2.4.4.3. Alcohol ...........................................................................80 
3 Incidence and prevalence of cirrhosis in the UK ............................. 82 
3.1 Introduction .........................................................................82 
3.2 Methods ................................................................................82 
3.2.1 Dataset used ....................................................................82 
3.2.2 Additional definitions ......................................................82 
4 
3.2.2.1 Incident and prevalent cases ....................................82 
3.2.2.2 Aetiology of cirrhosis ..................................................85 
3.2.2.3 Age .................................................................................85 
3.2.3 Validation ..........................................................................86 
3.2.4 Statistical analysis ..........................................................86 
3.2.4.1 Incidence ......................................................................86 
3.2.4.1.1 Alternative case definitions .......................................87 
3.2.4.2 Prevalence ....................................................................87 
3.2.4.3 Application of results to 2008 population ...............87 
3.3 Results ..................................................................................88 
3.3.1 Study population .............................................................88 
3.3.2 Incidence ..........................................................................90 
3.3.2.1 Alcoholic and non-alcohol-related cirrhosis ............94 
3.3.2.2 Incidence using alternative case definitions ...........97 
3.3.3 Prevalence ........................................................................99 
3.3.4 Validation ........................................................................ 101 
3.4 Discussion .......................................................................... 102 
3.4.1 Key findings ................................................................... 102 
3.4.2 Strengths and limitations ............................................ 102 
3.4.3 Comparison with previously published work ............ 104 
3.4.4 Conclusions .................................................................... 106 
4 All-cause mortality in people with cirrhosis compared with 
the general population ............................................................................... 107 
4.1 Introduction ....................................................................... 107 
4.2 Methods .............................................................................. 107 
4.2.1 Dataset used .................................................................. 107 
4.2.2 Additional definitions .................................................... 109 
4.2.2.1 Date of diagnosis / pseudo-diagnosis .................... 109 
4.2.2.2 Age ............................................................................... 109 
4.2.2.3 Body Mass Index ....................................................... 109 
4.2.2.4 Smoking ...................................................................... 110 
4.2.2.5 Alcohol use ................................................................. 110 
4.2.2.6 Comorbidity ................................................................ 110 
4.2.2.7 Liver transplant ......................................................... 112 
4.2.2.8 Compensated and decompensated disease .......... 112 
5 
4.2.2.9 Aetiology of cirrhosis ................................................ 112 
4.2.3 Statistical analysis ........................................................ 114 
4.3 Results ................................................................................ 116 
4.3.1 Population characteristics ............................................ 116 
4.3.2 Cox regression modelling ............................................ 118 
4.3.2.1 Overall survival .......................................................... 118 
4.3.2.2 Testing the proportional hazards assumptions .... 121 
4.3.2.3 Survival by follow-up and comorbidity score ....... 124 
4.3.2.4 Survival by presumed aetiology ............................. 126 
4.3.2.5 Cox proportional hazards model using different 
cohort definitions ........................................................................... 129 
4.4 Discussion .......................................................................... 132 
4.4.1 Key findings ................................................................... 132 
4.4.2 Strengths and limitations ............................................ 132 
4.4.3 Comparison with previously published work ............ 136 
4.4.4 Conclusions .................................................................... 138 
5 Progression of disease in people with cirrhosis ............................. 140 
5.1 Introduction ....................................................................... 140 
5.2 Methods .............................................................................. 140 
5.2.1 Dataset used .................................................................. 140 
5.2.2 Additional definitions .................................................... 140 
5.2.2.1 Stages of disease ...................................................... 140 
5.2.3 Statistical analysis ........................................................ 146 
5.3 Results ................................................................................ 148 
5.4 Discussion .......................................................................... 154 
5.4.1 Key findings ................................................................... 154 
5.4.2 Strengths and limitations ............................................ 154 
5.4.3 Comparison with previously published work ............ 157 
5.4.4 Conclusions .................................................................... 162 
6 7KH³05&(OGHUO\´'DWDEDVH ............................................................. 163 
6.1 Original data collection .................................................... 163 
6.2 Data flow ............................................................................ 166 
6.3 Strength and weaknesses ............................................... 168 
6.3.1 Representative ............................................................... 168 
6.3.2 Availability of data on liver function tests ................ 168 
6 
6.3.3 Follow-up ........................................................................ 169 
6.4 Data used for chapters 7-9 ............................................. 169 
7 Prevalence of elevated liver function tests in the elderly ............ 170 
7.1 Introduction ....................................................................... 170 
7.2 Methods .............................................................................. 170 
7.2.1 Data set used ................................................................. 170 
7.2.2 Imputation of laboratory reference ranges .............. 170 
7.2.2.1 AST .............................................................................. 172 
7.2.2.2 ALP ............................................................................... 176 
7.2.2.3 Bilirubin ....................................................................... 182 
7.2.3 Additional definitions .................................................... 186 
7.2.3.1 Elevated liver function .............................................. 186 
7.2.4 Statistical analysis ........................................................ 186 
7.3 Results ................................................................................ 187 
7.3.1 Prevalence of elevated liver function ......................... 187 
7.3.1.1 AST .............................................................................. 187 
7.3.1.2 ALP ............................................................................... 187 
7.3.1.3 Bilirubin ....................................................................... 187 
7.3.1.4 Any elevated liver function ...................................... 191 
7.4 Discussion .......................................................................... 193 
7.4.1 Key findings ................................................................... 193 
7.4.2 Strengths and limitations ............................................ 193 
7.4.3 Comparison with previously published work ............ 194 
7.4.4 Conclusions .................................................................... 195 
8 Demographic, lifestyle and medical characteristics 
associated with an elevated liver function test ...................................... 197 
8.1 Introduction ....................................................................... 197 
8.2 Methods .............................................................................. 197 
8.2.1 Dataset used .................................................................. 197 
8.2.2 Additional definitions .................................................... 197 
8.2.2.1 Alcohol consumption ................................................. 197 
8.2.2.2 Smoking ...................................................................... 198 
8.2.2.3 Body Mass Index ....................................................... 198 
8.2.2.4 Waist:hip ratio ........................................................... 198 
8.2.2.5 Comorbidities ............................................................. 198 
7 
8.2.3 Statistical analysis ........................................................ 199 
8.3 Results ................................................................................ 200 
8.3.1 AST .................................................................................. 200 
8.3.1.1 Univariable associations ........................................... 200 
8.3.1.2 Multivariable associations ........................................ 202 
8.3.2 ALP ................................................................................... 206 
8.3.2.1 Univariable associations ........................................... 206 
8.3.2.2 Multivariable associations ........................................ 207 
8.3.3 Bilirubin ........................................................................... 211 
8.3.3.1 Univariable associations ........................................... 211 
8.3.3.2 Multivariable associations ........................................ 212 
8.4 Discussion .......................................................................... 217 
8.4.1 Key findings ................................................................... 217 
8.4.2 Strengths and limitations ............................................ 218 
8.4.3 Comparison with previous studies ............................. 219 
8.4.4 Conclusions .................................................................... 221 
9 Mortality associated with elevated liver function tests ................ 223 
9.1 Introduction ....................................................................... 223 
9.2 Methods .............................................................................. 223 
9.2.1 Dataset used .................................................................. 223 
9.2.2 Additional definitions .................................................... 223 
9.2.2.1 Cause of death ........................................................... 223 
9.2.3 Statistical analysis ........................................................ 224 
9.3 Results ................................................................................ 225 
9.3.1 Mortality of whole population ...................................... 225 
9.3.2 Associations between death and demographic, 
lifestyle and clinical characteristics ............................................ 227 
9.3.3 Mortality associated with elevated AST ..................... 230 
9.3.4 Mortality associated with elevated ALP ..................... 235 
9.3.5 Mortality associated with elevated bilirubin ............. 240 
9.3.6 Mortality associated with any elevated LFT .............. 245 
9.4 Discussion .......................................................................... 250 
9.4.1 Key findings ................................................................... 250 
9.4.2 Strengths and limitations ............................................ 250 
9.4.3 Comparison with previously published work ............ 251 
8 
9.4.4 Conclusions .................................................................... 252 
10 Conclusions .......................................................................................... 254 
10.1 Overall findings ................................................................. 254 
10.2 Suggestions for further research ................................... 255 
10.3 Overall conclusion ............................................................. 257 
11 References ........................................................................................... 258 
Appendix I Papers published from the work in this thesis ................... 274 
Appendix II Abstracts presented at conferences based on work 
in this thesis ................................................................................................. 275 
Appendix III Code lists ............................................................................... 276 
Appendix III-a Codes for liver disease ...................................... 277 
Appendix III-b Codes for death .................................................. 306 
Appendix III-c Codes for alcohol use ......................................... 310 
Appendix III-d Codes for viral hepatitis .................................... 315 
Appendix III-e Codes for autoimmune liver disease ............... 317 
Appendix III-f Codes for metabolic liver disease ..................... 318 
Appendix III-g Codes for encephalopathy ................................ 319 
Appendix III-h Codes for smoking ............................................. 320 
Appendix III-j Codes for comorbidity ........................................ 323 
Appendix III-k Codes for liver transplant .................................. 397 
 
9 
Abstract 
Background 
Liver disease is a serious problem both in the UK and globally.  While the 
incidence and mortality from several chronic diseases are decreasing, 
mortality from liver disease is increasing.  As well as the medical sequelae for 
an individual with liver disease, in the UK the increase in chronic liver disease 
poses particular problems with respect to increasing hospital admissions, 
mortality and significant costs to the public both in terms of treatment and in 
loss of productivity.  The increase in society of several risk factors for chronic 
liver disease, notably alcohol intake, obesity and type 2 diabetes, mean that 
these problems are likely to increase in the future. 
   
Despite these apparent problems there are surprisingly few reliable sources of 
data on the occurrence of chronic liver disease (cirrhosis) in the general 
population of the UK and the rate and consequence of disease progression 
particularly among ambulatory patients.  Nor are their robust estimates of the 
prevalence of abnormal liver function tests (which may represent undiagnosed 
liver disease) and their associations with mortality.   
 
This thesis utilises two distinct datasets to examine separate areas of interest 
in the epidemiology of liver disease in the UK.  The first three studies 
contained within this thesis are concerned with the epidemiology of cirrhosis in 
the general population of the UK.  The second group of three studies focuses 
on the prevalence of elevated liver function tests in a population of older 
people in the UK, the demographic, clinical and lifestyle factors associated 
with such and the mortality following an elevated liver function test. 
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Objectives 
1. To estimate the incidence and prevalence of cirrhosis in the population 
of the UK 
2. To describe the mortality associated with cirrhosis compared with the 
general population and the disease progression of cirrhosis  
3. To estimate the prevalence of elevated liver function tests among 
people aged 75 and over in the UK 
4. To describe the association between elevated liver function test and 
demographic, lifestyle, clinical characteristics and mortality among 
people aged 75 and over. 
  
Methods 
To examine objectives 1 and 2 I utilised the General Practice Research 
Database (GPRD) constructing a population based cohort of 4537 subjects 
with cirrhosis and 44,403 age, sex and practice matched controls.  I used 
Poisson regression to estimate incidence rate ratios and describe trends in 
alcoholic and non-alcohol-related cirrhosis.  Using Cox regression within an 
historical matched cohort design I estimated the absolute excess mortality 
rates and hazard ratios for mortality in people with cirrhosis compared to the 
general population.  I described the probability of progressing from one 
disease state to another.   
 
To examine objectives 3 and 4 I accessed data from one arm of the Medical 
Research Council (MRC) Trial of Assessment and Management of Older 
People in the Community, a representative sample of community dwelling 
people aged 75 and over, totalling 15,308 participants.  The prevalence of 
abnormal liver function was described as the proportion of study participants 
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with elevated aspartate transaminase, alkaline phosphatase or serum bilirubin.  
Associations between elevated liver function and demographic, lifestyle and 
clinical factors were examined using multivariable logistic regression.  I 
determined the absolute mortality rates and hazard ratios for all-cause and 
cause-specific mortality using a Cox proportional hazards model.   
 
Findings 
Epidemiology of cirrhosis (GPRD) 
These studies have shown an increasing trend in both the incidence and 
prevalence of cirrhosis in the UK with an estimated 45% increase in incidence 
of cirrhosis in the 10-year period studied. I estimate that 76 per 100,000 
people were living with cirrhosis in 2001.  Just over half of all cirrhosis was 
associated with alcoholism.  Disease progression with cirrhosis among this 
mainly ambulatory population was rapid with a rate of decompensation in 
people with compensated disease of 5% per year and 1 in 10 dying in the first 
year following diagnosis.  This figure increased to 25% of people dying within 
one year for those with decompensated disease.  Mortality in subjects with 
compensated and decompensated cirrhosis was 93.4 and 178.0 per 1000 
person years compared with only 19.2 per 1000 person years in the general 
control population.  Following adjustment for age and sex people with 
compensated and decompensated disease were respectively 5 and 10 times 
more likely to die than the general population.      
 
Epidemiology of abnormal liver function tests (MRC cohort) 
Abnormalities in liver function were common with roughly 1 in 6 people aged 
75 and over having at least one elevated liver enzyme, although most of these 
elevations were mild.  A single elevated measurement of aspartate 
transaminase was associated with an increased consumption of alcohol and a 
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lower age in contrast with that of a single measurement of alkaline 
phosphatase which showed an association with higher age and lower alcohol 
consumption.  An elevated bilirubin measurement was strongly associated 
with being male.  Having a single elevated liver function test was associated 
with a modest increase in the hazard of death compared with people with 
normal liver function tests (adjusted hazard ratio for death 1.27 (95% CI[1.19, 
1.36]).  As well as an unsurprising increase in the hazard ratio for death from 
liver disease, elevated aspartate transaminase or alkaline phosphatase were 
both associated with modest increases in the hazard of death from cancer 
(adjusted hazard ratios of 1.56 (95%CI[1.21, 2.01]) and 1.61 (95%CI[1.39, 
1.86]) respectively).  Elevated alkaline phosphatase was additionally 
associated with increases in the hazard of death from respiratory disease 
(adjusted hazard ratio 1.58 (95%CI[1.32, 1.90])) and cardiovascular disease 
(adjusted hazard ratio 1.34 (95%CI[1.17, 1.55])). 
 
Conclusions 
From my work on the incidence and prevalence of cirrhosis I estimate that a 
minimum of 31,000 people in the UK are living with cirrhosis, a figure which is 
likely to rise given increasing trends in the incidence of cirrhosis described in 
this thesis.  The significant mortality and disease progression associated with 
cirrhosis means that more needs to be done to combat both the incidence and 
progression of this disease both on an individual and population level. 
 
Elevations in enzymes regarded as reflecting liver function are common in 
people aged 75 and over and in most people these abnormalities are less than 
2x the upper limit of normal for the assays used.  These elevations I observed 
are associated with both a modest increase in all-cause mortality and also with 
an increase in death due to specific causes.  Rather than simply a marker of 
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liver function the investigation of people with elevated liver function tests, 
particularly those with severely elevated tests, may lead to the identification of 
potentially treatable conditions that underlie death.  
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1. Introduction 
This thesis utilises two distinct datasets to examine separate areas of interest 
in the epidemiology of liver disease in the UK.  The first three studies 
contained within this thesis concentrate on the incidence and prevalence of 
cirrhosis, an examination of the mortality of people with diagnosed cirrhosis 
compared with those people in the general population and the progression of 
this disease.  The second group of three studies focuses on the prevalence of 
elevated liver function tests in a population of older people in the UK, the 
demographic, clinical and lifestyle factors associated with such and the 
mortality following an elevated liver function test. 
 
To contextualise these studies this introduction provides a brief consideration 
of some benefits and pitfalls in the methods of measurement of disease 
burden and gives an overview of the current burden of liver disease, globally 
and in the UK.  I also describe what is presently known and unknown about 
the epidemiology of cirrhosis and that of elevated liver function tests in the 
elderly.  Finally, a summary of the content of the subsequent chapters in this 
thesis is provided.  
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1.1. Measuring the burden of disease 
The burden of disease, or the burden of a specific disease, can encompass a 
wide range of measures.  These include 
 the frequency of disease,  
 the mortality from disease (and consequent years of life lost), 
 the morbidity associated with disease, and  
 aspects of societal burden such as the financial and service 
requirements associated with disease. 
 
This section discusses briefly some relevant issues in measuring the burden 
of disease particularly with respect to chronic liver disease.   
1.1.1. Measuring the frequency of disease 
In its crudest form measuring the frequency of a specific disease can be 
considered as simply counting the number of people with that disease.  
Though this may appear, at first consideration, a very easy task it is in fact 
anything but for the vast majority of diseases.   
 
The two principal ways of considering the frequency of disease in a population 
are the incidence rate and the prevalence of disease.  The incidence rate 
refers to the identification of new cases of a disease within a determined 
population over a specified period of time.  Prevalence is concerned with the 
total number of people within a given population who are presently living with 
the disease of interest.  Incidence and prevalence are intrinsically linked with 
prevalence being a function of incidence and survival time consequent to the 
acquisition of disease in closed populations.  In open populations the 
prevalence of disease may additionally be affected by migration.   
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Central to determining either incidence or prevalence are a precise definition 
of the disease of interest, knowledge of the total population at risk of the 
disease as well as the means with which to identify people with that disease.   
1.1.1.1. The definition of a disease 
Several methods may be employed which in isolation or combination lead to 
the diagnosis of a particular disease, or indeed the assertion that a particular 
disease is not present in an individual.  These include the identification of 
histological changes in cell or tissue architecture, the presence or absence of 
clinical signs and symptoms, and the use of test results, such as laboratory 
diagnostic tests including blood serology.  Frequently such signs, symptoms 
and tests in isolation are indicative of a disease but are not sufficient to 
warrant a formal diagnosis.  As such the presence of signs and symptoms or 
positive tests can often be used as a measure of undiagnosed disease.  In 
almost all circumstances to acquire a diagnosis a person must be seen by a 
health care professional of some sort.   
1.1.1.2. Defining the population at risk 
If a person is to acquire a disease at some point in their life they must be at 
risk of it.  It is self-evident that women are not at risk of testicular cancer and 
any calculation of the incidence or prevalence of testicular cancer would 
therefore include as its denominator only the total number of men in that 
population.  Similarly, studies of occupational injuries would only include 
working people within the population at risk.   
However, for most diseases it is not possible or practical to identify people 
who are specifically at risk of the disease.  For example, in a disease which 
requires genetic susceptibility it would be very difficult to exclude from the 
denominator those people who are not genetically susceptible.  Consequently 
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the vast majority of incidence and prevalence calculations assume that the 
whole population is at risk of the disease.   
Should the population of interest be a geographically determined region then 
administrative sources of data such as vital statistics (based on birth and 
death registers) or census data may provide an accurate estimate of the total 
SRSXODWLRQµDWULVN¶+RZHYHULIFDVHVRIGLVHDVHDUHEHLQJLGHQWLILHGWKURXJK
specific means e.g. presentation at hospital with particular symptoms, then it 
may not be as clear what the total population at risk is (see section 1.1.1.3).   
1.1.1.3. Identification of people with disease 
In an ideal world it would be very easy to identify the exact moment of disease 
onset (or time zero).  Particularly with chronic diseases this is far from the 
case as disease can frequently be present before the onset of any signs or 
symptoms that would warrant investigation by a health care professional.   
Frequently in epidemiological studies the identification of cases of disease is a 
pragmatic one where the date on which a subject acquires a diagnosis of a 
particular disease is considered the date of disease onset.   
Identifying all people with a particular disease on a truly population-based 
level is fraught with problems particularly if the diagnosis of disease requires 
histological confirmation, as is the case with several chronic liver diseases.  
Clearly it would be impractical and indeed unethical to perform an invasive 
procedure with attendant risks e.g. liver biopsy on all members of the general 
population, including those who are otherwise in apparently good health.  
Frequently, epidemiological studies are therefore based on populations of 
µKHDOWK-VHHNHUV¶LHSHRSOHZKRKDYHIRUVRPHUHDVRQEHHQVHHQDWDKRVSLWDO
or at the community level by a health practitioner, be it for the investigation of 
particular symptoms, following referral, for a routine health check or for an 
admission following an acute event.  Whilst these study populations may be 
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representative of the total population of interest there is often likely to be some 
selection bias in those who are able to seek care. 
For all calculations of incidence and prevalence the ideal scenario is a truly 
population-based approach but this is seldom achieved.  However, it may be 
possible to conduct specific studies on a representative sample of a 
population, determine clinical signs and symptoms or obtain biological 
samples for laboratory testing and analysis, and then to extrapolate the results 
seen from this study population to the general population.   
1.1.2. Measuring the mortality and morbidity associated 
with disease 
Ideally once a person has acquired a diagnosis of a particular disease that 
person would be followed up for life and details regarding morbidity and death 
associated with the progression of that disease would be recorded and 
available for analysis.   
Concerning morbidity, all aspects of altered health consequent to the 
acquisition of a disease should be recorded.  This would include altered 
physical health in terms of the clinical manifestation of disease as well as the 
potential psychological impact of living with a disease.   
With respect to mortality it is important to know whether the death of that 
person is a direct result of the disease in question, whether the disease has 
been a contributing factor in the death or indeed whether the disease played 
no SDUWLQWKDWLQGLYLGXDO¶VGHPLVHIt is of benefit to know both the absolute 
mortality rates and the mortality relative to the general population to 
understand the effect of that disease on mortality.   
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1.1.3. Measuring the financial and service requirements 
associated with disease 
In addition to the measurement of morbidity itself it is often desirable to obtain 
knowledge of the interventions, prescriptions or therapies that are associated 
with the management of disease and its symptoms as well as the effects of a 
GLVHDVHZLWKUHVSHFWWRDQLQGLYLGXDO¶VDELOLW\WRJRDERXWWKHLUHYHU\GD\OLIH 
In a country like the UK, where the overwhelming majority of healthcare is 
delivered free at the point of access through the National Health Service 
(NHS), it is essential that there are adequate estimates of the frequency and 
cost of treatments associated with a disease.  For these figures to be of any 
real use in terms of the planning of services there must also be accurate 
estimates of the frequency of disease within a population to enable sufficient 
resource (personnel, equipment, facilities, in short, money) to be devoted to 
the treatment of particular diseases.  Knowledge of the likely trends in the 
frequency of a disease is also of paramount importance for future planning 
requirements.   
In addition, knowledge of the potential loss of productivity of individuals with a 
specific disease allows the assessment of the economic loss associated with 
the acquisition of disease.  Several specific measures can be calculated 
including disability adjusted life-years (DALYs) and years lived with a disability 
(YLD).   
1.1.4. Data used to measure the burden of disease  
In the vast majority of settings and for the vast majority of diseases there are 
not sufficiently robust data available regarding the progress of individuals with 
disease to enable comprehensive assessment of the burden of disease with 
respect to any of the areas highlighted above.  Indeed for most diseases there 
27 
are not sufficient data available concerning the incidence of disease, let alone 
the follow-up of patients with disease.   
Notable exceptions to this include the monitoring of particular infectious 
diseases, for example cases of anthrax or cholera are required, by law, to be 
reported in the UK, and in many countries cancer, where comprehensive 
cancer registries exist, many of which can be aggregated to look at supra-
national trends.   
 
For other diseases aside from conducting specific bespoke studies there are 
sources of data which are commonly used to describe some aspects of the 
burden of disease among particular populations.  I will consider the role of vital 
statistics, such as birth and death registration data, administrative health care 
data and long-standing surveys. 
1.1.4.1. Vital statistics 
Many estimates of the burden of disease rely on the estimation of total 
SRSXODWLRQQXPEHUVJDLQHGIURPµYLWDOVWDWLVWLFV¶ i.e. the number of births and 
deaths (and ideally figures reporting migration) within a particular population.  
In many countries where birth and death registration are required by law these 
numbers are readily obtainable at a national and often at a fairly fine local 
level.  However, in many countries, particularly in the developing world, 
estimates of total population numbers are more difficult to obtain with any 
precision.   
In addition to the recording of the simple fact and date of these events, in 
many countries the registration of a birth or death must be accompanied by 
several pieces of information.  For example, in the UK at the time of 
registering a birth information concerning the sex and birth weight of the child 
and country of birth of the mother are also collected.  When registering a 
28 
death in the UK, information regarding the date, place and cause of death, as 
well as other information such as the occupation of the deceased, is collected.  
These two data sources are able to be linked together allowing, for example, 
the examination of trends in infant mortality based on birth weight of child and 
country of birth of mother.   
Used alone, information regarding the cause of death is often used as an 
estimate of the frequency of disease within a population.  For diseases with 
very high 1-year mortality, such as oesophageal cancer, this is a fairly good 
way to obtain incidence figures, providing the recording of cause of death 
includes that particular disease.  With chronic diseases such as many liver 
diseases which people can live with for a very long time this measure will likely 
lag behind true population estimates of the frequency of disease.  Additionally, 
the recording of cause of death on a death certificate is driven by what an 
individual doctor believes to be of importance. Though a person may have a 
long-standing illness, this illness may not have been of direct relevance to the 
fact of death and hence would not be recorded on the death certificate, 
leading to underestimates of the true population burden of that disease.  For 
diseases where there are potential stigma attached to the diagnosis, such as 
liver disease with an aetiology of alcoholism, omission of certain diagnoses on 
the death certificate may be common in order to alleviate the suffering of the 
family members registering the death, again leading to underestimates of the 
true population burden of that disease. 
Notwithstanding these limitations the availability of vital statistics is an 
extremely useful and well-used tool in measuring key population statistics 
which are readily comparable across nations and time.   
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1.1.4.2. Administrative health care data 
In the course of providing care and treatment to patients in health care 
settings a significant quantity of data is collected which can potentially be used 
for epidemiological research and in part to measure the burden of disease.   
In the UK there are sources of data from both primary and secondary care.   
 
Many practices in the primary care setting contribute data collected as part of 
the standard delivery of care to bespoke research databases which then allow 
access to researchers to study particular questions.  I have used data from 
one such database for studies contained within this thesis and discuss the 
relative merits of such data in detail in Chapter 2.   
 
In secondary care much of the information collected at a hospital level in the 
8.LVDYDLODEOHDVSDUWRIµ+RVSLWDO(SLVRGHV6WDWLVWLFV¶+(6(DFKWLPHD
patient is admitted to hospital a certain amount of information is collected 
including the date of admission, demographic information about the patient 
and diagnostic and procedural codes determined by those administering care.   
Data on these admissions are often used as estimators of the incidence of 
disease within the population.  As a patient can be seen many times for a 
single disease unless only the first episode of care a patient receives is 
counted these figures will inflate estimates of incidence.  However, these data 
remain extremely useful for measuring the burden with respect to the service 
requirements of a particular disease.    
Data collection at a hospital level is not driven by a specific research question 
eliminating much of the selection bias that may be present in bespoke 
research studies but limiting data in terms of what is collected.  Indeed there 
are reported issues with the reliability of the recording of diagnoses and 
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procedures.  With respect to the measurement of disease progression and 
morbidity, differences in surveillance and follow-up will exist in different 
locations rendering data from individual sites less generalisable than data 
obtained from the national database, which additionally provides large 
numbers with which to conduct a study.   
1.1.4.3. Surveys 
As a substitute or adjunct to data available from administrative health care 
data the collection of data through repeated cross-sectional surveys can 
provide a very valuable resource for the measurement of disease burden 
within a population.  One such example of this, which has been used to great 
effect, is the National Health and Nutrition Examination Survey (NHANES), 
which periodically samples the US population.  This survey constitutes a 
nationally representative sample of approximately 5000 people in the US, 
collecting information regarding risk factors for disease such as obesity, 
alcohol consumption and environmental exposures, as well as the presence or 
absence of chronic conditions such as diabetes, cardiovascular disease and 
kidney disease.  All participants additionally attend a physician-led 
appointment where blood samples and body measurements are taken.  
A similar survey in the UK exists in the form of the Health Survey for England 
(HSE) though this is not as comprehensive or well utilised.   
Although there are limitations in the usefulness of data gained from cross-
sectional surveys, not least the inability to assess the temporal nature of 
exposure and disease, these surveys nonetheless provide substantial 
information for the description of the burden of disease in the populations 
covered and, assuming the sampling has been well carried out, these data 
can be broadly generalised to the whole population.   
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Data from other cohort studies with substantial follow-up have been made 
available to researchers including, in the UK, the 1970 British Cohort Study 
and the Millennium Cohort Study.   
1.1.5. Limitations in the measurement of disease 
burden 
Although significant quantities of data are collected either routinely or as part 
of repeated surveys they are either a) not always appropriate for use in 
measuring the disease burden within a population or b) under-used 
considering they are available.   
In the UK the provision of health care is increasingly concentrated to specialist 
services with tertiary referral centres for the treatment of particular diseases.  
As such, the use of single-centre (or indeed multi-centre) studies is more 
limited now as these study populations are often no longer representative of 
the geographic area normally served by that hospital.  Rather than rely on 
WUDGLWLRQDOµJROG-VWDQGDUG¶HSLGHPLRORJ\SURVSHFWLYHO\LGHQWLILHGFRKRUWVZLWK
long follow-up) which necessitate a considerable length of time before results 
are available it is perhaps increasingly more appropriate to utilise aggregated 
databases that are often available at a national level.   
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Having briefly discussed how we commonly measure disease I will now 
describe the burden of liver disease globally and in the UK. 
 
1.2. The global burden of liver disease 
Liver disease covers a broad spectrum of diseases including acute and 
chronic liver diseases.  The International Classification of Diseases (ICD-10) 
includes within the specific section for liver disease (K70-K77) alcoholic liver 
disease (K70), toxic liver disease (K71), hepatic failure (K72), chronic hepatitis 
(K73), fibrosis and cirrhosis of liver (K74), inflammatory liver diseases (K75) 
and other diseases of liver (K76 including fatty liver K76.0).  In addition, viral 
hepatitis (B15-19) and neoplasms of the liver and intrahepatic bile ducts (C22) 
are classed as liver diseases.   
 
Throughout the world liver disease accounts for a considerable proportion of 
death, hospital admission, cost and DALYs.  The relative contribution of 
specific liver diseases to the total burden of liver disease varies across the 
globe.  I will briefly consider the global burden of chronic liver disease, viral 
hepatitis and liver cancer. 
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1.2.1. Chronic liver disease 
The availability of data on chronic liver diseases varies dependent on the 
research activities and relative importance of chronic liver disease in individual 
countries or regions.  The vast majority of the available data is concerned 
principally with cirrhosis, which I consider separately in section 1.4.1.   
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1.2.2. Viral hepatitis 
Hepatitis is a general term referring to the inflammation of the liver.  There are 
many different strains of viral hepatitis, the most common globally being 
hepatitis B and hepatitis C.    
1.2.2.1. Hepatitis B 
Hepatitis B, caused by the hepatitis B virus (HBV) is believed to have infected 
ELOOLRQRIWKHZRUOG¶VSRSXODWLRQ1  Most adult patients will recover from the 
infection but approximately 5-10% of people will not clear the virus.  The 
prevalence of hepatitis B varies considerably across the globe with chronic 
HBV infection endemic (defined as greater than 8% of the population being 
carriers) in some areas of south-east Asia, sub-Saharan Africa, the Amazon 
Basin, part of the Middle East, central Asian Republics and some countries in 
eastern Europe (see Figure 1-1).  Areas of low endemicity (carriers represent 
less than 2% of the population) include North America, Western and Northern 
Europe, Australia and part of South America with the rest of the world being 
classed as intermediate endemicity (carriers representing between 2 and 8 % 
of the population).   
The principle route of transmission depends on the level of endemicity in a 
country, with mother-to-child transmission the most frequent method in areas 
of higher endemicity.  In areas of lower endemicity more common 
transmission routes include high-risk sexual activity, blood transfusion in 
countries without donor screening, needle sharing and sometimes, although 
relatively rarely, through exposure to blood products in health care settings.   
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An estimated 350 million people worldwide are carriers of the HBV, often 
asymptomatic but frequently developing into chronic hepatitis, cirrhosis and/or 
liver cancer.   
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Figure 1-1 Global Hepatitis B prevalence, 2005.  
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1.2.2.2. Hepatitis C 
Hepatitis C, caused by the hepatitis C virus (HCV), was identified in 1989, 
previously having been referred to as non-A non-B hepatitis.  HCV is much 
less common than HBV with an estimated 3% RIWKHZRUOG¶VSRSXODWLRQEHLQJ
infected.2  HCV is more evenly distributed across the world than HBV but there 
remains substantial variation in the prevalence (see Figure 1-2).   
The principle routes of transmission are through needle sharing, transfusion of 
unscreened blood products and, principally in areas of high endemicity, 
mother-to-child transmission.   
Incidence of HCV is believed to be declining thanks to donor blood screening 
and needle-exchange programmes.  As with HBV, most cases of HCV are 
asymptomatic so precise estimation of the prevalence is very difficult.  HCV 
can progress to chronic hepatitis, leading to cirrhosis and liver failure in 
approximately 10-20%.2 3 4 
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Figure 1-2 Global Hepatitis C prevalence, 1997.   
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1.2.3. Liver cancer 
An estimated 632,000 cases of liver cancer occur every year across the 
globe.5 Liver cancer ranks as the 6th most common cancer worldwide and the 
third most common cause of death from cancer worldwide.6   The number of 
new cases of liver cancer is highest in the Western Pacific region (an 
estimated 386,000 in 2004) accounting for over three fifths of all cases whilst 
age-standardised incidence rates are highest for Eastern and South-East Asia 
and Middle and Eastern Africa (see Figure 1-3).   
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Figure 1-3 Age-standardised liver cancer incidence rates, by region and sex, 
2002 estimates.  
from Ferlay J. GLOBOCAN 2002. IARC CancerBase No.5, Version 2.0 
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1.3. Liver disease in the UK 
The focus on liver disease in the UK is now principally concerned with chronic 
liver disease (including hepatocellular carcinoma), particularly chronic liver 
disease relating to increasing alcohol consumption, and, to a slightly lesser 
extent, HCV.   
 
In the first decade of the 21st century there have been several documents 
published concerning the increasing problem of liver disease in the UK.  
Foremost was a chapter from the Annual Report of the Chief Medical Officer 
(CMO) for England in 2001 highlighting the problem of liver cirrhosis, 
particularly at younger ages.7  Subsequent to this were four not insubstantial 
reports each concerning, at least in part, the burden of liver disease in the 
UK.8 9 10 11  
The appointment of a National Clinical Director for Liver Disease in January 
2010 would indicate that liver disease is considered a significant challenge to 
the NHS in the 21st Century.12 
I will briefly consider the national burden of chronic liver disease, viral 
hepatitis, liver cancer and the demand for liver transplants.  
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1.3.1. Chronic liver disease 
Estimates of the burden of chronic liver disease are largely based on mortality 
statistics and to a lesser extent on hospital admission statistics.   
 
I will briefly summarise the five reports mentioned in section 1.3.   
The report from the CMO highlighted a 3-fold increase in deaths from chronic 
liver disease (which it subsequently refers to as cirrhosis) over the period 
1970-2000, with an 8-fold increase seen in men aged 35-44 and a 7-fold 
increase in women of the same age based on death certification data.7  The 
most likely reason for this increase, according to this report, is the higher level 
of alcohol consumption in the UK over the same period.  The report also 
briefly considers the role of viral hepatitis (particularly HCV) as an important 
cause of cirrhosis.   
 
7KHVHFRQGUHSRUWHQWLWOHGµ7KHHSLGHPLRORJ\DQGKHDOWKFDUHEXUGHQRI
FKURQLFOLYHUGLVHDVH¶FRPPLVVLRQHGE\Whe British Liver Trust and the 
Foundation for Liver Research, published in December 2004 and included an 
examination of current knowledge of the epidemiology of several chronic liver 
diseases utilising data from mortality statistics, hospital episode statistics, 
cancer registry statistics and viral hepatitis notifications from the Health 
Protection Agency.8  Analyses were limited to simple examination of time 
trends in mortality from particular diseases and admissions to hospital from 
these diseases and, in general, showed an increase in the burden of chronic 
liver disease.  Again, considerable focus was given to the observed increase 
in alcohol consumption contemporaneously with an increase in mortality from 
liver disease.   
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,Q-DQXDU\DUHSRUWSUHSDUHGIRUWKH&02E\WKH'HSDUWPHQWRI+HDOWK¶V
Quality Strategy Team µ/LYHU'LVHDVHDVFRSLQJVWXG\LQWRWKHQDWXUHDQG
EXUGHQRIWKHGLVHDVH¶DJDLQSURYLGHGDOLPLWHGGHVFULSWLRQRIWKHEXUGHQRI
liver disease based on mortality statistics, data from the General Household 
Survey and the World Health Organization, as well as a brief summary of the 
current provision of liver services in the UK.9  This report highlighted the lack 
of evidence about the incidence, nature and progression of liver disease in the 
United Kingdom.   
 
The fourth report to consider was commissioned by the British Society of 
Gastroenterology (BSG) and published in February 2007.10  µ*DVWURHQWHURORJ\
services in the UK. The burden of disease, and the organisation and delivery 
RIVHUYLFHVIRUJDVWURLQWHVWLQDODQGOLYHUGLVRUGHUVDUHYLHZRIWKHHYLGHQFH¶
included a section on the incidence of liver diseases and mortality from liver 
disease based on a systematic review of the available literature and an 
examination of mortality statistics, with similar conclusions to the above 
reports, and a further consideration of the level of service provision in the UK.  
 
The fifth report of noteµ$7LPHWR$FW,PSURYLQJOLYHUKHDOWKDQGRXWFRPHVLQ
OLYHUGLVHDVH¶SXEOLVKHGLQSUHSDUHGE\WKH%ULWLVK$VVRFLDWLRQIRUWKH
6WXG\RIWKH/LYHU%$6/DQGWKH%6*¶V/LYHU6HFWLRQSUHVHQWHGWKHQDWLRQDO
plan for liver services in the UK.11  This report highlighted the potential 
preventability of much of the chronic liver disease affecting the UK, through 
alcohol harm reduction strategies, identification and reduction in transmission 
of HCV and through decreasing the prevalence of obesity.   
 
In 2008 a paper summarised the trends in UK hospital admissions with a code 
for chronic liver disease and mortality rates based on death certification data 
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for all patients with a mention of liver disease.13  Both hospital admissions and 
mortality from chronic liver disease were seen to increase over the period of 
1989-2002.   
 
There are, of course, many individual studies considering the burden of 
specific chronic liver diseases and the progression and mortality associated 
with such.  However, a detailed examination of each of these diseases is 
beyond the scope of this thesis.   A consideration of the epidemiology of 
cirrhosis is given in section 1.4.1. 
 
1.3.2. Viral hepatitis 
In the UK there is a low prevalence of active carriers of viral hepatitis with 
roughly 0.3% and 0.4% of the population infected with HBV and HCV 
respectively.1 14   
However, there is considerable uncertainty surrounding the prevalence of 
these two viral hepatitides as so many patients whilst infected remain 
asymptomatic.   
The reported increase in the prevalence of HBV is believed to be largely 
driven by immigration from areas of high endemicity.11  The prevalence of 
HCV is reported to be lower in more recent birth cohorts, perhaps due to a 
decreased risk of infection in younger generations following the advent of 
blood screening and changes in injecting drug-users¶ habits.15  Progression 
with HCV to cirrhosis in the UK is estimated at 12% (95% CI [6%, 22%]) over 
20 years.16   
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1.3.3. Liver cancer 
Figures from Cancer Research UK based on the cancer registrations of 
England, Scotland, Wales and Northern Ireland show an incidence of liver 
cancer in the UK in 2006 of 3193 new cases, accounting for just over 1% of all 
new cancers in the UK17 placing liver cancer as the 18th most common cancer 
in the UK.  Between the years 1975 and 2006 the age-standardised incidence 
rates of liver cancer in Great Britain have increased nearly 3-fold, from 1.4 to 
3.9 per 100,000 person years.17   
 
1.3.4. Liver transplant 
Figures from the UK NHS Blood and Transplant Authority show 607 liver 
transplants in 2008/09 with a further 338 on the active transplant list at 31 
March 2009.18  For all patients on the transplant list, the most common reason 
for a liver transplant in the UK is cirrhosis (49% of all transplant patients) with 
metabolic and hereditary chronic liver diseases accounting for the majority of 
the remainder.(Personal Communication, UK NHS Blood and Transplant 
Authority, March 2010)   
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1.4. Rationale behind the studies in this thesis 
1.4.1. Cirrhosis 
What is cirrhosis? 
 
Cirrhosis is a chronic liver disease defined anatomically as a diffuse process 
with fibrosis and nodule formation.19  Its causes are myriad and it is 
considered the end point of most chronic liver diseases.  Principle aetiologies 
are viral hepatitis, alcohol, autoimmune disorders such as autoimmune 
hepatitis and primary biliary cirrhosis, and metabolic disorders including 
KDHPRFKURPDWRVLVDQG:LOVRQ¶VGLVease.  Recent studies have suggested the 
progression of non-alcoholic fatty liver disease (NAFLD) to steatohepatitis, 
fibrosis and cirrhosis.20  Frequently the aetiology of cirrhosis is unknown with 
VXFKFDVHVEHLQJFRPPRQO\UHIHUUHGWRDVµFU\SWRJHQLF¶FLUUKRVLVThe 
aetiology of cirrhosis differs across the world, with alcohol representing a more 
common cause of cirrhosis in much of the Western world. 
 
Diagnosis of cirrhosis 
The diagnosis of cirrhosis is often based on a combination of clinical, 
ultrasound, biochemical and histological findings but liver biopsy is still 
FRQVLGHUHGWKHµJROG-VWDQGDUG¶IRUWKHGLDJQRVLVRIFLUUKRVLV.21  A liver biopsy 
carries with it some procedural risks, including bleeding, considerable 
discomfort for the patient and even a small risk of death,22 23 so several other 
non-invasive methods for diagnosis are being more commonly employed and 
evaluated.  These include transient elastography (Fibroscan), magnetic 
resonance elastography and combinations of ultrasound CT and MRI.24 25 
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Disease progression and treatment 
Cirrhosis in the absence of complications is referred to as compensated 
cirrhosis but following the appearance of ascites, oesophageal variceal 
bleeding, encephalopathy or jaundice is considered to be decompensated.   
Cirrhosis has until recently been considered irreversible, but this concept is no 
longer absolute as regression of fibrosis can be seen DQGµUHYHUVDO¶RIFLUUKRVLV 
has been reported.26 27 28 29 30 31  The principle aim for therapies in patients 
with cirrhosis is to slow the rate of progression which would lead eventually to 
liver failure or death.  Treatments are few and are mostly focussed on the 
removal of the aetiologic agent(s), the suppression of hepatic inflammation, 
inhibition of hepatic stellate cell activation and then therapeutic strategies for 
the common sequelae of cirrhosis including the early detection of 
hepatocellular failure, hepatocellular carcinoma, fluid retention, 
encephalopathy and prevention or treatment of oesophageal varices and 
oesophageal bleeding.   
 
Global burden of cirrhosis 
The global burden of cirrhosis of the liver is significant, accounting for an 
estimated 800,000 deaths (1.3%) worldwide in 2004 according to the World 
Health Organization (WHO) ranking it as the 18th highest cause of death.5  In 
Europe, it is estimated to have contributed to 3.1 million DALYs (2.0% of total 
DALYs), ranking it as the 9th leading disease burden.  Estimates of the years 
lived with a disability (YLD) for cirrhosis of the liver are as high as 3.79 million 
based on population estimates for 2000.32   
 
  
48 
UK burden of cirrhosis 
In contrast to much of Western Europe, America and Australasia, where 
mortality from cirrhosis has remained constant or in decline, mortality from 
cirrhosis in the UK has tripled across the last few decades. 7 33  Although this 
increase is considerable the age-standardised mortality rates in England and 
Wales remain lower than those in most other countries studied, with the 
notable exceptions of Canada, Greece, and the Scandinavian countries 
(excepting Denmark).33 Much of the increase in mortality from cirrhosis seen in 
the UK is attributed to the increase in alcohol consumption in the UK.7 34 35   
The commonly used definition for cirrhosis when examining mortality statistics 
includes codes for alcoholic liver disease (K70), chronic hepatitis (K73) as well 
as codes for fibrosis and cirrhosis of the liver (K74).  In 2008, 1.3% of all 
deaths of people aged 25 years or over in England and Wales were attributed 
to these codes (K70, K73 and K74) according to death certification 
information.36   
 
Despite the significant apparent burden of cirrhosis globally and the 
observation of an increasing trend in cirrhosis mortality in the UK there is little 
contemporary data surrounding the frequency of cirrhosis in the population of 
the UK, the mortality associated with a diagnosis of cirrhosis and the 
progression of the disease.   
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1.4.1.1. Incidence and prevalence of cirrhosis in the 
UK 
Most reports examining the burden of cirrhosis in the UK concentrate on 
figures derived from death certificate information referring to a combination of 
chronic liver disease and cirrhosis (ICD-9 571 and ICD-10 K70, K73 and K74).  
As discussed above (section 1.1.4.1) there are significant limitations of 
mortality statistics to measure the burden of disease within a population, 
particularly a chronic disease such as cirrhosis.  In addition, the inclusion of 
other chronic liver diseases which may not yet have developed into cirrhosis 
could lead to an overestimate in the burden of cirrhosis itself at a population 
level.  These opposing potential misclassification biases mean estimates of 
incidence based on these mortality statistics are unlikely to be valid.    
 
Despite the observed 3-fold rise in mortality from chronic liver disease the last 
studies to truly try to look at the incidence of cirrhosis in the population of the 
UK were reported nearly 30 years ago.37 38   
The study by Saunders et al reported in 1981 presented a summary of data 
collected over 18 years in the 1960s and 1970s concerning patients aged 15 
years and over identified to have cirrhosis from a single hospital in west 
%LUPLQJKDPDQGIURP&RURQHU¶VSRVW-mortem reports.37  The incidence of 
cirrhosis was reported as 10.3 per 100,000 population.  Though probably 
representative of the population served by this hospital, these figures are not 
generalisable to the rest of the UK as the West Midlands region has a higher 
than average mortality from liver disease compared with the general 
population of the UK.39  In addition, 11.3% of the subjects in this study were 
LGHQWLILHGDVµLQFLGHQW¶FDVHVDVDUHVXOWRILQFLGHQWDOILQGLQJVDWSRVW-mortem 
examination.  
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Information provided by Hislop in the form of a letter to the British Medical 
Journal in 1981 reports an incidence of cirrhosis of 14.6 per 100,000 
population over the period of 1975-9.38  Unfortunately I could not find a full 
publication of these results and the methods of data collection are unclear 
leaving the validity of these results questionable.   
A third study reporting the incidence of cirrhosis on the islands of Lewis and 
Harris off the north-west coast of Scotland reported an incidence of 5.5 per 
100,000 population based on only 12 patients with confirmed cirrhosis 
between 1977 and 1982.40   
 
These wide estimates of incidence, mostly based on data from over 30 years 
ago and studies with varied methodology, provide considerable uncertainty to 
the present burden of cirrhosis in the UK.  With this absence of contemporary 
studies on the incidence of cirrhosis we also have little idea as to future trends 
in mortality and we are unable to project the level of service provision required 
for treatments associated with the progression of cirrhosis, including liver 
transplantation and oesophageal banding.   
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1.4.1.2. Mortality experience of patients with 
cirrhosis 
Whilst there are several studies which report the number of people who die 
with a recording of cirrhosis on their death certificate and the trends in such 
data there is little information about the mortality experience of patients with 
cirrhosis.  We also have little idea of the comparative mortality experience of 
people with cirrhosis with reference to the general population.   
 
The most recent estimate of survival in patients with cirrhosis in the UK comes 
from a regional study based on data from 1968-1999.41  This study considered 
all patients in the Oxford Regional Health Authority who were admitted to 
hospital for any chronic liver disease (ICD-10 codes K70, K73, K74 and K76; 
ICD-9 and ICD-8 code 571) comprising 8192 patients across the whole period.  
The standardised mortality ratio (SMR), compared to mortality in the Oxford 
regional population, was 16.3 in the first year.  The inclusion of only 
hospitalised patients will likely lead to an overestimate in the SMR as these 
patients requiring hospital admission are likely to be patients with more severe 
disease.  As discussed above the inclusion of patients with other chronic liver 
diseases, not just specifically cirrhosis, may introduce some error into the 
estimates of mortality, though without knowledge of the relative mortality 
experience of patients with different liver diseases it is not possible to know in 
which direction this may change the point estimate of mortality.  Additionally, it 
has been shown that the use of population death rates for comparators in 
mortality studies leads to an overestimate in the mortality risk suggesting an 
internal comparison group would be more appropriate.42   
Other estimates of mortality in patients with cirrhosis in the UK come from 
much older studies.  In the same study examining incidence Saunders et al 
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report the 5-year survival of patients with alcoholic cirrhosis, 36%, and non-
alcohol related cirrhosis, 14%.37  An earlier study, also from Birmingham, 
covering patients with cirrhosis in a single hospital between 1959-64 reports 
similarly low 5-year survival figures of 14.4% after first admission to hospital, 
again with patients with alcoholic cirrhosis having a better prognosis (5-year 
survival of 20% compared with 5.1% for patients with cryptogenic cirrhosis).43 
 
There have been varying estimates in the mortality associated with a 
diagnosis of cirrhosis provided from other countries within Europe and the 
USA, all of which were based on hospitalised patients.  
Perhaps the most commonly referenced figures in the literature looking at the 
mortality experience of patients with cirrhosis are those based on 1155 
consecutive patients admitted to a single hospital in Sicily during the 1970s 
and 1980s which reported 6-year survival of 54% and 21% in patients with 
compensated and decompensated cirrhosis respectively.44    
In Denmark between 1995 and 2006 a hospital cohort of 14,976 patients with 
cirrhosis described a 1-year survival of 65.5% and 5-year survival of 37.5%.45  
This study was not able to categorise patients into severity of disease and 
additionally did not report the hazard ratios for mortality compared with their 
matched control cohort.  Previously these same authors had reported SMRs 
for patients hospitalized with cirrhosis compared with the general population of 
32.3 for the first year following diagnosis and 5.7 thereafter.46   
Two papers considering the experience of patients from the 1950s and 1960s 
report survival varying from less than 50% in the first year following diagnosis 
in Malmo, Sweden47, to 60% in Brisbane, Australia.48  Neither of these studies 
reported comparisons with a general population cohort.   
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Thus, most of our knowledge on the mortality experience of people with 
cirrhosis is from a few highly selected populations which may not be broadly 
representative of the whole population of people with cirrhosis, particularly 
with the absence of ambulatory patients.  Previous studies have also been 
unable to take into account comorbid conditions and the aetiology and severity 
of cirrhosis itself.  Indeed in a recent health technology assessment (HTA) 
systematic review it was claimed that existing data suggest that there is no 
excess mortality in those patients with compensated disease compared with 
the general population for the purposes of the cost-effectiveness analysis 
carried out.49  Differences in the aetiology of cirrhosis in different countries 
may also render these estimates of mortality inappropriate for a UK cohort of 
patients with cirrhosis.  There is clearly a need for contemporary estimates of 
the mortality experience of patients with cirrhosis within the UK, compared 
with a valid comparison cohort from the general population.   
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1.4.1.3. Progression with cirrhosis 
Knowledge of the progression of disease is of natural interest to both 
physicians and patients alike wishing to understand the likely risks of 
subsequent morbidity and mortality associated with a diagnosis of cirrhosis.   
At an individual level and near the end stage of liver disease there are scoring 
systems commonly used to rank patients in order of risk of death and to 
enable identification of patients suitable for transplantation.   
Two commonly used prognostic models in liver disease are the Child-Turcotte-
Pugh (CTP) classification50 and the Model for End-Stage Liver Disease 
(MELD) score.51  The CTP score is a combination of five clinical measures of 
liver disease, each graded 1, 2 or 3.  These are total bilirubin, serum albumin, 
internationalized normal ratio (INR), presence and severity of ascites and the 
presence and severity of hepatic encephalopathy.  Limitations of the CTP 
score have led to the increasing use of the MELD score, a calculation 
combining serum bilirubin, serum creatinine and INR measurements using the 
following formula: 
MELD = 3.78 [ln serum bilirubin (mg/dL)] + 11.2 [ln INR] + 9.57 [ln serum 
creatinine (mg/dL)] +6.43 
Several modifications have been suggested to improve the measurements of 
current MELD components and the incorporation of other measurements, 
including coagulopathy, renal dysfunction and serum sodium, have also been 
suggested to improve the accuracy of the score¶s ability to predict survival.52   
The development of these scores primarily as a tool for identifying patients 
suitable for transplant may also mean that their utility as a score for cirrhosis 
itself may not be as valid as individual prognostic markers.53  Some studies 
have examined prognostic factors specifically in cirrhosis using complex 
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regression models including 46 and 174 variables,54 55 while there is a wide 
literature base of studies examining one or more individual prognostic factors.   
Whilst these scores are undoubtedly useful to clinicians in assessing the 
survival probability of an individual patient the complicated nature of the 
calculation and component parts may not be as readily comprehensible to 
patients themselves.  As such, it is useful to have some knowledge of the 
progression of cirrhosis based on clinical symptoms which are easily 
understood by patients and clinicians alike and which do not necessitate 
laboratory tests.    
Current knowledge of the progression of cirrhosis as a whole based on stage 
of disease is limited to a single centre study in Sicily, Italy from 1970s-80s,55 
and a recent study of hospitalised patients with alcoholic cirrhosis in 
Denmark.56  Other studies have considered the prognosis of patients with 
cirrhosis once they have acquired certain symptoms such as oesophageal 
varices,57 or variceal bleeding.58 59 60  Whilst the more recent of these studies 
may provide useful information on the likely progression for patients with a 
diagnosis of cirrhosis they were all based on hospitalised patients only, some 
in populations with quite different risk factor prevalences to the UK, and were 
not able to examine the progression of disease based on severity and 
aetiology. 
 
Understanding the contemporary disease progression in people with cirrhosis 
is key to determining the prognosis, health needs and burden of disease 
consequent upon having this serious condition.  
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1.4.2. Liver function tests 
Several markers of liver function are included as part of standard laboratory 
blood tests which in the UK are frequently requested both in primary and 
secondary care.   Standard blood tests which may be bracketed under the 
QRPHQFODWXUHRIµOLYHUIXQFWLRQWHVWV¶ (LFTs) include serum bilirubin, alanine 
transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase 
(ALP), albumin, prothrombin time (INR) and gamma-glutamyl transpeptidase 
(GGT).  None of these are truly specific in the measurement of liver function 
DQGDVVXFKWKHODEHORIµOLYHUIXQFWLRQWHVW¶LVSHUKDSVDOLWWOHPLVOHDGLQJ   
Nonetheless, these tests are useful on the diagnostic pathway and also as a 
prognostic tool.  Additional tests that may be ordered on suspicion of liver 
disease may include several measurement of immunogloblulins (IgG, IgA, 
IgM), antimitochondrial antibody (AMA, used in the diagnosis of primary biliary 
cirrhosis), antinuclear antibodies (ANA, used in the diagnosis of autoimmune 
hepatitis), alpha-1 antitrypsin (used in the diagnosis of alpha-1 antitrypsin 
GHILFLHQF\FDHUXORSODVPLQXVHGLQWKHGLDJQRVLVRI:LOVRQ¶VGLVHDVH and 
viral marker tests e.g. antibodies for the HBV and HCV.   
 
I will focus the remainder of this section on a discussion of three commonly 
XVHGµOLYHUIXQFWLRQWHVWV¶QDPHO\DPLQRWUDQVIHUDVHVSDUWLFXODUO\$67$/3
and bilirubin. 
 
Aminotransferases (ALT and AST) 
ALT is a cytosolic enzyme present in the liver, and to a lesser extent in the 
heart and skeletal muscles.  AST is a mitochondrial enzyme which is present 
in large quantities in the heart, skeletal muscle and kidney and also in the 
liver.   
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Variations in the serum prevalence of ALT and AST are indicative of the early 
stages of viral hepatitis, as well as other liver insults or injuries including 
alcohol abuse, autoimmune hepatitis, non-alcoholic steatohepatitis, 
haemochromatosis, :LOVRQ¶V disease and alpha-1 antitrypsin deficiency.   
Non-hepatic causes of elevations in ALT or AST include coeliac disease, 
striated muscle disorders, some endocrine diseases (hyperthyroidism and 
$GGLVRQ¶VGLVHDVH) as well as glycogen storage diseases.61   Often the ratio of 
the two enzymes is used in the diagnosis of alcoholic hepatitis and cirrhosis.   
 
Alkaline phosphatase (ALP) 
Alkaline phosphatase is an enzyme present in the liver and bile ducts.  
Elevations in ALP are common in cholestatic diseases (such as primary 
sclerosing cholangitis and primary biliary cirrhosis) but as ALP is also 
particularly concentrated in some other tissues (such as bones, placental 
tissue and in the kidneys) the specificity of ALP DVDµOLYHUIXQFWLRQWHVW¶ is not 
very high.  Elevations of ALP can occur in a wide variety of other diseases 
LQFOXGLQJ3DJHW¶VGLVHDVHDQGRWKHUERQHGLVRUGHUVZLWKPDOLJQDQWWXPRXUV
in renal disease as well as natural elevations being seen during pregnancy.  A 
simultaneous elevation in GGT would suggest a problem of liver origin.   
 
Bilirubin 
Bilirubin is a product of haemoglobin catabolism.  An increase in serum 
bilirubin can be as a result of additional bilirubin production, decreased hepatic 
uptake or decreased conjugation (occurring within the liver).  Elevations in 
unconjugated bilirubin can indicate haemolysis or familial abnormalities of 
bilirubin metabolism such as *LOEHUW¶VV\QGURPH.  Elevations in conjugated 
bilirubin are more indicative of congenital hyperbilirubinaemias such as Dubin-
Johnson syndrome and 5RWRU¶VV\QGURPH62 
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AltKRXJKWKHVHµOLYHUIXQFWLRQWHVWV¶DUHSHUIRUmed frequently in both primary 
and secondary care the prevalence and consequences of these standard 
markers of liver disease have been ill-described in the UK making the 
interpretation of them difficult, particularly in the case of an isolated elevation 
in one of these tests.   
A finding of an elevation of serum aminotransferase, ALP and / or bilirubin 
may be used as an indication of potential liver disease with subsequent follow-
up or more invasive testing probable in such patients although specific 
guidance is not available in the UK.   
 
One study in the UK examined the records of all patients from a single centre 
in the UK with an abnormal liver function based on a test requested from their 
GP.63  Of 342 patients with an elevated LFT (a single measurement of ALT, 
ALP or GGT twice the upper limit of normal) just under half (157 patients 
(46%)) had initially not been considered to warrant further investigation.  The 
authors invited these patients for subsequent tests which diagnosed liver 
disease in 97 (62%) of these patients.  The remaining 195 patients from the 
original sample had their liver function test repeated with only 38% showing 
spontaneous resolution of the abnormal test results.  Other studies from 
outside of the UK have reported high levels of liver disease in patients with 
persistently raised LFTs but who are otherwise asymptomatic.64 65 
 
$UHSRUWIURPWKH'HSDUWPHQWRI+HDOWK¶V4XDOLW\6WUDWHJ\7HDP-DQXDU\
UHFRPPHQGHGµSURYLGLQJJXLGDQFHWRJHQHUDOSUDFWLWLRQHUVRQWKHXVH
DQGLQWHUSUHWDWLRQRIOLYHUIXQFWLRQWHVWV¶9  Current consensus opinion in the 
UK suggests that patients should be investigated only if abnormalities persist 
for between 3 and 6 months.   
59 
 
As the data I examined for chapters 7-9 only include measurements of AST, 
ALP and bilirubin for the remainder of this section when I refer to LFTs I am 
principally concerned with the measurement of serum AST, ALP and bilirubin 
only.  As these data are also only concerned with people aged 75 and over I 
have tried to report studies specific to populations of older people.  As this is a 
rapidly growing sector of the UK population who may be undergoing several 
tests as part of routine care for other conditions the quantification of the 
prevalence of abnormal LFTs, the association with demographic, lifestyle and 
clinical factors as well as subsequent mortality is of particular interest to 
clinicians who will be treating these patients.   
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1.4.2.1. Prevalence of elevated liver function tests 
Information on the prevalence of elevated LFTs in the UK is surprisingly 
lacking.  The only study I could find that specifically addressed the issue of 
prevalence of elevated LFTs in a UK population is the recent publication from 
McLernon and colleagues which examines LFTs in a population of adults of all 
ages from Scotland.66  This study reports 21.7% of all study participants 
having at least one abnormal LFT with 7.0% having an elevated AST, 10.4% 
an elevated ALP and 7.1% an elevated bilirubin.  Unfortunately this sample is 
unlikely to be representative of the general population as subjects were 
identified based on having already had a LFT recorded in primary care.  As 
this is likely to include patients undergoing investigations for suspected liver 
disease these results cannot be widely generalised.   
 
Other estimates of the prevalence of elevated LFTs come from outside of the 
UK and are often based on highly selected populations.  Conflicting estimates 
from studies focussing on healthy employed workers place the range of 
elevated AST as low as 4.2% in Maryland, US67 or as high as 21.8% in 
German construction workers68 with a further study from the US placing the 
estimate of the prevalence of elevated AST at 14.9%.69   
One study from America which identified patients who had had at least one 
healthcare encounter in the year 1995 estimated a prevalence of elevated 
AST of 13%.  Again, as these patients are likely to include those who are 
sicker than the general population and therefore seeking health care this 
figure is probably an overestimate of the true population prevalence of 
elevated AST.  Further studies from the USA using survey data from 
NHANES, a more representative sample of the population, have shown a 
much lower prevalence than that seen in the UK study, with 3.7% and 4.9% of 
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the population aged 20 or over having an elevated measurement of AST in 
1988-1994 and 1999-2002 respectively.70 71   
Fewer studies considered elevations in ALP and bilirubin.  The study of a 
working population from Maryland, US reported a prevalence of elevated ALP 
of 5.9% and of elevated bilirubin of 8%.67   
I did not identify any studies looking specifically at this problem in a population 
of older people.   
Differences in the distribution of various risk factors, the prevalence of different 
liver diseases in these populations, the definitions of normal and abnormal 
tests as well as the methodological limitations in the selection of study 
populations mean that we are without a valid estimate of the prevalence of 
elevated LFTs in a UK population.   
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1.4.2.2. Associations with elevated liver function 
tests 
Knowledge of the clinical, demographic and lifestyle factors that are 
associated with elevations in LFTs is crucial in the management of patients 
who may present with an elevated LFT.   
It is important to know whether patients with elevated LFTs are a particular 
group of people (aside from whether they have liver disease) in order that we 
can potentially target the groups of people in whom further follow-up may be 
appropriate and also to aid in the understanding consequent to the 
identification of a person with elevated LFTs, particularly if there are specific 
comorbidities that are associated with elevations in LFT.   
 
0DQ\VWXGLHVKDYHORRNHGDWWKHDVVRFLDWLRQRIFHUWDLQµULVNIDFWRUV¶IRU
elevated LFTs.  Often these include the examination of elevated 
transaminases (either an elevation of ALT or AST) so it is not possible to 
determine what an elevation of one of these enzymes may be associated with.  
Markedly different associations have been shown, both in magnitude and 
indeed in some cases in the direction of the association.  In addition, there is 
little consistency in the definition of abnormality employed in these myriad 
studies making comparisons and extrapolations to other populations difficult.   
 
In the recent study from Scotland, an elevated measurement of ALP was 
associated with a statistically significant lower risk of several comorbidities 
(ischaemic heart disease, diabetes, respiratory disease and cancer) but with 
an increased risk of biliary disease.66  However there were no statistically 
significant associations seen between transaminase elevations and these 
comorbidities studied.  This is in contrast to the data from NHANES which 
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show an increased prevalence of type 2 diabetes and hypertension in patients 
with elevated transaminases as well as associations with younger ages, 
increasing BMI and being male70 and data from Germany where elevated AST 
was associated with hypertension, ischaemic heart disease, hyperlipidaemia 
and higher BMI.72  Of specific interest appears to be the association between 
abnormal LFTs and diabetes.  Several papers have reported elevations of 
transaminases being associated with existing diabetes or the development of 
diabetes. 68 72 73 74   
There are again conflicts in the literature surrounding the association of 
elevated LFTs with alcohol consumption.  Whilst three studies have reported 
an association between increasing alcohol intake and elevated 
transaminases,68 71 75 another found no association between drinking 3 or more 
units per day and elevated LFTs.69 
 
Differences in populations, definitions of abnormality and indeed the lack of 
FRQVLVWHQF\EHWZHHQWKHVHVWXGLHV¶ILQGLQJVOHDYHDVXEVWDQWLDOJDSLQRXU
knowledge of the associations between elevated LFTs and clinical, 
demographic and lifestyle factors.  I was not able to find any papers that 
looked at the associations between elevated liver function tests and other 
characteristics specifically in a population of older people.   
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1.4.2.3. Mortality associated with liver function 
tests  
Few studies have assessed the association between elevated LFTs and 
mortality in the general population as opposed to populations with known liver 
disease.  Most of these studies have been performed in selected populations 
not broadly representative of the general population.   
The only study to attempt to describe the relationship between elevated LFTs 
and mortality in the UK on a population-based level is the study by McLernon 
et al, described above.66  This study reported statistically significant 
associations between elevated LFTs (transaminases, ALP and bilirubin) with 
increased all-cause mortality.  Although moderate in absolute terms (for 
example, mildly elevated ALP (defined as elevated ALP between 1 and 2.5 
times the upper limit of normal) was associated with a hazard ratio of 1.8 for 
all-cause mortality) the authors reported a higher risk of death with 
increasingly abnormal transaminases and ALP.  The increased risk of death 
from liver disease specifically was markedly higher with hazard ratios of 3.8 
and 5.4 for mildly elevated ALP and transaminases respectively.   
A relatively recent study from the USA reported similar increased risks of 
death with elevated transaminases anGDFRPSDUDEOHµGRVH-UHVSRQVH¶HIIHFW.76  
The study population was selected based on subjects who had had a 
healthcare encounter in a small geographically defined region of Minnesota 
and had at least 2 years of follow-up.  Not all patients had their LFTs 
measured and as with the study in Scotland these populations are likely to 
include a significant proportion of subjects who were being actively 
investigated for liver disease meaning results cannot be widely generalised to 
the general population.   
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Two further studies from working populations in Germany and South Korea 
report markedly higher risks of death with elevated AST than the two studies 
described above.68 75  Arndt and colleagues report a 3-fold increased relative 
risk of death from all causes in construction workers with an elevated AST, 
where Kim et al. report relative risks of mortality of 5.6 and above for 
increasing levels of abnormal AST.  Indeed even within accepted normal limits 
subjects with a higher AST measurement than baseline (<20 IU/l) were seen 
to have an increased risk of death (relative risk 1.8 (95% CI[1.4, 2.4])).   
I identified one study which looked specifically at the association between liver 
function and mortality in the elderly, which came from a small population of 70 
year-olds in Jerusalem.77  Categorising subjects as above or below the mean 
value of LFT, this study did not show a statistically significant association 
between elevated AST or ALP and all-cause mortality.  However, they 
reported a higher mortality in patients with low ALT measurement in contrast 
to the above studies which considered transaminases together.  No increased 
mortality was seen with elevated AST in a population of adults in the US.73  
The exclusion of subjects with excess alcohol consumption again introduces a 
significant selection bias into this population. 
I did not identify any studies which specifically looked at the relationship 
between either AST, ALP or bilirubin with mortality from causes other than 
liver disease.   
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1.5. Thesis objectives 
 
The overall objective of this thesis was to examine aspects regarding the 
epidemiology of cirrhosis and elevated liver function tests in the UK.  
Specifically, six linked studies were conducted and are outlined below.  
 
Chapter 3 reports on the incidence and prevalence of cirrhosis in the 
UK. 
Chapter 4 describes the mortality of people with cirrhosis in the UK 
compared with the general population.  
Chapter 5 examines the progression of people with cirrhosis in the UK 
based on the identification of clinical symptoms. 
 
Chapter 7 reports the prevalence of elevated liver function tests in a 
population of people aged 75 and over in the UK. 
Chapter 8 describes the demographic, lifestyle and clinical factors 
associated with elevated liver function tests in this same population.   
Chapter 9 examines the association of elevated liver function tests with 
all-cause and cause-specific mortality in people aged 75 and over in the 
UK.   
 
In addition, Chapter 2 describes the General Practice Research Database 
(GPRD) ± the database used for the studies described within Chapters 3, 4 
and 5 ± and Chapter 6 describes the ³05&(lderly´ database ± the database 
used for the studies described within Chapters 7, 8 and 9.   
Finally, Chapter 10 provides a summary of the main findings of this work and 
suggests directions for future research that have arisen from this thesis.   
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2. The General Practice Research Database 
This chapter provides an overview of the General Practice Research 
Database (GPRD), its data format, its strengths and weaknesses particularly 
with reference to the studies in chapters 3 through 5 and details concerning 
the data extracted for use in the studies on cirrhosis contained within these 
three chapters.  Additional study-specific information on the exact data used is 
detailed in the methods section of each individual chapter.   
 
2.1. Introduction to the GPRD 
The GPRD is a longitudinal database consisting of anonymous, computerised 
primary care records for over 13 million patients in the UK, including over 40 
million person-years of data.  Data included within this database are recorded 
through direct entry during face-to-face general practice appointments and 
also following information received from hospital care, including hospital letters 
and discharge summaries.  
The GPRD was established in June 1987 as the VAMP (Value Added Medical 
Products) Research Databank as a commercial venture.  In 1993 VAMP Ltd. 
was subsumed by Reuters, who donated the database to the Department of 
Health and renamed it as the GPRD.  The GPRD is currently administered 
through the Medicines & Healthcare products Regulatory Agency (MHRA).   
 
As part of the GPRD recording guidelines General Practitioners (GPs) are 
required to record certain data onto their desktop computers using Vision 
software which enables the database to be subsequently used for research 
purposes.78  For all active patients in the practice the following data are 
required to be completed: 
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 Registration details, including date of birth, sex, date of registration 
with the individual practice and current registration status. 
 Morbidity events, including events resulting in a hospitalisation or 
referral; events resulting in the prescription of a drug; and events 
requiring more than one consultation. 
 Diagnoses, symptoms, procedures and investigations. 
 Death details, including date of death and cause, if known. 
 Pregnancy outcomes. 
 Prescribing information. 
Following entry into the GPRD a practice is required to submit at least 95% of 
WKLVµ5HVHDUFK,QIRUPDWLRQ¶WREHFRQVLGHUHG³XS-to-VWDQGDUG´ (UTS).   
 
2.2. Data format of the GPRD 
The GPRD is a relational database which, at the time of data extraction for the 
work contained within this thesis (April 2002), was provided as four data files 
linked by a unique patient identifier (see Figure 2-1).  The unique patient 
identifier in all files is a string variable combining the encrypted practice 
identification number and the encrypted patient identification number.   
The four files comprise a patient data file, a medical data file, a therapy data 
file and a prevention data file.   
The patient data file contains one line of data per patient per practice including 
WKHSDWLHQW¶VGDWHRIELUWKIDPLO\LGHQWLILFDWLRQQXPEHUVH[UHJLVWUDWLRQGDWH
with the practice, registration status, date of transfer out of the practice (if 
applicable) and the start and end dates pertaining to UTS data.   
The medical data file contains information recorded each time the patient has 
DQµHSLVRGH¶LQFOXGLQJWKHHYHQWGDWHa code for the medical diagnosis, 
symptom or intervention utilising a modification of the Oxford Medical 
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Information System (OXMIS) classification and Read codes and the location of 
the consultation.   
The therapy data file contains information recorded on any prescriptions that 
the patient might have received including the prescription date, the drug 
prescribed (coded using the Multilex drug code), and the quantity, dosage and 
duration of the prescription.   
The prevention data file contains information recorded each time a patient has 
a test e.g. blood tests, and information recorded on other aspects of medical 
care including weight and height, vaccinations, smoking status and alcohol 
intake.  The event date and the location are again recorded.   
There can be several lines of data per patient in each of the medical, therapy 
and prevention files.   
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Figure 2-1 Structure of GPRD at time of data extraction
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2.3. Strengths and weaknesses of the GPRD 
The GPRD is an excellent resource for descriptive epidemiology and has been 
well utilised as such.  However, as with any database there are limitations to 
its usefulness which should be considered.  The relative merits and limitations 
of the GPRD, particularly with reference to studies of cirrhosis, are discussed 
below. 
 
2.3.1. Size 
The GPRD is a very large longitudinal primary care database making it a 
particularly attractive database for research into relatively uncommon 
conditions, including cirrhosis.  Utilising such a large database as the GPRD 
will allow more precise estimates of the prevalence of cirrhosis and outcomes 
associated with this chronic disease than would previously have been afforded 
using smaller, clinically driven databases.  
 
2.3.2. Representative  
The practices included within the GPRD were initially self-selected but have 
subsequently been shown to be broadly representative of the general 
population of the UK in respect to estimates of levels of morbidity and 
mortality.42 79  It would therefore seem reasonable to generalise results from 
the GPRD to the population of the UK as a whole with respect to the burden of 
a disease.   
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2.3.3. Prospectively collected 
The majority of data within the GPRD are prospectively collected as part of the 
general course of medical care for each individual patient.  Using the dates of 
WKHSDWLHQW¶VHQWU\LQWRWKHSUDFWLFHDQGHYHQWGDWHVLWLVSRVVLEOHWRDVFHUWDLQ
which data are prospectively collected and which are retrospectively collected.  
Hence there is much less opportunity for bias in the recording of individual 
diagnoses, symptoms or particularly exposures than might be present in 
smaller studies designed to answer a specific research question.  Indeed there 
is no opportunity for bias in the reporting of primary care prescriptions as the 
prescription information contained within the database is generated 
electronically at the exact same time as the prescription itself is generated.   
However, as some of the data included in the GPRD are based on 
correspondence from secondary care it is possible that there is some 
misclassification in the recording of exact dates of events.   
 
2.3.4. Contemporaneous 
The data used in this thesis were extracted based on code lists for all patients 
with a record of one or more liver diseases between June 1987 and April 
2002.  For the assessment of the incidence of cirrhosis and subsequent 
mortality of those patients with cirrhosis, this represents a fairly 
contemporaneous data source for both those patients with cirrhosis and also 
the general population control cohort.   
 
2.3.5. Validity 
As well as ensuring that practices are contributing data that are considered 
³XS-to-VWDQGDUG´WKH0+5$HQDEOHVWKHLQGHSHQGHQWYDOLGDWLRQRIGDWDE\
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researchers.  Following the request for paper records, based on the unique 
patient identifier, GPs provide anonymised copies of the notes which can then 
be examined.  Alternatively some GPs will be willing to complete 
questionnaires to validate particular points of interest on cases within the 
database.  This cost of this service (at £100 upwards per validated subject) 
prohibits the validation of a large number of cases unless specific funding is 
obtained but does allow for the validation of a sample of cases.  A recent 
systematic review identified 212 publications which included 357 validations of 
183 different diagnoses and reported a median validation of 89% (range 24-
100%).80  A description of a validation for the diagnosis of cirrhosis is provided 
in Chapter 3. 
 
2.3.6. Incomplete recording 
As data in the GPRD are collected routinely as part of the normal course of 
care certain information that may be desirable for research purposes, 
particularly those regarding past exposures, may be missing.  In addition, as 
the data collection is based on what is important in the opinion of the GP for 
the ongoing care of the individual patient it is likely that there is a bias to which 
information is collected.  Looking at information regarding any chronic liver 
disease a particular example of this is in the recording of alcohol intake.  It is 
highly likely that a GP will record the knowledge of a patient drinking heavily 
as this may affect health but conversely a patient may not be recorded as 
being teetotal unless they actually suffered from a condition that may be 
considered to be associated with alcohol use. 
Another potential gap in the information recorded within the GPRD is that of 
medications that are either prescribed in secondary care or taken as over the 
counter medication without the need for a prescription.   
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2.3.7. Duration of follow-up 
Although the GPRD is the largest longitudinal database of primary care data 
its size is limited in terms of the length of follow-up time that is contained on 
any individual patient with the maximum length of follow-up from index date in 
these data being 15 years.  Indeed, as patients are free to change general 
practice whenever they wish, and there has been substantial turnover in 
participating practices during the lifetime of the GPRD, most subjects have 
considerably less follow-up than this.  Though the power for the estimation of 
incidence within this database will be strong, the power for the follow-up of 
these incident cohorts is reduced due to the short length of individual person 
time.   
 
2.3.8. Reproducibility 
The GPRD is an ongoing database allowing for the application of the same 
methods again in order to assess trends over time.   
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2.4. Data used for chapters 3-5 
2.4.1. Original data extracted for liver disease grant 
Data were requested from the MHRA for all patients with a record of one or 
more liver diseases recorded between June 1987 and April 2002 based on 
several code lists. (See Appendix III-a Codes for liver disease)  
For each case up to ten controls were requested, to be matched by gender, 
age (within 5 years) and practice.  Each control had to be alive and 
contributing data to the GPRD on the date of the first occurrence of any liver 
disease (between June 1987 and April 2002) LQWKHLUPDWFKHGFDVH¶VUHFRUGV
The control was not allowed to have a diagnosis of that same first recorded 
liver disease as their matched case throughout their GPRD record.   
All data contained within the GPRD on both cases and controls (patient data 
files, medical data files, therapy data files, prevention data files and a linkage 
file to determine which controls were linked to which case) were provided in 
ASCII format.  I subsequently imported these data into Stata version 9.2SE for 
all further manipulation and analyses.   
2.4.2. Data manipulation for date variables 
To ensure successful anonymisation of patients within the GPRD only the year 
of birth is included within the database.  To enable suitable manipulation of 
these data the assumption of a date of birth of July 1 was imputed for all 
subjects.  Though this will change the exact true length of follow-up for an 
individual patient the overall aggregated estimates of follow-up should not be 
biased unduly.   
In addition the GPRD uses a redundant date of 1/1/1900.  Any episodes with 
this date assigned were dropped from the data used for these studies.   
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2.4.3. Extraction of data on patients with cirrhosis 
From this large dataset of all patients with any recorded liver disease and their 
matched controls I then extracted data for all patients with cirrhosis.  Cirrhosis 
was defined using code lists for diagnostic and therapeutic codes for cirrhosis, 
portal hypertension and oesophageal varices (Table 2-1, Table 2-2, Table 2-3 
respectively).   
Codes for the specific disease of primary biliary cirrhosis were not included as 
this disease, although often a precursor to cirrhosis, is a distinct and different 
disease to cirrhosis itself.    
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Table 2-1 Medical codes for cirrhosis of the liver 
Description medcode 
[X]OTHER AND UNSPECIFIED CIRRHOSIS OF LIVER Jyu7100 
ALCOHOLIC CIRRHOSIS OF LIVER J612.00 
BACTERIAL PORTAL CIRRHOSIS J615D00 
BILIARY CIRRHOSIS J616.00 
BILIARY CIRRHOSIS NOS J616z00 
BILIARY CIRRHOSIS OF CHILDREN J616200 
CAPSULAR PORTAL CIRRHOSIS J615600 
CARDIAC PORTAL CIRRHOSIS J615700 
CARDITUBERCULOUS CIRRHOSIS J615E00 
CIRRHOSIS 5719CL 
CIRRHOSIS - NON ALCOHOLIC J615.00 
CIRRHOSIS ALCOHOLIC 5710CA 
CIRRHOSIS AND CHRONIC LIVER DISEASE J61..00 
CIRRHOSIS CARDIAC 5719CC 
CIRRHOSIS OF LIVER NOS J615z13 
CIRRHOSIS PORTAL 5719CP 
CONGESTIVE CIRRHOSIS J615711 
CRYPTOGENIC CIRRHOSIS OF LIVER J615z12 
DIFFUSE NODULAR CIRRHOSIS J615300 
FATTY PORTAL CIRRHOSIS J615400 
FLORID CIRRHOSIS J612.11 
GLYCOGENOSIS WITH HEPATIC CIRRHOSIS C310400 
HYPERTROPHIC PORTAL CIRRHOSIS J615500 
INFECTIOUS CIRRHOSIS NOS J615H00 
LAENNEC'S CIRRHOSIS J612.12 
LAENNEC'S CIRRHOSIS, NON-ALCOHOLIC J615z14 
LIVER CIRRHOSIS 5719HP 
MACRONODULAR CIRRHOSIS 5719MA 
MACRONODULAR CIRRHOSIS OF LIVER J615z11 
MICRONODULAR CIRRHOSIS 5710MC 
MIXED PORTAL CIRRHOSIS J615200 
MULTILOBULAR PORTAL CIRRHOSIS J615100 
NON-ALCOHOLIC CIRRHOSIS NOS J615z00 
OESOPHAGEAL VARICES IN ALCOHOLIC CIRRHOSIS OF THE LIVER G852300 
OESOPHAGEAL VARICES IN CIRRHOSIS OF THE LIVER G852200 
PIGMENTARY CIRRHOSIS OF LIVER C350012 
PIGMENTARY PORTAL CIRRHOSIS J615900 
PIPE-STEM PORTAL CIRRHOSIS J615A00 
PORTAL CIRRHOSIS J615.11 
PORTAL CIRRHOSIS UNSPECIFIED J615y00 
POSTNECROTIC CIRRHOSIS OF LIVER J615111 
SECONDARY BILIARY CIRRHOSIS J616100 
SECONDARY BILIARY CIRRHOSIS (LIVER) 5719CB 
SYPHILITIC PORTAL CIRRHOSIS J615F00 
TOXIC LIVER DISEASE WITH FIBROSIS AND CIRRHOSIS OF LIVER J635600 
TOXIC PORTAL CIRRHOSIS J615B00 
UNILOBULAR PORTAL CIRRHOSIS J615000 
XANTHOMATOUS PORTAL CIRRHOSIS J615C00 
ZOOPARASITIC PORTAL CIRRHOSIS J615G00 
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Table 2-2 Medical codes for oesophageal varices 
Description medcode 
[X]OESOPHAGEAL VARICES IN DISEASES CLASSIFIED ELSEWHERE Gyu9400 
FIBREOPTIC ENDOSCOPIC BANDING OF OESOPHAGEAL VARICES 760C500 
FIBREOPTIC ENDOSCOPIC INJECTION SCLEROTHERAPY OESOPH 
VARICES 760C300 
FUND HOLDING OP OESOPHAGEAL VARICES K298 FH 
GASTRIC VARICES G857.00 
INJECTION OESOPHAGEAL VARICES K2982 
LIGATION OESOPHAGEAL VARICES K2981 
LOCAL LIGATION OF OESOPHAGEAL VARICES 7609300 
OESOPHAGEAL VARICES G85..11 
OESOPHAGEAL VARICES IN DISEASES EC G852.00 
OESOPHAGEAL VARICES IN DISEASES EC NOS G852z00 
OESOPHAGEAL VARICES NOS G858.00 
OESOPHAGEAL VARICES WITH BLEEDING G850.00 
OESOPHAGEAL VARICES WITH BLEEDING IN DISEASES EC G852000 
OESOPHAGEAL VARICES WITHOUT BLEEDING G851.00 
OESOPHAGEAL VARICES WITHOUT BLEEDING IN DISEASES EC G852100 
OPEN INJECTION SCLEROTHERAPY TO OESOPHAGEAL VARICES 7609400 
OPEN OPERATION ON OESOPHAGEAL VARICES NOS 7609z00 
OPEN OPERATIONS ON OESOPHAGEAL VARICES 7609 
OTHER SPECIFIED OPEN OPERATION ON OESOPHAGEAL VARICES 7609y00 
RIGID OESOPHAGOSCOPIC BANDING OF OESOPHAGEAL VARICES 760F400 
RIGID OESOPHAGOSCOPIC INJECTION SCLEROTHERAPY OESOPH 
VARICES 760F300 
TANNER DEVASCULARISATION FOR BLEEDING VARICES 7609y11 
VARIX OESOPHAGUS 4560 
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Table 2-3 Medical codes for portal hypertension 
Description medcode 
PORTAL HYPERTENSION 5719PH 
PORTAL HYPERTENSION J623.00 
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2.4.4. Definitions used throughout 
2.4.4.1. Death 
Death was defined through a combination of medical codes denoting death 
within the medical data file (see Appendix III-b Codes for death), a recording 
of death in the prevention data file (code 16000000 denoting death) and the 
registration status of case within the patient data file (code 13 representing 
that the patient had died).  As it is possible that recording of information on the 
registration status of a person could lag behind the recording of fact of death 
the earliest date of first recording of any of these codes was taken as the date 
of death of the patient. 
2.4.4.2. Age 
Age was defined both at index date and at date of diagnosis.  Age was then 
categorised as necessary for individual studies (as described in the methods 
section for each chapter). 
The studies in this thesis are concerned with adult liver disease.  In order to 
examine only adult onset cirrhosis I excluded all cases with an age at 
diagnosis of less than 25 years to rule out the potential for including childhood 
diagnosed cirrhosis. 
2.4.4.3. Alcohol 
Within the GPRD it is possible to examine the alcohol consumption of an 
individual patient using information contained within the prevention data file on 
reported units of alcohol consumed in a week.   
First of all I attempted to define alcohol consumption based on units of alcohol 
consumed as recorded in the prevention file.  This had a high proportion of 
missing data rendering these data unusable in isolation for the purposes of 
identifying problem alcohol use.  I then adopted a pragmatic approach of 
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classifying patients as non-drinkers, drinkers, alcoholics (including patients 
referred to alcohol cessation services) and patients with other problems 
associated with drinking based on combination of recorded medical codes 
relating to alcohol use and also unit consumption.(see Appendix III-c Codes 
for alcohol use) 
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3 Incidence and prevalence of cirrhosis in the UK 
3.1 Introduction  
This study aims to quantify the occurrence and prevalence of cirrhosis in the 
general population of the UK and describes the trends in liver cirrhosis 
incidence with respect to age, sex and presumed aetiology for the period 
1992-2001.   
 
3.2 Methods 
3.2.1 Dataset used 
Data on all cases with cirrhosis (as described in section 2.4.3) were used in 
this analysis.  Patients were assigned an UTS date as either the same UTS 
date as their general practice (for patients registered before the practice was 
considered ³XS-to-VWDQGDUG´) or their date of registration (for patients 
registering after their general SUDFWLFHZDVFRQVLGHUHG³up-to-VWDQGDUG´).   
 
3.2.2 Additional definitions 
3.2.2.1 Incident and prevalent cases 
Patients were considered incident if the first recording of a diagnostic or 
therapeutic code for cirrhosis, oesophageal varices or portal hypertension 
occurred at least 12 months after the beginning of their UTS GPRD record.  
This method corrects for the potential for a prevalent case to be misclassified 
as an incident case following registration with a new practice and has 
previously been shown to more accurately reflect incidence rather than 
prevalence of other chronic diseases.81  All patients with a first diagnosis of 
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cirrhosis before the beginning of their UTS GPRD record, or within the first 12 
months following the start of their UTS record, were considered to be 
prevalent (see Figure 3-1).   
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Figure 3-1 Timeline to represent selection of cases as prevalent or incident 
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3.2.2.2 Aetiology of cirrhosis 
I examined 4 specific presumed aetiologies: alcoholic, viral hepatitis, 
autoimmune liver disease and metabolic liver disease.  All aetiologies were 
ascribed using data from the whole GPRD record, not just before the 
diagnosis of cirrhosis to capture investigations into the aetiology that may 
have been instigated subsequent to the diagnosis.   
 
For the purposes of aetiology analysis alcoholic cirrhosis was defined as any 
mention of alcoholism, alcohol abuse, addiction or dependence i.e. all those 
SDWLHQWVFODVVLILHGDVµDOFRKROLF¶LQWKHLUPHGLFDOILOHV (see section 2.4.4.3).  
Viral hepatitis included all forms of known viral hepatitis (see Appendix III-d 
Codes for viral hepatitis).  Autoimmune liver disease consisted of primary 
biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis (see 
Appendix III-e Codes for autoimmune liver disease).  Metabolic liver disease 
consisted of haePRFKURPDWRVLV:LOVRQ¶VGLVHDVHDQG alpha-1 antitrypsin 
deficiency (see Appendix III-f Codes for metabolic liver disease).  All other 
SDWLHQWVZHUHVXEVHTXHQWO\ODEHOOHGDVµRWKHUXQVSHFLILHGFDXVHVRIFLUUKRVLV¶   
For the purposes of trend analysis, all cases not fulfilling the definition of 
alcoholic cirrhosis were grouped together as non-alcohol-related cirrhosis.   
3.2.2.3 Age 
Age at diagnosis was subsequently categorised into 10-year age bands from 
25-34 to 85+ years.   
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3.2.3 Validation  
In order to assess the accuracy of the recording of the diagnosis of cirrhosis 
paper records from the GPs were requested from a stratified, random sample 
RISDWLHQWVZLWKDGLDJQRVWLFRUWKHUDSHXWLFFRGHIRUFLUUKRVLV7KHSDWLHQWV¶
paper records were then examined by a consultant hepatologist (Guruprasad 
P Aithal).  Information was gathered on whether there was any record of 
cirrhosis, whether the diagnosis had been made in primary or secondary care, 
whether this had been confirmed by biopsy and whether there was any record 
of the presumed aetiology of the cirrhosis.   
 
3.2.4 Statistical analysis 
3.2.4.1 Incidence 
To calculate overall incidence I used the total number of new cases of 
cirrhosis i.e. those cases whose first record of cirrhosis was recorded 12 
PRQWKVDIWHUWKHVWDUWRIWKHµXS-to-VWDQGDUG¶SHULRGsee section 3.2.2.1) as 
the numerator and the total population of the GPRD aged 25 years and over 
as the denominator, by summing the mid-year population numbers for each 
valid year.  I excluded data previous to 1992 owing to the small number of 
practices contributing data in these years.  Data from 2002 were also excluded 
as there was not a full calendar year of data available.  I initially calculated 
crude incidence rates and then stratified by year of diagnosis, age group and 
sex. I also examined the trend in incidence of alcoholic and non-alcohol-
related cirrhosis.  Poisson regression was used to model fully adjusted 
incidence rate ratios and estimate confidence intervals.   
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3.2.4.1.1 Alternative case definitions 
To account for potential over- and under-ascertainment bias I performed two 
additional analyses.  To minimise the potential over-ascertainment bias 
introduced by including cases with oesophageal varices and portal 
hypertension who may not actually have cirrhosis I calculated incidence based 
purely on those cases with a medical code for cirrhosis (see Table 2-1).  This 
provided a minimal estimate of incidence. 
 
To minimise the potential of missing cases with underlying cirrhosis but 
lacking a formal diagnosis I searched the GPRD for patients with recorded 
liver disease and a further recording of non-malignant ascites (see Table 5-1) 
and/or encephalopathy (see Appendix III-g Codes for encephalopathy).  I 
examined the trend in incidence with and without these cases.   This provided 
a maximal estimate of incidence.   
 
3.2.4.2 Prevalence 
I calculated three separate point estimates of prevalence using all cases who 
were still contributing data to GPRD at 1 July 1993, 1 July 1997 and 1 July 
2001.  The total GPRD population aged 25 years or older at each time point 
was used as the denominator. 
 
3.2.4.3 Application of results to 2008 population 
I applied the age- and sex-specific incidence and prevalence figures to the 
2008 age- and sex-stratified population of the United Kingdom to estimate the 
number of people being newly diagnosed with cirrhosis in the UK and the 
number of people living with cirrhosis in the UK.82   
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3.3 Results 
3.3.1 Study population 
A total of 3,360 incident cases of cirrhosis aged 25 or over were identified 
between 1992 and 2001, 58% of whom were male.  The median age at 
diagnosis was 56.3 years in men and 61.3 years in women (p<0.001).  
Thirteen per cent of cases had their first recording of cirrhosis concurrent with 
the recording of time of death following correspondence from secondary care 
services.  Over half of patients (n=1690, 50.3%) had a recording of alcoholism 
at any point within their GP records (see Table 3-1). For 1591 cases (47.4%) 
alcohol was the only specified associated factor.  Overall, just under two-fifths 
of cases had no specified aetiologies within their GP record (n=1328, 39.5%), 
a proportion which remained roughly constant across the study period.   
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Table 3-1 Presumed aetiology of incident cirrhosis cases 
Presumed aetiology* n (%) 
N=3360 
Alcohol-related 1690 (50.3) 
Alcohol-related only 1591 (47.4) 
Alcohol-related and viral hepatitis 77 (1.7) 
Alcohol-related and autoimmune disease 11 (0.3) 
Alcohol-related and metabolic disease 10 (0.3) 
Alcohol-related, viral hepatitis and metabolic disease 1 (<0.1) 
  
Viral hepatitis 181 (5.4) 
Viral hepatitis only 111 (3.3) 
Viral hepatitis and alcohol-related 77 (1.7) 
Viral hepatitis and autoimmune disease 5 (0.1) 
Viral hepatitis, alcohol-related and metabolic disease 1 (<0.1) 
  
Autoimmune disease 237 (7.1) 
Autoimmune disease only 225 (6.7) 
Autoimmune disease and alcohol-related 11 (0.3) 
Autoimmune disease and viral hepatitis 5 (0.1) 
  
Metabolic disease 29 (0.9) 
Metabolic disease only 19 (0.6) 
Metabolic disease and alcohol-related 10 (0.3) 
Metabolic disease, alcohol-related and viral hepatitis 1 (<0.1) 
  
Other, unspecified 1328 (39.5) 
*NB As some combinations of presumed aetiologies are included more than once, numbers in 
the table do not add up to 3360 
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3.3.2 Incidence 
Over the 10-year period crude incidence was 14.5 cases per 100 000 person 
years, increasing from 12.0 in 1992 to 17.0 cases per 100 000 person years in 
2001 (see Table 3-2).   
This increase fitted a continuous model with an average yearly incidence rate 
ratio of 1.04 (95%CI [1.03, 1.06]) adjusted for age and sex, corresponding to a 
45% increase in incidence over the decade studied.  Incidence was about 
50% higher in men than women, 17.5 cases per 100 000 person years and 
11.8 cases per 100 000 person years respectively (incidence rate ratio 1.52; 
95% CI [1.42-1.63] adjusted for age and year of diagnosis) (see Figure 3-2).  
Figure 3-3 shows that the incidence of cirrhosis was higher in men than 
women for all age groups.  The highest incidence for women occurred at age 
65-74 years (22.7 per 100 000 person years).  Incidence at all age groups 
from 45-84 years for men was higher than this maximum for women.   
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Table 3-2 Incidence of cirrhosis, 1992-2001 
 Cases P-years Crude incidence rates [95% CI] 
per 100 000 p-years 
Total 3360 23 093 805 14.5 [14.1, 15.0] 
Sex    
Female 1406 11 934 462 11.8 [11.2, 12.4] 
Male 1954 11 159 343 17.5 [16.8, 18.3] 
Age (years)    
25-34 122 5 194 894 2.3 [2.0, 2.8] 
35-44 461 4 776 754 9.7 [8.8, 10.6] 
45-54 816 4 419 818 18.5 [17.2, 19.8] 
55-64 790 3 362 078 23.5 [21.9, 25.2] 
65-74 727 2 854 265 25.5 [23.7, 27.4] 
75-84 386 1 828 533 21.1 [19.1, 23.3] 
85+ 58 657 463 8.8 [6.8, 11.4] 
Year    
1992 339 2 813 552 12.0 [10.8, 13.4] 
1993 337 2 771 663 12.2 [10.9, 13.5] 
1994 378 2 674 596 14.1 [12.8, 15.6] 
1995 339 2 655 872 12.8 [11.5, 14.2] 
1996 352 2 411 170 14.6 [13.2, 16.2] 
1997 357 2 253 388 15.8 [14.3, 17.6] 
1998 355 2 157 349 16.5 [14.8, 18.3] 
1999 340 2 036 987 16.7 [15.0, 18.6] 
2000 319 1 883 106 16.9 [15.2, 18.9] 
2001 244 1 436 120 17.0 [15.0, 19.3] 
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Figure 3-2 Incidence of cirrhosis (per 100,000 person years) by year and sex, UK, 1992-2001
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Figure 3-3 Incidence of cirrhosis by age group and sex, UK, 1992-2001 
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3.3.2.1 Alcoholic and non-alcohol-related cirrhosis 
Within the study population just over half (50.3%) of people with a record of 
cirrhosis were defined as alcoholic cirrhosis, according to the criteria 
described above (see Table 3-1).  An increase in the incidence of both 
alcoholic cirrhosis and non-alcohol-related cirrhosis was seen in men, 70% 
(p<0.001) and 30% (p=0.017) increase respectively across the 10-year period, 
and also in women, 28% (p=0.068) and 36% (p=0.004) increase respectively 
over the 10-year period (see Figure 3-4 and Figure 3-5).  
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Figure 3-4 Incidence of alcoholic and non-alcohol-related cirrhosis in males, UK, 1992-2001 
96 
 
Figure 3-5 Incidence of alcoholic and non-alcohol related-cirrhosis in females, UK, 1992-2001 
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3.3.2.2 Incidence using alternative case definitions 
Including only patients with a diagnosis of cirrhosis itself i.e. excluding those 
patients with a diagnosis of oesophageal varices and portal hypertension the 
overall crude incidence, 1992-2001, decreased by 15% from 14.5 to 12.4 per 
100,000 person years (see Figure 3-6). 
 
 
Using the extended definition of cirrhosis an additional 505 incident cases 
were included.  The overall crude incidence, 1992-2001, when the additional 
patients with liver disease and non-malignant ascites or encephalopathy were 
included, increased by 15% from 14.55 to 16.74 per 100,000 person years 
(see Figure 3-6). 
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Figure 3-6 Incidence of cirrhosis using alternative case definitions 
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3.3.3 Prevalence 
Using all cases contributing to the GPRD at three separate time points I 
observed an increase in the prevalence of cirrhosis between 1 July 1993 and 
1 July 2001 from 45.4 to 76.3 per 100,000 population aged 25 years or over 
(see Table 3-3) representing a 68% increase in the prevalence of this disease 
over the period studied.  Prevalence was higher in men than women at all 
three time points.      
  
100 
Table 3-3 Prevalence of cirrhosis 
 Prevalence (per 100,000 population) 
 Females Males Total Prevalence 
rate ratio * 
1 July 1993 38.6 52.8 45.4 1 
1 July 1997 58.2 74.8 66.2 1.46 
1 July 2001 65.9 87.2 76.3 1.68 
*compared with 1 July 1993 
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3.3.4 Validation 
Responses were received for 49/59 patients whose notes were requested, a 
response rate of 83%.  Of the responses received 13 sets of case notes were 
not available because either the patient had subsequently moved from the GP 
surgery (6), the patient had died (2) or the GP was unable to help (5).  Of the 
36 sets of case notes that could therefore be examined, 35 cases had chronic 
liver disease (97%, 95% confidence interval [85%, 99.9%]).  A total of 27 
patients (75%, 95% confidence interval [58%, 88%]) had evidence confirming 
cirrhosis, either biopsy proven cirrhosis, evidence of portal hypertension (with 
supportive evidence of liver disease as the cause of the portal hypertension) 
or clinical decompensation in the presence or absence of advanced changes 
seen at biopsy.  Of the nine cases where cirrhosis could not be confirmed, all 
bar one had evidence of chronic liver disease - three cases of primary biliary 
cirrhosis, three cases of alcoholic liver disease and one each of Budd-Chiari 
and autoimmune hepatitis.  The one case which could not be considered as 
chronic liver disease was a patient with alcoholic pancreatitis.  All of these 
diagnoses occurred in secondary care.   
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3.4 Discussion 
3.4.1 Key findings 
This study has described a 45% increase in the incidence of cirrhosis in the 
UK in the decade between 1992 and 2001 and a 68% rise in the prevalence.  
Cirrhosis occurred more commonly and at younger ages in men than women.  
Nonetheless, a significant increase in incidence was seen for all age groups 
and for both sexes across the period under study.  Incidence of both alcoholic 
and non-alcohol-related cirrhosis increased in males and in females during the 
period.   
Applying the 2001 prevalence and incidence figures to the 2008 age- and sex-
stratified population of the UK, I estimate that, over the age of 25, at least 
31,000 people in the UK are currently living with cirrhosis and approximately 
7100 people are being newly diagnosed with this disease each year.  If I use 
the estimate from the wider definition of cirrhosis this figure increases to an 
estimated 8000 people being newly diagnosed with cirrhosis each year.  
These figures are still likely to be an underestimate of the burden of cirrhosis 
since they are based on diagnosed disease and do not take into account the 
possibility of a continuing increasing trend.  This clearly represents a 
challenge for health care services and will have substantial implications for the 
future trends in mortality from this disease.   
 
3.4.2 Strengths and limitations 
This is the first UK-wide population-based study of the occurrence of cirrhosis.  
I have examined contemporary data from general practices representative of 
the UK collected over a period of 10 years.  The collection of data within the 
GPRD is not driven by a specific research question and is hence not subject to 
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the same ascertainment biases as may be present in smaller, hospital-based 
series.   
 
The biggest potential limitation of this study lies with the case definition, 
having included as cases all patients with any mention of cirrhosis, 
oesophageal varices or portal hypertension within the primary care records.   
Although it is possible that portal hypertension and oesophageal varices are 
manifestations of diseases other than cirrhosis it was decided to include these 
codes within the list for cirrhosis as these symptom are widely regarded as 
being representative of cirrhosis in developed countries.  The validation 
exercise, which took the form of a case note review, showed that the majority 
(75%) of the sampled cases had an assertion of cirrhosis within the medical 
records.  Of the remaining 25% of patients, 8/9 had a confirmed chronic liver 
disease with the potential to develop cirrhosis, although cirrhosis itself was not 
recorded in the notes available to us.  All of the confirmed diagnoses 
examined in the case note review had been communicated to the GP directly 
from secondary care.  It is reasonable to suppose that this is a sufficiently 
robust definition to accurately capture cases of cirrhosis recorded in the GPRD 
and in such a way which is easily replicated allowing valid examination of 
trends over time.  Although I may have inadvertently included as cases a few 
patients who did not have cirrhosis it is more likely that I am missing cases of 
cirrhosis where diagnosis was unconfirmed and/or not fed back from 
secondary care into the primary care records.  This finding of an increase in 
incidence is unlikely to be due to increased ascertainment through diagnostic 
procedures as UK Hospital Episode Statistics report a decrease in the number 
of diagnostic fibre optic examinations of the upper gastrointestinal tract (-4%) 
in the period 1995/6 to 2004/5.83 
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While it was not possible to assign a presumed aetiology to 39% of cases from 
the available data this is similar to the largest previous study of cirrhosis with 
35% being labelled as cryptogenic cirrhosis.37  I have considered all patients 
with specific recording of alcoholism as having alcoholic cirrhosis.  Owing to 
the known limitations of recording and referral for alcohol-related problems by 
GPs within this dataset,84 it is likely that I have underestimated the number of 
patients with alcoholic cirrhosis.  Although it is possible in a patient with 
recorded alcohol problems that alcohol intake itself was not the underlying 
cause of the cirrhosis, it is more likely that the true proportion of alcoholic 
cirrhosis is greater than the 50% seen in these data.   
3.4.3 Comparison with previously published work 
The largest study, prior to this study, looking at the incidence of cirrhosis in the 
UK was a summary of data collected over 18 years in the 1960s and 1970s.37  
This previous study, which comprised 512 people identified to have cirrhosis, 
reported an incidence of cirrhosis of 10.3 per 100,000 population aged 15 
years and over from patients diagnosed in a single district general hospital in 
ZHVW%LUPLQJKDPDQGIURP&RURQHU¶Vpost-mortem reports.  Though 
representative of the population served by this hospital, these figures are not 
generalisable to the rest of the UK as the West Midlands region has a higher 
than average mortality from liver disease compared with the general 
population of the UK.39  With any hospital-based series there is the potential 
for an ascertainment bias with active case finding being employed, leading to 
a further over-estimate of incidence.  In addition, in the study by Saunders et 
al, 11.3% of the subjects included as incident cases were as a result of 
incidental findings at post-mortem examination.  The same factors are unlikely 
to have operated in my study.   
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The results displayed in this study show a higher or similar incidence of 
cirrhosis compared with the previous studies of cirrhosis in the UK37 38 40 but 
owing to the small, non-representative nature of these studies, and a lack of 
clarity as to exact methods used, direct comparisons should be avoided.  This 
study is the only study based on a contemporary, representative sample of the 
entire UK population and has utilised data collected for general medical 
purposes over a period of 10 years.   
 
My data contrast with recent data from a hospital-based study in Denmark 
where no discernible trend in incidence of alcoholic cirrhosis was seen from 
1994-2005.45  The figures reported in this study similarly showed a higher 
incidence and prevalence of cirrhosis for men than women, and for those aged 
between 45 and 64 years of age, although the crude incidence figures for 
alcoholic cirrhosis were higher than I saw in my study.  Other data from 
Scandinavia report similar figures to those reported in this chapter for 
Gothenburg, Sweden (incidence of 15.3 per 100,000 person years)85 and 
Oslo, Norway (incidence of 13.3 per 100,000 person years)86 but a much lower 
incidence for Iceland (incidence of 3.3 per 100,000 person years).85   
 
I have presented the first data quantifying the current burden of alcoholic 
cirrhosis in the UK but it is important to note that the incidence of non-alcohol 
related cirrhosis also increased over this period.  Though it is possible that 
some of these cases were indeed misclassified alcoholic cirrhosis, it is also 
possible that other causes of cirrhosis are also on the increase.  From a public 
health perspective a particularly important and potentially modifiable set of risk 
factors are those of obesity and its relationship with type 2 diabetes.  Where 
fatty liver leads to steatohepatitis, fibrosis can occur in roughly one third of 
patients.20  In one study, a history of obesity and/or type 2 diabetes was found 
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in 7RISDWLHQWVZLWKµFU\SWRJHQLF¶FLUUKRVLV87  Although cirrhosis is far from 
recognised as an end-point for diabetes or obesity the sustained increase in 
these two potential risk factors may lead to further increases in the incidence 
of cirrhosis in the UK in the years to come.   
 
 
3.4.4 Conclusions 
Liver disease is one of very few chronic diseases where mortality in the UK 
has increased over the past three decades.88  In contrast, mortality from 
ischaemic heart disease, cerebrovascular diseases and respiratory diseases 
have all decreased.  With a minimum estimate of 31,000 people over the age 
of 25 living with cirrhosis, a figure which is likely to increase, and with no good 
treatment options other than liver transplant, mortality from this disease will 
continue to rise.   
 
Although the accuracy of defining true incidence is somewhat difficult with a 
chronic condition with heterogeneic presentation such as cirrhosis the figures 
reported in this study represent the most up-to-date estimates of the absolute 
rates and trends in incidence and prevalence of cirrhosis in the UK having 
used population-based data over a period of 10 years.   
 
Cirrhosis represents a serious and growing burden of morbidity in the general 
population of the UK.  The continued rise in cirrhosis has significant 
implications for the provision of specialist services and the health of the nation.   
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4 All-cause mortality in people with cirrhosis 
compared with the general population 
4.1 Introduction 
This study aims to describe the mortality experience of people with cirrhosis 
with reference to a general population cohort without cirrhosis.   
 
4.2 Methods 
4.2.1 Dataset used 
The data used in this chapter were from all subjects with a diagnosis of 
cirrhosis (as described in section 2.4.3) and their matched controls.  By 
definition these controls were initially selected based on the exclusion of the 
first recorded liver disease within their matched case (see section 2.4.1).  It 
was therefore possible that a control subsequently had a diagnosis of a liver 
disease other than the liver disease that first identified their matched case¶V
record (see Figure 4-1).  As cirrhosis was potentially not the first liver disease 
that a case was diagnosed with I excluded controls who  
a) had cirrhosis as a diagnosis at any point in their GPRD record, or 
b) were not alive at the time of diagnosis of cirrhosis in their matched 
case.  
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Figure 4-1 Time-line showing potential diagnosis of cirrhosis in control subjects. 
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4.2.2 Additional definitions 
4.2.2.1 Date of diagnosis / pseudo-diagnosis 
Cases were assigned a date of diagnosis as the first recorded date of any of 
the codes for cirrhosis in their general practice record (see section 2.4.3).  
Matched cRQWUROVZHUHWKHQJLYHQWKLVGDWHDVWKHLUGDWHRIµSVHXGR-GLDJQRVLV¶ 
4.2.2.2 Age 
Age at diagnosis, or pseudo-diagnosis for controls, was categorised into 25-44 
years, 45-64 years and 65 years and above for the purposes of analysis.   
4.2.2.3 Body Mass Index  
Body Mass Index (BMI in kg/m2) was defined using data on height, weight 
and/or BMI contained within the prevention data file.  Data on height and 
weight contained several outliers of implausibly low or high values, mostly of 
an order of magnitude of 100 or 1000 times normal plausible values 
suggesting transcription errors in the number of zeroes recorded.  
Consequently weights of greater than 300kg or less than 30kg, heights of 
greater than 2.5m or less than 1m, and BMI values of greater than 100 were 
excluded.  Values of height and weight recorded at least one year before the 
date of diagnosis of cirrhosis for cases or date of pseudo-diagnosis for 
controls were then examined and the median value of each used to calculate 
the BMI RIWKHSDWLHQW:KHUHWKHUHZDVDYDOXHIRUDSDWLHQW¶V%0,DJDLQ
recorded at least one year before the date of diagnosis of cirrhosis or pseudo-
diagnosis, this was used in preference to a calculated value using height and 
weight measurements.  The 1-year cut off was used to try to ensure weight 
loss due to undiagnosed disease did not change the initial BMI categorisation 
of subjects. 
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BMI was then categorised according to recognised clinically meaningful limits: 
<18.5 (underweight), 18.5-24.9 (ideal weight), 25.0-29.9 (overweight), 30.0-
34.9 (obese) and 35.0+ (severely obese).     
4.2.2.4 Smoking 
Smoking status was ascribed using a combination of medical codes for 
smoking contained within the medical data file and information recorded within 
the prevention file on the number of cigarettes smoked before the date of 
diagnosis or pseudo-GLDJQRVLV6PRNLQJFRGHVLQDVXEMHFW¶VPHGLFDOILOH
ZHUHFDWHJRULVHGDVµ1RQ-VPRNHU¶µ([-VPRNHURUµ6PRNHU¶(see  
 
)  ,IWKHUHZDVPRUHWKDQRQHFDWHJRU\FRGHGLQDVXEMHFW¶VUHFRUGVXEMHFWV
were assigned the category that indicated greatest smoking experience during 
their record.      
4.2.2.5 Alcohol use 
Alcohol use was observed in two ways.  Firstly, looking at the alcohol 
consumption data from the prevention data file the number of units of alcohol 
consumption in a week was extracted.  Secondly, information on recorded 
alcohol status, prior to diagnosis, was extracted from the medical file using the 
codes for alcohol use (see Appendix III-c Codes for alcohol use).   
4.2.2.6 Comorbidity 
Comorbidity was described using a composite measure of illnesses diagnosed 
in each patient, based on the Charlson score.89  The original Charlson score 
includes a category for mild liver disease as a weighted score of 1 and a 
category for moderate or severe liver disease as a weighted score of 3 (see 
Table 4-1).  For this study I excluded liver disease from the comorbidity score.  
For the purposes of this study diseases had to be identified prior to the date of 
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diagnosis or pseudo-diagnosis.  Particular diseases were identified from data 
contained within the medical file, weighted and a comorbidity score derived 
(see Appendix III-j Codes for comorbidity).  Scores were then categorised as 
0, 1, or 2+ for the purposes of analysis.  This has subsequently been validated 
by others as a good predictor of mortality in the GPRD.90 
 
Table 4-1 Charlson score ± weighted index of comorbidity 
Assigned weights 
for diseases 
Conditions 
1 Myocardial infarction 
Congestive heart failure 
Peripheral vascular disease 
Cerebrovascular disease 
Dementia 
Chronic pulmonary disease 
Connective tissue disease 
Ulcer disease 
Mild liver disease (Not included in this study) 
Diabetes 
2 Hemiplegia 
Moderate or severe renal disease 
Diabetes with end organ damage 
Any tumour 
Leukaemia 
Lymphoma 
3 Moderate or severe liver disease  
(Not included in this study) 
6 Metastatic solid tumour 
AIDS 
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4.2.2.7 Liver transplant 
For the end-point of some of the analyses I included liver transplant as well as 
death.  Liver transplant was defined using medical codes from the medical file 
(see Appendix III-k Codes for liver transplant).  
4.2.2.8 Compensated and decompensated disease 
Cases were classified as being in a compensated or decompensated disease 
state at the date of diagnosis.  Cases with a code for ascites or 
gastrointestinal bleed at or before the date of diagnosis were classified as 
being in a decompensated disease state (see Table 4-2).   
4.2.2.9 Aetiology of cirrhosis 
Aetiology was ascribed as per the methods in section 3.2.2.2.   
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Table 4-2 Medical codes for ascites and GI bleed (decompensated disease) 
Description medcode 
[D]ASCITES R095.00 
[D]ASCITES NOS R095z00 
[D]FLUID IN PERITONEAL CAVITY R095000 
ACUTE GASTRIC ULCER WITH HAEMORRHAGE J110100 
ACUTE GASTRIC ULCER WITH HAEMORRHAGE AND 
PERFORATION J110300 
BLEEDING ACUTE GASTRIC ULCER J110111 
BLEEDING CHRONIC DUODENAL ULCER J121111 
BLEEDING CHRONIC GASTRIC ULCER J111111 
CHRONIC DUODENAL ULCER WITH HAEMORRHAGE J121100 
CHRONIC DUODENAL ULCER WITH HAEMORRHAGE AND 
PERFORATION J121300 
CHRONIC GASTRIC ULCER WITH HAEMORRHAGE J111100 
CHRONIC GASTRIC ULCER WITH HAEMORRHAGE AND 
PERFORATION J111300 
CHYLOUS ASCITES 457 CA 
CHYLOUS ASCITES G86y100 
DRAINAGE OF ASCITES NEC 7H2B200 
GASTROINTESTINAL HAEMORRHAGE UNSPECIFIED J68z.00 
GASTROTOMY AND LIGATION OF BLEEDING POINT OF 
STOMACH 7619100 
GI BLEEDING 569 M 
GIB - GASTROINTESTINAL BLEEDING J68z.11 
HAEMATEMESIS J680.00 
HAEMORRHAGE GASTROINTESTINAL 569 MI 
HEPATIC ASCITES 5719AH 
INSERTION OF DENVER PERITONEOVENOUS SHUNT 7H2B111 
INSERTION OF LE VEEN PERITONEOVENOUS SHUNT 7H2B112 
INSERTION OF PERITONEAL TO VENOUS SHUNT FOR 
ASCITES 7H2B113 
INTESTINAL HAEMORRHAGE 569 MH 
MELAENA J681.00 
OESOPHAGEAL VARICES WITH BLEEDING G850.00 
OESOPHAGEAL VARICES WITH BLEEDING IN DISEASES EC G852000 
OESOPHAGUS BLEEDING 5309H 
OESOPHAGUS HAEMORRHAGE 5309HA 
O/E - ASCITES 25O..00 
O/E - ASCITES - DIPPING SHOWN 25O2.00 
O/E - ASCITES NOS 25OZ.00 
O/E -ASCITES-SHIFTING DULLNESS 25O4.00 
O/E-ASCITES-FLUID THRILL SHOWN 25O3.00 
PARACENTESIS ABDOMINIS FOR ASCITES 7H2B000 
PERITONEAL TO VENOUS DRAINAGE FOR ASCITES 7H2B100 
TANNER DEVASCULARISATION FOR BLEEDING VARICES 7609y11 
UPPER GASTROINTESTINAL HAEMORRHAGE 569 ME 
VOMITING OF BLOOD J680.11 
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4.2.3 Statistical analysis 
Using Cox proportional hazards regression I modelled the hazard of death in 
the cirrhosis cohort (classifying subjects with cirrhosis as either compensated 
or decompensated at entry (as described in section 4.2.2.8)) compared with 
the control cohort employing an historical matched cohort study design.  
Subjects with cirrhosis and controls entered the analysis period at the date of 
diagnosis or pseudo-diagnosis respectively and exited at the earliest of either 
date of death, deregistration with their general practice or 30 April 2002 which 
was the last date of available data in this dataset.  This principal analysis was 
adjusted, a priori, for age and sex.  Additional potential confounders (BMI, 
smoking, alcohol intake and comorbidity group) were modelled as categorical 
variables (with a separate category for missing data) and included in the final 
Cox model if they conferred a 10% or greater adjustment in the hazard ratios 
seen.  
Owing to the probable high influence of comorbidity on mortality, particularly at 
early stages, I split follow up time at 1 year and modelled hazard ratios during 
the first year following diagnosis and after 1 year stratified by comorbidity.   
I then split the population of cases into those with alcoholic cirrhosis and those 
with non-alcohol related cirrhosis (as described in section 3.2.2.2) and 
examined the mortality rates and adjusted hazard ratios compared with their 
matched controls for these two aetiologic groups.  
To minimise the potential for survival bias I ran the principal analysis again 
comparing mortality between compensated and decompensated cases and 
controls using all incident cases (as described in section 3.2.2.1) and their 
matched controls.  To try to account for potential attrition bias I also ran the 
principal analysis using the earliest of date of death, deregistration or last 
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recorded appointment in the GPRD as the exit-point for the analysis.  Finally, 
the principal analysis was repeated using death and liver transplant as the 
end-point for the Cox model.   
Proportional hazards assumptions were checked using Schoenfeld residuals 
and log-log plots.   
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4.3 Results 
A total of 4537 subjects with cirrhosis and 44,403 appropriately matched 
controls contributing a total of 226,412 person years of follow-up were 
included within this analysis, with a median follow-up time of 3.5 years per 
patient.  
 
4.3.1 Population characteristics 
As would be expected due to the method of control selection the cirrhosis 
cohort and the control cohort had very similar age distributions and sex profile 
(see Table 4-3).  Most of the subjects in both the cirrhosis and control cohorts 
had no recorded comorbidity prior to diagnosis.  Subjects with cirrhosis were 
slightly more likely to have some recorded comorbidity than controls.  Notably 
there was a high proportion of missing data in both cohorts for BMI, smoking 
status and alcohol consumption (as measured by unit intake).  Subjects with 
cirrhosis were much more likely to have a recorded alcohol status (as per 
codes within the medical file) than controls prior to the date of diagnosis (or 
pseudo-diagnosis).   
There were few liver transplants recorded with only 2.3% of all cirrhosis 
subjects having a liver transplant subsequent to diagnosis with cirrhosis.  Just 
over four-fifths of the cirrhosis cohort entered the analysis in a compensated 
state of disease.  Just over half of the cirrhosis subjects (50.9%) had alcohol 
as their presumed aetiology (when taking into account recording of alcohol 
problems at any point in the record).   
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Table 4-3 Demographic, lifestyle and clinical characteristics of cirrhosis cohort 
and general population cohort 
 Cirrhosis Cohort 
(N=4537) 
Control Cohort 
(N=44 403) 
Demographics / lifestyle factors 
  
Age at diagnosis (years) 
Median age [IQR]  
(range) 
25-44 
45-64 
65+ 
 
56.5 [46.9, 67.0] 
(25.2, 99.6) 
943 (20.8) 
2256 (49.7) 
1338 (29.5) 
56.2 [46.8, 66.8] 
(25.2, 102.9) 
9403 (21.2) 
22 219 (50.0) 
12 781 (28.8) 
Sex 
Male 
Female 
 
2612 (57.6) 
1925 (42.4) 
25 599 (57.7) 
18 804 (42.3) 
BMI 
Median BMI [IQR] 
No recorded BMI 
 
25.5 [22.5, 28.7] 
3624 (80.0) 
25.3 [23, 28.2] 
33 294 (75.0) 
Smoking status (prior to diagnosis) 
No smoker 
Ex-smoker 
Smoker 
Missing 
 
10 (0.2) 
15 (0.3) 
387 (8.5) 
4125 (90.9) 
92 (0.2) 
113 (0.3) 
2461 (5.5) 
41 737 (94.0) 
Alcohol consumption (units) 
Median consumption per week 
[IQR] (range) 
Mean unit intake (sd) 
No recorded unit intake 
 
Alcohol status (prior to diagnosis) 
Non-drinker 
Drinker 
Alcoholic 
Not recorded 
 
7 [0, 29] 
(0, 400) 
20.8 (33.7) 
2577 (56.8) 
 
 
2 (<0.1) 
170 (3.8) 
1377 (30.4) 
2988 (65.9) 
2 [0, 10] 
(0, 700) 
7.2 (14.5) 
22 792 (51.3) 
 
 
10 (<0.1) 
1007 (2.3) 
740 (1.7) 
42 646 (96.0) 
Comorbidity score 
0 
1 
2+ 
 
3525 (77.7) 
534 (11.8) 
478 (10.5) 
37 085 (83.5) 
3704 (8.3) 
3614 (8.1) 
Clinical characteristics 
  
Liver transplants 
 
105 (2.3) 2 (<0.1) 
Disease state at entry 
Compensated  
Decompensated 
 
3660 (80.6) 
877 (19.4) 
 
- 
Presumed Aetiology 
Alcoholic 
Viral hepatitis 
Metabolic liver disease 
Autoimmune liver disease 
No specified aetiology  
 
2307 (50.9) 
238 (5.3) 
48 (1.1) 
354 (7.8) 
1730 (38.1) 
 
- 
DVDFDVHFRXOGKDYHPRUHWKDQRQHSUHVXPHGDHWLRORJ\QXPEHUVLQWKHWDEOHGRQRW
necessarily add up to 4537.  
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4.3.2 Cox regression modelling 
4.3.2.1 Overall survival 
When building the Cox regression model only the a priori confounders of age 
and sex remained in the model.   
Overall, patients with cirrhosis had a hazard ratio for death (adjusted for age 
and sex) of 5.8 (95%CI[5.5, 6.1]) compared with the general population cohort 
(see Table 4-4).  A still higher hazard ratio for death was seen in patients with 
decompensated disease compared with the general population with an 
adjusted hazard ratio of 9.6 (95%CI[8.7, 10.7]) but a significantly higher 
hazard of death was still seen for patients with compensated disease with an 
adjusted hazard ratio of 5.2 (95%CI[4.9, 5.5] (see Figure 4-2). 
Crude survival at 1 and 5 years was correspondingly lower for patients with 
decompensated disease (76.4% (95%CI[73.3%, 79.2%]) and 45.2% 
(95%CI[40.9%, 49.3%]) respectively) than for patients with compensated 
disease (85.2% (95%CI[84.0%, 86.3%]) and 63.5% (61.5%(95%CI[61.5%, 
65.3%]) respectively).  For all patients with cirrhosis survival was 83.5% 
(95%CI [82.4, 84.6]) at 1 year and 60.1% (95%CI [58.3, 61.8]) at 5 years 
compared with 98.0% (95%CI [97.9, 98.1]) and 90.7% (95%CI [90.3, 91.0]) 
respectively for the control population.
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Table 4-4 Cox proportional hazards model for overall mortality 
 Events Person-
years 
Mortality rate 
(per 1000 person years) 
Hazard ratio 
[95%CI] 
Adjusted Hazard 
ratio* [95%CI] 
Controls 4033 209 554 19.2 [18.7, 19.8] - - 
All cirrhosis 1769 16 858 104.9 [100.1, 109.9] 5.4 [5.1, 5.7] 5.8 [5.5, 6.1] 
Compensated 
cirrhosis 1360 14 560 93.4 [88.6, 98.5] 4.8 [4.5, 5.1] 5.2 [4.9, 5.5] 
Decompensated 
cirrhosis 409 2298 178.0 [161.5, 196.1] 8.8 [8.0, 9.8] 9.6 [8.7, 10.7] 
*adjusted for age and sex 
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Figure 4-2 Survival estimates for controls, subjects with compensated cirrhosis 
and subjects with decompensated cirrhosis. 
  
0.
00
0.
25
0.
50
0.
75
1.
00
877 384 208 108 60Decompensated
3660 2037 1294 827 521Compensated
43355 29489 19951 12905 8139Controls
Number at risk
0 2 4 6 8
Follow-up time (years)
Controls Compensated
Decompensated
Kaplan-Meier survival estimates
121 
 
4.3.2.2 Testing the proportional hazards 
assumptions 
Examination of the log-log plot and the plot of Schoenfeld residuals against 
time showed that there was a significant decrease in the hazard of death in 
the first year or so of follow-up (see Figure 4-3, Figure 4-4).  As I had already 
planned to split follow-up time at one year I present all the remaining results 
as mortality during the first year and mortality subsequent to the first year.  
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Figure 4-3 Log-log plot for overall mortality analysis 
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Figure 4-4 Schoenfeld residuals against time for overall mortality 
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4.3.2.3 Survival by follow-up and comorbidity score 
Mortality for subjects with cirrhosis was higher during the first year following 
diagnosis than subsequently but also remained substantial beyond one year 
(see Table 4-5).  Stratification by comorbidity showed that although the 
absolute mortality rates were lowest in those with no recorded comorbidity the 
adjusted hazard ratios for death were highest in this group.  This high relative 
risk of death was most noticeable in the first year following diagnosis with 
hazard ratios of 8.5 for the compensated cohort compared with the general 
population and 14.2 for the decompensated cohort, approximately double 
those seen in the years following the first year after diagnosis.   
Comorbidity appeared to have more of an influence on the mortality of the 
subjects with compensated disease than those with decompensated disease.   
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Table 4-5 Overall mortality analysis split by follow-up time and stratified by Charlson index 
 Mortality rate (per 1000) Adjusted hazard ratio * 
 Control 
cohort 
Compensated 
cohort 
Decompensated 
cohort 
Compensated 
cohort 
Decompensated 
cohort 
During first year 
Overall 20.1 167.1 288.1 8.5 [7.6, 9.5] 14.2 [12.1, 16.6] 
Charlson score 
     
0 16.5 159.1 266.3 9.9 [8.7, 11.2] 16.6 [13.7, 20.3] 
1 28.6 174.8 249.0 6.8 [4.9, 9.4] 9.3 [6.0, 14.3] 
2+ 49.5 233.9 424.5 4.8 [3.5, 6.4] 8.9 [6.4, 12.5] 
      
Following first year 
Overall 19.0 73.8 133.0 4.3 [3.9, 4.6] 7.9 [6.9, 9.1] 
Charlson score 
     
0 16.4 70.6 118.9 4.7 [4.3, 5.1] 8.3 [7.0, 9.8] 
1 32.8 90.3 126.0 3.2 [2.6, 4.1] 5.2 [3.6, 7.4] 
2+ 43.0 94.6 246.1 2.4 [1.8, 3.1] 7.2 [5.2, 10.0] 
*adjusted for age and sex 
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4.3.2.4 Survival by presumed aetiology 
As might be expected following the previous analysis mortality during the first 
year for both alcoholic cirrhosis and non-alcohol related cirrhosis was higher 
than in subsequent years (see Table 4-6).   
The absolute mortality rate of subjects with non-alcohol related cirrhosis was 
higher than that of subjects with alcoholic cirrhosis in the first year following 
diagnosis.  Subsequent to the first year mortality was similar in both groups.  
However, the adjusted hazard ratios for mortality were much higher in the 
subjects with alcoholic cirrhosis compared to those with non-alcohol-related 
cirrhosis.  This is a result of the absolute mortality rates seen in the control 
population.  The matched controls of subjects with alcoholic cirrhosis had a 
considerably lower mortality than the matched controls of subjects with non-
alcohol related cirrhosis.  Examining the age and sex distribution of the 
patients with cirrhosis showed a significantly higher age at diagnosis for 
subjects with non-alcohol related cirrhosis compared to those with alcoholic 
cirrhosis (see Table 4-7).   
 
The age- and sex-adjusted hazards ratios for subjects with alcoholic cirrhosis 
following the first year after diagnosis were similar to those of non-alcohol 
related cirrhosis during the first year following diagnosis.   
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Table 4-6 Mortality split by follow-up time and stratified by alcoholic aetiology 
 
 Events Person-
years 
Mortality rate  
(per 1000 person years) 
Adjusted hazard 
ratio* [95%CI] 
During first year 
    
Alcoholic cirrhosis 
    
Controls 271 20 344 13.3 [11.8, 15.0] - 
Compensated cirrhosis 234 1519 154.1 [135.5, 175.1] 11.8 [9.9, 14.1] 
Decompensated 
cirrhosis 
94 393 239.0 [195.2, 292.5] 17.6 [13.9, 22.2] 
Non-Alcohol-related 
cirrhosis 
    
Controls 525 19 257 27.3 [25.0, 29.7] - 
Compensated cirrhosis 278 1544 180.0 [160.0, 202.4] 6.9 [5.9, 7.9] 
Decompensated 
cirrhosis 
 
98 273 358.9 [294.4, 437.4] 12.3 [9.9, 15.3] 
Following first year 
    
Alcoholic cirrhosis 
    
Controls 1181 90 469 13.1 [12.3, 13.8] - 
Compensated cirrhosis 465 5825 79.8 [72.9, 87.4] 6.4 [5.7, 7.1] 
Decompensated 
cirrhosis 
128 960 133.3 [112.1, 158.5] 12.4 [10.3, 14.9] 
Non-Alcohol-related 
cirrhosis 
    
Controls 2056 79 485 25.9 [24.8, 27.0] - 
Compensated cirrhosis 383 5671 67.5 [61.1, 74.6] 3.1 [2.7, 3.4] 
Decompensated 
cirrhosis 
89 671 132.6 [107.7, 163.2] 5.2 [4.2, 6.4] 
*adjusted for age and sex 
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Table 4-7 Sex and age distribution of subjects with alcoholic and non-alcohol-
related cirrhosis 
 All cirrhosis 
 
N=4537   
n(%) 
Alcoholic cirrhosis 
 
N=2307   
n(%) 
Non-alcohol-related 
cirrhosis 
N=2230   
n(%) 
Sex 
Male 
Female 
 
 
2612 (57.6) 
1925 (42.4) 
 
1528 (66.2) 
779 (33.8) 
 
1084 (48.6) 
1146 (51.4) 
Age (in years) 
Median [IQR] 
25-44 
45-64 
65+ 
 
 
56.5 [46.9, 67.0] 
943 (20.8) 
2256 (49.7) 
1338 (29.5) 
 
51.7 [44.1, 60.5] 
643 (27.9) 
1311 (56.8) 
353 (15.3) 
 
62.6 [52.0, 71.9] 
300 (13.5) 
945 (42.4) 
985 (44.2) 
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4.3.2.5 Cox proportional hazards model using 
different cohort definitions 
Running the analyses using an incident cohort, censoring subjects at the date 
of their last appointment within the GPRD, or using death or liver transplant as 
the end-point led to no substantial differences in the adjusted hazard ratios for 
mortality either during the first year following diagnosis or subsequently (see 
Table 4-8).     
 
Analysis using an incident cohort restricted the number of cases to 2787 and 
26,176 appropriately matched controls.  I showed a slightly higher hazard of 
death for subjects with compensated cirrhosis both during the first year 
following diagnosis and subsequently compared to the initial analysis including 
both prevalent and incident cases.  Patients with decompensated disease 
showed a slightly lower hazard of death in the first year following diagnosis but 
a greater hazard of death subsequently compared to the initial analysis.   
 
When censoring subjects at either death, de-registration or date of last 
appointment within the GPRD (as opposed to the end of the UTS period) there 
was a slightly lower hazard of death for both subjects with compensated and 
decompensated disease at both time periods studied compared to the initial 
analysis.   
 
For the analysis using death and liver transplant as the outcome there was a 
slight increase in the adjusted hazard ratios for death in all subjects at both 
time periods studied compared with the initial analysis.   
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None of the hazard ratios observed in any of these three variations on 
analysis led to any significant differences to those calculated from the initial 
analysis.
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Table 4-8 Cox proportional hazards model using different cohort definitions 
 Mortality rate (per 1000) Adjusted hazard ratio * 
 Control cohort Compensated 
cohort 
Decompensated 
cohort 
Compensated 
cohort 
Decompensated 
cohort 
During first year 
     
Principal analysis 20.1 167.1 288.1 8.5 [7.6, 9.5] 14.2 [12.1, 16.6] 
Incident cohort 24.1 212.3 309.7 9.0 [7.9, 10.2] 13.1 [11.0, 15.8] 
Censoring at last GPRD appointment 22.5 171.1 293.8 7.9 [7.1, 8.9] 13.2 [11.3, 15.5] 
Death and liver transplant end point 20.1 172.8 300.1 8.8 [7.8, 9.8] 14.7 [12.6, 17.2] 
      
Following first year 
     
Principal analysis 19.0 73.8 133.0 4.3 [3.9, 4.6] 7.9 [6.9, 9.1] 
Incident cohort 22.7 96.1 158.1 4.6 [1.4, 5.1] 8.8 [7.4, 10.5] 
Censoring at last GPRD appointment 21.3 75.8 137.2 4.0 [3.7, 4.3] 7.4 [6.5, 8.5] 
Death and liver transplant end point 19.1 80.6 142.0 4.6 [4.3, 5.0] 8.3 [7.2, 9.5] 
*adjusted for age and sex
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4.4 Discussion 
4.4.1 Key findings 
Patients with a diagnosis of cirrhosis are at an increased risk of death than 
their age- and sex-matched general population controls with an adjusted 
hazard ratio for death of 5.8 (95%CI[5.5, 6.1]).  Those with decompensated 
disease have an even worse prognosis with 5- year survival only 45.2% 
compared with 63.5% for those with compensated disease.  The increased 
risk of death was particularly high during the first year following diagnosis but 
remained high subsequently, even following adjustment for some measure of 
comorbidity.  The hazard ratio for death was highest in those with no reported 
comorbidity although absolute mortality rates were highest in those with 
reported comorbidities.  Patients with a presumed aetiology of alcoholic 
cirrhosis had a worse survival at all stages than those with non-alcohol related 
cirrhosis.   
 
4.4.2 Strengths and limitations 
This study has been performed using a large, representative, population-
based cohort of patients with cirrhosis alongside an appropriately matched 
general population based control cohort.  These cohorts were identified 
relatively recently (1987 ± 2002) and the results observed reflect the natural 
history of cirrhosis during this time period.   
The size of the dataset used for this analysis has allowed the estimation of 
mortality rates and adjusted hazard ratios for death stratifying by severity of 
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Perhaps the most significant potential limitation of this analysis is related to 
the coding of the diagnosis of cirrhosis.  As discussed in section 3.4.2 the 
inclusion of all patients with any mention of cirrhosis, oesophageal varices or 
portal hypertension within the medical records may have led to the inclusion of 
some patients who did not have cirrhosis.  However, the same counter-
argument is applicable in this situation that it is more likely that there are 
cases with cirrhosis that are missing from the data source where the diagnosis 
of cirrhosis was unconfirmed and / or not fed back from secondary care to 
primary care records.  This will potentially have led to an underestimate of the 
hazard ratio for death as cases with undiagnosed cirrhosis may be included 
within the control population.   
In addition to the potential for misclassification of the diagnosis of cirrhosis it is 
possible that there exists further misclassification in the accuracy of the 
severity of cirrhosis as compensated or decompensated.  Whilst the results of 
the validation described in section 3.3.4 lend credence to the diagnosis of 
cirrhosis itself, with evidence that most diagnoses occurred in secondary care, 
the prohibitive cost of validation within the GPRD system did not allow for the 
validation of the additional signs and symptoms of ascites and gastrointestinal 
bleeding used to define decompensated disease.  Indeed, these clinical 
symptoms may only be recorded if they are of obvious clinical relevance to the 
GP.  Ascites and gastrointestinal bleeding are however serious complications 
of cirrhosis and as such one might expect that these events would be 
considered important and therefore recorded within the primary care record, 
either following hospital correspondence or from an individual patient 
consultation.  It is possible that the recording of ascites, if it occurred in the 
absence of further information from hospital, would only be large-volume, 
clinically significant ascites visible at the general practice appointment rather 
than that only identified by ultrasound.  Assuming that the misclassification is 
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most likely to act through misclassifying patients with decompensated cirrhosis 
as having compensated disease this will have led to an overestimate of the 
hazard ratios for death for people with compensated disease and a 
corresponding underestimate of the hazard ratios for death for people with 
decompensated disease.   
 
The size of the database used has allowed the description of the mortality 
experience of patients with both alcoholic and non-alcohol related cirrhosis 
alongside their matched controls.  The small numbers of cases with other 
presumed aetiologies meant that it was not possible to model the hazard of 
death for other causes of cirrhosis with any precision.   
 
It could be argued that the inclusion of both incident and prevalent cases in 
the cirrhosis cohort might lead to the introduction of survival bias as those 
cases who are prevalent have, by definition, already survived a particular 
length of time to still be included in the analysis.  As such, I ran the principal 
analysis using only those subjects who were considered incident as defined in 
section 3.2.2.1.  The estimates of the mortality rates and therefore the hazard 
ratios for death were slightly higher than those seen when including all 
incident and prevalent cases, apart from subjects with decompensated 
disease in the first year following diagnosis who showed a slightly lower 
hazard ratio for death.  However, all estimates remained within the 95% 
confidence interval of the principal analysis.  The results I have reported 
including all incident and prevalent cases probably more accurately reflects 
the real world of clinical practice within the general population and allows for 
the communication of results that are directly valid to the patients an individual 
GP may see in their practice.   
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Though the data available have allowed for an appropriate individually-
matched adjustment for some confounders (age and sex) it was not possible 
to examine the potential associations or modifying effects of other variables 
either because they are not available in the GPRD at all e.g. any measure of 
socio-economic status which is known to be associated with mortality, or 
because there was such a high proportion of missing data.  Recent studies 
have suggested an interaction between raised BMI and alcohol consumption 
leading to an increased risk of death from liver disease.91 Additionally it was 
not possible within this dataset to examine the cause of death of these 
patients as this information was not systematically available.   
Of note is the discrepancy in the proportion of patients who were recorded to 
be alcoholics before the diagnosis of cirrhosis (30.4%) and the proportion of 
patients assigned a presumed aetiology of alcoholism (50.9%).  Aetiologies 
were ascribed using information contained in the whole medical record 
(including after the diagnosis of cirrhosis).  This would therefore suggest that 
roughly two-fifths of those patients with alcoholic cirrhosis were not known to 
be (or at least not recorded as) alcoholics before the onset of their disease.  
However, when taken in context to the 96.0% of controls who did not have 
their alcohol status recorded before the date of pseudo diagnosis, it is perhaps 
encouraging that so many patients with cirrhosis had already been identified 
as alcoholics.   
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4.4.3 Comparison with previously published work 
In the UK the most recent published study on cirrhosis mortality observed the 
mortality of patients with all chronic liver disease who had been admitted to 
hospital in a small geographically distinct region of the UK between 1968 and 
1999.41  This study reported an SMR for one year follow-up of 16.3.  This 
figure is higher than the 1-year adjusted hazard ratios that I have reported for 
either patients with compensated or decompensated disease.   
Other large cohort studies from European centres have similarly shown worse 
survival than I have reported in this chapter.  In Denmark between 1995 and 
2006 a hospital cohort of 14,976 patients with cirrhosis described a 1-year 
survival of only 65.5% and 5-year survival of 37.5%, notably lower than that I 
have reported.92  This study was not able to categorise patients into 
compensated or decompensated disease and additionally did not report the 
hazard ratios for mortality compared with their matched control cohort.  
Previously the same authors had reported SMRs for patients hospitalized with 
cirrhosis compared with the general population of 32.3 for the first year 
following diagnosis and 5.7 thereafter.46   
These poorer survival estimates are perhaps unsurprising as these previous 
studies used cohorts of patients admitted to hospital.  Whilst the diagnosis of 
cirrhosis in my study population is likely to have come from a hospital 
diagnosis it does not necessarily follow that these patients were hospitalized 
for this diagnosis to occur.  As my study is a population-based cohort the 
results seen are also unlikely to have been affected by the variation in 
referrals and follow-ups seen in cohorts selected from secondary care.  As 
such it is probable that my results can be more widely generalised to patients 
diagnosed with cirrhosis including those ambulatory patients who have not 
been admitted to hospital.   
137 
 
Perhaps the most commonly referenced figures in the literature looking at the 
mortality experience of patients with cirrhosis based on the severity of disease 
are those based on 1155 consecutive patients admitted to a single hospital in 
Sicily during the 1970s and 1980s which reported 6-year survival of 54% and 
21% in patients with compensated and decompensated cirrhosis 
respectively.44   It is possible that the survival figures I report are better than 
those reported in this smaller study, particularly for those patients with 
decompensated disease, because there have been significant improvements 
in the management and outcomes of the complications of cirrhosis in the 
intervening decades.  This has been shown for oesophageal varices in studies 
in both the USA and more recently Sweden.58 60  Additionally, the proportion of 
cases ascribed as alcoholic cirrhosis is lower in the Sicilian population than in 
my study population with a correspondingly higher proportion of patients with 
hepatitis B virus.  It is therefore possible that the survival figures reflect a 
different spectrum of aetiology of cirrhosis in the two populations.   
 
Other estimates of mortality in patients with cirrhosis in the UK come from 
much older studies.  Saunders et al report the 5-year survival of patients with 
alcoholic cirrhosis, 36%, and non-alcohol related cirrhosis, 14%.37  An earlier 
study, also from Birmingham, covering patients with cirrhosis in a single 
hospital between 1959-64 reports similarly low 5-year survival figures of 
14.4% after first admission to hospital, again with patients with alcoholic 
cirrhosis having a better prognosis (5-year survival of 20% compared with 
5.1% for patients with cryptogenic cirrhosis).43 
The survival figures I have reported are better than these two previous studies 
but conversely show that survival with non-alcohol related cirrhosis confers a 
lower risk of mortality than that seen with an alcoholic aetiology.   
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4.4.4 Conclusions 
In this study I have shown that the survival of patients with a diagnosis of 
cirrhosis, whilst better than previously reported studies,37 41 43 44 45 46 47 48 57 93 
is still poor with 1-year survival of 83% and 5-year survival of 60%.  This study 
represents the most contemporary estimate of the mortality experience of 
patients with cirrhosis and also allows comparison with the general population.  
Even in those patients with no comorbidity the adjusted hazard ratio for death 
is significantly higher than that of the general population.   
 
I have been able to describe the mortality experience of patients with 
compensated and decompensated disease, showing a substantial increase in 
mortality for those with decompensated disease at diagnosis.   
Defining decompensated cirrhosis as the presence of ascites or GI bleeding 
appears to accurately reflect an increased probability of death compared to 
compensated cirrhosis. Although there is the possibility of misclassification of 
patients with decompensated disease as compensated as differences in 
follow-up at individual sites may exist, these general population based data 
SURYLGHDQµDYHUDJH¶HVWLmate of the mortality experienced by patients with 
cirrhosis.  These figures will be of particular importance for service providers 
and for individual clinicians and general practitioners to communicate to their 
patients. 
 
For the purposes of service provision and planning it is important to note that 
even patients with compensated disease had an increased hazard of death 
compared to the general population.  This is in contrast to the assumptions 
made for the purposes of the cost-effectiveness analysis carried out in a 
recent HTA systematic review where it was claimed that existing data suggest 
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that there is no excess mortality in those patients with compensated disease 
compared with the general population.49 
 
An aetiology of alcoholic cirrhosis remains a particularly bad prognostic 
indicator with mortality in patients with alcoholic cirrhosis nearly double that of 
patients with non-alcohol related cirrhosis.  With roughly 60% of all patients 
with alcoholic cirrhosis being known to their GPs as alcoholics before the date 
of diagnosis of cirrhosis this may provide an opportunity for intervention(s) 
leading to behaviour and risk modification.   
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5 Progression of disease in people with cirrhosis  
5.1 Introduction 
This study aims to describe the progression of people with a diagnosis of 
cirrhosis based on clinical symptoms.   
 
5.2 Methods 
5.2.1 Dataset used 
Data on all cases with cirrhosis (as described in section 2.4.3) were used in 
this analysis.  Both subjects with incident and prevalent cirrhosis (as described 
in section 3.2.2.1), were included in this analysis.  Subjects with no follow-up 
time were subsequently excluded from this analysis.   
 
5.2.2 Additional definitions 
5.2.2.1 Stages of disease 
Within the population of cases with cirrhosis it was necessary for this study to 
define different stages or status of disease.  I utilised the stages of cirrhosis as 
agreed at the Baveno IV consensus conference.94  Each of these four stages 
is defined by the presence or absence of certain clinical symptoms: 
Stage 1 ± cirrhosis, no oesophageal varices, no ascites 
Stage 2 ± cirrhosis with oesophageal varices, no ascites, no bleeding 
Stage 3 ± cirrhosis with ascites with or without oesophageal varices 
Stage 4 ± cirrhosis with GI bleeding with or without ascites 
Code lists were therefore constructed to represent ascites (Table 5-1) and any 
GI bleeding (see Table 5-2).  The original code list for oesophageal varices 
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(see Table 2-2) was split into 2 separate lists ± one representing non-bleeding 
oesophageal varices to represent stage 2 (see Table 5-3) and the second for 
bleeding oesophageal varices (see Table 5-4).  These codes for bleeding 
oesophageal varices are also found in the code list for any GI bleeding.     
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Table 5-1 Medical codes for ascites (stage 3) 
Description medcode 
[D]ASCITES R095.00 
[D]ASCITES NOS R095z00 
[D]FLUID IN PERITONEAL CAVITY R095000 
ASCITES (ABDOMINAL) 7853 
CHYLOUS ASCITES 457 CA 
CHYLOUS ASCITES G86y100 
DRAINAGE OF ASCITES NEC 7H2B200 
HEPATIC ASCITES 5719AH 
INSERTION OF DENVER PERITONEOVENOUS SHUNT 7H2B111 
INSERTION OF LE VEEN PERITONEOVENOUS SHUNT 7H2B112 
INSERTION OF PERITONEAL TO VENOUS SHUNT FOR 
ASCITES 7H2B113 
O/E - ASCITES 25O..00 
O/E - ASCITES - DIPPING SHOWN 25O2.00 
O/E - ASCITES NOS 25OZ.00 
O/E -ASCITES-SHIFTING DULLNESS 25O4.00 
O/E-ASCITES-FLUID THRILL SHOWN 25O3.00 
PARACENTESIS ABDOMINIS FOR ASCITES 7H2B000 
PERITONEAL TO VENOUS DRAINAGE FOR ASCITES 7H2B100 
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Table 5-2 Medical codes for GI bleed (stage 4) 
Description medcode 
ACUTE GASTRIC ULCER WITH HAEMORRHAGE J110100 
ACUTE GASTRIC ULCER WITH HAEMORRHAGE AND 
PERFORATION J110300 
BLEEDING ACUTE GASTRIC ULCER J110111 
BLEEDING CHRONIC DUODENAL ULCER J121111 
BLEEDING CHRONIC GASTRIC ULCER J111111 
CHRONIC DUODENAL ULCER WITH HAEMORRHAGE J121100 
CHRONIC DUODENAL ULCER WITH HAEMORRHAGE AND 
PERFORATION J121300 
CHRONIC GASTRIC ULCER WITH HAEMORRHAGE J111100 
CHRONIC GASTRIC ULCER WITH HAEMORRHAGE AND 
PERFORATION J111300 
GASTROINTESTINAL HAEMORRHAGE UNSPECIFIED J68z.00 
GASTROTOMY AND LIGATION OF BLEEDING POINT OF 
STOMACH 7619100 
GI BLEEDING 569 M 
GIB - GASTROINTESTINAL BLEEDING J68z.11 
HAEMATEMESIS J680.00 
HAEMORRHAGE GASTROINTESTINAL 569 MI 
INTESTINAL HAEMORRHAGE 569 MH 
MELAENA J681.00 
OESOPHAGEAL VARICES WITH BLEEDING G850.00 
OESOPHAGEAL VARICES WITH BLEEDING IN DISEASES EC G852000 
OESOPHAGUS BLEEDING 5309H 
OESOPHAGUS HAEMORRHAGE 5309HA 
TANNER DEVASCULARISATION FOR BLEEDING VARICES 7609y11 
UPPER GASTROINTESTINAL HAEMORRHAGE 569 ME 
VOMITING OF BLOOD J680.11 
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Table 5-3 Code list for non-bleeding oesophageal varices (stage 2) 
Description medcode 
[X]OESOPHAGEAL VARICES IN DISEASES CLASSIFIED 
ELSEWHERE Gyu9400 
FIBREOPTIC ENDOSCOPIC BANDING OF OESOPHAGEAL 
VARICES 760C500 
FIBREOPTIC ENDOSCOPIC INJECTION SCLEROTHERAPY 
OESOPH VARICES 760C300 
FUND HOLDING OP OESOPHAGEAL VARICES K298 FH 
GASTRIC VARICES G857.00 
INJECTION OESOPHAGEAL VARICES K2982 
LIGATION OESOPHAGEAL VARICES K2981 
LOCAL LIGATION OF OESOPHAGEAL VARICES 7609300 
OESOPHAGEAL VARICES G85..11 
OESOPHAGEAL VARICES IN DISEASES EC G852.00 
OESOPHAGEAL VARICES IN DISEASES EC NOS G852z00 
OESOPHAGEAL VARICES NOS G858.00 
OESOPHAGEAL VARICES WITHOUT BLEEDING G851.00 
OESOPHAGEAL VARICES WITHOUT BLEEDING IN 
DISEASES EC G852100 
OPEN INJECTION SCLEROTHERAPY TO OESOPHAGEAL 
VARICES 7609400 
OPEN OPERATION ON OESOPHAGEAL VARICES NOS 7609z00 
OPEN OPERATIONS ON OESOPHAGEAL VARICES 7609 
OTHER SPECIFIED OPEN OPERATION ON 
OESOPHAGEAL VARICES 7609y00 
RIGID OESOPHAGOSCOPIC BANDING OF 
OESOPHAGEAL VARICES 760F400 
RIGID OESOPHAGOSCOPIC INJECTION 
SCLEROTHERAPY OESOPH VARICES 760F300 
VARIX OESOPHAGUS 4560 
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Table 5-4 Code list for bleeding oesophageal varices 
Description medcode 
OESOPHAGEAL VARICES WITH BLEEDING G850.00 
OESOPHAGEAL VARICES WITH BLEEDING IN DISEASES 
EC G852000 
TANNER DEVASCULARISATION FOR BLEEDING 
VARICES 7609y11 
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I assigned a date of entry to each stage as the earliest date of any recorded 
code contained within each stage including data collected in the pre-UTS 
period.  Cases were then assigned a stage of entry into the study as the 
earliest of these 4 stages.  Due to the nature of the original extraction of cases 
with cirrhosis (including therapeutic or diagnostic codes for oesophageal 
varices and codes for portal hypertension) it was possible for a case to enter 
this study at a stage later than stage 1.  It was also possible for a case to have 
a code for an early stage subsequent to a code for a later stage.  For example, 
if a case had a code for stage 1 subsequent to a code for stage 3 the case 
would be assigned an entry stage as stage 3 and would not be included in 
stage 1 or 2 at any point in the analysis. 
Compensated cirrhosis was then defined as patients when in either of stages 
1 and 2 with decompensated cirrhosis as stages 3 and 4.   
 
To minimise the potential for misclassification of patients with decompensated 
cirrhosis as patients with compensated disease I additionally looked for 
recording of one or more prescriptions for spironolactone as evidence for 
decompensation.   
 
5.2.3 Statistical analysis 
I examined the probabilities of patients with cirrhosis progressing from an 
individual stage to a subsequent stage or death within one year and state 
progressions across the whole time period of their records.  95% CIs were 
calculated using the binomial distribution.  I calculated the proportion of GI 
bleed that was coded as oesophageal bleeding.   
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As mortality was seen to vary substantially by presumed aetiology (see 
section 4.3.2.4) I also then stratified the cohort into those with alcoholic 
cirrhosis and those with non-alcohol related cirrhosis.   
Using Cox proportional hazards I modelled the rate of decompensation in the 
group of patients with compensated disease.  Subjects entered the analysis 
period at the date of earliest recorded code for stage 1 or 2 and exited at the 
earliest of either date of earliest recorded code for stage 3 or 4, date of death, 
date of deregistration with their general practice or 30 April 2002 which was 
the last date of available data in this dataset.  Again, I examined progression 
for subjects with alcoholic cirrhosis and those with non-alcohol related 
cirrhosis.  Follow-up time was split at 1 year and I modelled the rate of 
decompensation during the first year after diagnosis and subsequent to that 
first year again stratifying by presumed aetiology.   
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5.3 Results 
Of the 4,537 patients identified with cirrhosis, 66.0% entered the study cohort 
at stage 1, 14.6% at stage 2, 10.5% at stage 3 and 8.8% at stage 4.  
Of the 877 patients considered decompensated at entry 71% had evidence of 
spironolactone use at any point in their record compared with 43% of subjects 
considered compensated (at entry).  Of the 3660 patients considered 
compensated at entry, 505 (13.8%) had evidence of a prescription of 
spironolactone occurring before a recording of decompensation within their 
GPRD record.  Of the patients with a record of GI bleed at any point in their 
record, for only 7.4% of these patients was this specified as oesophageal 
bleeding.   
 
Outcome probabilities in the first year are shown in Figure 5-1. Patients in 
stage 1 and 2, i.e. compensated cirrhosis, had a one-year probability of 
proceeding directly to death of just over 10%. The mortality in patients in stage 
3 and 4, i.e. decompensated cirrhosis, was much higher with 25.9% and 
18.2% respectively of patients proceeding directly to death.   
State progressions across the whole study period are shown in Figure 5-2.  Of 
note is the high proportion of people in the early stages of disease i.e. patients 
with compensated cirrhosis, who progressed directly to death without the 
recording of other clinical symptoms of decompensation.   
 
The probability of progressing both during the first year and state progressions 
subsequently for those with alcoholic cirrhosis and non alcohol-related 
cirrhosis are shown in Table 5-5 and Table 5-6 respectively.  Reading across 
the table shows the stage at which patients began their follow-up.  The rows in 
the column represent the stage to which the patients directly progressed.  For 
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example looking at the first column we can see that alcoholics who began 
follow-up in stage 1 had a 74.4% chance of remaining in stage 1 during the 
first year, with 4.0% progressing directly to stage 2 (oesophageal varices), and 
so on.  In the first year following diagnosis patients with alcoholic cirrhosis had 
a slightly higher probability of progressing to another stage of cirrhosis than 
those with non-alcohol related cirrhosis but a lower probability of progressing 
directly to death. Across the whole study period patients with a presumed 
aetiology of alcoholic cirrhosis were again more likely to progress to another 
later stage of cirrhosis than those with non-alcohol related cirrhosis.  The 
differences in progression directly to death were not so marked across the 
whole time period, rather less patients with alcoholic cirrhosis remained in 
their entry stage with the exception of patients in stage 3.  
 
Overall, the rate of decompensation for those patients with compensated 
disease was 5.5% per year (95%CI[5.1%, 5.9%]).  As might be expected 
(following the results in Chapter 4 and those reported above) this figure varied 
considerably both by length of follow-up and by presumed aetiology.   
During the first year after diagnosis the rate of decompensation for those 
patients with a presumed aetiology of alcoholic cirrhosis was 16% (95%CI 
[14.1%, 18.3%]) compared with only 9.7% (95%CI [8.2%, 11.4%] for those 
with non-alcohol related cirrhosis.   
Following the first year the rate of decompensation did not vary much by 
presumed aetiology with a rate of  3.8% per year (95%CI [3.3%, 4.4%)] for 
those with alcoholic cirrhosis compared with a rate of decompensation of 3.0% 
per year (95%CI [2.6%, 3.6%]) for those with non-alcohol related cirrhosis.   
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Death
Stage 1
No ascites
No varices
Stage 2
Varices
No ascites
Stage 3
Ascites
+/- varices
Stage 4
GI bleeding
+/- ascites
3.8%
5.8%
7.1%
5.5%
18.2%
25.9%
10.5%
11.8%
2.2%
7.1%
 
Figure 5-1 Probabilities for progression within one year, all patients
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Death
Stage 1
No ascites
No varices
Stage 2
Varices
No ascites
Stage 3
Ascites
+/- varices
Stage 4
GI bleeding
+/- ascites
7.6%
11.5%
12.1%
11.6%
45.4%
47.4%
24.2%
24.4%
5.7%
11.1%
 
Figure 5-2 State progression across whole record, all patients 
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Table 5-5 Probability of progression in first year, patients with alcoholic and non-alcohol related cirrhosis 
  Stage from 
  Stage 1 Stage 2 Stage 3 Stage 4 
  Alcoholic Non-alcohol 
related Alcoholic 
Non-alcohol 
related Alcoholic 
Non-alcohol 
related Alcoholic 
Non-alcohol 
related 
Pr
o
gr
es
si
on
 
di
re
ct
ly
 
to
 
/ r
em
a
in
ed
 
in
 
Stage 1 74.4  [72.2, 76.5] 
77.4  
[75.1, 79.5] - - - - - - 
Stage 2 4.0 [3.1, 5.1] 3.6 [2.7, 4.7] 74.0  [69.0, 78.6] 
78.8  
[75.1, 82.2] - - - - 
Stage 3 8.6 [7.2, 10.1] 5.5 [4.4, 6.9] 6.2 [3.9, 9.3] 5.0 [3.3, 7.2] 72.7  [68.8, 76.4] 
61.7  
[56.5, 66.7] - - 
Stage 4 3.2 [2.3, 4.1] 1.1 [0.7, 1.8] 9.4 [6.5, 13.1] 5.6 [3.8, 7.9] 7.0 [5.0, 9.4] 4.1 [2.3, 6.6] 83.5  [79.5, 86.9] 
79.6  
[74.8, 83.8] 
Death 9.9 [8.5, 11.5] 12.3  [10.7, 14.2] 10.3 [7.3, 14.1] 10.6 [8.1, 13.5] 
20.3  
[17.0, 24.0] 
34.2  
[29.4, 39.3] 
16.5  
[13.1, 20.5] 
20.4  
[16.2, 25.2] 
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Table 5-6 State progression across whole record, patients with alcoholic and non-alcohol related cirrhosis 
  Stage from 
  Stage 1 Stage 2 Stage 3 Stage 4 
  Alcoholic Non-alcohol 
related Alcoholic 
Non-alcohol 
related Alcoholic 
Non-alcohol 
related Alcoholic 
Non-alcohol 
related 
Pr
o
gr
es
si
on
 
di
re
ct
ly
 
to
 
/ r
em
a
in
ed
 
in
 
Stage 1 47.4  [44.9, 49.9] 
55.4  
[52.8, 58.0] - - - - - - 
Stage 2 8.1 [6.8, 9.5] 7.1 [5.8, 8.6] 47.2  [41.8, 52.7] 
55.2  
[50.9, 59.5] - - - - 
Stage 3 13.2  [11.6, 15.0] 8.8 [7.4, 10.4] 13.6 [10.1, 17.7 10.4 [8.0, 13.3] 
45.2  
[41.0, 49.5] 
35.1 
 [30.2, 40.2] - - 
Stage 4 6.8 [5.6, 8.2] 4.4 [3.4, 5.6] 15.3  [11.7, 19.6] 10.0 [7.6, 12.9] 
13.2  
[10.5, 16.3] 9.0 [6.3, 12.4] 
54.7  
[49.8, 59.5] 
54.5  
[48.9, 60.0] 
Death 24.5  [22.4, 26.7] 
24.3  
[22.1, 26.6] 
23.9  
[19.35, 28.8] 
24.3  
[20.8, 28.2] 
41.6  
[37.4, 45.8] 
56.0  
[50.7, 61.1] 
45.3  
[40.5, 50.2] 
45.5  
[40.0, 51.1] 
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5.4 Discussion 
5.4.1 Key findings 
Using the clinical observations recorded in the primary care records of people 
with cirrhosis I have described the progression of disease as experienced by 
patients and as recorded by primary care physicians in the UK.  The presence 
of ascites rather than GI bleed appears to represent a more serious marker of 
mortality within the first year following diagnosis.   
Overall the rate of decompensation was 5.5% per year (95%CI[5.1%, 5.9%]).   
The rate of decompensation varied considerably by presumed aetiology of 
cirrhosis with alcoholic cirrhosis conferring a worse prognosis in the first year 
following diagnosis (16% versus 10%).  These differences were largely 
removed following this first year and the rate of decompensation was 
approximately 3-4% per year for all patients.   
 
5.4.2 Strengths and limitations 
This study has tried to utilise a recognised staging system of cirrhosis and 
apply its definitions to a cohort of patients whose data are recorded in primary 
care.  The usefulness of a staging system such as this, particularly one with 
no reliance on laboratory measurements, allows for a simpler identification of 
patients at a higher risk of progression and/or mortality and the easier 
communication of this risk to patients and their families.  
 
This study is three times the size of that of the previous study upon which the 
Baveno IV consensus stages were derived and on which I have based my 
methodology.  The inclusion of patients who did not necessarily have to be 
hospitalised in this study means that the results are perhaps more relevant to 
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those ambulatory patients, as would be being seen in primary care and 
outpatients clinics, than previously available figures.  By virtue of the size of 
this study it was possible to stratify the probabilities of progression by 
presumed aetiology.   
 
The principal limitation with this study, similar to that with the previous two 
studies, is that of the diagnosis and recording of the symptoms of cirrhosis that 
define the staging.  The cost of requesting records of patients within each 
stage means that I was unable to validate the specific stages of cirrhosis in 
this cohort.  Within the GPRD itself there is insufficient data to assess what 
level of follow-up was being performed for an individual patient.  It is probable 
that many patients in stage 1 were not undergoing regular screening 
endoscopies for the presence of oesophageal varices and so the probability of 
progressing from stage 1 to stage 2 is therefore underestimated with 
oesophageal varices perhaps only being recorded if they had led to a bleed.   
Similarly it is possible that only more severe bleeds are being recorded if a 
patient was not undergoing regular screening endoscopies.  It is additionally 
possible that those patients who died in hospital following bleeding 
oesophageal varices (or indeed any other sort of GI bleed) had the fact of 
death communicated to the GP but not the circumstances leading up to it.  For 
this reason it is possible that the progression to stage 4, and the probability of 
proceeding from stage 4 to death is underestimated within these data.  These 
limitations in the validity of the staging system could also lead to an 
overestimate in the progression directly to death for earlier stages.  However, I 
ZRXOGDUJXHWKDWWKHILJXUHV,KDYHUHSRUWHGUHSUHVHQWWKHµUHDO-OLIH¶VLWXDWLRQRI
what is identified and communicated regardless of the  variation in the follow-
up of patients that may exist in different regions or indeed individual hospitals.  
These figures are therefore a useful adjunct to other available data for the 
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communication of risk to patients in both the primary care and outpatient 
settings.   
 
I was not able to calculate other more commonly used measures of severity of 
disease such as the Child-Pugh score or MELD score as the blood indices 
required for the calculation of these scores were not available in the data.  
There are however limitations in these scores, particularly the speed with 
which it is possible to calculate a Child-Pugh or MELD score and the day-to-
day clinically observed variations in blood measurements that may cause a 
significant change in the scores (particularly with respect to creatinine and 
prothrombin time).  These scores are also more difficult to communicate in a 
meaningful way to most patients where the presence or absence of clinical 
symptoms is likely to be more readily understood.  Indeed a considerable 
wealth of literature exists suggesting that rather than a measure of individual 
risk patients are more likely to comprehend figures which are described in 
terms of the proportions of patients likely to experience an outcome.95  These 
sorts of figures can easily be extracted from the results reported above e.g. if 
a patient has been diagnosed with alcoholic cirrhosis in stage 1 it would be 
SRVVLEOHWRFRPPXQLFDWHWRWKDWSDWLHQWµ,QWKHILUVW\HDUIROORZLQJGLDJQRVLV
with alcoholic cirrhosis, such as yourself, 3 in 4 patients will remain in this 
disease stage and not experience any further sequelae. The other 1 in 4 
patients will experience some further symptoms including varices, ascites, 
bleeding and 1 in 10 may even die within a year¶RUsimilar.  
 
With respect to the presumed aetiology of cirrhosis there are potential 
limitations in the methods I have employed to assign the cause of cirrhosis as 
described in section 3.4.2. The likelihood of misclassifying patients with 
alcoholic cirrhosis as non-alcohol related cirrhosis could lead to an 
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underestimate of the true progression associated with an aetiology of alcoholic 
cirrhosis and a corresponding overestimate of the progression associated with 
non-alcohol related cirrhosis.  Again, owing to the relatively small number of 
patients with other known aetiologies (viral hepatitis, autoimmune liver disease 
or metabolic liver disease) it was not possible to describe the progression of 
these patients with precision.   
 
5.4.3 Comparison with previously published work 
In this study I have attempted to replicate a staging system for cirrhosis 
adopted at the Baveno IV consensus conference.94  These stages are based 
on data from a single hospital in Sicily in the 1970s and 1980s, published as 
one paper and one abstract.44 96  The two studies were aggregated and the 1-
year outcome probabilities were published in a systematic review looking at 
prognostic indicators of survival in cirrhosis.55   The methods for calculating the 
1-year outcome probabilities are uncertain as there are no methods included 
in this latter paper.  Going back to the original paper and the abstract, 1-year 
outcome probabilities for the occurrence of oesophageal varices were 
calculated as cumulative 10-year progression divided by 10 to get the annual 
progression, with the methods for progression to other states not clarified.  
Progression is not necessarily uniform across time, particularly not within the 
first year as I have demonstrated with my data, and as such the validity of 
these widely referenced figures is somewhat questionable.    
Bearing in mind the limitations of the description of the methods employed to 
calculate data, the 1-\HDUSURJUHVVLRQSUREDELOLWLHVGHVFULEHGE\'¶$PLFRDQG
colleagues are the most logical comparison for my results and are displayed in 
Table 5-7.   
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Table 5-7 Probability of progression in cirrhosis 
DVUHSRUWHGLQ'¶$PLFR*Garcia-7VDR*3DJOLDUR/µ1DWXUDOKLVWRU\DQG
prognostic indicators of survival in cirrhosis: A systematic review of 118 
VWXGLHV¶-+HSDWRO-231 
  Progression from 
  Stage1 Stage 2 Stage 3 Stage 4 
Pr
o
gr
es
si
on
 
to
 
Stage 1 88.6% - - - 
Stage 2 7% 86% - - 
Stage 3 4.4% 6.6% 72.4% - 
Stage 4 0% 4% 7.6% 43% 
Death 1% 3.4% 20% 57% 
 
In terms of mortality my results show a much higher progression to death from 
both stage 1 and stage 2 but a very much lower progression to death from 
stage 4.  Aside from the possible methodological considerations there are 
probably two principal reasons for these observed differences.  Firstly, as 
described above it is possible that without regular follow-up there is 
misclassification of patients as stage 1 when in fact they have already reached 
a later stage, but that this has not been diagnosed or has not been reported 
back to primary care and therefore is not recorded in the GPRD.  However, as 
we do not know the exact methods of follow-up in the Sicilian population (the 
DEVWUDFWUHIHUHQFHVSDWLHQWVXQGHUJRLQJµHQGRVFRS\DW-3 year intervals or at 
bleedLQJ¶)96 it is not conclusive that it is difference in follow-up that would have 
led to these differences in reported survival.  Secondly, it is possible that the 
composition of the cirrhosis cohorts in this earlier study and in my study have 
significant differences in aetiology.  Indeed the population of Sicily has a much 
higher prevalence of hepatitis than I have reported in my data.  Given that 
patients with alcoholic cirrhosis appear to have a worse prognosis (as seen 
from my data) it is possible that this discrepancy in survival for compensated 
patients is a reflection of the large proportion of alcoholic cirrhosis within the 
UK population who fare worse than those with an aetiology of non-alcohol 
related cirrhosis.   
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The observation that the presence of ascites rather than GI bleed seems to 
confer a greater risk of mortality within the first year is in contrast to those data 
from Sicily.  However, given that the main period of data collection is some 20 
years later, it is probable that the patients included in my study have had 
available to them many of the clinical improvements in the management of 
variceal bleeding that were not likewise available for those people in the 
earlier study.  These improvements include endoscopic sclerotherapy, 
endoscopic ligation, medications such as vasopressin, somatostatin and 
octreotide, all of which are likely to have been available during the period of 
my study but not for the patients in the study in Sicily.97  Indeed, three 
relatively recent papers from the USA, France and Sweden report improved 
survival after oesophageal variceal bleeding.58 59 60  However, the overall 
mortality from GI bleeding in my data is still lower than the 579 days median 
survival reported in the US for patients hospitalized with an oesophageal bleed 
in 1988-91,58 or the 1-year mortality of over 50% reported in Sweden for 
patients discharged between 1990-2002  after a diagnosis of oesophageal 
varices.60  Gastrointestinal bleeding is multi-factorial and it is possible that the 
bleeding I have identified and included in my study is not as severe as the 
bleeding reported in these previous studies.  Indeed only 7.4% of the bleeding 
identified was recorded as variceal in origin.    
 
The 1-year probability of progression from stage 1 to stage 2 of 3.8% though 
VLPLODUWRWKDWVHHQLQVRPHVWXGLHVGHVFULELQJWKH\HDUO\µLQFLGHQFH¶RI
varices98 99 is lower than that reported in most studies looking at the natural 
history of cirrhosis including the study from Sicily. 55 100 101 102  This is quite 
likely to be due to the fact that we do not know what, if any, level of 
endoscopic surveillance was being undertaken on these patients.  There was 
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no definitive screening guideline in place in the UK at the time of data 
collection and as such I will likely have an underestimate of the progression 
from stage 1 to stage 2 (as discussed in section 5.4.2).  However, if I include 
the 2.2% of patients who progressed directly from stage 1 to stage 4 i.e. 
identification of bleeding without prior identification of varices, assuming all 
these bleeds were of variceal origin, the progression to varices becomes quite 
similar, at 6%.  Inevitably, in the absence of routine screening endoscopies, 
some varices will be identified only if they bleed.   
 
The 1-year progression to stage 3 from either stage 1 or stage 2 (cumulative 
progression 12.6%) was simLODUWRWKHREVHUYHGE\'¶$PLFRDQG
colleagues. 55  Studies looking at populations with a high proportion of viral 
cirrhosis report variable rates of progression to ascites with 5-year incidence 
of only 11%103 and 24.8%.101  The study by Benvegnu et al. showed that 
alcohol abuse was associated with a higher incidence of ascites compared 
with those with no history of alcohol abuse.103  Overall progression to ascites 
in my study with over half of the study population having a presumed aetiology 
of alcoholic cirrhosis was 22.7%.  Progression to ascites was higher in those 
with alcoholic cirrhosis than those with non-alcohol related cirrhosis both 
within the first year and throughout the study period.   
 
Progression to stage 4 (GI bleeding) within the first year following diagnosis is 
VOLJKWO\KLJKHULQP\VWXG\WKDQWKDWUHSRUWHGE\'¶$PLFRDQG colleagues55 but 
is consistent with the 24% bleeding rate at 2 years from two earlier studies.104 
105
 
 
It is possible to compare the prognosis figures for patients with alcoholic 
cirrhosis directly to a study conducted in Denmark and reported in 2009.56  
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The authors report on 449 patients with alcoholic cirrhosis diagnosed and 
followed up between 1993 and 2005 in a single hospital centre.  The 1-year 
progression directly to death in this hospital was 10% for those with no 
reported complications, almost identical to the 9.9% I saw in my study.  The 1-
year progression directly to death for patients with clinical symptoms of ascites 
and variceal bleeding was 15% and 11% respectively, slightly lower than the 
figures I reported for stage 3 and stage 4 (20.3% and 16.5%) although the 
confidence intervals around these point estimates do overlap.  Perhaps 
unsurprisingly, this study reported that the complications of cirrhosis do not 
develop in such a well-determined order as put forward by the staging system 
I have tried to replicate with ascites reported as the most frequent first 
complication (in 12% of patients) but nearly as many (10% in total) developing 
variceal bleeding (6%) or hepatic encephalopathy (4%) as their first 
complication.  There are no such comparable figures for patients with non-
DOFRKROUHODWHGFLUUKRVLVDOWKRXJKWKHZRUNIURP'¶$PLFRDQGFROOHDJXHVLV
probably more likely to reflect non-alcohol related cirrhosis given the high 
proportion of hepatitis in that population.55    
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5.4.4 Conclusions 
This study has described the clinical progression following a diagnosis of 
cirrhosis as recorded in contemporary clinical practice in primary care.   
The figures based on this relatively simplistic staging system are potentially 
more relevant and readily understood by those living with cirrhosis and those 
communicating risk to these patients.   
 
This study is the first (to my knowledge) to describe the rate of 
decompensation in patients with compensated disease stratified by aetiology 
and shows a significantly higher rate of decompensation for those with 
alcoholic cirrhosis in the first year compared to those with non-alcohol related 
cirrhosis.  These figures will be of use to service providers to factor in the 
aetiology of cirrhosis in the planning of therapies, interventions and follow-up 
as well as to individual clinicians and their patients to enable a clearer 
understanding of the likely clinical course of this disease.   
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6 7KH³MRC Elderly´'DWDEDVH 
This chapter provides an overview of the ³MRC Elderly´ database, its data 
format, its strengths and weaknesses particularly with reference to the studies 
in chapters 7 through 9 and details regarding the data used for studies 
contained within these three chapters. Additional study-specific information on 
the exact data used is detailed in the methods section of each individual 
chapter.   
 
6.1 Original data collection 
These studies utilise data collected as part of the Medical Research Council 
(MRC) Trial of Assessment and Management of Older People in the 
Community which has been reported on previously.106 107 108  Briefly, practices 
within the MRC General Practice Research Framework with list sizes of 
between 200 and 700 patients aged 75 and over, selected to represent the 
population of the UK based on mortality (SMRs) and deprivation (Jarman 
score), were eligible to be randomised into the trial.  In total, 109 practices 
were invited to participate in the trial and a final total of 106 practices provided 
data.   
All people aged 75 or over registered with the selected general practices, non-
resident in nursing homes, and who were not known to be terminally ill, were 
eligible for inclusion in the data collection which comprised two arms 
comparing multi-dimensional assessment of the elderly.  The first arm 
(universal arm) invited all patients to an in-depth health assessment whilst the 
second arm (targeted arm) invited only selected patients.   
Recruitment and data collection took place between 1995 and 1999.  Local 
Research Ethics Committee approvals were obtained for each participating 
practice.   
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All participants in the original trial received a brief assessment of health 
covering all areas included within the GP contract109 with data collected either 
at interview with a lay person, at interview by a study nurse or by postal 
questionnaire (see Figure 6-1).  Following this brief assessment subjects in 
the universal arm of the trial had a detailed nurse assessment covering these 
same areas but in more detail.  Additional biological measurements were 
made, including blood pressure and heart rate, and participants had a blood 
sample taken for a biochemical screen including measurements of serum 
aspartate aminotransferase (AST), alkaline phosphatase (ALP) and bilirubin.   
The studies described in chapters 7-9 utilise data collected from participants 
within the universal arm of the trial only.   
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Figure 6-1 Design of the MRC trial of assessment and management of older people in the community 
General Practice 
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Nurse interview
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6.2 Data flow 
Data flow was initiated following the recruitment of participants from general 
practices registered as part of the MRC General Practice Research 
Framework.  All participants then had information recorded from the brief 
assessment questionnaires stored LQWKHµEULHI¶Gatabase.  All data collected 
during the detailed assessment were VWRUHGLQWKHµGHWDLO¶GDWDEDVH 
All participants in the trial were registered with the NHS central register 
(NHSCR) and listings of events including death, embarkation, registration with 
tKHDUPHGVHUYLFHVµFDQFHOODWLRQV¶ZKHQDSDWLHQWFDQQRORQJHUEHFRQWDFWHG
DWDSDUWLFXODUJHQHUDOSUDFWLFHWKH1+6&5ZLOOPDUNWKHUHFRUGDVµFDQFHOOHG¶
until such time as the patient transfers to another GP or a death occurs and 
can be traced to that individual) and re-entries were received on a monthly 
EDVLV$OOµQRQ-GHDWK¶HYHQWVZHUHVWRUHGLQWKHµFHQVRULQJ¶GDWDEDVH'HDWK
certificates were also received on a monthly basis with coded cause of death 
and date of death UHFRUGHGLQWKHµGHDWKV¶GDWabase.   
A schematic diagram of the data flows is shown in Figure 6-2.   
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Figure 6-2 Data repositories and information flow in the MRC elderly study 
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6.3 Strength and weaknesses 
7KH³05&(lderly´ is a useful resource for descriptive epidemiology and has 
recently been utilised to describe kidney disease in older people.110  However, 
as with any database there are limitations to its usefulness which should be 
considered.  The relative merLWVDQGOLPLWDWLRQVRIWKH³05&(lderly´ database, 
particularly with reference to studies of liver function, are discussed below. 
 
6.3.1 Representative 
The cluster randomised nature of the initial study means that participants 
included in the universal arm of the trial (and therefore the subjects in my 
following studies) were chosen in a way which is representative of the 
population of the UK with respect to mortality and deprivation.  The 
subsequent exclusion of patients who were in long-term care or those with 
terminal illness should mean that the results of these subsequent studies can 
be generalised to the ambulatory, non-terminally ill population of the UK aged 
75 and over.   
 
6.3.2 Availability of data on liver function tests 
All participants in the universal arm had a blood sample taken with several 
biochemical markers examined including three markers commonly used in the 
assessment of liver function, namely serum aspartate transaminase (AST), 
alkaline phosphatase (ALP) and bilirubin.  As these data are being used as a 
secondary source and there was no opportunity for further data collection from 
the participants there are certain data items that are not available that would 
have been desirable if setting up this study specifically to look at liver function 
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tests.  These include particular biochemistry markers e.g. alanine 
aminotransferase, INR or pro-thrombin time, and also potential confounders 
such as the diagnosis of recognised liver disease.   
 
6.3.3 Follow-up 
Follow-up of the ³MRC Elderly´ cohort for the principal event of interest of 
death was well executed through the flagging with the NHSCR and continues 
to be updated.  At the time of data extraction for these studies death data were 
available up until 5 November 2005.  With death being a common event in a 
population of people aged 75 and over this gives the study good power to 
examine the association between elevated liver function tests with mortality.   
 
6.4 Data used for chapters 7-9 
For the purposes of the following studies I obtained data on those subjects 
from 53/106 general practices which comprised the universal arm.  This 
included all of the information from the detailed nurse interview, including 
blood test results, and separate data files from the NHSCR giving information 
on the subjects within the study who had subsequently died or migrated.  
Details on the exact data used for each study are described in the appropriate 
chapter.   
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7 Prevalence of elevated liver function tests in the 
elderly 
7.1 Introduction 
This study aims to estimate the prevalence of elevated liver function tests in a 
sample of people aged 75 and over resident in the UK.   
 
7.2 Methods 
7.2.1 Data set used 
The data used in this study are those from the detailed nurse assessment 
containHGZLWKLQWKHµGHWDLO¶GDWDEDVH (see Figure 6-2).  A total of 15,308 
participants aged 75 and over are included in the subsequent analyses.     
 
7.2.2 Imputation of laboratory reference ranges 
In order to assess the prevalence of elevated liver function it is necessary to 
have an agreed cut off limit or definition for abnormality.  However, there was 
no standard definition of abnormality in use at the time of data collection for 
any of the three tests that I was interested in.  Different laboratories used 
different assays and these were calibrated individually and hence had different 
designated limits of normality.  In addition, reference ranges were frequently 
set at different levels for males and for females.   
 
Reference ranges for the upper and lower limits of normal tests were not 
collected at the time of the study and, following requests after the completion 
of the study, only half of the practices involved had any recorded reference 
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ranges for the three liver function tests I was interested in.  For those practices 
where I did not have a provided reference range it was therefore necessary to 
impute a sensible value to use as a cut off for limits of normality.   
 
To do this I examined the distribution of the values of the upper and lower 
limits of normal for the laboratories which had provided reference ranges.  
Where the distribution of tests appeared to be unimodal I inferred that there 
was broadly one standard test in operation for the particular test.  Where the 
distribution of tests appeared to be bimodal I inferred that there were two 
standard tests operating in parallel.  This assumption was discussed with 
clinical colleagues using these tests throughout the time period of the data 
collection and was agreed to be representative of laboratory practices at that 
time.  Practices were assigned to either the lower or upper test limit depending 
on the median value of test results from participants within that practice.   
 
For those practices where information on reference ranges was provided 
these values were used.  For practices without reference ranges I derived 
three sets of upper limits: 
1. Upper limit based on the median values given for those practices for 
which information was already available. 
2. Upper limit based on the minimum upper limit for those practices for 
which information was already available ± this provides an estimate of 
the maximum number of abnormal test results. 
3. Upper limit based on the maximum upper limit for those practices for 
which information was already available ± this provides an estimate of 
the minimum number of abnormal test results. 
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7.2.2.1 AST 
A total of 28/53 (53%) practices had some information recorded on AST 
reference ranges.  All reference ranges provided were for adults of all ages.  
Some practices provided different reference ranges dependent on the sex of 
the patient.  It was therefore necessary to impute value for upper limits for 
men and women for 25 practices without a given reference range.  Graphical 
representation of the upper limits showed the distributions of the upper limits 
to be largely unimodal around 40IU/l for both males and females (see Figure 
7-1 for males; same distribution seen for females (not shown)).  Interrogation 
of the actual test results showed a similar unimodal distribution of the median 
values by practice (see Figure 7-2).     
I therefore inferred that there was only one primary test in operation for AST 
among the practices included in the trial at the time these data were collected.  
Summary statistics on the distribution of given reference ranges can be seen 
in Table 7-1.   
For practices without reference ranges the three sets of upper limits imputed 
were: 
1. Based on the median values ± 40IU/l for both males and females. 
2. Based on the minimum upper limit ± 31IU/l for males, 30IU/l for 
females. 
3. Based on the maximum upper limit ± 57IU/l for males, 53IU/l for 
females. 
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Figure 7-1 Graphical representation of upper limits of reference range for AST 
test by size of practice (males only) 
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Figure 7-2 Graphical representation of median AST test measurements by size 
of practice (males only) 
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Table 7-1 Lower and upper limits of normal range of AST 
  Number of 
practices 
Median 
[IQR] (IU/l) 
Range 
(IU/l) 
Males Lower limit 20 10 [0.5, 11] 0-20 
 Upper limit 28 40 [39, 44] 31-57 
Females Lower limit 20 5 [0.5, 10] 0-15 
 Upper limit 28 40 [35, 42] 30-53 
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7.2.2.2 ALP 
A total of 28/53 (53%) practices had some information recorded on ALP 
reference ranges.  Reference ranges provided were for adults of all ages or for 
adults aged 60 and over.  Some practices provided different reference ranges 
dependent on the sex of the patient.  It was therefore necessary to impute 
upper limits for 25 practices without a given reference range.  Graphical 
representation of the upper limits showed the distributions to be bimodal with 
one peak at around 110IU/l and another at around 300IU/l for both males and 
females (see Figure 7-3 for males; same distribution for females (not shown)).    
Interrogation of actual test results showed a similar bimodal distribution of the 
median values by practice (see Figure 7-4).  I therefore inferred that there 
were two primary tests in operation for ALP among the practices included in 
the trial at the time these data were collected.  Practices without reference 
ranges were assigned to the lower or higher test based on the median of 
actual test results of the participants within the practice.  Summary statistics 
on the distribution of given reference ranges for the lower and higher test can 
be seen in Table 7-2 and Table 7-3 respectively.   
For practices without reference ranges the three sets of upper limits imputed 
were: 
1. Based on the median values ± 120IU/l for both males and females in 
lower test group; 330IU/l for both males and females in higher test 
group. 
2. Based on the minimum upper limit ± 50IU/l for both males and females 
in lower test group; 129IU/l for males and 104IU/l for females in higher 
test group. 
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3. Based on the maximum upper limit ± 237IU/l for both males and 
females in lower test group; 350IU/l for both males and females in 
higher test group.   
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Figure 7-3 Graphical representation of upper limits of reference range for ALP 
test by size of practice (males only) 
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Figure 7-4 Graphical representation of median ALP test measurements by size 
of practice (males only) 
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Table 7-2 ALP Lower test ± known reference ranges 
  Number of 
practices 
Median  
[IQR] (IU/l) 
Range 
(IU/l) 
Males Lower limit 17 30 [25, 35] 0-40 
 Upper limit 17 120 [105, 130] 50-237 
Females Lower limit 17 30 [25, 35] 0-40 
 Upper limit 17 120 [105, 135] 50-237 
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Table 7-3 ALP Higher test ± known reference ranges  
  Number of 
practices 
Median [IQR] 
(IU/l) 
Range 
(IU/l) 
Males Lower limit 11 70 [0, 100] 0-100 
 Upper limit 11 330 [280, 350] 129-350 
Females Lower limit 11 70 [0, 100] 0-100 
 Upper limit 11 330 [280, 350] 104-350 
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7.2.2.3 Bilirubin 
A total of 30/53 (57%) of practices had some information recorded on bilirubin 
reference ranges.  Reference ranges provided were for adults of all ages.  No 
practices provided different reference ranges dependent on the sex of the 
patient.  It was therefore necessary to impute upper limits for 23 practices 
without a given reference range.  Graphical representation of the upper limits 
showed the distribution to be unimodal around 17µmol/l (see Figure 7-5).    
Interrogation of actual test results showed a similar unimodal distribution of the 
median values by practice (see Figure 7-6).  I therefore inferred that there was 
only one primary test in operation for bilirubin among the practices included in 
the trial at the time these data were collected.  Summary statistics on the 
distribution of given reference ranges can be seen in Table 7-4.   
For practices without reference ranges the three upper limits imputed were: 
1. Based on the median values ± 17µmol/l for both males and females. 
2. Based on the minimum upper limit ± 15µmol/l for both males and 
females. 
3. Based on the maximum upper limit ± 25µmol/l for both males and 
females. 
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Figure 7-5 Graphical representation of upper limits of reference range for 
bilirubin test by size of practice 
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Figure 7-6 Graphical representation of median bilirubin test measurements by 
size of practice 
 
 
 
 
0
20
0
40
0
60
0
0 5 10 15 20 25
Median bilirubin measurement (umol/l)
185 
Table 7-4 Bilirubin tests ± known reference ranges 
 
 Number of 
practices 
Median [IQR] 
(µmol/l) 
Range 
(µmol/l) 
Lower limit 30 0 [0, 3] 0-5 
Upper limit 30 17 [17, 19] 15-25 
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7.2.3 Additional definitions 
7.2.3.1 Elevated liver function 
Elevated liver function tests were defined as the result being above the upper 
limit of normal (ULN) relative to the reported or imputed laboratory reference 
range.  Elevated results were then categorised as being between 1 and 2x the 
ULN or above 2x the ULN.   
7.2.4 Statistical analysis 
Prevalence of elevated liver function tests were calculated as the number of 
people with an elevated result (or multiple elevated test results) divided by the 
number of participants with a valid test (or combination of tests).  95% CIs 
were calculated using the binomial distribution. 
I examined the association between median age, sex and comorbidity and not 
having a valid liver function test result.   
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7.3 Results 
7.3.1 Prevalence of elevated liver function 
7.3.1.1 AST 
I examined the proportion of patients who had an elevated AST test result 
based on the reference ranges given by their individual laboratory.   
Between 2.3% and 6.7% of the patients with a valid AST measurement had an 
elevated AST according to the reference ranges given (or imputed) by the 
laboratory (see Table 7-5).  Using the median imputed reference ranges, 3.3% 
of participants had an elevated AST.   
 
7.3.1.2 ALP 
I examined the proportion of patients who had an elevated ALP test result 
based on the reference ranges given by their individual laboratory 
Between 5.8% and 41.3% of the patients with a valid ALP measurement had 
an elevated ALP according to the reference ranges given (or imputed) by the 
laboratory(see Table 7-6).  Using the median imputed reference ranges, 9.2% 
of participants had an elevated ALP.   
 
7.3.1.3 Bilirubin 
I examined the proportion of patients who had an elevated bilirubin test result 
based on the reference ranges given by their individual laboratory.   
Between 3.6% and 7.2% of the patients with a valid bilirubin measurement 
had an elevated bilirubin according to the reference ranges given (or imputed) 
by the laboratory (see Table 7-7).  Using the median imputed reference 
ranges, 5.4% of participants had an elevated bilirubin.   
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Table 7-5 Prevalence of elevated AST 
 
Above upper limit of 
reference 
n (% of those with valid test 
result) 
Within 
reference 
range 
Below lower 
limit of reference 
No value 
for test Total 
Using median reference 429 (3.3) 12,287 110 2,482 15,308 
Using minimum reference 865 (6.7) 11,851 110 2,482 15,308 
Using maximum reference 301 (2.3) 12,415 110 2,482 15,308 
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Table 7-6 Prevalence of elevated ALP 
 
Above upper limit of 
reference  
n (% of those with valid test 
result) 
Within 
reference 
range 
Below lower 
limit of reference 
No value 
for test Total 
Using median reference 1,246 (9.2) 12,207 46 1,809 15,308 
Using minimum reference 5,572 (41.3) 7,881 46 1,809 15,308 
Using maximum reference 783 (5.8) 12,670 46 1,809 15,308 
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Table 7-7 Prevalence of elevated bilirubin 
 
Above upper limit of 
reference 
n (% of those with valid test 
result) 
Within 
reference 
range 
Below lower 
limit of reference 
No value 
for test Total 
Using median reference 690 (5.4) 11,980 20 2,618 15,308 
Using minimum reference 918 (7.2) 11,752 20 2,618 15,308 
Using maximum reference 452 (3.6) 12,218 20 2,618 15,308 
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7.3.1.4 Any elevated liver function 
For the rest of the analyses imputation according to the median reference 
ranges is used. 
 
Of 15 308 participants in the universal arm of the trial, 13 276 (86.7%) had at 
least one valid measurement of liver function.  Participants who did not have a 
valid test result were more likely to be female (OR 1.33 [1.19, 1.49]), were 
slightly older (median age 81.5 years for those without a valid test result 
compared with 80.2 years for those with a test) and had more missing data 
with respect to comorbidity compared with those people who had at least one 
valid test result.   
 
Overall, 16.1% of those with one or more valid measurement had at least one 
elevated liver function test.  The most common elevated liver function test 
within this population was ALP with 9.2% (95%CI [8.7%, 9.7%]) of people 
having a result above the ULN (see Table 7-8).  Only 5.4% (95%CI [5.0%, 
5.8%]) of people had an elevated bilirubin test, whilst an even smaller 
proportion had an elevated AST result, 3.3% (95%CI [3.0%, 3.7%]) of those 
with a valid measurement.  The majority of subjects with an elevated 
measurement had a test result less than or equal to 2x the ULN: 86.2% AST; 
90.0% ALP, 93.8% bilirubin.   
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Table 7-8 Prevalence of elevated liver function tests 
Elevated test(s) 
(Number with valid test) 
Number 
elevated (% of 
elevated) 
% of valid tests  
elevated [95% CI] 
 
Any elevated (N=13546) 2175 16.1 [15.4, 16.7] 
 
  
AST (N=12826) 429 (100) 3.34 [3.04, 3.67] 
 
[ULN 370 (86.2) 2.88 [2.60, 3.19] 
 
Above 2x ULN 59 (13.8) 0.46 [0.35, 0.59] 
 
   
ALP (N=13499) 1246 (100) 9.23 [8.75, 9.73] 
 
[ULN 1122 (90.0) 8.31 [7.85, 8.79] 
 
Above 2x ULN 124 (10.0) 0.92 [0.76, 1.09] 
 
   
Bilirubin (N=12690) 690 (100) 5.44 [5.05, 5.85] 
 
[ULN 647 (93.8) 5.10 [4.72, 5.50] 
 
Above 2x ULN 43 (6.2) 0.34 [0.25, 0.46] 
 
   
AST and ALP (N=12794) 90 0.70 [0.57, 0.86] 
AST and bilirubin (N=12021) 42 0.35 [0.25, 0.47] 
ALP and bilirubin (N=12648) 67 0.52 [0.41, 0.67] 
   
AST, ALP and bilirubin 
(N=11994) 
9 0.07 [0.03, 0.14] 
   
All 3 within reference range 
(N=11994) 
10025 83.6 [82.9, 84.2] 
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7.4 Discussion 
7.4.1 Key findings 
I found that nearly 1 in 6 of the general population aged 75 and over had at 
least one elevated liver function test.  Over half of these abnormalities can be 
accounted for by an elevated measurement of ALP (9.2% of all subjects) and 
the vast majority were within 1x the upper limit of normal for the test 
measured.  Very few participants had more than one recorded elevated liver 
function test (<1% for any combinations of one or more elevated liver function 
tests) with only 9 participants having all 3 liver function tests recorded as 
elevated.   
 
7.4.2 Strengths and limitations 
In this study I was able to assess, for the first time, the liver function of a 
representative randomly selected community-based sample of people aged 75 
and over.  That blood samples were available for most of the people in the 
MRC elderly gives this study a distinct advantage over many other studies 
looking at liver function insofar as the study population was not selected on 
the basis of known or suspected liver disease.   
 
Arguably, abnormalities of AST, ALP and bilirubin are of secondary 
importance when looking at liver function compared with a measurement of 
alanine aminotransferase (ALT) which is specific to the liver.  I was unable to 
investigate this as a blood test for this enzyme was not a part of the original 
study design.   
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As a result of the multi-site nature of this large study I was reliant on data 
collection from several laboratories across the UK.  Not all laboratories were 
able to provide reference ranges for the liver function tests so I relied on 
imputation for nearly half of the reference ranges.  Basing the upper limit of 
normal on the median reference range for those practices where imputation 
was necessary may under- or over-estimate the true level of elevated liver 
function in this population.  This could make a significant difference to the 
proportion of older people who would be considered to have elevated liver 
function as seen particularly in the measurement of ALP.  Using the minimum 
reference ranges for elevated upper limits an estimated 41.3% of participants 
had an elevated ALP test result compared with only 9.2% when using the 
median reference range.   
Data having been collected from multiple laboratories also meant that I was 
unable to describe absolute values of enzymatic activity as there was not one 
uniform test in operation at all of the different sites.   
 
In some laboratories there were different normal reference ranges provided for 
ALP for people aged 60 and above, those aged less than 60 and in some 
cases for children.  It may be that reference ranges for the LFTs measured 
should be provided in even finer categories than this.  I examine the 
association between abnormal measurements and age in the next chapter. 
 
7.4.3 Comparison with previously published work 
Information on the prevalence of elevated liver function in the UK is 
surprisingly lacking.  These results show a lower prevalence of elevated 
transaminase (3.3% elevated AST vs. 7.0% elevated AST or alanine 
transaminase), ALP (9.2% vs. 10.4%) and bilirubin (5.4% vs. 7.1%) than those 
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reported in a recent study of adults of all ages from Scotland.66  This is 
perhaps expected as the population within this study was selected on the 
basis that subjects already had a measurement of liver function contained 
within their primary care records.  The authors acknowledge that they do not 
know why liver function tests were requested and this is likely to include the 
investigation of suspected liver disease leading to a non-representative 
sample of the general population.   
In a study in America,76 again only a selected group of participants had a 
blood test, and it is likely that the true population prevalence of elevated liver 
function tests may have been over estimated.  Indeed, 12.8% of those with a 
measurement of AST had an elevated test, nearly four times that seen in my 
study.  Another study from the USA also showed a slightly higher prevalence 
of elevated AST to that which I have described in this study, with 3.7% and 
4.9% of the population aged 20 or over having an elevated AST in 1988-1994 
and 1999-2002 respectively.71  However, given that my study looks only at 
people aged 75 and over, it may be that the prevalence of elevated liver 
function tests in a population of older people is indeed lower than that found in 
the general adult population of all ages.  This is supported by data from 
America where the prevalence of elevated ALT or AST in the population aged 
70 or older was reported as 4.9%, statistically significantly lower than the 
prevalence of elevated transaminases in younger age groups.70   
 
7.4.4 Conclusions 
Current guidelines recommend that liver function tests should be carried out 
before and within 1-3 months of starting treatment on statins to monitor for 
signs of altered liver function.111  With an estimated 40% of all 75-79 year olds 
have at least one prescription for statins annually,112 incidental findings of 
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elevated LFTs in this age group of the population in the absence of symptoms 
are likely to occur regularly.  The study reported in this chapter has shown that 
abnormalities in liver function are fairly common in people aged 75 and over.  
Using population estimates for 2008 if every person aged 75 and over was to 
undergo these three blood tests elevated levels in one or more of the LFTs 
would be found in 770,000 patients.  It will be important to determine the 
correct course of action for the follow-up and assessment of older people with 
elevated liver function tests to avoid unnecessary follow-up and investigation 
and potential anxiety for an individual.   
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8 Demographic, lifestyle and medical 
characteristics associated with an elevated liver 
function test 
 
 
8.1 Introduction 
This study aims to examine the association between elevated liver function 
tests and selected demographic, lifestyle and clinical characteristics in people 
aged 75 and over.  
 
8.2 Methods 
8.2.1 Dataset used 
The data used in this study are those from the detailed nurse assessment 
containHGZLWKLQWKHµGHWDLO¶GDWDEDVH (see Figure 6-2).  A total of 15,308 
participants aged 75 and over are included in the subsequent analyses.  The 
definition of elevated liver function is as described in section 7.2.3.1 following 
imputation of missing upper limits using the median reference ranges.  
 
8.2.2 Additional definitions 
8.2.2.1 Alcohol consumption 
Alcohol consumption was calculated as the total number of self-reported units 
of alcohol consumed as beer (assuming one unit per half pint), wine 
(assuming one unit per glass of wine, sherry or port) and spirits (assuming one 
unit in a single measure) in the past week.  Intake was then categorised as 
none and in seven-unit increments.   
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8.2.2.2 Smoking  
Smoking status was recorded at the time of interview as either current smoker, 
ex-smoker or never a smoker. 
8.2.2.3 Body Mass Index 
Body Mass Index (BMI) was defined as weight (in kg) divided by height (in m) 
squared, each of which were measured once only.  I subsequently categorised 
BMI into clinically recognised categories: <18.5 (underweight), 18.5-24.9 
(normal weight), 25.0-29.9 (overweight) and 30+ (obese).   
8.2.2.4 Waist:hip ratio 
Waist circumference was measured to the nearest 0.1cm midway between the 
iliac crest and the lower rib margin by using an insertion tape.  Hip 
circumference was measured as the widest circumference over the buttocks 
and below the iliac crest.  Hip and waist were both measured twice (having 
asked patients to roll down their undergarments) and an average of the two 
values used in the calculation of waist:hip ratio (WHR).   
8.2.2.5 Comorbidities 
Diabetes was classified as present following either a self-reported medical 
diagnosis, prescription of anti-diabetic medication or a single high random 
blood glucose measurement.113  Heart attack, hypertension, stroke, cancer 
and ulcer were defined as a positive self-reported medical diagnosis.  Angina 
was defined as full angina as per the Rose score.114  Dementia was defined as 
a score of <9 on the mini-mental state examination.115    
In order to assess the potential for correlation between multiple co-morbid 
illnesses I derived a co-morbidity score.  A patient was given a score of zero 
(not present) or one (present ever before the date of interview) for each of the 
following self-reported medical conditions:, asthma, stomach / digestive ulcer, 
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hypertension, heart attack, stroke, fractured hip or spine (within last year only), 
3DUNLQVRQ¶VGLVHDVHFDQFHUDQGIRUHDFKRIWKHIROORZLQJDQJLQDGHPHQWLD
and diabetes (as per definitions above).  Scores were added together to give 
an overall score and then categorised into 0, 1, 2 and 3 or more comorbidities.   
 
8.2.3 Statistical analysis 
To examine the association between elevated liver function tests and 
demographic, lifestyle and medical characteristics I used logistic regression to 
calculate odds ratios and 95% CIs.  Analysis was performed treating an 
individual practice as a clustered unit with a random effects model employed.   
After univariable analyses, a priori confounders of age, sex and comorbidity 
plus additional statistically significant associations were built into a 
multivariable logistic regression model to account for potential confounding.   
Multivariable models were constructed in 2 ways.  Firstly, missing values for 
covariables were modelled as a separate category to ensure all subjects 
remained within the analysis.  Secondly, multivariable models were fitted using 
only participants with complete data and modelling continuous variables as 
linear trends. 
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8.3 Results  
8.3.1 AST 
Of the 12,836 participants with a valid measurement of AST, 429 (3.3%) had 
an elevated serum level of AST (as reported in section 7.3.1.1).   
8.3.1.1 Univariable associations 
Sex 
Of those with an elevated AST 60% were female which was not statistically 
different to the 61% of those with a normal measurement of AST, OR 0.96 
(95%CI [0.79, 1.18]) (see Table 8-1).   
 
Age 
Participants with an elevated AST were more likely to be younger than those 
with a normal AST measurement.  For example, those over 90 years of age 
were 50% less likely to have an abnormal AST measurement than those aged 
75.  The odds ratio for a yearly increase in age fitted a linear trend and was 
0.97 (95% CI[0.94, 0.99]).   
 
Alcohol consumption 
Data on total number of units of alcohol consumed in the previous week were 
missing for 18.5% of those with a normal AST and for 16.1% of those with an 
elevated AST.  A further 35.9% of both groups recorded no consumption of 
alcohol within the previous week.  There was a statistically significant 
association between alcohol consumption and an elevated AST with an odds 
ratio of 1.22 (95% CI[1.08, 1.37]) for each 7-unit increase in weekly 
consumption.  Patients reported as consuming 22 or more units of alcohol in a 
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week were over twice as likely to have an elevated AST measurement than 
those who did not drink any alcohol.   
 
Smoking 
A much smaller percentage of participants had missing data on smoking 
compared with alcohol consumption, only 2.7% compared with 18.4% 
respectively.  There was no statistically significant association between 
elevated AST and either being an ex- or current smoker compared with being 
classified as a never smoker.    
 
Body size (BMI and WHR) 
The majority of participants (52.8%) were recorded as being overweight or 
obese i.e. having a BMI of 25 or above with a further 8.5% having missing 
data on BMI.  Having an elevated AST was not associated with either a low or 
high BMI.  Having a higher waist-to-hip ratio was associated with elevated 
AST.  For example, the odds of having an elevated AST if you had a WHR of 
between 1.05 and 1.15 were over 3 times that compared to if you had a WHR 
of between 0.75 and 0.84.  Although no other individual category of WHR 
conferred a statistically significant association with elevated AST when 
examined a continuous categorical variable there was an association with 
higher WHR group and elevated AST (OR 1.17 (95% CI[1.03, 1.32])). 
 
Comorbidities 
Of the comorbidities examined only diabetes and dementia were seen to be 
associated with an elevated AST.  Having had a heart attack, hypertension, a 
stroke, cancer, ulcer or angina were not statistically significantly associated 
with an elevated AST.  When examining comorbidity as a composite score 
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there was no statistically significant association seen between the derived 
comorbidity index and elevation of AST.   
 
8.3.1.2 Multivariable associations 
To build the multivariable model a priori confounders of age, sex and 
comorbidity as well as alcohol consumption and WHR were included.  Upon 
adjustment there remained a statistically significant association between 
elevated AST and age, alcohol consumption and high WHR (see Table 8-1).  
There was no evidence of substantial confounding with the exception of the 
estimates for the association with sex which increased following adjustment 
for age, alcohol consumption, WHR and comorbidity.  The change in 
association between sex and elevated AST suggested some form of 
interaction.  Fitting a third multivariable model including an interaction term for 
age and sex led to a further slight increase in the association between being 
female and having an elevated measurement of AST.  
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Table 8-1 Associations between elevated AST test and demographic, lifestyle and clinical characteristics 
 Normal AST 
(N=12397) 
Elevated AST (N=429) OR [95% CI] OR [95% CI] OR [95% CI] OR [95% CI] 
 N % N % Univariable Model 1* Model 2* Model 3* 
Sex  
Male 4838 39.0 173 40.0 - -   
Female 7559 61.0 256 60.0 0.96 [0.79, 1.18] 1.27 [0.98, 1.64] 1.34 [1.01, 1.78] 1.47 [0.99, 2.18] 
  
Age (years) 
 
Median age 
[IQR]  
(range) 
80.2 [77.2, 84.2] 
(75, 108) 
79.2 [77, 83.2]  
(75, 99) 
    
75- 1099 8.9 56 13.1 - -   
76- 1569 12.7 52 12.1 0.70 [0.47, 1.05] 0.70 [0.47, 1.04]   
77- 1300 10.5 55 12.8 0.90 [0.60, 1.33] 0.89 [0.60, 1.33]   
78- 936 7.6 41 9.6 0.95 [0.62, 1.45] 0.94 [0.61, 1.45]   
79- 943 7.6 29 6.8 0.66 [0.41, 1.06] 0.67 [0.41, 1.07]   
80- 878 7.1 25 5.8 0.59 [0.36, 0.96] 0.59 [0.36, 0.97]   
81- 874 7.1 35 8.2 0.85 [0.54, 1.32] 0.87 [0.55, 1.36]   
82- 774 6.2 25 5.8 0.67 [0.41, 1.11] 0.70 [0.43, 1.16]   
83- 706 5.7 17 4.0 0.46 [0.26, 0.80] 0.47 [0.27, 0.84]   
84- 624 5.0 18 4.2 0.63 [0.36, 1.10] 0.65 [0.37, 1.13]   
85- 527 4.3 15 3.5 0.61 [0.34, 1.10] 0.62 [0.34, 1.13]   
86- 449 3.6 13 3.0 0.65 [0.35, 1.22] 0.68 [0.36, 1.28]   
87- 404 3.3 10 2.3 0.52 [0.26, 1.04] 0.54 [0.27, 1.09]   
88- 323 2.6 13 3.0 0.89 [0.47, 1.69] 0.93 [0.49, 1.76]   
89- 264 2.1 9 2.1 0.69 [0.33, 1.43] 0.71 [0.34, 1.49]   
90+ 665 5.4 16 3.7 0.49 [0.28, 0.88] 0.52 [0.29, 0.94]   
Missing 62 0.5 0 0 - -   
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Odds ratio for yearly increase in age 0.97 [0.94, 0.99]  0.97 [0.94, 1.00] 1.00 [0.91, 1.10] 
  
Alcohol  
Median units of 
alcohol intake in 
past week [IQR] 
(range) 
1  
[0,4]  
(0,90) 
N=10106 
1  
[0,7]  
(0,87) 
N=360 
    
Alcohol units  
0 4453 35.9 154 35.9 -    
1- 4341 35.0 133 31.0 0.86 [0.68, 1.10] 0.86 [0.67, 1.10]   
8- 856 6.9 43 10.0 1.54 [1.07, 2.21] 1.51 [1.04, 2.20]   
15- 250 2.0 15 3.5 1.85 [1.04, 3.29] 1.83 [1.02, 3.28]   
22+ 206 1.7 15 3.5 2.36 [1.33, 4.22] 2.37 [1.31, 4.30]   
Missing 2291 18.5 69 16.1 0.85 [0.63, 1.15] 0.86 [0.64, 1.17]   
Odds ratio for step increase in alcohol 1.22 [1.08, 1.37]  1.16 [1.02, 1.32] 1.16 [1.02, 1.32] 
  
Smoking  
Never 4774 38.5 177 41.3     
Ex 6081 49.1 200 46.6 0.86 [0.70, 1.07]    
Current 1200 9.7 47 11.0 0.97 [0.69, 1.35]    
Missing 342 2.8 5 1.2 0.48 [0.19, 1.19]    
  
BMI group  
<18.5 253 2.0 6 1.4 0.73 [0.32, 1.69]    
18.5- 4541 36.6 152 35.4 -    
25- 4719 38.1 167 38.9 1.08 [0.86, 1.36]    
30- 1495 12.1 61 14.2 1.26 [0.92, 1.72]    
35+ 328 2.7 14 3.3 1.28 [0.72, 2.27]    
Missing 1061 8.6 29 6.8 0.95 [0.62, 1.43]    
Increase in BMI group 1.11 [0.98, 1.26]    
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Waist:hip  
0.65-0.74 421 3.4 10 2.3 0.81 [0.42, 1.56] 0.80 [0.41, 1.56]   
0.75-0.84 3908 31.5 127 29.6     
0.85-0.94 4775 38.5 175 40.8 1.10 [0.86, 1.39] 1.13 [0.87, 1.47]    
0.95-1.04 2161 17.4 74 17.3 1.12 [0.83, 1.51] 1.14 [0.80, 1.63]   
1.05-1.15 197 1.6 17 4.0 3.26 [1.88, 5.65] 3.22 [1.79, 5.80]   
Missing 935 7.5 26 6.1 1.00 [0.65, 1.56] 1.10 [0.70, 1.73]   
Increase in waist:hip ratio group 1.17 [1.03, 1.32]  1.27 [1.07, 1.50] 1.27 [1.08, 1.50] 
  
Presence of Co-morbidity   
Diabetes 977 7.9 48 11.2 1.53 [1.12, 2.10]    
Heart attack 1319 10.6 39 9.1 0.87 [0.62, 1.22]    
Hypertension 4121 33.2 152 35.4 1.13 [0.92, 1.39]    
Stroke 1070 8.6 36 8.4 1.04 [0.73, 1.49]    
Cancer 1272 10.3 45 10.5 1.09 [0.79, 1.50]    
Ulcer 1476 11.9 57 13.3 1.15 [0.86, 1.54]    
Angina 778 6.3 23 5.4 0.88 [0.57, 1.36]    
Dementia 80 0.7 6 1.4 2.71 [1.15, 6.37]    
  
Co-morbidity score  
0 4427 34.5 852 34.3     
1 4809 37.5 850 34.3 1.14 [0.90, 1.44] 1.11 [0.88, 1.41]   
2 2353 18.4 442 17.8 1.21 [0.91, 1.61] 1.18 [0.88, 1.57]   
3+ 1036 8.1 189 7.6 1.27 [0.87, 1.84] 1.23 [0.84, 1.80]   
Missing 201 1.6 149 6.0 0.80 [0.34, 1.87] 0.81 [0.34, 1.94]   
Odds ratio for increase in co-morbidity score 1.09 [0.98, 1.21]  1.08 [0.96, 1.22] 1.08 [0.96, 1.22] 
*Multivariable model 1 adjusted for sex, age, alcohol consumption, WHR and comorbidity as categorical variables; model 2 using only subjects 
with complete data adjusted for sex plus age, alcohol consumption, WHR and comorbidity fitted as linear trend variables; model 3 as model 2 
with an interaction term for age and sex.  
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8.3.2 ALP 
Of the 13,499 participants with a valid measurement of ALP, 1246 (9.2%) had 
an elevated serum level of ALP (as reported in section 7.3.1.2).   
 
8.3.2.1 Univariable associations 
Sex 
Of those with an elevated ALP 62.9% were female which was not statistically 
different to the 60.9% of those with a normal measurement of ALP, OR 1.05 
(95%CI [0.93, 1.19]) (see Table 8-2).   
 
Age 
In direct contrast to that seen with elevations of AST (section 8.3.1 above) 
participants with an elevated ALP were more likely to be older than those with 
a normal ALP measurement, the odds ratio for a yearly increase in age being 
1.05 (95% CI[1.04, 1.07]).  Those aged 90 and over were twice as likely to 
have an elevated measurement of ALP than those aged 75.   
 
Alcohol consumption 
There was a statistically significant association between lower alcohol 
consumption and an elevated ALP with an odds ratio of 0.81 (95% CI[0.74, 
0.88]) for each 7-unit increase in weekly consumption meaning that for each 
additional 7 units consumed in a week participants were 20% less likely to 
have a measurement of elevated ALP.  Those participants reported as 
consuming 22 or more units of alcohol per week were 50% less likely to have 
an elevated measurement of ALP than those who did not report consuming 
any alcohol.   
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Smoking 
There was no statistically significant association between elevated ALP and 
being a current VPRNHUEXWWKHUHZDVDVPDOOµSURWHFWLYH¶HIIHFWFRQIHUUHGLQ
those recorded as ex-smokers with an odds ratio of 0.82 (95% CI[0.72, 0.94]) 
of having an elevated ALP compared with never smokers.   
 
Body size (BMI and WHR) 
There was no trend in association seen with increasing BMI category and 
elevated ALP.  However, those participants in the highest BMI category ± 
severely obese (BMI 35 or more) ± had a 50% greater chance of having an 
elevated ALP (OR 1.52 (95% CI[1.10, 2.10])).  There were no statistically 
significant associations seen between WHR and elevated ALP measurement.   
 
Comorbidities 
Reported history of diabetes and heart attack were associated with an 
elevated ALP (OR 1.64 (95% CI[1.35, 1.99]) and 1.24 (95% CI[1.03, 1.49]) 
respectively).  Additionally an assessment of dementia was significantly 
associated with an elevated measurement of ALP (OR 2.64 (95% CI[1.58, 
4.42])).   
 
8.3.2.2 Multivariable associations 
To build the multivariable model a priori confounders of age, sex and 
comorbidity as well as alcohol consumption were included.  Upon adjustment 
there remained a statistically significant association between elevated ALP 
and age, alcohol consumption and comorbidity score (see Table 8-2).  
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Table 8-2 Associations between demographic, lifestyle and medical characteristics and elevated ALP test 
 Normal ALP 
(N=12253) 
Elevated ALP (N=1246) OR [95% CI] OR [95% CI]  
 N % N % Univariable Model 1* Model 2* 
Sex        
Female 7456 60.9 784 62.9 1.05 [0.93, 1.19] 0.90 [0.79, 1.03] 0.94 [0.80, 1.09] 
Male 4797 39.1 462 37.1    
        
Age (years)        
Median age [IQR]  
(range) 
80.2 [77.2, 84.0] 
(75, 108) 
81.4 [77.6, 85.8]  
(75, 98) 
   
75- 1127 9.2 87 7.0 - - - 
76- 1581 12.9 139 11.2 1.01 [0.76, 1.34] 1.02 [0.76, 1.35]  
77- 1319 10.8 106 8.5 0.95 [0.71, 1.29] 0.96 [0.71, 1.30]  
78- 939 7.7 81 6.5 1.01 [0.73, 1.40] 1.01 [0.73, 1.39]  
79- 927 7.6 89 7.1 1.14 [0.83, 1.56] 1.12 [0.82, 1.54]  
80- 893 7.3 67 5.4 0.85 [0.61, 1.19] 0.83 [0.59, 1.16]  
81- 861 7.0 77 6.2 1.07 [0.77, 1.49] 1.06 [0.76, 1.47]  
82- 767 6.3 83 6.7 1.28 [0.93, 1.77] 1.24 [0.90, 1.72]  
83- 689 5.6 77 6.2 1.29 [0.92, 1.79] 1.25 [0.90, 1.74]  
84- 609 5.0 71 5.7 1.42 [1.01, 1.99] 1.37 [0.97, 1.92]  
85- 515 4.2 61 4.9 1.35 [0.95, 1.92] 1.30 [0.91, 1.85]  
86- 428 3.5 51 4.1 1.40 [0.96, 2.04] 1.34 [0.92, 1.95]  
87- 385 3.1 49 3.9 1.56 [1.07, 2.28] 1.47 [1.00, 2.15]  
88- 319 2.6 34 2.7 1.22 [0.80, 1.88] 1.16 [0.76, 1.79]  
89- 240 2.0 46 3.7 2.39 [1.60, 3.56] 2.29 [1.53, 3.42]  
90+ 600 4.9 117 9.4 2.40 [1.77, 3.25] 2.33 [1.71, 3.17]  
Missing 54 0.4 11 0.9 2.54 [1.24, 5.21] 2.38 [1.16, 4.90]  
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Odds ratio for yearly increase in age 1.05 [1.04, 1.07]  1.05 [1.03, 1.06] 
      
Alcohol      
Median units of 
alcohol intake in 
past week 
1 [0,4] (0,90) 
N=10008 
1 [0,4] (0,87) 
N=960 
   
Alcohol units      
0 4369 35.7 493 39.6 -   
1- 4305 35.1 356 28.6 0.70 [0.61, 0.82] 0.72 [0.62, 0.83]  
8- 866 7.1 77 6.2 0.71 [0.55, 0.92] 0.71 [0.54, 0.93]  
15- 251 2.1 20 1.6 0.54 [0.34, 0.88] 0.57 [0.35, 0.93]  
22+ 217 1.8 14 1.1 0.49 [0.28, 0.86] 0.49 [0.28, 0.87]  
Missing 2245 18.3 286 23.0 1.09 [0.93, 1.29] 1.04 [0.89, 1.23]  
Odds ratio for increase in alcohol group 0.81 [0.74, 0.88]  0.83 [0.76, 0.91] 
        
Smoking        
Never 4696 38.3 519 41.7    
Ex 6028 49.2 557 44.7 0.82 [0.72, 0.94] 0.92 [0.80, 1.06] 0.91 [0.77, 1.06] 
Current 1189 9.7 142 11.4 1.06 [0.86, 1.29] 1.22 [0.99, 1.51] 1.25 [0.98, 1.58] 
Missing 340 2.8 28 2.3 0.79 [0.52, 1.18] 0.76 [0.50, 1.15]  
        
BMI group        
<18.5 239 2.0 34 2.7 1.36 [0.93, 1.99]   
18.5- 4470 36.5 475 38.1 -   
25- 4709 38.4 414 33.2 0.85 [0.74, 0.98]   
30- 1521 12.4 125 10.0 0.79 [0.64, 0.98]   
35+ 317 2.6 51 4.1 1.52 [1.10, 2.10]   
Missing 997 8.1 147 11.8 1.57 [1.28, 1.94]   
    Trend 0.95 [0.88, 1.03]   
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Waist:hip 
0.65-0.74 411 3.4 40 3.2 1.02 [0.72, 1.45]   
0.75-0.84 3886 31.7 367 29.5 -   
0.85-0.94 4721 38.5 499 40.1 1.09 [0.94, 1.26]   
0.95-1.04 2130 17.4 196 15.7 0.99 [0.83, 1.21]   
1.05-1.15 204 1.7 16 1.3 0.90 [0.53, 1.54]   
Missing 901 7.4 128 10.3 1.75 [1.40, 2.19]   
    Trend 1.00 [0.93, 1.08]   
        
Presence of Co-morbidity       
Diabetes 925 7.6 144 11.6 1.64 [1.35, 1.99]   
Heart attack 1277 10.4 159 12.8 1.24 [1.03, 1.49]   
Hypertension 4114 33.6 388 31.1 0.89 [0.78, 1.01]   
Stroke 1045 8.5 111 8.9 1.05 [0.85, 1.29]   
Cancer 1242 10.1 126 10.1 0.97 [0.80, 1.19]   
Ulcer 1461 11.9 159 12.8 1.11 [0.92, 1.32]   
Angina 753 6.2 82 6.6 1.02 [0.80, 1.30]   
Dementia 77 0.6 20 1.6 2.64 [1.58, 4.42]   
        
Co-morbidity score        
0 4262 34.8 413 33.2 - -  
1 4593 37.5 468 37.6 1.06 [0.92, 1.22] 1.08 [0.94, 1.25]  
2 2238 18.3 228 18.3 1.04 [0.87, 1.24] 1.08 [0.91, 1.29]  
3+ 972 7.9 115 9.2 1.25 [1.00, 1.57] 1.29 [1.03, 1.62]  
Missing 188 1.5 22 1.8 1.45 [0.91, 2.31] 1.22 [0.76, 1.96]  
Odds ratio for increase in co-morbidity score 1.05 [0.99, 1.12]  1.12 [1.04, 1.21] 
*Multivariable model 1 adjusted for sex, age, alcohol consumption, smoking status and comorbidity as categorical variables; model 2 using only 
subjects with complete data adjusted for sex, smoking status plus age, alcohol consumption and comorbidity fitted as linear trend variables 
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8.3.3 Bilirubin 
Of the 12,690 participants with a valid measurement of bilirubin, 690 (5.4 %) 
had an elevated serum level of bilirubin (as reported in section 7.3.1.3).   
 
8.3.3.1 Univariable associations 
Sex 
Of those with an elevated bilirubin only 38.3% were female which was 
significantly different to the 62.4% of those with a normal measurement of 
bilirubin (OR 0.37 (95%CI [0.32, 0.44])) (see Table 8-3).   
 
Age 
Unlike with AST and ALP there was no association seen between elevated 
bilirubin and age (OR 0.99 (95% CI[0.97, 1.01])). 
 
Alcohol consumption 
There was a statistically significant association between higher alcohol 
consumption and an elevated bilirubin with an odds ratio of 1.20 (95% CI[1.09, 
1.31]) for each 7-unit increase in weekly consumption meaning that for each 
additional 7 units consumed in a week a participants were 20% more likely to 
have a measurement of elevated bilirubin.  Those participants who reported 
consuming 22 or more units of alcohol in a week were over twice as likely to 
have an measurement of elevated bilirubin compared to those who did not 
consume any alcohol.  
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Smoking 
There was a statistically significant association between elevated bilirubin and 
being an ex-smoker (OR 1.22 (95% CI[1.03, 1.44])) but there was no 
association for those recorded as current smokers compared with never 
smokers (OR 0.76 (95% CI[0.56, 1.05])).   
 
Body Size (BMI and WHR) 
There was no trend in association seen with increasing BMI category and 
elevated bilirubin.  However, those participants in the highest BMI category ± 
severely obese (BMI 35 or more) ± had a greater than 50% reduction in the 
chance of having an elevated bilirubin measurement (OR 0.44 (95% CI[0.22, 
0.86])).  There was a statistically significant association seen in increasing 
WHR and elevated bilirubin with each increase in WHR category conferring a 
27% increase in odds of having an elevated bilirubin (OR 1.27 (95% CI[1.15, 
1.40])).   
 
Comorbidities 
None of the individual comorbidities examined showed any association with 
elevated bilirubin.  Unsurprisingly, when examining comorbidity as a 
composite score there was no statistically significant association seen 
between increasing score in the derived comorbidity index and elevation of 
bilirubin.   
8.3.3.2 Multivariable associations 
To build the multivariable model a priori confounders of age, sex and 
comorbidity as well as alcohol consumption, smoking and WHR were 
included.  Upon adjustment there remained a statistically significant 
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association between elevated bilirubin and sex but the associations between 
alcohol consumption and WHR with elevated bilirubin were removed (see 
Table 8-3) 
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Table 8-3  Associations between demographic, lifestyle and medical characteristics and an elevated bilirubin test 
 Normal bilirubin 
(N=12000) 
Elevated bilirubin 
(N=690) 
OR [95% CI] Adjusted OR 
[95% CI] 
Adjusted OR  
[95% CI] 
 N % N % Univariable Model 1* Model 2* 
Sex        
Male 4518 37.6 426 61.7 -   
Female 7482 62.4 264 38.3 0.37 [0.32, 0.44] 0.33 [0.27, 0.41] 0.33 [0.26, 0.42] 
        
Age (years)        
Median age [IQR] 
(range) 
80.2 [77.2, 84.1] 
(75, 108) 
80.0 [77.0, 83.4]  
(75, 98) 
   
75- 1056 8.8 66 9.6 - -  
76- 1536 12.8 98 14.2 0.99 [0.71, 1.37] 0.99 [0.71, 1.37]  
77- 1261 10.5 66 9.6 0.83 [0.58, 1.18] 0.83 [0.58, 1.19]  
78- 934 7.8 50 7.3 0.82 [0.56, 1.20] 0.83 [0.57, 1.23]  
79- 899 7.5 59 8.6 1.03 [0.71, 1.48] 1.04 [0.72, 1.51]  
80- 865 7.2 42 6.1 0.75 [0.50, 1.12] 0.79 [0.52, 1.18]  
81- 831 6.9 55 8.0 1.00 [0.69, 1.46] 1.05 [0.71, 1.53]  
82- 748 6.2 53 7.7 1.11 [0.76, 1.62] 1.21 [0.83, 1.78]  
83- 681 5.7 40 5.8 0.94 [0.62, 1.41] 0.99 [0.65, 1.50]  
84- 604 5.0 27 3.9 0.69 [0.43, 1.10] 0.72 [0.45, 1.16]  
85- 515 4.3 26 3.8 0.79 [0.49, 1.26] 0.80 [0.50, 1.30]  
86- 436 3.6 15 2.2 0.53 [0.30, 0.94] 0.56 [0.31, 1.01]  
87- 380 3.2 30 4.4 1.22 [0.77, 1.92] 1.36 [0.86, 2.16]  
88- 318 2.7 15 2.2 0.75 [0.42, 1.34] 0.86 [0.48, 1.55]  
89- 257 2.1 12 1.7 0.70 [0.37, 1.33] 0.79 [0.41, 1.50]  
90+ 623 5.2 29 4.2 0.73 [0.46, 1.15] 0.87 [0.55, 1.39]  
Missing 56 0.5 7 1.0 1.71 [0.74, 3.98] 1.75 [0.74, 4.14]  
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Odds ratio for yearly increase in age 0.99 [0.97, 1.01]  0.99 [0.97, 1.01] 
      
Alcohol      
Median units of 
alcohol intake in past 
week 
1  
[0, 4]  
(0, 90) 
N=9746 
1  
[0, 6]  
(0, 44) 
N=585 
   
Alcohol units      
0 4361 36.3 234 33.9 -   
1- 4117 34.3 251 36.4 1.15 [0.96, 1.39] 1.02 [0.85, 1.24]  
8- 830 6.9 61 8.8 1.42 [1.05, 1.91] 1.04 [0.76, 1.41]  
15- 243 2.0 19 2.8 1.60 [0.98, 2.63] 1.10 [0.66, 1.81]  
22+ 195 1.6 20 2.9 2.24 [1.37, 3.66] 1.45 [0.88, 2.40]  
Missing 2254 18.8 105 15.2 0.90 [0.71, 1.15] 0.94 [0.73, 1.20]  
Odds ratio for increase in alcohol group 1.20 [1.09, 1.31]  1.06 [0.96, 1.18] 
        
Smoking        
Never 4617 38.5 244 35.4    
Ex 5823 48.5 381 55.2 1.22 [1.03, 1.44] 0.83 [0.69, 1.00] 0.79 [0.65, 0.97] 
Current 1212 10.1 50 7.3 0.76 [0.56, 1.05] 0.53 [0.38, 0.73] 0.47 [0.32, 0.68] 
Missing 348 2.9 15 2.2 0.86 [0.50, 1.48] 0.63 [0.36, 1.10]  
        
BMI group        
<18.5 247 2.1 14 2.0 0.95 [0.54, 1.66]   
18.5- 4402 36.7 256 37.1 -   
25- 4504 37.5 292 42.3 1.10 [0.92, 1.31]   
30- 1452 12.1 79 11.5 0.91 [0.70, 1.19]   
35+ 333 2.8 9 1.3 0.44 [0.22, 0.86]   
Missing 1062 8.9 40 5.8 0.67 [0.47, 0.94]   
Odds ratio for increase in BMI group 0.94 [0.85, 1.04]   
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Waist:hip 
       
0.65-0.74 391 3.3 20 2.9 1.36 [0.84, 2.20] 1.51 [0.93, 2.45]  
0.75-0.84 3827 31.9 149 21.6    
0.85-0.94 4608 38.4 314 45.5 1.73 [1.41, 2.12] 1.07 [0.85, 1.34]  
0.95-1.04 2008 16.7 154 22.3 1.88 [1.48, 2.38] 0.86 [0.65, 1.13]  
1.05-1.15 195 1.6 15 2.2 1.65 [0.94, 2.90] 0.75 [0.41, 1.35]  
Missing 971 8.1 38 5.5 1.00 [0.69, 1.45] 0.72 [0.49, 1.06]  
    Trend 1.27 [1.15, 1.40]  0.90 [0.79, 1.03] 
        
Presence of Co-morbidity  
Diabetes 941 7.8 61 8.8 1.12 [0.85, 1.48]   
Heart attack 1283 10.7 71 10.3 0.97 [0.75, 1.25]   
Hypertension 3987 33.2 231 33.5 1.00 [0.85, 1.18]   
Stroke  1041 8.7 48 7.0 0.77 [0.57, 1.04]   
Cancer 1219 10.2 62 9.0 0.90 [0.68, 1.17]   
Ulcer 1446 12.1 91 13.2 1.14 [0.90, 1.43]   
Angina 746 6.2 47 6.8 1.14 [0.84, 1.56]   
Dementia 92 0.8 2 0.3 0.38 [0.09, 1.54]   
        
Co-morbidity score       
0   4152 34.6 238 34.5 -   
1 4502 37.5 254 36.8 0.99 [0.82, 1.19] 0.98 [0.81, 1.18]  
2 2174 18.1 137 19.9 1.10 [0.88, 1.37] 1.07 [0.85, 1.34]  
3+ 980 8.2 48 7.0 0.87 [0.63, 1.21] 0.86 [0.65, 1.13]  
Missing 192 1.6 13 1.9 1.30 [0.72, 2.34] 0.75 [0.41, 1.35]  
Odds ratio for increase in co-morbidity score 0.99 [0.91, 1.07]  0.98 [0.89, 1.08] 
*Multivariable model 1 adjusted for sex, age, alcohol consumption, smoking status, WHR and comorbidity as categorical variables; model 2 
using only subjects with complete data adjusted for sex, smoking status plus age, alcohol consumption, WHR and comorbidity fitted as linear 
trend variables
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8.4 Discussion 
8.4.1 Key findings 
This study has determined the associations between elevated LFTs and 
various demographic, lifestyle and clinical characteristics in a population of 
people aged 75 and over.   
Of note were the observed associations between age and alcohol 
consumption with elevated AST and ALP.  The odds ratios for the associations 
between AST and these variables were almost exactly the inverse of the 
associations seen between ALP and these variables. Increasing age was 
associated with a decreased risk of an elevated measurement of AST 
(adjusted OR for 1-year increase in age 0.97 (95% CI[0.94, 0.99])) but an 
increased risk of an elevated measurement of ALP (adjusted OR for 1-year 
increase in age 1.04 (95% CI[1.03, 1.06])).  Increasing alcohol consumption 
was associated with an increased risk of an elevated measurement of AST 
(adjusted OR for seven unit increase in alcohol consumption 1.16 (95% 
CI[1.02, 1.32])) but a decreased risk of an elevated measurement of ALP 
(adjusted OR for seven unit increase in alcohol consumption 0.83 (95% 
CI[0.76, 0.91])).     
Both elevated AST and ALP were shown to be associated with the diagnosis 
of diabetes and dementia.  Additionally elevated ALP was associated with 
heart attack.   
Being male was very highly associated with having a abnormal measurement 
of bilirubin (adjusted OR for elevated bilirubin for females 0.45 (95% CI[0.35, 
0.58])). Upon multivariable adjustment both being an ex-smoker or a current 
smoker appeared to confer some protection against having an elevated 
bilirubin measurement.   
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8.4.2 Strengths and limitations 
This study relied on a single measurement of each of AST, ALP and bilirubin.  
Naturally it would be desirable to have multiple measurements of these liver 
function tests in order to assess whether an abnormality was persistent and 
therefore that there was a consistent association with any given characteristic 
of interest.   
 
Although I have been able to examine the associations of several 
characteristics with elevated LFTs in this large population there are limitations 
in the interpretation of these findings resulting from the absence of particular 
data items from the initial data collection.  Particularly the absence of data on 
diagnosed or recognised liver disease means that I am not able to exclude the 
presence of liver disease as a potential confounder of any of the associations 
seen.  The examination of so many associations will also potentially have led 
to some statistically significant findings occurring just through chance alone.   
 
I was able to examine the associations between several individual diseases 
and elevated LFTs as well as a derived comorbidity index.  The derivation of a 
comorbidity index was a pragmatic approach to try and account for the 
potential for multiple diseases to be present in one individual.  As I was 
analysing these data as a secondary source it was not possible to derive a 
more recognised comorbidity index, such as the Charlson score (described in 
section 4.2.2) as several of the data items needed to create such a score were 
not available from the original questionnaires.   
As well as not being able to adjust for some relevant comorbidity it was also 
not possible to adjust for any medications that the participants may have been 
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taking (as this information was not available to me) which may have affected 
the levels of serum enzymes recorded.  However, the adjusted odds ratios 
include a measure of comorbidity which may have partially taken this into 
account.  
 
As with any cross-sectional study it is not possible to infer anything regarding 
causality from these results.  For example, it is equally possible that having 
had a heart attack led to an elevation in ALP or that the underlying reason for 
the elevation in ALP was also the mechanism that led to the heart attack.  
Either pathway would result in a positive association as seen in these data.   
 
8.4.3 Comparison with previous studies 
As discussed in section 1.4.2.2 there have been a number of studies reporting 
associations between various characteristics and elevated LFTs but with little 
consistency in the definition of abnormality and some disagreement in the 
direction and magnitude of the associations.  Many of these studies have also 
focussed on abnormalities in transaminases, considering elevations of AST 
and ALT together, with a lack of data on individual elevations of AST, ALP or 
bilirubin.   
 
The recent study of residents in Tayside, Scotland with a measurement of liver 
function showed a very different pattern of association with comorbidity to that 
which I have described in this study.66  An elevated measurement of ALP was 
associated with a statistically significant lower risk of several comorbidities 
(ischaemic heart disease, diabetes, respiratory disease and cancer) but with a 
slightly higher risk of biliary disease probably reflecting the selection bias 
inherent in this study.  My analysis has shown an increased risk of diabetes, 
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heart attack and dementia with elevated ALP.  In the study in Tayside, an 
elevated measurement of bilirubin was associated with a statistically 
significant lower risk of all of these comorbidities with the exception of 
diabetes in contrast with my analysis where there was no association between 
bilirubin and any of the diagnosed or self-reported diseases recorded.  
However, the proportion of patients within this study with these diagnosed co-
morbidities is much lower than that seen in my study, perhaps reflecting the 
older age group of my study.   
Similar to the results shown in section 8.3.1 the authors of the study in 
Scotland showed a higher proportion of patients with elevated transaminases 
to have a record of alcohol abuse.66  However, they did not present any data 
on actual alcohol consumption.  In contrast to my results in section 8.3.2 they 
also report a higher proportion of patients with an elevated ALP to have a 
record of alcohol abuse.   
 
One study from America showed a lower prevalence of elevated 
aminotransferases in older ages (70+), which would be consistent with my 
findings of lower risk of elevated AST with increasing age, but there were no 
details presented at the fine level as in my study.70 
 
Several studies report an association between an elevated measurement of 
AST and the presence or development of diabetes similar to that seen in my 
study. 68 70 73 74  
Many studies also report an association between increasing BMI and elevated 
liver function tests, particularly transaminases.69 70 71 75   I did not see a 
relationship between increasing BMI and elevated liver function but did 
observe a relationship between increasing WHR category and elevated AST 
and also elevated bilirubin.  This is possibly due to the fact that WHR is 
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considered a more accurate assessment of body fatness in older people 
owing to the increase in BMI that will occur as a result of shortening height.116 
A similar relationship as I have described between increasing alcohol 
consumption and elevated transaminases has previously been shown in 
studies in both the USA and South Korea.68 71 75   Another study has not 
shown this relationship though it is hard to directly compare my data with this 
study as they classify drinkers as simply more or less than 3 units per day as 
opposed to examining a trend in increasing consumption.69 
 
8.4.4 Conclusions  
This study has shown a number of potentially interesting associations between 
demographic, lifestyle and clinical factors and elevated liver function tests.  
That the results for measurement of elevated AST and ALP with respect to 
age and alcohol are almost the exact opposite of each other is particularly 
worthy of note.  That an elevated measurement of AST is associated with an 
increasing alcohol consumption even at older ages may suggest continued 
damage or sustained damage following earlier damage caused by consistently 
high levels of alcohol consumption.   
The finding of elevated bilirubin to be so strongly associated with being male is 
also worth consideration.  It is possible that there is a much higher prevalence 
oI*LOEHUW¶VV\QGURPHDPRQJPHQDOWKRXgh I could not examine this within 
these data.   
 
The LFTs that I have studied may not actually be markers of liver function (as 
discussed in section 1.4.2).  Indeed the observed associations with other 
comorbid conditions, particularly diabetes, might suggest that these enzymes 
are produced in more significant amounts in the presence of other diseases.   
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It is possible that diabetes is a marker of undiagnosed (or non-recorded) non-
alcoholic fatty liver disease or other underlying syndromes that may be the 
precursor of liver disease.   
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9 Mortality associated with elevated liver function 
tests 
9.1 Introduction 
This study aims to determine the health consequences in people aged over 75 
with elevated liver function tests, in terms of the risk of all cause and cause-
specific mortality.   
 
9.2 Methods 
9.2.1 Dataset used 
The data used in this study are those from the detailed nurse assessment 
FRQWDLQHGZLWKLQWKHµGHWDLO¶GDWDEDVHDVZHOl as information taken from the 
µGHDWKV¶DQGµFHQVRULQJ¶GDWDEDVHV6HHFigure 6-2).  A total of 15,308 
participants aged 75 and over are included in the subsequent analyses.  The 
definition of elevated liver function is as described in section 7.2.3.1 following 
imputation of missing upper limits using the median reference ranges.  
 
9.2.2 Additional definitions 
9.2.2.1 Cause of death 
Deaths were coded according to the International Classification for Diseases, 
9th revision (ICD9) until September 2002, and according to the 10th revision 
(ICD10) afterwards.  I specifically examined causes of death that are most 
common in patients of this age group,117 namely from cardiovascular disease 
(ICD9 401-405, 410-414, 425-447; ICD10 I10-I15, I20-I25, I42-I52, I6-I77, 
I79), cancer (all cancers excluding liver cancer (ICD9 140-154, 156-239; 
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ICD10 C0-C21, C23-D4)), respiratory disease (ICD9 46-51; ICD10 J).  I was 
additionally interested in mortality from liver disease (viral hepatitis, liver 
cancer and liver disease (ICD9 070, 155, 570-573; ICD10 B15-B19, C22, K7)).  
Participants were assigned cause of death based on the underlying cause of 
death as given by the NHSCR. 
 
9.2.3 Statistical analysis 
Subjects were considered as contributing time to the analysis from the date of 
interview until death, censoring (migration) or 5 November 2005 (the last date 
of available data from the ONS) whichever came earliest.  Associations 
between death and demographic, lifestyle and medical characteristics were 
examined in a control population consisting of all those people without any 
LFT abnormality in order to identify appropriate confounding variables.  All 
cause and cause-specific mortality were examined for each elevated LFT in 
turn.  Cox proportional hazards regression analysis was used to compare the 
survival of cohorts with normal and elevated LFTs.  Analysis was performed 
treating an individual practice as a clustered unit.  A priori confounders of age, 
sex and co-morbidity as well as other confounders identified in Section 8.3 for 
individual LFTs were included within multivariate cox proportional hazards 
models to provide adjusted hazard ratios.  Proportional hazards assumptions 
were checked using Schoenfeld residuals and log-log plots.   
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9.3 Results 
9.3.1 Mortality of whole population 
Of the 15,308 participants in this study, 9268(60.5%) had died by 5 November 
2005 (see Table 9-1).  Deaths from cardiovascular disease, cancer and 
respiratory disease accounted for 7200 (77.7%) of all deaths in this 
population.  Only 52 (0.6%) participants were recorded as having died from 
liver disease.   
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Table 9-1 Selected causes of death 
Cause of death  
 N 
% 
(of total 
deaths) 
Total deaths 9268 100 
Cancer 1715 18.5 
CVD 3912 42.2 
Respiratory 1573 17.0 
Liver 52 0.6 
All other 1999 21.6 
Missing 17 0.2 
Alive 6040  
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9.3.2 Associations between death and demographic, 
lifestyle and clinical characteristics 
Examining the population of participants with no elevated LFTs revealed 
significant associations between sex, age, smoking status, BMI, WHR and 
comorbidity and risk of death on univariable analysis (see Table 9-2).  There 
was a decreased risk of death associated with being female and increasing 
BMI for increase in BMI category) but an increased risk of death associated 
with increasing age, being a smoker (current or ex-), increasing WHR and 
increasing comorbidity score.  All individual comorbidities examined showed 
an increased risk of death, bar cancer and hypertension.  There was no 
statistically significant association between increasing alcohol consumption 
and death.   
Multivariable analysis included sex, age, smoking status, WHR and 
comorbidity score with all variables remaining statistically significantly 
associated with death upon mutual adjustment.   
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Table 9-2 Association between demographic, lifestyle and clinical factors and 
death in population with no elevated liver function test 
 Alive 
(N=4227) 
Dead 
(N=5798) 
OR [95% CI] OR [95% CI] 
 N % N % Univariable Multivariable 
Sex       
Female 2841 67.2 3381 58.3 0.67 [0.61, 0.72] 0.62 [0.55, 0.70] 
Male 1386 32.8 2417 41.7   
       
Age       
Median age 
[IQR] (range) 
    
Age group 
(fine) 
      
75- 539 12.7 352 6.1   
76- 766 18.1 517 8.9   
77- 629 14.9 450 7.7.   
78- 408 9.7 376 6.5   
79- 350 8.3 400 6.9   
80- 326 7.7 406 7.0   
81- 306 7.2 406 7.0   
82- 234 5.5 382 6.6   
83- 166 3.9 403 7.0   
84- 148 3.5 350 6.0   
85- 97 2.3 323 5.6   
86- 78 1.9 292 5.0   
87- 61 1.4 255 4.4   
88- 44 1.0 224 3.9   
89- 23 0.5 175 3.0   
90+ 31 0.7 463 8.0   
Missing 21 0.5 24 0.4   
Odds ratio for yearly increase in age 1.20 [1.18, 1.21] 1.22 [1.20, 1.23] 
     
Alcohol     
Median units 
of alcohol 
intake in past 
week 
    
Alcohol units     
0 1490 35.3 2104 36.3   
1- 1640 38.8 1919 33.1   
8- 309 7.3 383 6.6   
15- 92 2.2 114 2.0   
22+ 58 1.4 104 1.8   
Missing 638 15.0 1174 20.2   
Odds ratio for increase in alcohol group 0.95 [0.91, 1.01] - 
       
Smoking       
Never 1743 41.2 2074 35.8   
Ex 2070 49.0 2854 49.2 1.16 [1.06, 1.26] 1.18 [1.06, 1.31] 
Current 301 7.1 685 11.8 1.88 [1.61, 2.18] 2.42 [2.04, 2.87] 
Missing 113 2.7 185 3.2   
       
BMI group       
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<18.5 49 1.2 156 2.7 2.16 [1.56, 3.01]  
18.5- 1505 35.6 2152 37.1 -  
25- 1837 14.5 1998 34.5 0.76 [0.69, 0.83]  
30- 543 12.9 679 11.7 0.87 [0.76, 0.99]  
35+ 124 2.9 132 2.3 0.72 [0.56, 0.93]  
Missing 169 4.0 681 11.8   
Odds ratio for increase in BMI group 0.86 [0.82, 0.91]  
 
      
Waist:hip 
      
0.65-0.74 174 4.1 157 2.7 0.87 [0.69, 1.10]  
0.75-0.84 1580 37.4 1638 28.3 -  
0.85-0.94 1573 37.2 2253 38.9 1.42 [1.29, 1.56]  
0.95-1.04 665 15.7 1047 18.1 1.59 [1.41, 1.80]  
1.05-1.15 52 1.2 110 1.9 2.20 [1.56, 3.09]  
Missing 183 4.3 593 10.2   
    Trend 1.28 [1.21, 1.34] 1.08 [1.01, 1.16] 
       
Presence of Co-morbidity 
Diabetes 219 5.2 530 9.1 1.85 [1.57, 2.19]  
Heart attack 303 7.2 741 12.8 1.89 [1.64, 2.18]  
Hypertension 1406 33.3 1925 33.2 1.02 [0.93, 1.11]  
Stroke  196 4.6 684 11.8 2.74 [2.32, 3.23]  
Cancer 419 9.9 616 10.6 1.09 [0.95, 1.24]  
Ulcer 468 11.1 734 12.7 1.14 [1.01, 1.29]  
Angina 236 5.6 393 6.8 1.21 [1.02, 1.44]  
Dementia 5 0.1 56 1.0 7.86 [3.14, 19.7]  
       
Co-morbidity score      
0  1677 39.7 1813 32.3   
1 1635 38.7 2114 36.5 1.20 [1.09, 1.31]  
2 648 15.3 1171 20.2 1.68 [1.49, 1.89]  
3+ 224 5.3 583 10.0 2.43 [2.05, 2.88]  
Odds ratio for increase in co-morbidity score 1.32 [1.26, 1.38] 1.39 [1.32, 1.46] 
*adjusted for age, sex, smoking, WHR and comorbidity score.   
  
230 
 
9.3.3 Mortality associated with elevated AST 
Mortality in subjects with an elevated AST was 104.8 per 1000 person-years 
representing an increase of 10 deaths per 1000 person-years of follow-up 
compared to subjects with a normal AST (see Table 9-3).  This corresponded 
to an adjusted hazard ratio of 1.27, i.e. an elevated AST was associated with a 
27% (95% CI [9%, 47%]) increased hazard for all-cause mortality.  This is 
displayed visually in the Kaplan-Meier plot (see Figure 9-1).  There was an 
increased hazard of death observed with increasing levels of abnormality with 
patients, with an elevated AST over 2 times the ULN having a 62% increased 
hazard of death.   
An elevated AST was associated with an increase in mortality from cancer 
(56% increased hazard) and mortality from liver disease (7-fold increased 
hazard) (see Table 9-3).  It should be noted that only 8 out of 429 subjects 
(1.8%) with an elevated AST died from liver disease.   
Examining the Schoenfeld residuals and log-log plots gave no evidence of 
invalidation of the proportional hazards assumption (see Figure 9-2 and Figure 
9-3). 
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Table 9-3 Cox proportional hazards model for death (all-cause and cause-specific mortality) by AST test 
 Events Person-
years 
Mortality rate  
(per 1000 
person years) 
Hazard ratio 
[95%CI] 
Adjusted Hazard ratio* [95%CI] 
All-cause mortality 
    
Normal AST 7319 77485 94.5 -  
Elevated AST 271 2586 104.8 1.11 [0.99, 1.26] 1.27 [1.09, 1.47] 
Elevated AST within 1x 229 2267 101.0 1.07 [0.92, 1.24] 1.17 [1.02, 1.34] 
Elevated AST over 2x 42 319 131.7 1.43 [1.04, 1.96] 1.62 [1.22, 2.16] 
Hazard ratio for increase in AST abnormality group 1.12 [1.02, 1.24] 1.26 [1.12, 1.41] 
 
Cause-specific mortality     
CVD      
Normal AST 3097 77485 40.0 -  
Elevated AST 109 2586 42.1 1.06 [0.87, 1.28] 1.15 [0.92, 1.44] 
Cancer (excluding liver cancer)    
Normal AST 1359 77485 17.5 -  
Elevated AST 63 2586 24.4 1.40 [1.09, 1.80] 1.56 [1.21, 2.01] 
Respiratory disease     
Normal AST 1235 77485 15.9 -  
Elevated AST 33 2586 12.7 0.80 [0.57, 1.13] 1.03 [0.70, 1.52] 
Liver disease      
Normal AST 38 77485 0.49 -  
Elevated AST 8 2586 3.09 6.28 [2.92, 13.5] 7.00 [2.88, 17.06] 
*adjusted for age, sex, comorbidity group, alcohol intake and WHR group. 
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Figure 9-1 Kaplan-Meier survival estimates for all-cause mortality for AST 
measurement 
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Figure 9-2 Log-log plot for all-cause mortality for AST measurement 
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Figure 9-3 Schoenfeld residuals against time for all-cause mortality for 
measurement of AST 
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9.3.4 Mortality associated with elevated ALP 
Mortality in subjects with an elevated ALP was 138.8 per 1000 person-years of 
follow-up representing an increase of nearly 50 deaths per 1000 person years 
compared with subjects with a normal ALP measurement (see Table 9-4).   An 
elevated ALP measurement was associated with a 47% increase in hazard of 
death, adjusted for age, sex, co-morbidity score and alcohol intake (hazard 
ratio 1.47; 95% CI [1.35, 1.61]).  This higher hazard of death is shown 
graphically in the Kaplan-Meier plot (see Figure 9-4). 
An elevated ALP was associated with an increased hazard for death from 
CVD (34% increase), death from cancer (61% increase), death from 
respiratory disease (58% increase) and death from liver disease (nearly 6-fold 
increase) (see Table 9-4).   However, only 13 out of 1246 subjects (1.0%) with 
an elevated ALP died from liver disease.   
Examining the Schoenfeld residuals and log-log plots gave no evidence of 
invalidation of the proportional hazards assumption (see Figure 9-5 and Figure 
9-6).   
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Table 9-4  Cox proportional hazards model for death (all-cause and cause-specific mortality) by ALP test 
 Events Person-
years 
Mortality rate  
(per 1000 
person years) 
Hazard ratio [95%CI] Adjusted Hazard ratio* 
[95%CI] 
All-cause mortality 
    
Normal ALP 7068 77752 90.9 -  
Elevated ALP 903 6503.9 138.8 1.58 [1.47, 1.69] 1.47 [1.35, 1.61] 
Elevated ALP within 1x 809 5895.7 137.2 1.56 [1.44, 1.68] 1.42 [1.32, 1.52] 
Elevated ALP over 2x 94 608.3 154.5 1.76 [1.44, 1.68] 1.44 [1.13, 1.84] 
Hazard ratio for increase in ALP abnormality group 1.47 [1.39, 1.56] 1.37 [1.26, 1.48] 
 
Cause-specific mortality 
Cardiovascular disease     
Normal ALP 3010 77752 38.7 -  
Elevated ALP 358 6504 55.0 1.46 [1.30, 1.62] 1.34 [1.17, 1.55] 
Cancer (excluding liver cancer)    
Normal ALP 1324 77752 17.0 -  
Elevated ALP 174 6504 26.8 1.61 [1.37, 1.89] 1.61 [1.39, 1.86] 
Respiratory disease     
Normal ALP 1181 77752 15.2 -  
Elevated ALP 161 6504 24.8 1.68 [1.42, 1.98] 1.58 [1.32, 1.90] 
Liver disease      
Normal ALP 35 77752 0.45 -  
Elevated ALP 13 6503.9 2.00 4.59  [2.43, 8.69] 5.95 [2.83, 12.51] 
*adjusted for age, sex, comorbidity group and alcohol intake 
237 
 
 
 
Figure 9-4 Kaplan-Meier survival estimates for all-cause mortality for ALP 
measurement 
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Figure 9-5 Log-log plot for all-cause mortality for ALP measurement 
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Figure 9-6 Schoenfeld residuals against time for all-cause mortality for 
measurement of ALP 
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9.3.5 Mortality associated with elevated bilirubin 
Elevated bilirubin was associated with a small increase in hazard of death 
(15%, 95%CI [2%, 30%]) following adjustment for the confounding factors of 
age, sex, comorbidity score, smoking status, alcohol consumption and WHR 
group (see Table 9-5).  This slight increase in hazard of death is shown 
graphically in the Kaplan-Meier plot (see Figure 9-10). 
Elevated bilirubin was not associated with a change in hazard of any cause-
specific mortality examined (see Table 9-5).   
Examining the Schoenfeld residuals and log-log plots gave no evidence of 
invalidation of the proportional hazards assumption (see Figure 9-8 and Figure 
9-9).   
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Table 9-5  Cox proportional hazards model for death (all-cause and cause-specific mortality) by bilirubin test 
 Events Person-
years 
Mortality rate  
(per 1000 
person years) 
Hazard ratio [95%CI] Adjusted Hazard ratio* 
[95%CI] 
All-cause mortality 
    
Normal Bilirubin 7063 75176 94.0 -  
Elevated Bilirubin 416 4109 101.2 1.09 [0.99, 1.20] 1.15 [1.02, 1.30] 
Elevated bilirubin within 1x 388 3866 100.4 1.08 [0.98, 1.19] 1.14 [0.99, 1.29] 
Elevated bilirubin over 2x 28 243 115.3 1.24 [0.86, 1.79] 1.35 [0.91, 2.00] 
Hazard ratio for increase in bilirubin abnormality group 1.09 [1.00, 1.18] 1.07 [0.98, 1.17] 
 
Cause-specific mortality 
Cardiovascular disease     
Normal Bilirubin 2981 75176 39.7 -  
Elevated Bilirubin 190 4109 46.2 1.18 [1.02, 1.36] 1.15 [0.98, 1.36] 
Cancer (excluding liver cancer)    
Normal Bilirubin 1331 75176 17.7 -  
Elevated Bilirubin 69 4109 16.8 0.96 [0.75, 1.22] 0.90 [0.68, 1.19] 
Respiratory disease     
Normal Bilirubin 1203 75176 16.0 -  
Elevated Bilirubin 58 4109 14.1 0.89 [0.68, 1.16] 0.97 [0.69, 1.35] 
Liver disease      
Normal Bilirubin 44 75176 0.6   
Elevated Bilirubin 5 4109 1.22 2.11 [0.84, 5.32] 1.71 [0.63, 4.65] 
*adjusted for age, sex, comorbidity group, alcohol intake, smoking status and WHR group.
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Figure 9-7 Kaplan-Meier survival estimates for all-cause mortality for bilirubin 
measurement 
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Figure 9-8 Log-log plot for all-cause mortality for bilirubin measurement 
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Figure 9-9 Schoenfeld residuals against time for all-cause mortality for 
measurement of bilirubin 
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9.3.6 Mortality associated with any elevated LFT 
Mortality in subjects with any elevated LFT was 118.4 per 1000 person-years 
representing an increase of nearly 18 deaths per 1000 person-years of follow-
up compared to subjects with all normal LFTs (see Table 9-6).  This 
corresponded to an adjusted hazard ratio of 1.27, i.e. any elevated LFT was 
associated with a 27% (95% CI [19%, 36%]) increased hazard for all-cause 
mortality.  This is displayed visually in the Kaplan-Meier plot (see Figure 9-10).     
Any elevated LFT was associated with an increase in mortality from all the 
specific causes that were examined.  For deaths from cardiovascular disease 
a 27% increased hazard was seen, death from cancer a 23% increased 
hazard, death from respiratory disease a 21% increased hazard and a 3-fold 
hazard of death from liver disease (see Table 9-6).  There was less than 1 
excess death from liver disease per 1000 person years for persons with any 
abnormal LFT compared with those with all normal LFTs.    
Examining the Schoenfeld residuals and log-log plots gave no evidence of 
invalidation of the proportional hazards assumption (see Figure 9-11 and 
Figure 9-12).   
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Table 9-6  Cox proportional hazards model for death (all-cause and cause-specific mortality) for any elevated LFT 
 Events Person-
years 
Mortality rate  
(per 1000 
person years) 
Hazard ratio [95%CI] Adjusted Hazard ratio* 
[95%CI] 
All-cause mortality 
    
Normal  6556 72,320 90.7   
Elevated  1447 12,217 118.4 1.33 [1.26, 1.41] 1.27 [1.19, 1.36] 
 
Cause-specific mortality 
Cardiovascular disease     
Normal  2768 72,320 38.3   
Elevated  611 12,217 50.0 1.33 [1.22, 1.45] 1.27 [1.16, 1.39] 
Cancer (excluding liver cancer)    
Normal  1240 72,30 17.1   
Elevated  266 12,217 21.8 1.29 [1.13, 1.47] 1.23 [1.10, 1.39] 
Respiratory disease     
Normal  1112 72,30 15.4   
Elevated  234 12,217 19.2 1.27 [1.10, 1.46] 1.21 [1.02, 1.42] 
Liver disease      
Normal  32 72,30 0.44   
Elevated  17 12,217 1.39 3.22 [1.79, 5.79] 3.11 [1.74, 5.54] 
*adjusted for sex, age and comorbidity group 
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Figure 9-10 Kaplan-Meier survival estimates for all normal LFTs vs. any elevated 
LFT 
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Figure 9-11 Log-log plot for all-cause mortality for any elevated LFT 
measurement 
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Figure 9-12 Schoenfeld residuals against time for all-cause mortality for any 
elevated LFT measurement 
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9.4 Discussion 
9.4.1 Key findings 
A single elevated liver function test was associated with a higher risk of death 
overall, and for AST and ALP in particular a higher risk of death from liver 
disease, compared to those with normal liver function tests.   
 
9.4.2 Strengths and limitations 
In this study I was able to assess the association of certain liver function tests 
with subsequent mortality in a representative sample of all people aged 75 
and over. Given that people of this age have such a high mortality and 
therefore there were a large number of events (deaths) I was able to perform 
survival analysis looking at both all-cause mortality and specific causes of 
death.  This has enabled me to provide estimates of the association of 
elevated liver function test and cause-specific mortality which has not been 
previously available.  In addition to an unsurprising increased risk of death 
from liver disease (albeit mediated through very small absolute numbers of 
deaths) both elevated AST and ALP were seen to be associated with an 
increased risk of death from cancer (excluding liver cancer).  Elevated ALP 
was also associated with an increased risk of the other two specific causes of 
death examined, cardiovascular disease and respiratory disease.  Rather than 
being related to liver function per se, this may reflect the fact that these 
enzymes are also present in other body tissues, not just specific to the liver.  
As previously discussed it is arguable that abnormalities of AST, ALP and 
bilirubin are of secondary importance when looking at liver function compared 
with a measurement of alanine aminotransferase (ALT) which is specific to the 
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liver.  I was unable to investigate this as a blood test for this enzyme was not a 
part of the original study design.   
  
9.4.3 Comparison with previously published work 
Although I was unable to exclude people with previously diagnosed liver 
disease, the representative nature of this study enables me to provide a 
possibly more accurate estimate of the association of elevated liver function 
tests in the general population with mortality than has been previously 
available.66 76 A higher risk of death was seen with increasingly abnormal 
results in both these studies as with my data.  These previous studies, by 
virtue of the method of data collection, will have introduced an inherent 
selection bias to their study populations as to which people within the 
geographic area had a recorded measurement of liver function, most likely to 
lead to an overestimate of the association between elevated liver function and 
mortality.  Indeed the estimates of mortality associated with transaminases 
and ALP in the population from Scotland are slightly higher than those 
reported in this chapter.66  Further studies from working populations in 
Germany and South Korea also report greater increases in hazard of all-cause 
mortality than those shown in my data.68 75   
 
I identified one study that specifically looked at the association between liver 
function and mortality in the elderly, which came from a small population of 70 
year-olds in Jerusalem.77  This study did not show any significant associations 
between either AST or ALP and all-cause mortality.  However, the 
categorisation of liver function as above or below the mean value in the study 
population makes the interpretation of these results difficult to compare with 
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my study where I was specifically looking at abnormalities as defined by upper 
limits of normal reference ranges.   
 
 
9.4.4 Conclusions 
This study has shown that although abnormalities in liver function are fairly 
common they are associated with only a modest increased risk in all-cause 
mortality in the elderly population.   
The findings of an association between elevated liver function tests and 
mortality from cardiovascular disease, cancer, respiratory disease as well as 
liver disease, independent of comorbidity, suggest that rather than simply a 
marker of liver function the investigation of people with elevated LFTs, 
particularly those greater than 2 x the ULN, may lead to the identification of 
potentially treatable conditions that underlie death.  However, by comparison 
the simply derived comorbidity score exhibited a stronger relationship with 
death than any of the LFTs examined.  
 
A recent report from Department of Health Quality Strategy Team on Liver 
Disease called for guidance to be made available to general practitioners on 
the use and interpretation of liver function tests.9  I await the results of two 
HTA funded studies which may provide additional recommendations for the 
management of elevated liver function tests.118 119  
 
It will be particularly important to evaluate the use of liver function tests and 
subsequent referrals in this growing sector of the population of the UK,120 
those aged 75 and over, where incidental findings, and therefore potentially 
costly and avoidable referral and follow-up, are even more likely owing to 
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prescribing practices (as discussed in section 7.4.4). What action needs to be 
taken on obtaining a single elevated liver function test in this group of older 
people remains open to debate and further study.  Though two studies have 
shown that underlying liver disease was present in the majority of people who 
presented with elevated liver function tests but were otherwise asymptomatic 
for liver disease and did not have a history of drug or alcohol problems121 122 it 
would seem that, in the absence of any evidence for any overwhelming 
increases in mortality following a single elevated measurement of liver 
function, current practise of referral and active investigation of patients only 
with persistent abnormalities should be continued.   
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10 Conclusions 
10.1 Overall findings 
In describing some aspects of the epidemiology of cirrhosis and liver function 
this thesis has addressed, in part, the burden of liver disease in the UK as 
highlighted in the four areas discussed in section 1.1. 
1. I have considered the frequency of liver disease through examination 
of the incidence and prevalence of cirrhosis and the frequency of 
potentially undiagnosed liver disease through examination of the 
prevalence of abnormal liver function tests in a group of people aged 
75 and over. 
2. I have considered the mortality from liver disease through examination 
of mortality subsequent to a diagnosis of cirrhosis and subsequent to a 
single elevated LFT measurement.   
3. I have considered the morbidity associated with liver disease through 
examination of the progression of cirrhosis using recognised clinical 
sequelae including an estimate of the rate of decompensation.   
4. Although I have not attempted to consider the financial or service 
requirements associated with liver disease through any formal 
mechanisms the measures described above will of themselves be 
useful in the modelling and cost-effectiveness analyses that could be 
undertaken to look at the burden of liver disease in the UK.  I have also 
applied my results to recent UK population figures to provide an 
estimate of the annual number of new cases of cirrhosis, the total 
number of people living with cirrhosis and the number of older people 
who might be expected to have one or more abnormal LFTs.   
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10.2 Suggestions for further research 
Epidemiology of cirrhosis 
The data used in chapters 3 through 5 were extracted from the GPRD in April 
2002.  Recently (2009) the GPRD has established formal data links with the 
HES data and with the ONS vital statistics database of death registrations.  
Using a more recent extraction of data it should be possible  
a) to explore if the increasing trend in incidence of cirrhosis has continued 
throughout the last decade, 
b) to examine the cause of death of patients with cirrhosis compared with 
the general population (available in new GPRD data extractions), and 
c) to describe the progression of cirrhosis using information contained 
within linked hospital data, including additional clinical sequelae and 
commonly used prognostic scores through the availability of laboratory 
data (again, available in new GPRD data extractions).  
In addition, it is probable that a diagnosis of cirrhosis is associated with other 
sequelae that have not been addressed in this thesis.  Of particular interest 
clinically is the occurrence of hepatocellular carcinoma.  Further exploration of 
readily available data would inform the current practices for surveillance of 
hepatocellular carcinoma and potentially identify both high and low risk groups 
in which to either target or stop surveillance.   
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Epidemiology of liver function 
I have described the epidemiology of elevated liver function in a particular 
group of the population, those aged 75 and above.  It would be interesting to 
obtain data from cohorts of people of younger age groups to observe  
a) the absolute proportion of people who had elevated liver function, and 
b) whether similar associations between clinical, demographic and 
lifestyle factors and mortality exist at other ages 
 
As elevated AST and ALP were both associated with deaths from cancer it 
would be interesting to examine whether these elevated LFTs were also 
associated with the incidence of cancer.  This should be possible using the 
VDPH³05&(OGHUO\´GDWDVHWDVWKLVKDVEHHQOLQNHGWRWKHQDWLRQDOFDQFHU
registry.   
 
The utility of a single measurement of elevated liver function remains 
questionable and it would be worthwhile to try to obtain data on patients who 
had had repeated measures of liver function to see if persistently elevated 
LFTs were more strongly associated with mortality, as would probably be 
expected.   
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10.3 Overall conclusion 
This thesis has described the increasing incidence of cirrhosis in the UK over 
the period 1992-2001 and the considerable excess mortality and rapid 
progression associated with a diagnosis of cirrhosis.   
As cirrhosis probably represents the end stage of many chronic liver diseases 
it is perhaps now of even greater importance to consider the aetiologic factors 
that lead to the acquisition of cirrhosis and consider measures to reduce the 
occurrence of these liver diseases and eventually cirrhosis.  
 
Elevated liver function tests appear to be associated with more than just liver 
disease.  It will be important to consider how these tests should in future be 
used ± more widely as a measure of general health or targeted more 
specifically.  The necessity of accurate estimates of the prevalence of elevated 
LFTs and their associations will be paramount to any changes in the current 
practices of investigation and referral.   
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Appendix III-a Codes for liver disease 
description medcode 
TYPHOIDAL HEPATITIS 001 C 
AMOEBIC ABSCESS LIVER 0060B 
HEPATITIS AMOEBIC 0060BH 
AMOEBIC ABSCESS BRAIN & LIVER 0060C 
AMOEBIC ABSCESS LUNG & LIVER 0060D 
AMOEBIC ABSCESS SPLEEN & LIVER 0060E 
TUBERCULOUS HEPATITIS 014 H 
TULARAEMIA HEPATITIS 021 H 
HEPATITIS BRUCELLOSIS 0239H 
LEPROTIC HEPATITIS 0309H 
PNEUMOCOCCAL HEPATITIS 0382H 
HEPATITIS GAS GANGRENE 0390H 
HERPES VIRUS HEPATITIS 054 H 
RUBELLA HEPATITIS 056 H 
YELLOW FEVER HEPATITIS 0609H 
INFECTIOUS HEPATITIS 70 
VIRUS HEPATITIS TYPE  A 070 A 
HEPATITIS C 070 AC 
HEPATITIS TYPE C 070 AD 
VIRUS HEPATITIS TYPE  B 070 B 
HEPATITIS CATARRHAL 070 C 
HEPATITIS FULMINANT 070 F 
HEPATITIS CHRONIC AGGRESSIVE 070 G 
JAUNDICE CATARRHAL 070 JC 
JAUNDICE EPIDEMIC 070 JE 
JAUNDICE FEBRILE 070 JF 
JAUNDICE INFECTIOUS 070 JN 
HEPATITIS TYPE NON- A NON- B 070 N 
HEPATITIS PERSISTENT CHRONIC 070 P 
VIRUS HEPATITIS 070 RL 
HEPATITIS COXSACKIE VIRUS 0749H 
INFECTIOUS MONONUCLEOSIS HEPATITIS 075 H 
HEPATITIS ADENOVIRUS 0788H 
HEPATITIS CYTOMEGALIC INCLUSION VIRUS 0795H 
Q FEVER HEPATITIS 0831H 
MALARIAL HEPATITIS 0840H 
SYPHILIS LIVER CONGENITAL 0900L 
SYPHILIS LIVER ACQUIRED 095 L 
HEPATITIS GONOCOCCAL 0988H 
PERIHEPATITIS GONOCOCCAL 0988PH 
SPIROCHAETAL HAEMORRHAGIC JAUNDICE 1000EJ 
LEPTOSPIRAL HEPATITIS 1000H 
JAUNDICE EPIDEMIC LEPTOSPIRAL 1000WL 
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JAUNDICE EPIDEMIC SPIROCHAETAL 1000WR 
ACTINOMYCOSIS LIVER 113 L 
COCCIDIOIDOMYCOSIS LIVER 114 L 
HISTOPLASMOSIS LIVER 115 L 
CRYPTOCOCCOSIS LIVER 1160CL 
BLASTOMYCOSIS LIVER 1169L 
SCHISTOSOMIASIS LIVER 1208L 
CAT LIVER FLUKE INFECTION 1210C 
CHINESE LIVER FLUKE DISEASE 1211CH 
INFESTATION DISTOMA HEPATICUM 1213D 
SHEEP LIVER FLUKE INFECTION 1213HF 
HYDATID CYST LIVER 1220C 
HYDATID CYST 1229C 
FH: PORPHYRIA 1265 
TOXOPLASMOSIS LIVER CONGENITAL 1302 
SARCOIDOSIS 135 
SARCOID 135 AA 
SARCOID BOECK'S 135 BK 
SARCOIDOSIS LIVER 135 L 
SARCOIDOSIS PULMONARY 135 P 
H/O: LIVER DISEASE 14C5.00 
H/O: JAUNDICE 14C6.00 
H/O: BILIARY DISEASE 14C7.00 
H/O: GALLBLADDER DISEASE 14C7.11 
H/O: LIVER RECIPIENT 14S8.00 
MALIGNANT NEOPLASM LIVER 1550A 
MALIGNANT NEOPLASM LIVER PRIMARY 1550AP 
HEPATOMA 1550B 
HAEMANGIOENDOTHELIAL SARCOMA LIVER 1550BH 
SARCOMA LIVER PRIMARY 1550BP 
CARCINOMA LIVER 1550C 
HEPATOBLASTOMA 1550HB 
MALIGNANT NEOPLASM HEPATOCELLULAR 1550HC 
MALIGNANT CHOLANGIOMA 1551A 
MALIGNANT NEOPLASM GALLBLADDER 1560A 
CARCINOMA GALLBLADDER 1560C 
MALIGNANT NEOPLASM EXTRAHEPATIC BILE DUC 1561A 
CARCINOMA EXTRAHEPATIC BILE DUCT 1561C 
MALIGNANT NEOPLASM AMPULLA OF VATER 1562A 
CARCINOMA AMPULLA VATER 1562C 
MALIGNANT NEOPLASM BILE/BILIARY TRACT 1569A 
YELLOW/JAUNDICED COLOUR 1675 
JAUNDICE - SYMPTOM 1675.11 
BILIARY COLIC 1965 
BILIARY COLIC SYMPTOM 1965.11 
SECONDARY NEOPLASTIC DEPOSITS LIVER 1977 
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MALIGNANT NEOPLASM LIVER SECONDARY 1977A 
METASTASIS LIVER 1977M 
BENIGN ADENOMA LIVER 2115AD 
BENIGN ANGIOMA LIVER 2115AN 
BENIGN CHOLANGIOMA 2115CH 
NEUROMA CYSTIC DUCT 2115CN 
FIBROMA EXTRAHEPATIC BILE DUCTS 2115EF 
HYPERPLASIA FOCAL NODULAR LIVER 2115FH 
ADENOMA GALLBLADDER 2115GA 
PAPILLOMA GALLBLADDER 2115GP 
ADENOMA EXTRAHEPATIC BILE DUCTS 2115HA 
PAPILLOMA EXTRAHEPATIC BILE DUCTS 2115HP 
BENIGN TERATOMA LIVER 2115TE 
O/E - JAUNDICED COLOUR 2274 
O/E - JAUNDICED 2274.11 
CYSTINE STORAGE DISEASE 2703T 
ANDERSEN'S GLYCOGEN STORAGE DISEASE 2711B 
GLYCOGEN STORAGE DISEASE SUBTYPE IIB 2711D 
RENAL INVOLVEMENT FABRY'S DISEASE 2728 
ERYTHROPOIETIC PORPHYRIA 2731E 
PORPHYRIA 2731P 
PORPHYRIA CONGENITAL 2731PC 
HAEMOCHROMATOSIS 2732 
IRON STORAGE DISEASE 2732A 
DIABETES BRONZE  (HAEMOCHROMATOSIS) 2732B 
HAEMOCHROMATOSIS IDIOPATHIC 2732HI 
HEPATOLENTICULAR DEGENERATION 2733 
WILSON'S DISEASE 2733W 
JAUNDICE IDIOPATHIC DYSERYTHROPOIETIC  - 2735 
SYNDROME DUBIN- JOHNSON 2735DJ 
SYNDROME ROTOR'S 2735R 
AMYLOIDOSIS CARDIAC 276 CD 
AMYLOIDOSIS FAMILIAL WITH FEBRILE URTICA 276 FR 
AMYLOIDOSIS 276 N 
AMYLOID NEPHROPATHY 276 NP 
AMYLOID NEUROPATHY 276 NR 
PERIODIC FEVER  (AMYLOIDOSIS) 276 PF 
AMYLOIDOSIS RENAL 276 RN 
PORPHYRIA SECONDARY/ACQUIRED 279 AP 
PORPHYRIA CUTANEA TARDA 279 E 
ANTITRYPSIN DEFICIENCY 2790AD 
JAUNDICE FAMILIAL/CONGENITAL ACHOLURIC 2820 
JAUNDICE HAEMOLYTIC 2839C 
JAUNDICE ACHOLURIC ACQUIRED 2839CA 
HEPATITIS A - CURRENT INFECTION 2J23.00 
PORPHYRIA ASSOCIATED WITH DRUG ADDICTION 3048PA 
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HEPATITIS B SURFACE ANTIG +VE 43B4.00 
HEPATITIS E ANTIGEN PRESENT 43B5.00 
MITOCHONDRIAL ANTIBODIES POSITIVE 43GB100 
MITOCHONDRIAL ANTIBODIES WEAKLY POSITIVE 43GB200 
HEPATITIS A TEST POSITIVE 43M2.00 
HEPATITIS C ANTIBODY TEST POSITIVE 43X3.00 
ARTERIOSCLEROSIS HEPATIC ARTERY 4403H 
ANEURYSM HEPATIC ARTERY 442 H 
OCCLUSION HEPATIC ARTERY 4449HC 
EMBOLISM HEPATIC ARTERY 4449HE 
THROMBOSIS HEPATIC ARTERY 4449HT 
LIVER FUNCTION TESTS ABNORMAL 44D2.00 
LIVER ENZYMES ABNORMAL 44G2.00 
THROMBOSIS PORTAL VEIN 452 
SYNDROME BUDD- CHIARI 453 BC 
OCCLUSION HEPATIC VEIN 453 HP 
VARIX OESOPHAGUS 4560 
PORPHYRINS IN URINE 46R3.11 
ALPHA-1-ANTITRYPSIN PHENOTYPE 4L00.00 
BILIARY CONTR.RADIOG.ABNORMAL 54G3.00 
PER-ORAL CHOLECYSTOGRAPHY ABNORMAL 54GA100 
ACUTE HEPATITIS 570 
HEPATITIS NEONATAL 570 AC 
HEPATITIS IDIOPATHIC 570 AG 
SUBACUTE MASSIVE HEPATIC NECROSIS 570 B 
NECROSIS MASSIVE HEPATIC ACUTE 570 M 
CIRRHOSIS ALCOHOLIC 5710CA 
HEPATITIS ALCOHOLIC 5710HA 
MICRONODULAR CIRRHOSIS 5710MC 
HEPATIC ASCITES 5719AH 
SECONDARY BILIARY CIRRHOSIS (LIVER) 5719CB 
CIRRHOSIS CARDIAC 5719CC 
FIBROSIS CARDIAC  (HEPATIC) 5719CF 
HEPATITIS CHRONIC 5719CH 
CIRRHOSIS 5719CL 
CIRRHOSIS PORTAL 5719CP 
FATTY LIVER 5719FL 
HEPATOLIENAL FIBROSIS 5719HL 
HEPATOSPLENOMEGALY 5719HM 
LIVER CIRRHOSIS 5719HP 
MACRONODULAR CIRRHOSIS 5719MA 
INDIAN CHILDHOOD CIRRHOSIS 5719NC 
PRIMARY BILIARY CIRRHOSIS (LIVER) 5719PB 
PORTAL HYPERTENSION 5719PH 
ABSCESS LIVER 572 A 
ABSCESS HEPATIC 572 AH 
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HEPATITIS SUPPURATIVE 572 PR 
STREPTOCOCCAL HEPATITIS 572 PT 
THROMBOPHLEBITIS PORTAL VEIN 572 TP 
HEPATIC COMA 573 B 
LIVER DISEASE 573 C 
INTRAHEPATIC CHOLESTASIS 573 CH 
CYST LIVER 573 CL 
PAIN LIVER 573 E 
HEPATIC FAILURE 573 FH 
SYNDROME HEPATORENAL 573 HR 
HEPATITIS 573 HT 
LIVER INFECTION 573 N 
PERIHEPATITIS ACUTE 573 PA 
PERIHEPATITIS 573 PH 
SYMPTOMS LIVER 573 PT 
TOXIC HEPATITIS 573 T 
TOXIC HEPATITIS DUE ANAESTHETIC AGENT 573 TA 
TOXIC HEPATITIS DUE ANTIBIOTICS 573 TB 
TOXIC HEPATITIS DUE CARBON TETRACHLORIDE 573 TC 
TOXIC HEPATITIS DUE DRUG SENSITIVITY 573 TD 
TOXIC HEPATITIS DUE CYTOTOXIC AGENTS 573 TE 
HEPATITIS DUE FOOD POISONING 573 TF 
TOXIC HEPATITIS DUE CHEMICALS 573 TH 
HEPATITIS TOXIC DUE HORMONES 573 TM 
TOXIC HEPATITIS DUE PLANT ALKALOIDS 573 TP 
TOXIC HEPATITIS DUE ANTIARTHRITIC AGENT 573 TR 
TRAUMATIC HAEMOBILIA 573 TT 
HEPATITIS CHRONIC ACTIVE 5730CA 
HEPATOCELLULAR DAMAGE 5730D 
GALLSTONES 574 A 
CHOLECYSTOLITHIASIS 574 AC 
CHOLEDOCHOLITHIASIS 574 AD 
CHOLELITHIASIS 574 AL 
CHOLANGITIS WITH STONE 574 B 
COLIC BILIARY 574 C 
GALLBLADDER COLIC 574 CG 
LITHIASIS BILIARY 574 L 
STONE CYSTIC DUCT 5740D 
CHOLECYSTITIS 575 
CHOLANGITIS 575 A 
SECONDARY SCLEROSING CHOLANGITIS 575 AD 
PERICHOLANGITIS 575 AE 
SCLEROSING CHOLANGITIS PRIMARY 575 AL 
SUPPURATIVE CHOLANGITIS 575 AP 
RECURRENT CHOLANGITIS 575 AR 
ABSCESS BILE/BILIARY DUCT 575 BB 
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ABSCESS GALLBLADDER 575 BG 
ABSCESS HEPATIC DUCT 575 BH 
ABSCESS PERICHOLECYSTIC 575 BP 
CHOLECYSTITIS ACUTE 575 CA 
CHRONIC CHOLECYSTITIS 575 CC 
SYNDROME CAROLI'S 575 CR 
GALLBLADDER EMPYEMA 575 EM 
INFECTION GALLBLADDER 575 NF 
OBSTRUCTIVE JAUNDICE 576 A 
OBSTRUCTION BILE DUCT 576 AB 
BILIARY TRACT DISEASE 576 B 
BILIARY DYSKINESIA 576 BD 
GALLBLADDER DYSKINESIA 576 BG 
GALLBLADDER DISEASE 576 C 
DISEASE CAROLI'S 576 CR 
PAIN GALLBLADDER 576 D 
CHOLESTEROSIS 576 E 
CHOLESTEROLOSIS 576 EL 
SYMPTOMS BILIARY 576 F 
FISTULA CHOLECYSTODUODENAL 576 FC 
PROBLEM GALLBLADDER 576 FP 
PERITONITIS BILE 576 G 
HYDROPS GALLBLADDER 576 H 
MUCOCELE GALLBLADDER 576 MC 
ABSENCE GALLBLADDER ACQUIRED 576 NA 
NONFUNCTIONING GALLBLADDER 576 NF 
PSEUDODIVERTICULUM GALLBLADDER 576 PD 
CYST BILE DUCT 576 RB 
CYST GALLBLADDER 576 RG 
TORSION GALLBLADDER 576 TG 
STRICTURE BILE DUCTS ACQUIRED 576 TR 
INFECTIOUS HEPATITIS VACCINAT 65O1.12 
VIRAL HEPATITIS CARRIER 65Q7.00 
NOTIFICATION OF INF. JAUNDICE 65V3.00 
HEPATITIS NOTIFICATION 65V3.11 
ABSENCE VEIN PORTAL CONGENITAL 7474PT 
ANOMALY HEPATIC ARTERY 7476HA 
SOLITARY NONPARASITIC LIVER CYST 7515LC 
CYSTIC LIVER DISEASE CONGENITAL 7515LD 
FIBROSIS HEPATIC CONGENITAL 7515LF 
ACCESSORY GALLBLADDER CONGENITAL 7516AC 
DOUBLE GALLBLADDER 7516AD 
MULTISEPTATE GALLBLADDER 7516AE 
BILOBED GALLBLADDER 7516AF 
PHRYGIAN-CAP GALLBLADDER 7516AG 
INTRAHEPATIC GALLBLADDER 7516AH 
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DIVERTICULA GALLBLADDER CONGENITAL 7516AK 
LEFT-SIDED GALLBLADDER 7516AL 
CONGENITAL ADHESIONS GALLBLADDER 7516AM 
ABERRANT HEPATIC DUCT 7516B 
ACCESSORY HEPATIC DUCTS CONGENITAL 7516BC 
ACCESSORY BILE DUCT CONGENITAL 7516CA 
ABSENCE BILE BILIARY DUCT CONGENITAL 7516CB 
ABERRANT BILE DUCTS 7516CD 
CONGENITAL BILIARY ATRESIA 7516CS 
CONGENITAL ATRESIA BILE DUCTS 7516CT 
ABSENCE LIVER CONGENITAL 7516DA 
ACCESSORY LIVER CONGENITAL 7516DC 
ECTOPIC LIVER 7516DE 
CORSET LIVER 7516DH 
ACCESSORY CYSTIC DUCT CONGENITAL 7516E 
FIBROCYSTIC DISEASE LIVER 7516FD 
CONGENITAL ABSENCE GALLBLADDER 7516GA 
PARTIAL ATROPHY LIVER CONGENITAL 7516HA 
ATROPHY PARTIAL LIVER 7516HB 
FAMILIAL INTRAHEPATIC CHOLESTASIS 7516JA 
DILATATION BILE DUCTS CONGENITAL 7516JD 
ROKITANSKY- ASCHOFF SINUSES GALLBLADDER 7516RA 
OPEN OPERATIONS ON OESOPHAGEAL VARICES 7609 
LOCAL LIGATION OF OESOPHAGEAL VARICES 7609300 
OPEN INJECTION SCLEROTHERAPY TO OESOPHAGEAL VARICES 7609400 
OTHER SPECIFIED OPEN OPERATION ON OESOPHAGEAL VARICES 7609y00 
TANNER DEVASCULARISATION FOR BLEEDING VARICES 7609y11 
OPEN OPERATION ON OESOPHAGEAL VARICES NOS 7609z00 
FIBREOPTIC ENDOSCOPIC INJECTION SCLEROTHERAPY OESOPH VARICES 760C300 
FIBREOPTIC ENDOSCOPIC BANDING OF OESOPHAGEAL VARICES 760C500 
RIGID OESOPHAGOSCOPIC INJECTION SCLEROTHERAPY OESOPH VARICES 760F300 
RIGID OESOPHAGOSCOPIC BANDING OF OESOPHAGEAL VARICES 760F400 
ENTEROTOMY AND REMOVAL OF GALLSTONE 7648700 
JAUNDICE BREAST MILK 7789AB 
NEONATAL JAUNDICE 7789NJ 
PHYSIOLOGICAL JAUNDICE NEWBORN 7799AJ 
LIVER OPERATIONS 780..00 
TRANSPLANTATION OF LIVER 7800 
ORTHOTOPIC TRANSPLANTATION OF LIVER 7800000 
HETEROTOPIC TRANSPLANTATION OF LIVER 7800100 
AUXILLARY LIVER TRANSPLANT 7800111 
PIGGY BACK LIVER TRANSPLANT 7800112 
REPLACEMENT OF PREVIOUS LIVER TRANSPLANT 7800200 
OTHER SPECIFIED TRANSPLANTATION OF LIVER 7800y00 
TRANSPLANTATION OF LIVER NOS 7800z00 
PARTIAL EXCISION OF LIVER 7801 
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PARTIAL HEPATECTOMY 7801.11 
RIGHT HEMIHEPATECTOMY 7801000 
LEFT HEMIHEPATECTOMY 7801100 
RESECTION OF SEGMENT OF LIVER 7801200 
WEDGE EXCISION OF LIVER 7801300 
MARSUPIALISATION OF LESION OF LIVER 7801400 
LEFT HEPATIC TRISEGMENTECTOMY 7801500 
OTHER SPECIFIED PARTIAL EXCISION OF LIVER 7801y00 
PARTIAL EXCISION OF LIVER NOS 7801z00 
EXTIRPATION OF LESION OF LIVER 7802 
EXCISION OF LESION OF LIVER 7802000 
DESTRUCTION OF LESION OF LIVER 7802100 
OTHER SPECIFIED EXTIRPATION OF LESION OF LIVER 7802y00 
EXTIRPATION OF LESION OF LIVER NOS 7802z00 
REPAIR OF LIVER 7803 
REMOVAL OF LACERATED FRAGMENT OF LIVER 7803000 
REPAIR OF LACERATION OF LIVER 7803100 
PACKING OF LACERATION OF LIVER 7803200 
OTHER SPECIFIED REPAIR OF LIVER 7803y00 
REPAIR OF LIVER NOS 7803z00 
HEPATOTOMY 7804.11 
OPEN DRAINAGE OF LIVER 7804000 
OPEN REMOVAL OF CALCULUS FROM LIVER 7804100 
OPEN WEDGE BIOPSY OF LESION OF LIVER 7804200 
LITTLE HEPATOTOMY 7804y11 
STROMEYER HEPATOTOMY 7804y12 
OTHER OPEN OPERATIONS ON LIVER 7805 
OPEN DEVASCULARISATION OF LIVER 7805000 
OPEN INSERTION OF CANNULA FOR PERFUSION OF LIVER 7805100 
EXPLORATION OF LIVER TRANSPLANT 7805211 
REMOVAL OF FOREIGN BODY FROM LIVER 7805300 
HEPATOPEXY 7805400 
BINNIE HEPATOPEXY 7805411 
KEHR HEPATOPEXY 7805412 
OTHER SPECIFIED OTHER OPEN OPERATION ON LIVER 7805y00 
OTHER OPEN OPERATION ON LIVER NOS 7805z00 
THERAPEUTIC ENDOSCOPIC OPERATIONS ON LIVER USING LAPAROSCOPE 7806 
ENDOSCOPIC REMOVAL OF CALCULUS FROM LIVER USING LAPAROSCOPE 7806000 
THERAPEUTIC LAPAROSCOPIC OPERATION ON LIVER OS 7806y00 
THERAPEUTIC LAPAROSCOPIC OPERATION ON LIVER NOS 7806z00 
DIAGNOSTIC LAPAROSCOPIC EXAMINATION AND BIOPSY LIVER LESION 7807000 
TRANSLUMINAL OPERATIONS ON BLOOD VESSEL OF LIVER 7808 
PERCUTANEOUS TRANSLUMINAL OPERATIONS ON LIVER BLOOD VESSEL 7808.11 
PERCUTANEOUS TRANSLUMINAL EMBOLISATION OF HEPATIC ARTERY 7808000 
PERCUTANEOUS TRANSLUMINAL EMBOLISATION OF PORTAL VEIN 7808100 
PERCUTANEOUS TRANSLUMINAL INJECT THERAPEUT SUBST INTO LIVER 7808200 
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TRANSLUMINAL OPERATION ON BLOOD VESSEL OF LIVER OS 7808y00 
TRANSLUMINAL OPERATION ON BLOOD VESSEL OF LIVER NOS 7808z00 
OTHER THERAPEUTIC PERCUTANEOUS OPERATIONS ON LIVER 7809 
PERCUTANEOUS DRAINAGE OF LIVER 7809000 
PERCUTANEOUS REMOVAL OF CALCULUS FROM LIVER 7809100 
THERAPEUTIC ASPIRATION OF LIVER 7809200 
OTHER THERAPEUTIC PERCUTANEOUS OPERATION ON LIVER OS 7809y00 
OTHER THERAPEUTIC PERCUTANEOUS OPERATION LIVER NOS 7809z00 
PERCUTANEOUS TRANSVASCULAR BIOPSY OF LESION OF LIVER 780A000 
PERCUTANEOUS BIOPSY OF LESION OF LIVER NEC 780A100 
OTHER SPECIFIED DIAGNOSTIC PERCUTANEOUS OPERATION ON LIVER 780Ay00 
OTHER PUNCTURE OF LIVER 780B.00 
BIOPSY OF LESION OF LIVER NEC 780B011 
ASPIRATION OF LIVER NEC 780B100 
ASPIRATION OF LESION OF LIVER NEC 780B111 
OTHER SPECIFIED OTHER PUNCTURE OF LIVER 780By00 
OTHER PUNCTURE OF LIVER NOS 780Bz00 
OTHER OPERATIONS ON LIVER 780C.00 
EXTRACORPOREAL ASSISTANCE TO LIVER 780C100 
OTHER SPECIFIED OTHER OPERATION ON LIVER 780Cy00 
OTHER OPERATION ON LIVER NOS 780Cz00 
OTHER SPECIFIED OPERATIONS ON LIVER 780y.00 
LIVER OPERATIONS NOS 780z.00 
CHOLECYST OPERATIONS 781..11 
CHOLECYSTECTOMY 7810.11 
TOTAL CHOLECYSTECTOMY AND EXCISION OF SURROUNDING TISSUE 7810000 
TOTAL CHOLECYSTECTOMY AND EXPLORATION OF COMMON BILE DUCT 7810100 
TOTAL CHOLECYSTECTOMY NEC 7810200 
CHOLECYSTECTOMY NEC 7810211 
PARTIAL CHOLECYSTECTOMY AND EXPLORATION OF COMMON BILE DUCT 7810300 
PARTIAL CHOLECYSTECTOMY NEC 7810400 
THOREK PARTIAL CHOLECYSTECTOMY 7810411 
ENDOSCOPIC CHOLECYSTECTOMY 7810500 
LAPAROSCOPIC CHOLECYSTECTOMY 7810511 
CHOLECYSTOGASTROSTOMY 7811011 
CHOLECYSTODUODENOSTOMY 7811111 
CHOLECYSTOJEJUNOSTOMY 7811211 
ROUX-EN-Y CHOLECYSTOJEJUNOSTOMY 7811212 
CHOLECYSTOENTEROSTOMY 7811311 
WINIWATER CHOLECYSTOENTEROSTOMY 7811312 
CLOSURE OF CHOLECYSTOTOMY 7812100 
CHOLECYSTOTOMY 7813.11 
CHOLECYSTOSTOMY NEC 7813111 
BILE DUCT OPERATIONS 782..00 
EXCISION OF BILE DUCT 7820 
EXCIS AMPULLA OF VATER & REPLANT COM BILE DUCT IN DUODENUM 7820000 
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PARTIAL EXCISION AND ANASTOMOSIS OF BILE DUCT TO DUODENUM 7820100 
PARTIAL EXCISION AND ANASTOMOSIS OF BILE DUCT TO JEJUNUM 7820200 
PARTIAL EXCISION AND END TO END ANASTOMOSIS OF BILE DUCT 7820300 
OTHER SPECIFIED EXCISION OF BILE DUCT 7820y00 
EXCISION OF BILE DUCT NOS 7820z00 
EXTIRPATION OF LESION OF BILE DUCT 7821 
EXCISION OF LESION OF BILE DUCT 7821000 
DESTRUCTION OF LESION OF BILE DUCT 7821100 
OTHER SPECIFIED EXTIRPATION OF LESION OF BILE DUCT 7821y00 
EXTIRPATION OF LESION OF BILE DUCT NOS 7821z00 
CONNECTION OF HEPATIC DUCT 7822 
ANASTOMOSIS OF HEPATIC DUCT 7822.11 
LONGMIRE ANASTOMOSIS OF HEPATIC DUCT 7822.12 
KASAI HEPATOJEJUNOSTOMY + INSERTION TUBAL PROSTHESIS 7822011 
RODNEY - SMITH HEPATOJEJUNOSTOMY+INSERTION TUBAL PROSTHESIS 7822012 
REVISION OF ANASTOMOSIS OF HEPATIC DUCT 7822200 
OPEN DILATION OF ANASTOMOSIS OF HEPATIC DUCT 7822300 
OTHER SPECIFIED CONNECTION OF HEPATIC DUCT 7822y00 
CONNECTION OF HEPATIC DUCT NOS 7822z00 
CONNECTION OF COMMON BILE DUCT 7823 
REVISION OF ANASTOMOSIS OF COMMON BILE DUCT 7823300 
OPEN DILATION OF ANASTOMOSIS OF COMMON BILE DUCT 7823400 
OTHER SPECIFIED CONNECTION OF COMMON BILE DUCT 7823y00 
CONNECTION OF COMMON BILE DUCT NOS 7823z00 
OPEN OPERATIONS ON PROSTHESIS IN BILE DUCT 7824 
OPEN INTRODUCTION OF PROSTHESIS INTO BILE DUCT 7824.11 
OPEN INSERT TUBAL PROSTHES IN BOTH HEPATIC+COMMON BILE DUCTS 7824000 
OPEN INSERT TUBAL PROSTHES IN ONE HEPATIC+COMMON BILE DUCTS 7824100 
OPEN RENEWAL OF TUBAL PROSTHESIS IN BILE DUCT 7824200 
OPEN REMOVAL OF TUBAL PROSTHESIS FROM BILE DUCT 7824300 
ROUX-EN-Y PROCEDURE FOR BILIARY ATRESIA 7824400 
SAWAGUCHI ROUX-EN-Y PROCEDURE FOR BILIARY ATRESIA 7824411 
OTHER SPECIFIED OPEN OPERATION ON PROSTHESIS IN BILE DUCT 7824y00 
OPEN OPERATION ON PROSTHESIS IN BILE DUCT NOS 7824z00 
REPAIR OF BILE DUCT 7825 
OTHER SPECIFIED REPAIR OF BILE DUCT 7825y00 
REPAIR OF BILE DUCT NOS 7825z00 
INCISION OF BILE DUCT 7826 
EXPLORATION OF BILE DUCT 7826.12 
OPEN REMOVAL OF CALCULUS AND DRAINAGE OF BILE DUCT 7826000 
OPEN REMOVAL OF CALCULUS FROM BILE DUCT NEC 7826100 
DRAINAGE OF BILE DUCT NEC 7826200 
INCISION AND DRAINAGE OF BILE DUCT NEC 7826211 
EXPLORATION OF BILE DUCT 7826300 
OTHER SPECIFIED INCISION OF BILE DUCT 7826y00 
INCISION OF BILE DUCT NOS 7826z00 
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PLASTIC REPAIR OF SPHINCTER OF ODDI USING DUODENAL APPROACH 7827 
SPHINCTEROPLASTY BILE DUCT & PANCREATIC DUCT DUODENAL APPR 7827000 
SPHINCTEROPLASTY OF BILE DUCT USING DUODENAL APPROACH NEC 7827100 
PLASTIC REPAIR OF SPHINCTER OF ODDI DUODENAL APPROACH OS 7827y00 
PLASTIC REPAIR OF SPHINCTER OF ODDI DUODENAL APPROACH NOS 7827z00 
INCISION OF SPHINCTER OF ODDI USING DUODENAL APPROACH 7828 
SPHINCTEROTOMY OF BILE DUCT & PANCREATIC DUCT DUODENAL APPR 7828000 
SPHINCTEROTOMY OF BILE DUCT USING DUODENAL APPROACH NEC 7828100 
INCISION OF SPHINCTER OF ODDI USING DUODENAL APPROACH OS 7828y00 
INCISION OF SPHINCTER OF ODDI USING DUODENAL APPROACH NOS 7828z00 
OTHER OPEN OPERATIONS ON BILE DUCT 782A.00 
OPEN BIOPSY OF LESION OF BILE DUCT 782A000 
OPERATIVE CHOLANGIOGRAPHY THROUGH CYSTIC DUCT 782A100 
OTHER SPECIFIED OTHER OPEN OPERATION ON BILE DUCT 782Ay00 
OTHER OPEN OPERATION ON BILE DUCT NOS 782Az00 
ENDOSCOPIC INCISION OF SPHINCTER OF ODDI 782B.00 
ENDOSC SPHINCTEROTOMY SPHINCTER OF ODDI+CALCULUS REMOVAL 782B000 
ERCP SPHINCTEROTOMY SPHINCTER OF ODDI AND CALCULUS REMOVAL 782B011 
ENDOSC SPHINCTEROT SPHINCT ODDI+INSERT BILE DUCT TUBE PROSTH 782B100 
OTHER SPECIFIED ENDOSCOPIC INCISION OF SPHINCTER OF ODDI 782By00 
ENDOSCOPIC INCISION OF SPHINCTER OF ODDI NOS 782Bz00 
ENDOSCOPIC RETROGRADE PLACEMENT OF PROSTHESIS IN BILE DUCT 782D.00 
ENDOSC RETROGRADE INSERT TUBAL PROSTH IN BOTH HEPATIC DUCTS 782D000 
ENDOSCOPIC RETROGRADE INSERT TUBAL PROSTH IN BILE DUCT NEC 782D100 
ENDOSCOPIC RETROGRADE RENEWAL TUBAL PROSTHESIS IN BILE DUCT 782D200 
ENDOSCOP RETROGRADE REMOVAL TUBAL PROSTHESIS FROM BILE DUCT 782D300 
ENDOSCOPIC RETROGRADE PLACEMENT PROSTHESIS IN BILE DUCT OS 782Dy00 
ENDOSCOPIC RETROGRADE PLACEMENT PROSTHESIS IN BILE DUCT NOS 782Dz00 
OTHER THERAPEUTIC ENDOSCOPIC RETROGRADE BILE DUCT OPERATIONS 782E.00 
ENDOSCOPIC RETROGRADE EXTRACTION OF CALCULUS FROM BILE DUCT 7.82E+02 
ENDOSCOPIC DILATATION OF BILE DUCT NEC 7.82E+102 
OTHER THERAPEUTIC ENDOSCOPIC RETROGRADE OP ON BILE DUCT OS 782Ey00 
OTHER THERAPEUTIC ENDOSCOPIC RETROGRADE OP ON BILE DUCT NOS 782Ez00 
ENDOSC RETROGRADE CHOLANGIOGRAPHY + BIOPSY LESION BILE DUCT 782H000 
THERAPEUTIC PERCUTANEOUS ATTENTION TO BILE DUCT CONNECTION 782K.00 
THERAPEUTIC PERCUTANEOUS ATTENTION TO BILE DUCT ANASTOMOSIS 782K.11 
PERCUTANEOUS DILATION ANAST BILE DUCT+INSERT TUBE PROSTH HFQ 782K000 
PERCUTANEOUS DILATION OF ANASTOMOSIS OF BILE DUCT NEC 782K100 
THERAPEUTIC PERCUTANEOUS ATTENTION TO BILE DUCT CONNECT OS 782Ky00 
THERAPEUTIC PERCUTANEOUS ATTENTION TO BILE DUCT CONNECT NOS 782Kz00 
THERAPEUTIC PERCUTANEOUS INSERTION PROSTHESIS INTO BILE DUCT 782L.00 
THERAPEUTIC PERCUTANEOUS INSERTION OF TUBE INTO BILE DUCT 782L.11 
PERCUTANEOUS INSERT TUBAL PROSTHESIS INTO BOTH HEPATIC DUCTS 782L000 
PERCUTAN INSERT TUBAL PROSTHESIS TO RIGHT HEPATIC DUCT NEC 782L100 
PERCUTAN INSERT TUBAL PROSTHESIS INTO LEFT HEPATIC DUCT NEC 782L200 
PERCUTANEOUS INSERT TUBAL PROSTHESIS INTO HEPATIC DUCT NEC 782L300 
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PERCUTANEOUS INSERTION TUBAL PROSTHESIS TO COMMON BILE DUCT 782L400 
THERAPEUTIC PERCUTANEOUS INSERT PROSTHESIS TO BILE DUCT OS 782Ly00 
THERAPEUTIC PERCUTANEOUS INSERT PROSTHESIS TO BILE DUCT NOS 782Lz00 
OTHER THERAPEUTIC PERCUTANEOUS OPERATIONS ON BILE DUCT 782M.00 
PERCUTANEOUS ATTENTION TO TUBE IN BILE DUCT 782M.11 
PERCUTANEOUS ATTENTION TO PROSTHESIS IN BILE DUCT 782M.12 
RENEWAL PERCUTANEOUSLY INSERTED TUBAL PROSTH IN BILE DUCT 782M000 
REMOVAL PERCUTANEOUSLY INSERTED TUBAL PROSTH FROM BILE DUCT 782M100 
ATTENTION TO PERCUT INSERTED TUBAL PROSTH IN BILE DUCT NEC 782M200 
OTHER THERAPEUTIC PERCUTANEOUS OPERATION ON BILE DUCT OS 782My00 
OTHER THERAPEUTIC PERCUTANEOUS OPERATION ON BILE DUCT NOS 782Mz00 
THERAPEUTIC OPERATIONS ON BILE DUCT ALONG T TUBE TRACK 782N.00 
ENDOSC REMOVAL OF CALCULUS FROM BILE DUCT ALONG T TUBE TRACK 782N000 
PERCUTAN REMOVAL CALCULUS FROM BILE DUCT ALONG T TUBE TRACK 782N100 
THERAPEUTIC OPERATION ON BILE DUCT ALONG T TUBE TRACK OS 782Ny00 
THERAPEUTIC OPERATION ON BILE DUCT ALONG T TUBE TRACK NOS 782Nz00 
PERCUTANEOUS EXAMINATION OF BILE DUCT 782P.00 
PERCUTANEOUS EXAMINATION OF BILE DUCT NOS 782Pz00 
OTHER OPERATIONS ON BILE DUCT 782Q.00 
EXTRACORPOREAL LITHOTRIPSY OF CALCULUS IN BILE DUCT 782Q000 
OTHER SPECIFIED OTHER OPERATION ON BILE DUCT 782Qy00 
OTHER OPERATION ON BILE DUCT NOS 782Qz00 
OTHER SPECIFIED OPERATIONS ON BILE DUCT 782y.00 
BILE DUCT OPERATIONS NOS 782z.00 
LIVER ENLARGED 7851E 
JAUNDICE 7852 
ICTERUS 7852C 
JAUNDICE INCREASING 7852CR 
JAUNDICE DECREASING 7852DC 
JAUNDICE FADING 7852FA 
JAUNDICE FLUCTUATING 7852FL 
JAUNDICE CHOLESTATIC 7852JC 
JAUNDICE PAINLESS 7852PL 
EXCISION OR BIOPSY OF PORTA HEPATIS LYMPH NODE 7H62500 
[SO]SPHINCTER OF ODDI 7N33400 
RUPTURE LIVER 8640R 
BILIARY STONE DISSOLVING DIET 8B54.00 
CHOLECYSTECTOMY PLANNED 8L1..00 
JAUNDICE DRUG INDUCED 9779PN 
PORPHYRIA DUE MEDICINAL DRUG 9779PR 
RADIATION HEPATITIS 9904HP 
REJECTION LIVER TRANSPLANT 9977LT 
SYNDROME CYSTIC DUCT 9989CD 
SERUM HEPATITIS 9992H 
SERUM JAUNDICE 9992J 
JAUNDICE AFTER INJECTION/INOCULATION/TRA 9992JA 
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AMOEBIC LIVER ABSCESS A053.00 
TUBERCULOSIS OF LIVER A17y400 
ACTINOMYCOSIS OF LIVER A392200 
VIRAL HEPATITIS A70..00 
VIRAL HEPATITIS A WITH COMA A700.00 
VIRAL (INFECTIOUS) HEPATITIS A A701.00 
INFECTIVE HEPATITIS A701.11 
VIRAL HEPATITIS B WITH COMA A702.00 
VIRAL (SERUM) HEPATITIS B A703.00 
OTHER SPECIFIED VIRAL HEPATITIS WITH COMA A704.00 
VIRAL HEPATITIS C WITH COMA A704000 
OTHER SPECIFIED VIRAL HEPATITIS WITH HEPATIC COMA NOS A704z00 
OTHER SPECIFIED VIRAL HEPATITIS WITHOUT COMA A705.00 
VIRAL HEPATITIS C WITHOUT MENTION OF HEPATIC COMA A705000 
ACUTE DELTA-(SUPER)INFECTION OF HEPATITIS B CARRIER A705100 
ACUTE HEPATITIS E A705200 
HEPATITIS NON A NON B A705400 
OTHER SPECIFIED VIRAL HEPATITIS WITHOUT MENTION OF COMA NOS A705z00 
UNSPECIFIED VIRAL HEPATITIS WITH COMA A706.00 
CHRONIC VIRAL HEPATITIS A707.00 
CHRONIC VIRAL HEPATITIS B WITH DELTA-AGENT A707000 
CHRONIC VIRAL HEPATITIS B WITHOUT DELTA-AGENT A707100 
CHRONIC VIRAL HEPATITIS C A707200 
CHRONIC VIRAL HEPATITIS, UNSPECIFIED A707X00 
UNSPECIFIED VIRAL HEPATITIS A70z.00 
HEPATITIS C A70z000 
MUMPS HEPATITIS A72x000 
CYTOMEGALOVIRAL HEPATITIS A785200 
CONGENITAL SYPHILITIC HEPATOMEGALY A900.15 
SECONDARY SYPHILITIC HEPATITIS A916100 
SYPHILIS OF LIVER A953.00 
GONOCOCCAL HEPATITIS A98yy11 
GONOCOCCAL PERIHEPATITIS A98yy13 
LEPTOSPIROSIS ICTEROHAEMORRHAGICA AA00.00 
SPIROCHAETAL JAUNDICE AA00.11 
COCCIDIOMYCOSIS LIVER AB31.11 
HISTOPLASMOSIS LIVER AB4z600 
BLASTOMYCOSIS LIVER AB50300 
CRYPTOCOCCOSIS LIVER AB65300 
CAT LIVER FLUKE INFECTION AC10.11 
CHINESE LIVER FLUKE DISEASE AC11.11 
LIVER FLUKES NOS AC13.11 
SHEEP LIVER FLUKE INFECTION AC13.12 
LIVER ECHINOCOCCUS GRANULOSUS AC20.00 
LIVER ECHINOCOCCUS MULTILOCULARIS AC25.00 
LIVER ECHINOCOCCUS UNSPECIFIED AC2y.00 
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CAPILLARIA HEPATICA AC8y100 
TOXOPLASMA HEPATITIS AD05.00 
SARCOIDOSIS AD5..00 
SARCOIDOSIS OF LUNG AD50.00 
SARCOIDOSIS OF LYMPH NODES AD51.00 
SARCOIDOSIS OF LUNG WITH SARCOIDOSIS OF LYMPH NODES AD52.00 
SARCOIDOSIS OF SKIN AD53.00 
SARCOIDOSIS OF INFERIOR TURBINATES AD54.00 
SARCOID ARTHROPATHY AD55.00 
SEQUELAE OF VIRAL HEPATITIS AE23.00 
[X]VIRAL HEPATITIS AyuB.00 
[X]OTHER SPECIFIED ACUTE VIRAL HEPATITIS AyuB000 
[X]OTHER CHRONIC VIRAL HEPATITIS AyuB100 
[X]CHRONIC VIRAL HEPATITIS, UNSPECIFIED AyuB200 
[X]UNSPECIFIED VIRAL HEPATITIS WITH COMA AyuB300 
[X]UNSPECIFIED VIRAL HEPATITIS WITHOUT COMA AyuB400 
[X]ECHINOCOCCOSIS, UNSPECIFIED, OF LIVER AyuG400 
[X]SEQUELAE OF VIRAL HEPATITIS AyuJ900 
MALIGNANT NEOPLASM OF LIVER AND INTRAHEPATIC BILE DUCTS B15..00 
PRIMARY MALIGNANT NEOPLASM OF LIVER B150.00 
PRIMARY CARCINOMA OF LIVER B150000 
HEPATOBLASTOMA OF LIVER B150100 
PRIMARY ANGIOSARCOMA OF LIVER B150200 
HEPATOCELLULAR CARCINOMA B150300 
PRIMARY MALIGNANT NEOPLASM OF LIVER NOS B150z00 
MALIGNANT NEOPLASM OF INTRAHEPATIC BILE DUCTS B151.00 
MALIGNANT NEOPLASM OF INTERLOBULAR BILE DUCTS B151000 
MALIGNANT NEOPLASM OF INTERLOBULAR BILIARY CANALS B151100 
MALIGNANT NEOPLASM OF INTRAHEPATIC BILIARY PASSAGES B151200 
MALIGNANT NEOPLASM OF INTRAHEPATIC CANALICULI B151300 
MALIGNANT NEOPLASM OF INTRAHEPATIC GALL DUCT B151400 
MALIGNANT NEOPLASM OF INTRAHEPATIC BILE DUCTS NOS B151z00 
MALIGNANT NEOPLASM OF LIVER UNSPECIFIED B152.00 
SECONDARY MALIGNANT NEOPLASM OF LIVER B153.00 
MALIGNANT NEOPLASM OF LIVER AND INTRAHEPATIC BILE DUCTS NOS B15z.00 
MALIGNANT NEOPLASM GALLBLADDER AND EXTRAHEPATIC BILE DUCTS B16..00 
MALIGNANT NEOPLASM OF GALLBLADDER B160.00 
CARCINOMA GALLBLADDER B160.11 
MALIGNANT NEOPLASM OF EXTRAHEPATIC BILE DUCTS B161.00 
MALIGNANT NEOPLASM OF CYSTIC DUCT B161000 
MALIGNANT NEOPLASM OF HEPATIC DUCT B161100 
MALIGNANT NEOPLASM OF COMMON BILE DUCT B161200 
CARCINOMA COMMON BILE DUCT B161211 
MALIGNANT NEOPLASM OF SPHINCTER OF ODDI B161300 
MALIGNANT NEOPLASM OF EXTRAHEPATIC BILE DUCTS NOS B161z00 
MALIGNANT NEOPLASM OF AMPULLA OF VATER B162.00 
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MALIGNANT NEOPLASM, OVERLAPPING LESION OF BILIARY TRACT B163.00 
MALIGNANT NEOPLASM OTHER GALLBLADDER/EXTRAHEPATIC BILE DUCT B16y.00 
MALIGNANT NEOPLASM GALLBLADDER/EXTRAHEPATIC BILE DUCTS NOS B16z.00 
SECONDARY MALIGNANT NEOPLASM OF LIVER B577.00 
LIVER METASTASES B577.11 
BENIGN NEOPLASM OF LIVER AND BILIARY DUCTS B715.00 
BENIGN NEOPLASM OF BILIARY SYSTEM B715.11 
BENIGN NEOPLASM OF LIVER B715000 
BENIGN NEOPLASM OF INTRAHEPATIC BILE DUCTS B715100 
BENIGN NEOPLASM OF GALLBLADDER B715200 
BENIGN NEOPLASM OF CYSTIC DUCT B715300 
BENIGN NEOPLASM OF HEPATIC DUCT B715400 
BENIGN NEOPLASM OF BILE DUCT B715500 
BENIGN NEOPLASM OF SPHINCTER OF ODDI B715600 
BENIGN NEOPLASM OF AMPULLA OF VATER B715700 
BENIGN NEOPLASM OF LIVER AND BILIARY DUCTS NOS B715z00 
CARCINOMA IN SITU OF LIVER AND BILIARY SYSTEM B808.00 
CARCINOMA IN SITU OF BILIARY SYSTEM B808.11 
CARCINOMA IN SITU OF LIVER B808000 
CARCINOMA IN SITU OF INTRAHEPATIC BILE DUCTS B808100 
CARCINOMA IN SITU OF HEPATIC DUCT B808200 
CARCINOMA IN SITU OF GALL BLADDER B808300 
CARCINOMA IN SITU OF CYSTIC DUCT B808400 
CARCINOMA IN SITU OF COMMON BILE DUCT B808500 
CARCINOMA IN SITU OF AMPULLA OF VATER B808600 
CARCINOMA IN SITU OF SPHINCTER OF ODDI B808700 
CARCINOMA IN SITU OF LIVER OR BILIARY SYSTEM NOS B808z00 
NEOPLASM OF UNCERTAIN BEHAVIOUR OF LIVER AND BILIARY PASSAGE B903.00 
NEOPLASM OF UNCERTAIN BEHAVIOUR OF BILIARY SYSTEM B903.11 
NEOPLASM OF UNCERTAIN BEHAVIOUR OF LIVER B903000 
NEOPLASM OF UNCERTAIN BEHAVIOUR OF INTRA-HEPATIC BILE DUCTS B903100 
NEOPLASM OF UNCERTAIN BEHAVIOUR OF HEPATIC DUCT B903200 
NEOPLASM OF UNCERTAIN BEHAVIOUR OF GALL BLADDER B903300 
NEOPLASM OF UNCERTAIN BEHAVIOUR OF CYSTIC DUCT B903400 
NEOPLASM OF UNCERTAIN BEHAVIOUR OF COMMON BILE DUCT B903500 
NEOPLASM OF UNCERTAIN BEHAVIOUR OF AMPULLA OF VATER B903600 
NEOPLASM OF UNCERTAIN BEHAVIOUR OF SPHINCTER OF ODDI B903700 
NEOP OF UNCERTAIN BEHAVIOUR OF LIVER OR BILIARY PASSAGES NOS B903z00 
[M]HEPATOBILIARY TRACT ADENOMAS AND CARCINOMAS BB5D.00 
[M]BILIARY TRACT ADENOMAS AND ADENOCARCINOMAS BB5D.11 
[M]BILE DUCT ADENOMA BB5D000 
[M]CHOLANGIOMA BB5D011 
[M]BILE DUCT CARCINOMA BB5D111 
[M]BILE DUCT CYSTADENOMA BB5D200 
[M]BILE DUCT CYSTADENOCARCINOMA BB5D300 
[M]LIVER CELL ADENOMA BB5D400 
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[M]HEPATOCELLULAR ADENOMA BB5D411 
[M]HEPATOMA, BENIGN BB5D412 
[M]HEPATOCELLULAR CARCINOMA NOS BB5D500 
[M]HEPATOMA NOS BB5D511 
[M]HEPATOMA, MALIGNANT BB5D512 
[M]LIVER CELL CARCINOMA BB5D513 
[M]HEPATOCHOLANGIOMA, BENIGN BB5D600 
[M]COMBINED HEPATOCELLULAR CARCINOMA AND CHOLANGIOCARCINOMA BB5D700 
[M]HEPATOCHOLANGIOCARCINOMA BB5D711 
[M]HEPATOCELLULAR CARCINOMA, FIBROLAMELLAR BB5D800 
[M]HEPATOBILIARY ADENOMA OR CARCINOMA NOS BB5Dz00 
[M]HEPATOBLASTOMA BBL8.00 
[M]EMBRYONAL HEPATOMA BBL8.11 
[X]OTHER SARCOMAS OF THE LIVER Byu1000 
[X]OTHER SPECIFIED CARCINOMAS OF LIVER Byu1100 
CYSTINE STORAGE DISEASE C300311 
GLYCOGENOSIS - GLYCOGEN STORAGE DISEASE C310.00 
GLYCOGEN STORAGE DISEASE C310.13 
GLYCOGENOSIS, TYPE 5 C310012 
GENERALISED GLYCOGENOSIS C310100 
GLYCOGENOSIS, TYPE 2 C310113 
HEPATORENAL GLYCOGENOSIS C310200 
GLYCOGENOSIS, TYPE 1 C310213 
GLYCOGENOSIS OF LIVER AND MUSCLE C310300 
GLYCOGENOSIS OF LIVER AND MUSCLE C310311 
GLYCOGENOSIS, TYPE 3 C310313 
GLYCOGENOSIS WITH HEPATIC CIRRHOSIS C310400 
GLYCOGENOSIS, TYPE 4 C310411 
OTHER SPECIFIED GLYCOGENOSIS C310y00 
GLYCOGENOSIS NOS C310z00 
ANDERSON'S DISEASE C327.11 
FABRY'S DISEASE C327.12 
GAUCHER'S DISEASE C327100 
FABRY'S DISEASE C327411 
ANDERSON'S DISEASE C327412 
ANDERSON-FABRY DISEASE C327413 
STEATOSIS C32y500 
HEPATIC FAMILIAL STEATOSIS C32y511 
HAEMOCHROMATOSIS C350000 
BRONZED DIABETES C350011 
PIGMENTARY CIRRHOSIS OF LIVER C350012 
HEPATOLENTICULAR DEGENERATION (WILSON'S DISEASE) C351000 
WILSON'S DISEASE C351011 
HYPERCUPRAEMIA C351100 
DISORDERS OF PORPHYRIN METABOLISM C371.00 
CONGENITAL PORPHYRIA C371000 
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ERYTHROPOIETIC PROTOPORPHYRIA C371100 
ACUTE INTERMITTENT PORPHYRIA C371200 
PROTOCOPROPORPHYRIA C371300 
PORPHYRIA CUTANEA TARDA C371400 
COPROPORPHYRIA C371500 
PORPHYRIA NOS C371z00 
AMYLOIDOSIS C373.00 
SPORADIC PRIMARY AMYLOIDOSIS C373000 
FAMILIAL NEUROPATHIC AMYLOID C373200 
FAMILIAL CARDIAC AMYLOID C373300 
SECONDARY AMYLOIDOSIS C373500 
NEPHROPATHIC AMYLOIDOSIS C373600 
PRIMARY AMYLOIDOSIS NEC C373700 
ORGAN LIMITED NON-HEREDITARY AMYLOIDOSIS C373900 
HEREDOFAMILIAL AMYLOIDOSIS, UNSPECIFIED C373X00 
OTHER SPECIFIED AMYLOIDOSIS C373y00 
AMYLOIDOSIS NOS C373z00 
CRIGLER - NAJJAR SYNDROME C374000 
DUBIN - JOHNSON SYNDROME C374100 
ROTOR SYNDROME C374300 
ALPHA-1-ANTITRYPSIN HEPATITIS C376100 
ALPHA-1-ANTITRYPSIN DEFICIENCY C376200 
[X]SARCOIDOSIS OF OTHER AND COMBINED SITES Cyu0600 
[X]OTHER LIPID STORAGE DISORDERS Cyu8900 
[X]OTHER PORPHYRIA Cyu8H00 
[X]OTHER AMYLOIDOSIS Cyu8L00 
[X]HEREDOFAMILIAL AMYLOIDOSIS, UNSPECIFIED Cyu8U00 
FOLATE-DEFICIENCY ANAEMIA DUE TO LIVER DISORDERS D012400 
ACHOLURIC FAMILIAL JAUNDICE D100.11 
DEFICIENCY OF COAGULATION FACTOR DUE TO LIVER DISEASE D307000 
MENINGITIS DUE TO SARCOIDOSIS F013.00 
AUTONOMIC NEUROPATHY DUE TO AMYLOID F171000 
MULTIPLE CRANIAL NERVE PALSIES IN SARCOIDOSIS F326300 
POLYNEUROPATHY IN AMYLOIDOSIS F374000 
POLYNEUROPATHY IN PORPHYRIA F374800 
POLYNEUROPATHY IN SARCOIDOSIS F374900 
MYOPATHY DUE TO AMYLOID F396000 
MYOPATHY DUE TO SARCOIDOSIS F396500 
DIFFUSE CHOLESTEATOSIS F553400 
AMYLOID HEART DISEASE G557000 
SARCOID HEART DISEASE G558300 
SARCOID MYOCARDITIS G5y7.00 
CEREBRAL AMYLOID ANGIOPATHY G674000 
ANEURYSM OF HEPATIC ARTERY G72yA00 
EMBOLISM AND THROMBOSIS OF THE HEPATIC ARTERY G74y900 
PORTAL VEIN THROMBOSIS G81..00 
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BUDD - CHIARI SYNDROME (HEPATIC VEIN THROMBOSIS) G820.00 
HEPATIC VEIN THROMBOSIS G820.11 
OESOPHAGEAL VARICES G85..11 
OESOPHAGEAL VARICES WITH BLEEDING G850.00 
OESOPHAGEAL VARICES WITHOUT BLEEDING G851.00 
OESOPHAGEAL VARICES IN DISEASES EC G852.00 
OESOPHAGEAL VARICES WITH BLEEDING IN DISEASES EC G852000 
OESOPHAGEAL VARICES WITHOUT BLEEDING IN DISEASES EC G852100 
OESOPHAGEAL VARICES IN CIRRHOSIS OF THE LIVER G852200 
OESOPHAGEAL VARICES IN ALCOHOLIC CIRRHOSIS OF THE LIVER G852300 
OESOPHAGEAL VARICES IN DISEASES EC NOS G852z00 
GASTRIC VARICES G857.00 
OESOPHAGEAL VARICES NOS G858.00 
[X]OESOPHAGEAL VARICES IN DISEASES CLASSIFIED ELSEWHERE Gyu9400 
EMPYEMA WITH HEPATOPLEURAL FISTULA H500200 
PULMONARY AMYLOIDOSIS H57y000 
PULMONARY SARCOIDOSIS H57y200 
GALLSTONE ILEUS J503000 
SUBHEPATIC ABSCESS J552000 
PERITONITIS DUE TO BILE J55y300 
ACUTE AND SUBACUTE LIVER NECROSIS J60..00 
ACUTE NECROSIS OF LIVER J600.00 
ACUTE HEPATIC FAILURE J600000 
ACUTE LIVER FAILURE J600011 
ACUTE HEPATITIS - NONINFECTIVE J600100 
ACUTE YELLOW ATROPHY J600200 
ACUTE NECROSIS OF LIVER NOS J600z00 
SUBACUTE NECROSIS OF LIVER J601.00 
SUBACUTE HEPATIC FAILURE J601000 
SUBACUTE HEPATITIS - NONINFECTIVE J601100 
SUBACUTE YELLOW ATROPHY J601200 
SUBACUTE NECROSIS OF LIVER NOS J601z00 
ACUTE AND SUBACUTE LIVER NECROSIS NOS J60z.00 
CIRRHOSIS AND CHRONIC LIVER DISEASE J61..00 
ALCOHOLIC FATTY LIVER J610.00 
ACUTE ALCOHOLIC HEPATITIS J611.00 
ALCOHOLIC CIRRHOSIS OF LIVER J612.00 
FLORID CIRRHOSIS J612.11 
LAENNEC'S CIRRHOSIS J612.12 
ALCOHOLIC FIBROSIS AND SCLEROSIS OF LIVER J612000 
ALCOHOLIC LIVER DAMAGE UNSPECIFIED J613.00 
ALCOHOLIC HEPATIC FAILURE J613000 
CHRONIC HEPATITIS J614.00 
CHRONIC PERSISTENT HEPATITIS J614000 
CHRONIC ACTIVE HEPATITIS J614100 
AUTOIMMUNE CHRONIC ACTIVE HEPATITIS J614111 
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CHRONIC AGGRESSIVE HEPATITIS J614200 
RECURRENT HEPATITIS J614300 
CHRONIC LOBULAR HEPATITIS J614400 
CHRONIC HEPATITIS UNSPECIFIED J614y00 
CHRONIC HEPATITIS NOS J614z00 
CIRRHOSIS - NON ALCOHOLIC J615.00 
PORTAL CIRRHOSIS J615.11 
UNILOBULAR PORTAL CIRRHOSIS J615000 
MULTILOBULAR PORTAL CIRRHOSIS J615100 
POSTNECROTIC CIRRHOSIS OF LIVER J615111 
MIXED PORTAL CIRRHOSIS J615200 
DIFFUSE NODULAR CIRRHOSIS J615300 
FATTY PORTAL CIRRHOSIS J615400 
HYPERTROPHIC PORTAL CIRRHOSIS J615500 
CAPSULAR PORTAL CIRRHOSIS J615600 
CARDIAC PORTAL CIRRHOSIS J615700 
CONGESTIVE CIRRHOSIS J615711 
JUVENILE PORTAL CIRRHOSIS J615800 
CHILDHOOD FUNCTION CIRRHOSIS J615811 
INDIAN CHILDHOOD CIRRHOSIS J615812 
PIGMENTARY PORTAL CIRRHOSIS J615900 
PIPE-STEM PORTAL CIRRHOSIS J615A00 
TOXIC PORTAL CIRRHOSIS J615B00 
XANTHOMATOUS PORTAL CIRRHOSIS J615C00 
BACTERIAL PORTAL CIRRHOSIS J615D00 
CARDITUBERCULOUS CIRRHOSIS J615E00 
SYPHILITIC PORTAL CIRRHOSIS J615F00 
ZOOPARASITIC PORTAL CIRRHOSIS J615G00 
INFECTIOUS CIRRHOSIS NOS J615H00 
PORTAL CIRRHOSIS UNSPECIFIED J615y00 
NON-ALCOHOLIC CIRRHOSIS NOS J615z00 
MACRONODULAR CIRRHOSIS OF LIVER J615z11 
CRYPTOGENIC CIRRHOSIS OF LIVER J615z12 
CIRRHOSIS OF LIVER NOS J615z13 
LAENNEC'S CIRRHOSIS, NON-ALCOHOLIC J615z14 
HEPATIC FIBROSIS J615z15 
BILIARY CIRRHOSIS J616.00 
PRIMARY BILIARY CIRRHOSIS J616000 
SECONDARY BILIARY CIRRHOSIS J616100 
BILIARY CIRRHOSIS OF CHILDREN J616200 
BILIARY CIRRHOSIS NOS J616z00 
ALCOHOLIC HEPATITIS J617.00 
CHRONIC ALCOHOLIC HEPATITIS J617000 
OTHER NON-ALCOHOLIC CHRONIC LIVER DISEASE J61y.00 
CHRONIC YELLOW LIVER ATROPHY J61y000 
NON-ALCOHOLIC FATTY LIVER J61y100 
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HEPATOSPLENOMEGALY J61y200 
PORTAL FIBROSIS WITHOUT CIRRHOSIS J61y300 
HEPATIC FIBROSIS J61y400 
HEPATIC SCLEROSIS J61y500 
HEPATIC FIBROSIS WITH HEPATIC SCLEROSIS J61y600 
STEATOSIS OF LIVER J61y700 
OTHER NON-ALCOHOLIC CHRONIC LIVER DISEASE NOS J61yz00 
CHRONIC LIVER DISEASE NOS J61z.00 
LIVER ABSCESS AND SEQUELAE OF CHRONIC LIVER DISEASE J62..00 
LIVER ABSCESS - EXCLUDING AMOEBIC LIVER ABSCESS J620.00 
LIVER ABSCESS DUE TO PORTAL PYAEMIA J620000 
LIVER ABSCESS DUE TO CHOLANGITIS J620100 
LIVER ABSCESS VIA HEPATIC ARTERY J620200 
LIVER ABSCESS VIA UMBILICUS J620300 
LIVER ABSCESS DUE TO DIRECT EXTENSION J620400 
LIVER ABSCESS NOS J620z00 
PORTAL PYAEMIA J621.00 
PHLEBITIS OF PORTAL VEIN J621.11 
HEPATIC COMA J622.00 
ENCEPHALOPATHY - HEPATIC J622.11 
PORTAL HYPERTENSION J623.00 
HEPATORENAL SYNDROME J624.00 
[X] HEPATIC FAILURE J625.00 
[X] LIVER FAILURE J625.11 
OTHER SEQUELAE OF CHRONIC LIVER DISEASE J62y.00 
HEPATIC FAILURE NOS J62y.11 
LIVER FAILURE NOS J62y.12 
HEPATIC FAILURE J62y.13 
LIVER ABSCESS AND CHRONIC LIVER DISEASE CAUSING SEQUELAE NOS J62z.00 
OTHER LIVER DISORDERS J63..00 
CHRONIC PASSIVE LIVER CONGESTION J630.00 
HEPATITIS IN VIRAL DISEASES EC J631.00 
HEPATITIS IN COXSACKIE VIRUS J631000 
HEPATITIS IN CYTOMEGALIC INCLUSION VIRUS J631100 
HEPATITIS IN INFECTIOUS MONONUCLEOSIS J631200 
HEPATITIS IN MUMPS J631300 
HEPATITIS IN YELLOW FEVER J631400 
HEPATITIS IN OTHER VIRAL DISEASE J631500 
HEPATITIS + ADENOVIRUS J631600 
HEPATITIS IN VIRAL DISEASES EC NOS J631z00 
HEPATITIS IN OTHER INFECTIOUS DISEASES EC J632.00 
HEPATITIS IN MALARIA J632000 
HEPATITIS IN LATE SYPHILIS J632100 
HEPATITIS IN SECONDARY SYPHILIS J632200 
HEPATITIS IN TOXOPLASMOSIS J632300 
HEPATITIS IN INFECTIOUS DISEASES EC NOS J632z00 
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HEPATITIS UNSPECIFIED J633.00 
TOXIC HEPATITIS J633000 
HEPATITIS UNSPECIFIED NOS J633z00 
HEPATIC INFARCTION J634.00 
TOXIC LIVER DISEASE J635.00 
TOXIC LIVER DISEASE WITH CHOLESTASIS J635000 
TOXIC LIVER DISEASE WITH HEPATIC NECROSIS J635100 
TOXIC LIVER DISEASE WITH ACUTE HEPATITIS J635200 
TOXIC LIVER DISEASE WITH CHRONIC PERSISTENT HEPATITIS J635300 
TOXIC LIVER DISEASE WITH CHRONIC LOBULAR HEPATITIS J635400 
TOXIC LIVER DISEASE WITH CHRONIC ACTIVE HEPATITIS J635500 
TOXIC LIVER DISEASE WITH FIBROSIS AND CIRRHOSIS OF LIVER J635600 
TOXIC LIVER DISEASE, UNSPECIFIED J635X00 
CENTRAL HAEMORRHAGIC NECROSIS OF LIVER J636.00 
HEPATIC VENO-OCCLUSIVE DISEASE J637.00 
PELIOSIS HEPATIS J638.00 
HEPATIC GRANULOMAS IN BERYLLIOSIS J639.00 
HEPATIC GRANULOMAS IN SARCOIDOSIS J63A.00 
GRANULOMATOUS HEPATITIS, NOT ELSEWHERE CLASSIFIED J63X.00 
OTHER SPECIFIED LIVER DISORDER J63y.00 
HEPATOPTOSIS J63y000 
NONSPECIFIC REACTIVE HEPATITIS J63y100 
LIVER CYST J63y200 
OTHER SPECIFIED LIVER DISORDER NOS J63yz00 
LIVER DISORDER NOS J63z.00 
CHOLELITHIASIS J64..00 
BILE DUCT CALCULUS J64..11 
CALCULUS - BILIARY J64..12 
CYSTIC DUCT CALCULUS J64..13 
GALLBLADDER CALCULUS J64..14 
GALLSTONES J64..15 
STONE - BILIARY J64..16 
GALLBLADDER CALCULUS WITH ACUTE CHOLECYSTITIS J640.00 
GALLBLADDER CALCULUS WITH ACUTE CHOLECYSTITIS +NO OBSTRUCT J640000 
GALLBLADDER CALCULUS WITH ACUTE CHOLECYSTITIS + OBSTRUCTION J640100 
GALLBLADDER CALCULUS WITH ACUTE CHOLECYSTITIS - OBST NOS J640z00 
GALLBLADDER CALCULUS WITH OTHER CHOLECYSTITIS J641.00 
GALLBLADDER CALCULUS WITH OTHER CHOLECYSTITIS +NO OBSTRUCT J641000 
GALLBLADDER CALCULUS WITH OTHER CHOLECYSTITIS + OBSTRUCT J641100 
GALLBLADDER CALCULUS WITH OTHER CHOLECYSTITIS - OBSTRUCT NOS J641z00 
GALLBLADDER CALCULUS WITHOUT MENTION OF CHOLECYSTITIS J642.00 
GALLBLADDER CALCULUS WITHOUT MENTION OF CHOLECYSTITIS J642.11 
GALLBLADDER CALCULUS WITHOUT MENTION CHOLECYSTITIS +NO OBSTR J642000 
GALLBLADDER CALCULUS WITHOUT MENTION CHOLECYSTITIS + OBSTRUC J642100 
BILIARY COLIC J642200 
GALLBLADDER CALCULUS WITHOUT CHOLECYSTITIS AND OBSTRUCT NOS J642z00 
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BILE DUCT CALCULUS WITH ACUTE CHOLECYSTITIS J643.00 
BILE DUCT CALCULUS + ACUTE CHOLECYSTITIS AND NO OBSTRUCTION J643000 
BILE DUCT CALCULUS + ACUTE CHOLECYSTITIS AND OBSTRUCTION J643100 
BILE DUCT CALCULUS + ACUTE CHOLECYSTITIS - OBSTRUCT NOS J643z00 
BILE DUCT CALCULUS WITH OTHER CHOLECYSTITIS J644.00 
BILE DUCT CALCULUS + OTHER CHOLECYSTITIS AND NO OBSTRUCTION J644000 
BILE DUCT CALCULUS + OTHER CHOLECYSTITIS AND OBSTRUCTION J644100 
BILE DUCT CALCULUS + OTHER CHOLECYSTITIS - OBSTRUCTION NOS J644z00 
BILE DUCT CALCULUS WITHOUT MENTION OF CHOLECYSTITIS J645.00 
CHOLEDOCHOLITHIASIS J645.11 
BILE DUCT CALCULUS WITHOUT CHOLECYSTITIS, NO OBSTRUCTION J645000 
BILE DUCT CALCULUS WITHOUT CHOLECYSTITIS WITH OBSTRUCTION J645100 
BILE DUCT CALCULUS NOS J645200 
BILE DUCT CALCULUS WITHOUT CHOLECYSTITIS NOS J645z00 
CALCULUS OF BILE DUCT WITH CHOLANGITIS J646.00 
CHOLELITHIASIS NOS J64z.00 
CHOLELITHIASIS WITHOUT OBSTRUCTION NOS J64z000 
CHOLELITHIASIS WITH OBSTRUCTION NOS J64z100 
CHOLELITHIASIS NOS J64zz00 
OTHER GALLBLADDER DISORDERS J65..00 
ACUTE CHOLECYSTITIS J650.00 
ABSCESS OF GALLBLADDER J650.11 
EMPYEMA OF GALLBLADDER J650.12 
ACUTE CHOLECYSTITIS UNSPECIFIED J650000 
ACUTE ANGIOCHOLECYSTITIS J650100 
ACUTE EMPHYSEMATOUS CHOLECYSTITIS J650200 
ACUTE SUPPURATIVE CHOLECYSTITIS J650300 
ACUTE GANGRENOUS CHOLECYSTITIS J650400 
ACUTE CHOLECYSTITIS NOS J650z00 
OTHER CHOLECYSTITIS J651.00 
CHRONIC CHOLECYSTITIS J651000 
OTHER CHOLECYSTITIS OS J651y00 
CHOLECYSTITIS NOS J651z00 
OBSTRUCTION OF GALLBLADDER J652.00 
OCCLUSION OF GALLBLADDER J652000 
STENOSIS OF GALLBLADDER J652100 
OCCLUSION OF CYSTIC DUCT J652200 
STENOSIS OF CYSTIC DUCT J652300 
OBSTRUCTION OF GALLBLADDER NOS J652z00 
MUCOCELE OF GALLBLADDER J653.00 
HYDROPS OF GALLBLADDER J653.11 
PERFORATION OF GALLBLADDER J654.00 
RUPTURE OF GALLBLADDER J654000 
RUPTURE OF CYSTIC DUCT J654100 
PERFORATION OF GALLBLADDER NOS J654z00 
FISTULA OF GALLBLADDER J655.00 
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BILIARY FISTULA J655000 
CHOLECYSTOGASTRIC FISTULA J655100 
CHOLECYSTODUODENAL FISTULA J655200 
CHOLECYSTOENTERIC FISTULA J655300 
FISTULA OF GALLBLADDER NOS J655z00 
CHOLESTEROLOSIS OF GALLBLADDER J656.00 
STRAWBERRY GALLBLADDER J656.11 
OTHER SPECIFIED GALLBLADDER DISORDERS J65y.00 
ADHESIONS OF GALLBLADDER J65y000 
ADHESIONS OF CYSTIC DUCT J65y100 
ATROPHY OF GALLBLADDER J65y200 
ATROPHY OF CYSTIC DUCT J65y300 
CYST OF GALLBLADDER J65y400 
CYST OF CYSTIC DUCT J65y500 
HYPERTROPHY OF GALLBLADDER J65y600 
HYPERTROPHY OF CYSTIC DUCT J65y700 
ULCER OF GALLBLADDER J65y800 
ULCER OF CYSTIC DUCT J65y900 
NONFUNCTIONING GALLBLADDER J65yA00 
BILIARY DYSKINESIA J65yB00 
POLYP OF GALLBLADDER J65yC00 
OTHER SPECIFIED GALLBLADDER DISORDER NOS J65yz00 
OTHER GALLBLADDER DISORDERS NOS J65z.00 
OTHER BILIARY TRACT DISORDERS J66..00 
POSTCHOLECYSTECTOMY SYNDROME J660.00 
CHOLANGITIS J661.00 
ACUTE CHOLANGITIS J661000 
CHRONIC CHOLANGITIS J661100 
RECURRENT CHOLANGITIS J661200 
SUPPURATIVE CHOLANGITIS J661300 
ASCENDING CHOLANGITIS J661400 
CHOLANGITIS LENTA J661500 
OBLITERATIVE CHOLANGITIS J661600 
PRIMARY SCLEROSING CHOLANGITIS J661700 
SECONDARY SCLEROSING CHOLANGITIS J661800 
SCLEROSING CHOLANGITIS UNSPECIFIED J661900 
OTHER CHOLANGITIS J661y00 
CHOLANGITIS NOS J661z00 
OBSTRUCTION OF BILE DUCT J662.00 
OCCLUSION OF BILE DUCT J662000 
STRICTURE OF BILE DUCT J662100 
OBSTRUCTION OF BILE DUCT NOS J662z00 
PERFORATION OF BILE DUCT J663.00 
FISTULA OF BILE DUCT J664.00 
FISTULA OF BILE DUCT NOS J664z00 
SPASM OF SPHINCTER OF ODDI J665.00 
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OTHER BILE DUCT DISORDERS J66y.00 
ADHESIONS OF BILE DUCT J66y000 
ATROPHY OF BILE DUCT J66y100 
CYST OF BILE DUCT J66y200 
HYPERTROPHY OF BILE DUCT J66y300 
STASIS OF BILE DUCT J66y400 
ULCER OF BILE DUCT J66y500 
OBSTRUCTIVE JAUNDICE NOS J66y600 
POST CHOLECYSTECTOMY BILE LEAKAGE J66y700 
OTHER BILE DUCT DISORDER NOS J66yz00 
BILE DUCT DISORDER NOS J66z.00 
[X]DISEASES OF THE LIVER Jyu7.00 
[X]TOXIC LIVER DISEASE WITH OTHER DISORDERS OF LIVER Jyu7000 
[X]OTHER AND UNSPECIFIED CIRRHOSIS OF LIVER Jyu7100 
[X]OTHER SPECIFIED INFLAMMATORY LIVER DISEASES Jyu7200 
[X]OTHER SPECIFIED DISEASES OF LIVER Jyu7300 
[X]LIVER DISORDERS IN INFECTIOUS AND PARASITIC DISEASES CE Jyu7400 
[X]LIVER DISORDERS IN OTHER DISEASES CLASSIFIED ELSEWHERE Jyu7500 
[X]TOXIC LIVER DISEASE, UNSPECIFIED Jyu7600 
[X]GRANULOMATOUS HEPATITIS, NOT ELSEWHERE CLASSIFIED Jyu7700 
[X]DISORDERS OF THE GALLBLADDER, BILIARY TRACT AND PANCREAS Jyu8.00 
[X]OTHER CHOLELITHIASIS Jyu8000 
[X]OTHER CHOLECYSTITIS Jyu8100 
[X]OTHER SPECIFIED DISEASES OF GALLBLADDER Jyu8200 
[X]OTHER SPECIFIED DISEASES OF BILIARY TRACT Jyu8300 
[X]DISORDERS OF GALLBLADDER+BILIARY TRACT IN DISEASES CE Jyu8600 
NEPHROTIC SYNDROME IN AMYLOIDOSIS K01x000 
FUND HOLDING OP OESOPHAGEAL VARICES K298 FH 
LIGATION OESOPHAGEAL VARICES K2981 
INJECTION OESOPHAGEAL VARICES K2982 
HEPATECTOMY K500 
EXCISION HEPATIC ABSCESS K5001 
REMOVAL HYDATID CYST K5001C 
TRANSPLANTATION LIVER K5005 
HEPATORRHAPHY K502 
LIVER OPERATION K509 
HEPATOSTOMY K5091 
HEPATOTOMY K5092 
EXPLORATION BILE DUCT K510 AA 
CRUSHING CALCULUS BILIARY K511 
LITHOTOMY HEPATIC DUCT K511 AA 
LITHOTOMY BILE DUCT K511 AB 
REMOVAL CALCULUS BILE DUCT K511 AC 
DRAINAGE BILE DUCT K512 
ROUX- Y ANASTOMOSIS BILE DUCT TO BOWEL K513 AA 
OPERATION ON THE BILE DUCTS K519 
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FUND HOLDING OP BILE DUCT K519 FH 
INSERTION TUBE HEPATIC DUCT K519 H 
REMOVAL STONES GALLBLADDER K521 AB 
CHOLECYSTECTOMY K522 
CHOLECYSTECTOMY PLANNED K522 X 
CHOLECYSTENTEROSTOMY K524 B 
GASTROCHOLECYSTOSTOMY K524 G 
CHOLECYSTOSTOMY K529 
ACUTE LIVER NECROSIS FOLLOWING ABORTIVE PREGNANCY L09y000 
HELLP - SYNDROME HAEMOLYSIS, ELEV LIVER ENZYME LOW PLATELETS L12A.00 
LIVER DISORDER IN PREGNANCY L167.00 
LIVER DISORDER IN PREGNANCY UNSPECIFIED L167000 
LIVER DISORDER IN PREGNANCY - DELIVERED L167100 
LIVER DISORDER IN PREGNANCY - NOT DELIVERED L167200 
LIVER DISORDER IN PREGNANCY NOS L167z00 
VIRAL HEPATITIS COMP PREGNANCY, CHILDBIRTH & THE PUERPERIUM L176500 
LIVER FUNCTION TEST ABNORMAL L3260AB 
LIVER BIOCHEMICAL DYSFUNCTION L3262AB 
LIVER ENZYMES ABNORMAL L3263AB 
RAISED LIVER ENZYMES L3263H 
HEPATIC FUNCTION ABNORMAL L3264AB 
PUERPERAL PERITONITIS - DELIVERED WITH POSTNATAL COMP L402100 
ANTIBODIES ANTI-MITOCHONDRIAL PRESENT L6652DM 
ANTIBODIES HEPATITIS B CORE PRESENT L6652DV 
ANTIBODIES HEPATITIS B E PRESENT L6652DW 
ANTIBODIES HEPATITIS E PRESENT L6652DY 
CHLOASMA HEPATICUM M290400 
AMYLOIDOSIS OF SKIN M2y9.00 
ARTHROPATHY IN AMYLOIDOSIS N030200 
MYOSITIS IN SARCOIDOSIS N233200 
[X]MYOSITIS IN SARCOIDOSIS CLASSIFIED ELSEWHERE Nyu8900 
ANOMALOUS PORTAL VEIN TERMINATION P743.00 
PORTAL VEIN - HEPATIC ARTERY FISTULA P744.00 
LIVER AND BILIARY SYSTEM ANOMALIES PB6..00 
BILE DUCT ANOMALIES PB6..11 
BILIARY ANOMALIES PB6..12 
GALLBLADDER ANOMALIES PB6..13 
LIVER ANOMALIES PB6..14 
LIVER AND BILIARY SYSTEM ANOMALIES, UNSPECIFIED PB60.00 
LIVER ANOMALY, UNSPECIFIED PB60000 
GALLBLADDER ANOMALY, UNSPECIFIED PB60100 
BILE DUCT ANOMALY, UNSPECIFIED PB60200 
UNSPECIFIED LIVER AND BILIARY SYSTEM ANOMALY NOS PB60z00 
BILIARY ATRESIA PB61.00 
BILE DUCT ATRESIA PB61.11 
CONGENITAL ABSENCE OF BILE DUCT PB61000 
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AGENESIS OF BILE DUCT PB61011 
CONGENITAL HYPOPLASIA OF BILE DUCT PB61100 
CONGENITAL OBSTRUCTION OF BILE DUCT PB61200 
CONGENITAL STRICTURE OF BILE DUCT PB61300 
CONGENITAL STRICTURE OF COMMON BILE DUCT PB61311 
ATRESIA OF BILE DUCT PB61400 
INTRAHEPATIC ATRESIA OF BILE DUCT PB61411 
EXTRAHEPATIC ATRESIA OF BILE DUCT PB61412 
CONGENITAL ABSENCE OF HEPATIC DUCTS PB61500 
AGENESIS OF HEPATIC DUCTS PB61511 
ATRESIA OF HEPATIC DUCTS PB61600 
BILIARY ATRESIA NOS PB61z00 
CONGENITAL CYSTIC LIVER DISEASE PB62.00 
CONGENITAL HEPATIC CYST PB62.11 
CONGENITAL POLYCYSTIC LIVER DISEASE PB62000 
FIBROCYSTIC LIVER DISEASE PB62100 
CONGENITAL CYSTIC LIVER DISEASE NOS PB62z00 
CONGENITAL ABSENCE OF LIVER AND GALLBLADDER PB63.00 
CONGENITAL ABSENCE OF GALLBLADDER PB63000 
AGENESIS OF GALLBLADDER PB63011 
CONGENITAL ABSENCE OF LIVER LOBE PB63100 
CONGENITAL AGENESIS OF LIVER LOBE PB63111 
CONGENITAL ABSENCE OF LIVER,TOTAL PB63400 
CONGENITAL AGENESIS LIVER,TOTAL PB63411 
ABSENCE OF LIVER OR GALLBLADDER NOS PB63z00 
LIVER AND BILIARY DUPLICATION PB64.00 
DUPLICATION OF BILIARY DUCT PB64000 
DUPLICATION OF CYSTIC DUCT PB64100 
DUPLICATION OF GALLBLADDER PB64200 
DUPLICATION OF LIVER PB64300 
ACCESSORY LIVER PB64311 
ACCESSORY HEPATIC DUCTS PB64400 
LIVER OR BILIARY DUPLICATION NOS PB64z00 
OTHER LIVER AND BILIARY ANOMALIES PB6y.00 
CONGENITAL CHOLEDOCHAL CYST PB6y000 
CONGENITAL HEPATOMEGALY PB6y100 
CONGENITAL FLOATING GALLBLADDER PB6y200 
INTRAHEPATIC GALLBLADDER PB6y400 
HYPOPLASIA OF GALLBLADDER PB6y500 
ATROPHY OF LEFT LOBE OF LIVER PB6y600 
CONGENITAL DILATION OF BILE DUCT PB6y700 
CONGENITAL DIVERTICULUM OF BILE DUCT PB6y800 
LIVER HYPERPLASIA PB6y900 
OTHER CONGENITAL ANOMALY OF LIVER PB6yw00 
LIVER HAMARTOMA PB6yw11 
TRILOBULAR LIVER PB6yw13 
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OTHER CONGENITAL ANOMALY OF GALLBLADDER PB6yx00 
OTHER CONGENITAL ANOMALY OF HEPATIC OR BILE DUCTS PB6yy00 
CONGENITAL KINK OF CYSTIC DUCT PB6yy11 
OTHER LIVER OR BILIARY SYSTEM ANOMALIES NOS PB6yz00 
LIVER OR BILIARY SYSTEM ANOMALIES NOS PB6z.00 
[X]OTHER CONGENITAL MALFORMATIONS OF GALLBLADDER Pyu5C00 
[X]OTHER CONGENITAL MALFORMATIONS OF BILE DUCTS Pyu5D00 
[X]OTHER CONGENITAL MALFORMATIONS OF LIVER Pyu5E00 
LIVER SUBCAPSULAR HAEMATOMA DUE TO BIRTH TRAUMA Q20y100 
LIVER RUPTURE DUE TO BIRTH TRAUMA Q20y400 
CONGENITAL VIRAL HEPATITIS Q409.00 
CONGENITAL HEPATITIS A INFECTION Q409000 
CONGENITAL HEPATITIS B INFECTION Q409100 
OTHER SPECIFIED CONGENITAL VIRAL HEPATITIS Q409y00 
CONGENITAL VIRAL HEPATITIS NOS Q409z00 
KERNICTERUS DUE TO ISOIMMUNISATION Q424.00 
OTHER PERINATAL JAUNDICE Q43..00 
PERINATAL JAUNDICE FROM HEREDITARY HAEMOLYTIC ANAEMIAS Q430.00 
NEONATAL JAUNDICE + GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFIC. Q430000 
PERINATAL JAUNDICE FROM HEREDITARY HAEMOLYTIC ANAEMIA NOS Q430z00 
PERINATAL JAUNDICE FROM OTHER EXCESSIVE HAEMOLYSIS Q431.00 
PERINATAL JAUNDICE FROM BRUISING Q431000 
PERINATAL JAUNDICE FROM MATERNAL TRANSMISSION DRUG OR TOXIN Q431100 
PERINATAL JAUNDICE FROM INFECTION Q431200 
PERINATAL JAUNDICE FROM POLYCYTHAEMIA Q431300 
PERINATAL JAUNDICE FROM SWALLOWED MATERNAL BLOOD Q431400 
PERINATAL JAUNDICE FROM BLEEDING Q431500 
PERINATAL JAUNDICE FROM OTHER SPECIFIED HAEMOLYSIS Q431y00 
PERINATAL JAUNDICE FROM HAEMOLYSIS NOS Q431z00 
PRETERM DELIVERY ASSOCIATED JAUNDICE Q432.00 
OTHER NEONATAL JAUNDICE - DELAYED CONJUGATION OTHER CAUSE Q433.00 
DELAYED CONJUGATION CAUSING NEONATAL JAUNDICE, UNSPECIFIED Q433000 
DELAYED CONJUGATION CAUSING NEONATAL JAUNDICE + DISEASE EC Q433100 
BREAST FEEDING INHIBITORS CAUSING NEONATAL JAUNDICE Q433200 
NEONATAL JAUNDICE WITH CRIGLER-NAJJAR SYNDROME Q433400 
NEONATAL JAUNDICE WITH DUBIN-JOHNSON SYNDROME Q433500 
NEONATAL JAUNDICE WITH GILBERT'S SYNDROME Q433600 
NEONATAL JAUNDICE WITH CONGENITAL HYPOTHYROIDISM Q433700 
NEONATAL JAUNDICE WITH PORPHYRIA Q433800 
NEONATAL JAUNDICE WITH ROTOR'S SYNDROME Q433900 
NEONATAL JAUNDICE FROM BREAST MILK INHIBITOR Q433A00 
DELAYED CONJUGATION CAUSING NEONATAL JAUNDICE OS Q433y00 
NEONATAL JAUNDICE - DEFICIENCY ENZYME FOR BILIRUBIN CONJUG. Q433y11 
DELAYED CONJUGATION CAUSING NEONATAL JAUNDICE NOS Q433z00 
PERINATAL JAUNDICE DUE TO HEPATOCELLULAR DAMAGE Q434.00 
PERINATAL HEPATITIS CAUSING JAUNDICE, UNSPECIFIED Q434000 
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GIANT CELL HEPATITIS CAUSING NEONATAL JAUNDICE Q434100 
PERINATAL JAUNDICE DUE TO HEPATOCELLULAR DAMAGE NOS Q434z00 
PERINATAL JAUNDICE DUE TO OTHER CAUSE Q435.00 
PERINATAL JAUNDICE DUE TO CONGENITAL OBSTRUCTION BILE DUCT Q435000 
PERINATAL JAUNDICE DUE TO GALACTOSAEMIA Q435100 
PERINATAL JAUNDICE DUE TO MUCOVISCIDOSIS Q435200 
PERINATAL JAUNDICE DUE TO OTHER SPECIFIED CAUSE Q435z00 
FETAL AND NEONATAL JAUNDICE, UNSPECIFIED Q436.00 
ICTERUS NEONATORUM, UNSPECIFIED Q436000 
NEWBORN PHYSIOLOGICAL JAUNDICE NOS Q436200 
UNSPECIFIED FETAL OR NEONATAL JAUNDICE NOS Q436z00 
KERNICTERUS NOT DUE TO ISOIMMUNISATION Q437.00 
KERNICTERUS OF NEWBORN NOS Q437z00 
PERINATAL JAUNDICE NOS Q43z.00 
BRONZE BABY Q47y100 
CONGENITAL HEPATIC FIBROSIS Q48yz11 
[X]OTHER SPECIFIED KERNICTERUS Qyu5700 
[X]NEONATAL JAUNDICE DUE/OTHER SPECIFD EXCESSIVE HAEMOLYSIS Qyu5900 
[X]NEONATAL JAUNDICE FROM OTHER+UNSPCF HEPATOCELLULAR DAMAGE Qyu5A00 
[X]NEONATAL JAUNDICE FROM OTHER SPECIFIED CAUSES Qyu5B00 
[D]JAUNDICE (NOT OF NEWBORN) R024.00 
[D]ICTERUS NOS R024100 
[D]JAUNDICE R024111 
[D]JAUNDICE (NOT OF NEWBORN) NOS R024z00 
[D]LIVER ENLARGEMENT R091000 
[D]BILIARY TRACT X-RAY OR SCAN ABNORMALITY R133.00 
[D]BILIARY X-RAY OR SCAN ABNORMALITY NOS R133z00 
[D]ABNORMAL LIVER FUNCTION TEST R148.00 
[D]ABNORMAL LIVER SCAN R148000 
[D]ABNORMAL LIVER FUNCTION TEST NOS R148z00 
INJURY TO LIVER S74..00 
CLOSED INJURY OF LIVER S740.00 
LIVER INJURY WITHOUT OPEN WOUND INTO CAVITY, UNSPECIFIED S740000 
LIVER HAEMATOMA AND CONTUSION WITHOUT OPEN WOUND INTO CAVITY S740100 
LIVER MINOR LACERATION WITHOUT OPEN WOUND INTO CAVITY S740200 
LIVER MODERATE LACERATION WITHOUT OPEN WOUND INTO CAVITY S740300 
LIVER MAJOR LACERATION WITHOUT OPEN WOUND INTO CAVITY S740400 
OTHER LIVER LACERATION WITHOUT OPEN WOUND INTO CAVITY S740y00 
LIVER INJURIES WITHOUT OPEN WOUND INTO CAVITY, NOS S740z00 
OPEN INJURY OF LIVER S741.00 
LIVER INJURY WITH OPEN WOUND INTO CAVITY, UNSPECIFIED S741000 
LIVER HAEMATOMA AND CONTUSION WITH OPEN WOUND INTO CAVITY S741100 
LIVER MINOR LACERATION WITH OPEN WOUND INTO CAVITY S741200 
LIVER MODERATE LACERATION WITH OPEN WOUND INTO CAVITY S741300 
LIVER MAJOR LACERATION WITH OPEN WOUND INTO CAVITY S741400 
OTHER LIVER INJURY WITH OPEN WOUND INTO CAVITY S741y00 
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LIVER INJURY WITH OPEN WOUND INTO CAVITY, NOS S741z00 
INJURY TO LIVER, NOS S74z.00 
RUPTURED LIVER NOS S74z.11 
BILE DUCT/GALLBLADDER INJURY WITHOUT OPEN WOUND INTO CAVITY S780200 
BILE DUCT INJURY WITHOUT OPEN WOUND INTO CAVITY S780211 
GALLBLADDER INJURY WITHOUT OPEN WOUND INTO CAVITY S780212 
BILE DUCT/GALLBLADDER INJURY WITH OPEN WOUND INTO CAVITY S781200 
BILE DUCT INJURY WITH OPEN WOUND INTO CAVITY S781211 
GALLBLADDER INJURY WITH OPEN WOUND INTO CAVITY S781212 
HEPATIC VEIN INJURY SB21100 
HEPATIC ARTERY INJURY SB22200 
PORTAL AND SPLENIC VEIN INJURY SB23.00 
PORTAL VEIN INJURY SB23200 
PORTAL AND SPLENIC VEIN INJURY NOS SB23z00 
MECHANICAL COMPLICATION OF BILE DUCT PROSTHESIS SP05100 
LIVER TRANSPLANT FAILURE AND REJECTION SP08600 
HEPATIC FAILURE AS A COMPLICATION OF CARE SP14200 
LIVER FAILURE AS A COMPLICATION OF CARE SP14211 
HEPATORENAL SYNDROME AS A COMPLICATION OF CARE SP14300 
LIVER TRANSPLANT WITH COMPLICATION, WITHOUT BLAME TB00200 
CONTACT SERUM HEPATITIS Y409 E 
CHOLECYSTOGRAM ABNORMAL Y500 BA 
DIETARY ADVICE FOR HEPATIC DISORDER ZC2CH00 
DIETARY ADVICE FOR LIVER DISEASE ZC2CH11 
[V]VIRAL HEPATITIS CARRIER ZV02600 
[V]HEPATITIS AUSTRALIA ANTIGEN CARRIER ZV02612 
[V]PERSONAL HISTORY OF MALIGNANT NEOPLASM OF LIVER ZV10015 
[V]LIVER TRANSPLANTED ZV42700 
[V]ASSESSMENT FOR LIVER TRANSPLANT ZV7C000 
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Appendix III-b Codes for death 
Description medcode 
O/E - dead 22J..00 
O/E - dead - condition fatal 22J..11 
Death 22J..12 
Died 22J..13 
Patient died 22J..14 
O/E - dead - unexpected 22J1.00 
O/E - dead - expected 22J2.00 
O/E - dead - unattended death 22J3.00 
O/E - dead - sudden death 22J4.00 
O/E - dead - cot death 22J5.00 
O/E - dead - suspicious death 22J6.00 
Postneonatal death 22J7.00 
O/E - dead NOS 22JZ.00 
O/E - respiratory death 236..12 
DELIVERY SUDDEN DEATH  (MOTHER) 661 DH 
SUDDEN DEATH CHILDBIRTH CAUSE UNKNOWN 661 DN 
DELIVERY DEATH DUE ANAESTHETIC 662 N 
SUDDEN DEATH PUERPERIUM CAUSE UNKNOWN 6770AD 
NEONATAL DEATH 7789ND 
DEATH IN UTERO 7799A 
STILLBIRTH 7799B 
SUDDEN DEATH INFANT SYNDROME 795 B 
COT DEATH 795 C 
DROPPED DEAD 795 DR 
SUDDEN DEATH NONVIOLENT 795 N 
FOUND DEAD 7962 
UNKNOWN CAUSE DEATH 7963 
Preoperative anaesthetic death 7L1M000 
Died in hospital 8HG..00 
Death in hospital 8HG..11 
Registration ghost - deceased 9134 
Registration ghost - dead 9134.11 
Registration ghost - died 9134.12 
FP22-death 9234 
Death administration 94...00 
Administration after pat. died 94...11 
Death certificate form Med A 941..00 
Death cert. Med A due 9411 
Death cert. Med A signed 9412 
Med A given to family 9413 
Med A not signed-coroner case 9414 
Death cert. Med A NOS 941Z.00 
Medical cert. of still-birth 942..00 
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Report for Coroner 943..00 
Coroner's post-mortem report 944..00 
Hospital death discharge notif 945..00 
Death notif. from hospital 9451 
Await hosp death disch letter 9452 
Receiv hosp death disch letter 9453 
Ask for hosp death disch lett. 9454 
Hospital death disch. NOS 945Z.00 
Death notif.- non.hosp source 946..00 
Cause of death clarif. SD17/18 947..00 
SD17 - cause of death clarif 947..11 
SD18 - cause of death clarif 947..12 
SD17/18 received-death clarif. 9471 
SD17/18 completed 9472 
SD17/18-no details, returned 9473 
SD17/18 cause of death NOS 947Z.00 
Cremation certification 948..00 
Stat B,C and F cremation certs 948..11 
Patient died - to record place 949..00 
Dead - place patient died 949..11 
Deceased - place patient died 949..12 
Died - place patient died 949..13 
Place of death 949..14 
Patient died at home 9491 
Patient died in part 3 accom. 9492 
Patient died in nursing home 9493 
Patient died in resid.inst.NOS 9494 
Patient died in hospital 9495 
Patient died in street 9496 
Patient died in publ.place NOS 9497 
Dead on arrival at hospital 9498 
Found dead at accident site 9499 
Patient died in hospice 949A.00 
Patient died in place NOS 949Z.00 
Unexpected death-Coroner told 94A..00 
Referral to coroner 94A..11 
Cause of death 94B..00 
Condition fatal-cause of death 94B..11 
Post mortem report 94C..00 
Hospital notified of death 94D..00 
Death administration NOS 94Z..00 
DEATH ANAESTHETIC 9681D 
Sudden cardiac death, so described G575100 
Intrauterine death L264.00 
Fetal death in utero L264.11 
Intrauterine death unspecified L264000 
308 
Intrauterine death - delivered L264100 
Intrauterine death with antenatal problem L264200 
Intrauterine death NOS L264z00 
Death obst cse occur more 42 day less than one yr aft deliv L39A.00 
Death from sequelae of direct obstetric causes L39B.00 
Obstetric death of unspecified cause L39X.00 
[X]Obstetric death of unspecified cause Lyu7500 
Fetal death due to prelabour anoxia Q210.00 
Fetal death due to labour anoxia Q211.00 
[X] Stillbirth Q48D.00 
Early neonatal death Q48y600 
Late neonatal death Q48y700 
Infant death Q4z..11 
Neonatal death Q4z..12 
Newborn death Q4z..13 
Perinatal death Q4z..14 
Stillbirth NEC Q4z..15 
[D]Mortality, cause unsure R2...12 
[D]Sudden death, cause unknown R21..00 
[D]Sudden infant death syndrome R210.00 
[D]Cot death R210000 
[D]Crib death R210100 
[D]Nonspecific sudden infant death R210200 
[D]Sudden infant death syndrome NOS R210z00 
[D]Instantaneous death R211.00 
[D]Death less than 24 hours from onset of illness R212.00 
[D]Death, not instantaneous cause unknown R212000 
[D]Died, with no sign of disease R212100 
[D]Death less than 24 hours from onset of illness NOS R212z00 
[D]Unattended death R213.00 
[D]Found after death, unknown cause of death R213000 
[D]Found dead R213100 
[D]Unattended death NOS R213z00 
[D]Sudden death, cause unknown NOS R21z.00 
[X]Ill-defined and unknown causes of mortality RyuC.00 
[X]Sudden infant death syndrome RyuC000 
[X]Other sudden death, cause unknown RyuC100 
[X]Other ill-defined and unspecified causes of death RyuC200 
Found dead on railway right-of-way unspecified T0y0.00 
Found dead on railway unspec - railway employee T0y0000 
Found dead on railway unspecified - passenger T0y0100 
Found dead on railway unspecified - pedestrian T0y0200 
Found dead on railway unspecified - cyclist T0y0300 
Found dead on railway unspecified - other spec person T0y0y00 
Found dead on railway unspecified - unspecified person T0y0z00 
DEATH T140 F 
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DEATH AT HOME T140 FH 
DEATH IN HOSPITAL T140 FP 
POST MORTEM RESULT T140 G 
DIED T1400M 
SUDDEN INFANT DEATH T1400SI 
PATIENT DIED T400 
VIOLENT DEATH T4001 
SUDDEN DEATH T4002 
[V]Issue of death certificate ZV68011 
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Appendix III-c Codes for alcohol use 
Description medcode 
Assigned alcohol 
status 
Teetotaller 1361 Non-drinker 
Non drinker alcohol 1361.11 Non-drinker 
Non-drinker alcohol 1361.12 Non-drinker 
Current non drinker 136M.00 Non-drinker 
NON-DRINKER ALCOHOL L5154NI Non-drinker 
ALCOHOL NONE L5154NO Non-drinker 
Alcohol consumption 136..00 Drinker 
Drinks rarely 1362.11 Drinker 
Drinks occasionally 1362.12 Drinker 
Stopped drinking alcohol 1367 Drinker 
Spirit drinker 136F.00 Drinker 
Beer drinker 136G.00 Drinker 
Drinks beer and spirits 136H.00 Drinker 
Drinks wine 136I.00 Drinker 
Social drinker 136J.00 Drinker 
Alcohol intake within recommended sensible limits 136L.00 Drinker 
Light drinker 136N.00 Drinker 
Moderate drinker 136O.00 Drinker 
Heavy drinker 136P.00 Drinker 
Very heavy drinker 136Q.00 Drinker 
Alcohol consumption NOS 136Z.00 Drinker 
O/E - breath - alcohol smell 2577 Drinker 
O/E - alcoholic breath 2577.11 Drinker 
INTOXICATION ALCOHOL ACUTE 3039AC Drinker 
INTOXICATION ALCOHOL 3039AD Drinker 
PIXILLATED 3039AE Drinker 
HUNG OVER (HANGOVER) 3039HR Drinker 
ALCOHOL BINGES 3039PB Drinker 
Health ed. - alcohol 6792 Drinker 
Pregnancy alcohol advice 67A5.00 Drinker 
Patient advised about alcohol 8CAM.00 Drinker 
Alcohol leaflet given 8CE1.00 Drinker 
Referral to community alcohol team 8H7p.00 Drinker 
INGESTION ALCOHOL 9890A Drinker 
Hangover (alcohol) E250.12 Drinker 
Inebriety NOS E250.13 Drinker 
Intoxication - alcohol E250.14 Drinker 
ADVISED TO STOP DRINKING L2621ST Drinker 
ALCOHOL CONSUMPTION L5150C Drinker 
ALCOHOL BEER L5154B Drinker 
ALCOHOL MIXED WINE BEER & SPIRITS L5154M Drinker 
311 
ALCOHOL SPIRITS L5154S Drinker 
ALCOHOL WINE L5154W Drinker 
[D]Alcohol blood level excessive R103.00 Drinker 
HEAVY DRINKER T514 Drinker 
ALCOHOL RARELY T5151 Drinker 
ALCOHOL MODERATE T5152 Drinker 
ALCOHOL OCCASIONALLY T5153 Drinker 
SOCIAL DRINKER ALCOHOL T5154 Drinker 
STOPPED DRINKING ALCOHOL T5156 Drinker 
Planned reduction of alcohol consumption Z191200 Drinker 
Self-monitoring of alcohol intake Z191400 Drinker 
Removal of alcohol Z9KF400 Drinker 
Removing alcohol from home Z9KF600 Drinker 
Advice to change alcoholic drink intake ZC22200 Drinker 
Advice to change alcohol intake ZC2H.00 Drinker 
Advice on alcohol consumption ZG23100 Drinker 
[V] Alcohol use ZV4KC00 Drinker 
Ex-trivial drinker (<1u/day) 136A.00 Drinker 
Ex-light drinker - (1-2u/day) 136B.00 Drinker 
Ex-moderate drinker - (3-6u/d) 136C.00 Drinker 
Ex-heavy drinker - (7-9u/day) 136D.00 Drinker 
Ex-very heavy drinker-(>9u/d) 136E.00 Drinker 
Trivial drinker - <1u/day 1362 Drinker 
Light drinker - 1-2u/day 1363 Drinker 
Moderate drinker - 3-6u/day 1364 Drinker 
Heavy drinker - 7-9u/day 1365 Drinker 
Very heavy drinker - >9u/day 1366 Drinker 
Alcohol intake above recommended sensible limits 136K.00 Alcoholic 
Alcoholics anonymous 13Y8.00 Alcoholic 
H/O: alcoholism 1462 Alcoholic 
ALCOHOL DRINKING EXCESSIVE 3031 Alcoholic 
ALCOHOL ADDICTION 3032 Alcoholic 
SYMPTOMS ALCOHOLIC WITHDRAWAL 3032B Alcoholic 
ALCOHOL DEPENDENCE 3032D Alcoholic 
ALCOHOL ABUSE INTOXICATION CHRONIC 3032NA Alcoholic 
INTOXICATION ALCOHOL CHRONIC 3032NB Alcoholic 
ABUSE ALCOHOL 3032NC Alcoholic 
WINE ADDICTION 3032WN Alcoholic 
ALCOHOLISM 3039A Alcoholic 
ABSINTHISM 3039AB Alcoholic 
PROBLEMS ALCOHOL RELATED 3039AP Alcoholic 
FALLS ALCOHOLIC 3039FL Alcoholic 
ALCOHOL ABUSE 3039PA Alcoholic 
PROBLEM DRINKING STRAIN ON SPOUSE 3039PP Alcoholic 
PROBLEM DRINKING (ALCOHOL) 3039PR Alcoholic 
CIRRHOSIS ALCOHOLIC 5710CA Alcoholic 
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SICKNESS AFTER ALCOHOL ABUSE 7841LA Alcoholic 
Alcohol detoxification 8BA8.00 Alcoholic 
Admitted to alcohol detoxification centre 8H35.00 Alcoholic 
Under care of community alcohol team 9NN2.00 Alcoholic 
Pathological alcohol intoxication E014.00 Alcoholic 
Drunkenness - pathological E014.11 Alcoholic 
Alcohol dependence syndrome E23..00 Alcoholic 
Alcoholism E23..11 Alcoholic 
Alcohol problem drinking E23..12 Alcoholic 
Alcohol dependence with acute alcoholic 
intoxication E230.11 Alcoholic 
Continuous acute alcoholic intoxication in 
alcoholism E230100 Alcoholic 
Episodic acute alcoholic intoxication in alcoholism E230200 Alcoholic 
Chronic alcoholism E231.00 Alcoholic 
Dipsomania E231.11 Alcoholic 
Unspecified chronic alcoholism E231000 Alcoholic 
Continuous chronic alcoholism E231100 Alcoholic 
Episodic chronic alcoholism E231200 Alcoholic 
Chronic alcoholism in remission E231300 Alcoholic 
Chronic alcoholism NOS E231z00 Alcoholic 
Alcohol dependence syndrome NOS E23z.00 Alcoholic 
Nondependent alcohol abuse E250.00 Alcoholic 
Drunkenness NOS E250.11 Alcoholic 
Nondependent alcohol abuse, unspecified E250000 Alcoholic 
Nondependent alcohol abuse, continuous E250100 Alcoholic 
Nondependent alcohol abuse, episodic E250200 Alcoholic 
Nondependent alcohol abuse in remission E250300 Alcoholic 
Nondependent alcohol abuse NOS E250z00 Alcoholic 
[X]Acute alcoholic drunkenness Eu10011 Alcoholic 
[X]Alcohol addiction Eu10211 Alcoholic 
[X]Chronic alcoholism Eu10212 Alcoholic 
[X]Dipsomania Eu10213 Alcoholic 
Alcoholic cirrhosis of the liver J612.00 Alcoholic 
HIGH RISK ALCOHOLISM T185 Alcoholic 
ALCOHOLICS ANONYMOUS ATTENDED T3810 Alcoholic 
DETOXIFICATION ALCOHOL T3821 Alcoholic 
Alcohol detoxification Z191.00 Alcoholic 
Drying out Z191111 Alcoholic 
Alcohol reduction programme Z191211 Alcoholic 
Alcoholism counselling Z4B1.00 Alcoholic 
[V]Personal history of alcoholism ZV11300 Alcoholic 
[V]Problems related to lifestyle alcohol use ZV11311 Alcoholic 
[V]Alcohol rehabilitation ZV57A00 Alcoholic 
[V]Alcohol abuse counselling and surveillance ZV6D600 Alcoholic 
SHAKES ALCOHOLIC 2910 Problem drinker 
KORSAKOV'S PSYCHOSIS ALCOHOLIC 2911 Problem drinker 
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HALLUCINATIONS ALCOHOLIC 2912 Problem drinker 
ALCOHOLIC PSYCHOSIS PARANOID 2913 Problem drinker 
DEMENTIA ALCOHOLIC 2919 Problem drinker 
PSYCHOSIS ALCOHOLIC 2919P Problem drinker 
ALCOHOLIC CARDIOPATHY 3032C Problem drinker 
EPILEPSY ALCOHOLIC 3032EP Problem drinker 
ALCOHOLIC GASTRITIS 3032G Problem drinker 
ALCOHOLIC GASTRITIS CHRONIC 3032GC Problem drinker 
NEUROPATHY ALCOHOLIC 3032R Problem drinker 
ALCOHOL RELATED DISTURBANCES 3039AR Problem drinker 
ALCOHOLIC GASTRITIS ACUTE 3039G Problem drinker 
POLYNEURITIS ALCOHOLIC 3039PN Problem drinker 
HEPATITIS ALCOHOLIC 5710HA Problem drinker 
MICRONODULAR CIRRHOSIS 5710MC Problem drinker 
Alcohol-induced pseudo-Cushing's syndrome C150500 Problem drinker 
Alcoholic psychoses E01..00 Problem drinker 
Alcohol withdrawal delirium E010.00 Problem drinker 
Alcohol amnestic syndrome E011.00 Problem drinker 
Korsakov's alcoholic psychosis E011000 Problem drinker 
Korsakov's alcoholic psychosis with peripheral 
neuritis E011100 Problem drinker 
Alcohol amnestic syndrome NOS E011z00 Problem drinker 
Other alcoholic dementia E012.00 Problem drinker 
Alcoholic dementia NOS E012.11 Problem drinker 
Chronic alcoholic brain syndrome E012000 Problem drinker 
Alcohol withdrawal hallucinosis E013.00 Problem drinker 
Alcoholic paranoia E015.00 Problem drinker 
Other alcoholic psychosis E01y.00 Problem drinker 
Alcohol withdrawal syndrome E01y000 Problem drinker 
Other alcoholic psychosis NOS E01yz00 Problem drinker 
Alcoholic psychosis NOS E01z.00 Problem drinker 
Acute alcoholic intoxication in alcoholism E230.00 Problem drinker 
Acute alcoholic intoxication, unspecified, in 
alcoholism E230000 Problem drinker 
Acute alcoholic intoxication in remission, in 
alcoholism E230300 Problem drinker 
Acute alcoholic intoxication in alcoholism NOS E230z00 Problem drinker 
[X]Mental and behavioural disorders due to use of 
alcohol Eu10.00 Problem drinker 
[X]Mental & behav dis due to use alcohol: acute 
intoxication Eu10000 Problem drinker 
[X]Mental and behav dis due to use of alcohol: 
harmful use Eu10100 Problem drinker 
[X]Mental and behav dis due to use alcohol: 
dependence syndr Eu10200 Problem drinker 
[X]Mental and behav dis due to use alcohol: 
withdrawal state Eu10300 Problem drinker 
[X]Men & behav dis due alcohl: withdrawl state Eu10400 Problem drinker 
314 
with delirium 
[X]Delirium tremens, alcohol induced Eu10411 Problem drinker 
[X]Mental & behav dis due to use alcohol: 
psychotic disorder Eu10500 Problem drinker 
[X]Alcoholic hallucinosis Eu10511 Problem drinker 
[X]Alcoholic jealousy Eu10512 Problem drinker 
[X]Alcoholic paranoia Eu10513 Problem drinker 
[X]Alcoholic psychosis NOS Eu10514 Problem drinker 
[X]Mental and behav dis due to use alcohol: 
amnesic syndrome Eu10600 Problem drinker 
[X]Korsakov's psychosis, alcohol induced Eu10611 Problem drinker 
[X]Men & behav dis due alcoh: resid & late-onset 
psychot dis Eu10700 Problem drinker 
[X]Alcoholic dementia NOS Eu10711 Problem drinker 
[X]Chronic alcoholic brain syndrome Eu10712 Problem drinker 
[X]Men & behav dis due to use alcohol: oth men & 
behav dis Eu10y00 Problem drinker 
[X]Ment & behav dis due use alcohol: unsp ment & 
behav dis Eu10z00 Problem drinker 
Cerebral degeneration due to alcoholism F11x000 Problem drinker 
Alcoholic encephalopathy F11x011 Problem drinker 
Cerebellar ataxia due to alcoholism F144000 Problem drinker 
Alcoholic polyneuropathy F375.00 Problem drinker 
Alcoholic myopathy F394100 Problem drinker 
Alcoholic cardiomyopathy G555.00 Problem drinker 
Alcoholic gastritis J153.00 Problem drinker 
Alcoholic fatty liver J610.00 Problem drinker 
Acute alcoholic hepatitis J611.00 Problem drinker 
Alcoholic cirrhosis of liver J612.00 Problem drinker 
Alcoholic fibrosis and sclerosis of liver J612000 Problem drinker 
Alcoholic liver damage unspecified J613.00 Problem drinker 
Alcoholic hepatic failure J613000 Problem drinker 
Alcoholic hepatitis J617.00 Problem drinker 
Chronic alcoholic hepatitis J617000 Problem drinker 
Alcohol-induced chronic pancreatitis J671000 Problem drinker 
Alcohol causing toxic effect SM0..00 Problem drinker 
Alcohol causing toxic effect NOS SM0z.00 Problem drinker 
Alcohol withdrawal regime Z191100 Problem drinker 
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Appendix III-d Codes for viral hepatitis 
description medcode 
HERPES VIRUS HEPATITIS 054 H 
VIRUS HEPATITIS TYPE  A 070 A 
HEPATITIS C 070 AC 
HEPATITIS TYPE C 070 AD 
VIRUS HEPATITIS TYPE  B 070 B 
HEPATITIS TYPE NON- A NON- B 070 N 
VIRUS HEPATITIS 070 RL 
HEPATITIS COXSACKIE VIRUS 0749H 
HEPATITIS ADENOVIRUS 0788H 
HEPATITIS CYTOMEGALIC INCLUSION VIRUS 0795H 
Hepatitis C status 2J1..00 
Hepatitis A status 2J2..00 
Hepatitis A - current infection 2J23.00 
Hepatitis B antibody present 43B2.11 
Hepatitis B surface antig +ve 43B4.00 
Hepatitis e antigen present 43B5.00 
Hepatitis A test positive 43M2.00 
Hepatitis C antibody test positive 43X3.00 
Viral hepatitis carrier 65Q7.00 
Viral hepatitis A70..00 
Viral hepatitis A with coma A700.00 
Viral (infectious) hepatitis A A701.00 
Viral hepatitis B with coma A702.00 
Viral (serum) hepatitis B A703.00 
Other specified viral hepatitis with coma A704.00 
Viral hepatitis C with coma A704000 
Other specified viral hepatitis with hepatic coma NOS A704z00 
Other specified viral hepatitis without coma A705.00 
Viral hepatitis C without mention of hepatic coma A705000 
Acute delta-(super)infection of hepatitis B carrier A705100 
Acute hepatitis E A705200 
Hepatitis non A non B A705400 
Other specified viral hepatitis without mention of coma NOS A705z00 
Unspecified viral hepatitis with coma A706.00 
Chronic viral hepatitis A707.00 
Chronic viral hepatitis B with delta-agent A707000 
Chronic viral hepatitis B without delta-agent A707100 
Chronic viral hepatitis C A707200 
Chronic viral hepatitis, unspecified A707X00 
Unspecified viral hepatitis A70z.00 
Hepatitis C A70z000 
Cytomegaloviral hepatitis A785200 
[X]Viral hepatitis AyuB.00 
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[X]Other specified acute viral hepatitis AyuB000 
[X]Other chronic viral hepatitis AyuB100 
[X]Chronic viral hepatitis, unspecified AyuB200 
[X]Unspecified viral hepatitis with coma AyuB300 
[X]Unspecified viral hepatitis without coma AyuB400 
Hepatitis in viral diseases EC J631.00 
Hepatitis in coxsackie virus J631000 
Hepatitis in cytomegalic inclusion virus J631100 
Hepatitis in other viral disease J631500 
Hepatitis in viral diseases EC NOS J631z00 
Viral hepatitis comp pregnancy, childbirth & the puerperium L176500 
ANTIBODIES HEPATITIS B CORE PRESENT L6652DV 
ANTIBODIES HEPATITIS B E PRESENT L6652DW 
ANTIBODIES HEPATITIS SURFACE PRESENT L6652DX 
ANTIBODIES HEPATITIS E PRESENT L6652DY 
Congenital viral hepatitis Q409.00 
Congenital hepatitis A infection Q409000 
Congenital hepatitis B infection Q409100 
Other specified congenital viral hepatitis Q409y00 
Congenital viral hepatitis NOS Q409z00 
[V]Hepatitis B carrier ZV02B00 
 
  
317 
Appendix III-e Codes for autoimmune liver disease 
 
Description medcode 
PRIMARY BILIARY CIRRHOSIS (LIVER) 5719PB 
SCLEROSING CHOLANGITIS PRIMARY 575 AL 
Autoimmune chronic active hepatitis J614111 
Primary biliary cirrhosis J616000 
Primary sclerosing cholangitis J661700 
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Appendix III-f Codes for metabolic liver disease 
Description medcode 
HAEMOCHROMATOSIS 2732 
DIABETES BRONZE  (HAEMOCHROMATOSIS) 2732B 
HAEMOCHROMATOSIS IDIOPATHIC 2732HI 
WILSON'S DISEASE 2733W 
ANTITRYPSIN DEFICIENCY 2790AD 
Alpha-1-antitrypsin phenotype 4L00.00 
Haemochromatosis C350000 
Bronzed diabetes C350011 
Von Recklinghausen - Applebaum disease C350013 
Hepatolenticular degeneration (Wilson's disease) C351000 
Wilson's disease C351011 
Alpha-1-antitrypsin hepatitis C376100 
Alpha-1-antitrypsin deficiency C376200 
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Appendix III-g Codes for encephalopathy 
 
description medcode 
WERNICKE'S ENCEPHALOPATHY 2639WN 
ENCEPHALOPATHY 7817 
Wernicke's encephalopathy C251.11 
Wernicke's encephalopathy C253.00 
Alcoholic encephalopathy F11x011 
Unspecified encephalopathy F283.00 
Hepatic coma J622.00 
Encephalopathy - hepatic J622.11 
Hepatorenal syndrome J624.00 
[X] Hepatic failure J625.00 
[X] Liver failure J625.11 
Liver failure NOS J62y.12 
Hepatic failure J62y.13 
Bilirubin encephalopathy Q437000 
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Appendix III-h Codes for smoking 
Description medcode 
Assigned 
smoking 
status 
Never smoked tobacco 1371 Non-smoker 
Non-smoker 1371.11 Non-smoker 
Current non-smoker 137L.00 Non-smoker 
SMOKER NON T5093 Non-smoker 
SMOKED NEVER T5093N Non-smoker 
Ex-trivial smoker (<1/day) 1377 Ex-Smoker 
Ex-light smoker (1-9/day) 1378 Ex-Smoker 
Ex-moderate smoker (10-19/day) 1379 Ex-Smoker 
Ex-heavy smoker (20-39/day) 137A.00 Ex-Smoker 
Ex-very heavy smoker (40+/day) 137B.00 Ex-Smoker 
Ex-smoker - amount unknown 137F.00 Ex-Smoker 
Stopped smoking 137K.00 Ex-Smoker 
Ex pipe smoker 137N.00 Ex-Smoker 
Ex cigar smoker 137O.00 Ex-Smoker 
Ex smoker 137S.00 Ex-Smoker 
Date ceased smoking 137T.00 Ex-Smoker 
Smoking free weeks 13p4.00 Ex-Smoker 
[X]Mental and behav dis due to use tobacco: withdrawal 
state Eu17300 Ex-Smoker 
[X]Men & behav dis due tobacco: withdrawl state wth 
delirium Eu17400 Ex-Smoker 
STOPPED SMOKING T5091 Ex-Smoker 
FORMER SMOKER T5091ES Ex-Smoker 
EX HEAVY SMOKER T5091HS Ex-Smoker 
Smoker - amount smoked 137..11 Smoker 
Trivial smoker - < 1 cig/day 1372 Smoker 
Occasional smoker 1372.11 Smoker 
Light smoker - 1-9 cigs/day 1373 Smoker 
Moderate smoker - 10-19 cigs/d 1374 Smoker 
Heavy smoker  - 20-39 cigs/day 1375 Smoker 
Very heavy smoker - 40+cigs/d 1376 Smoker 
Keeps trying to stop smoking 137C.00 Smoker 
Trying to give up smoking 137G.00 Smoker 
Pipe smoker 137H.00 Smoker 
Cigar smoker 137J.00 Smoker 
Rolls own cigarettes 137M.00 Smoker 
Cigarette smoker 137P.00 Smoker 
Smoker 137P.11 Smoker 
Smoking started 137Q.00 Smoker 
Smoking restarted 137Q.11 Smoker 
Current smoker 137R.00 Smoker 
Smoking reduced 137V.00 Smoker 
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Cigarette consumption 137X.00 Smoker 
Cigar consumption 137Y.00 Smoker 
Tobacco consumption NOS 137Z.00 Smoker 
Pipe tobacco consumption 137a.00 Smoker 
Ready to stop smoking 137b.00 Smoker 
Thinking about stopping smoking 137c.00 Smoker 
Not interested in stopping smoking 137d.00 Smoker 
Smoking restarted 137e.00 Smoker 
Reason for restarting smoking 137f.00 Smoker 
Negotiated date for cessation of smoking 13p0.00 Smoker 
Smoking cessation programme start date 13p5.00 Smoker 
Health ed. - smoking 6791 Smoker 
Smoking cessation advice 8CAL.00 Smoker 
Referral to smoking cessation advisor 8H7i.00 Smoker 
Seen by smoking cessation advisor 9N2k.00 Smoker 
Attends stop smoking monitor. 9OO1.00 Smoker 
Refuses stop smoking monitor 9OO2.00 Smoker 
Stop smoking monitor verb.inv. 9OO7.00 Smoker 
Stop smoking monitor phone inv 9OO8.00 Smoker 
Tobacco dependence E251.00 Smoker 
Tobacco dependence, unspecified E251000 Smoker 
Tobacco dependence, continuous E251100 Smoker 
Tobacco dependence, episodic E251200 Smoker 
Tobacco dependence in remission E251300 Smoker 
Tobacco dependence NOS E251z00 Smoker 
[X]Mental and behavioural disorder due to use of 
tobacco Eu17.00 Smoker 
[X]Mental and behav dis due to use of tobacco: harmful 
use Eu17100 Smoker 
[X]Mental and behav dis due to use tobacco: 
dependence syndr Eu17200 Smoker 
[X]Mental & behav dis due to use tobacco: psychotic 
disorder Eu17500 Smoker 
[X]Mental and behav dis due to use tobacco: amnesic 
syndrome Eu17600 Smoker 
[X]Men & beh dis due tobacco: resid & late-onset 
psychot dis Eu17700 Smoker 
[X]Men & behav dis due to use tobacco: oth men & 
behav dis Eu17y00 Smoker 
[X]Ment & behav dis due use tobacco: unsp ment & 
behav dis Eu17z00 Smoker 
SMOKING STARTED L5091S Smoker 
Toxic effect of tobacco and nicotine SMC..00 Smoker 
SMOKER T509 Smoker 
SMOKING RESTARTED T509 SR Smoker 
SMOKER OWN ROLLED T5090OR Smoker 
SMOKER CIGARETTES T5090XC Smoker 
SMOKING ADVISED TO STOP T5092 Smoker 
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SMOKING WISHES TO STOP T5092S Smoker 
SMOKING WANTS TO STOP T5092SA Smoker 
EXCESSIVE SMOKING T510 Smoker 
HEAVY SMOKER  (20-PLUS PER DAY) T510 HS Smoker 
SMOKING EXCESSIVE T510 SE Smoker 
SMOKER HEAVY (Ex-Smoker0-PLUS PER DAY) T510 SH Smoker 
SMOKER MODERATE (LESS THAN 20 PER DAY) T511 Smoker 
SMOKER (20 PER DAY) T5112 Smoker 
SMOKER (15 PER DAY) T5113 Smoker 
SMOKER (10 PER DAY) T5114 Smoker 
SMOKER (LESS THAN 10 PER DAY) T5115 Smoker 
SMOKER MILD (5 OR LESS PER DAY) T5115M Smoker 
SMOKER(OCCASIONAL) T5116 Smoker 
SMOKER (30 PER DAY) T5117 Smoker 
SMOKER PIPE T512 Smoker 
SMOKER CIGARS T513 Smoker 
[V]Tobacco use ZV4K000 Smoker 
[V]Tobacco abuse counselling ZV6D800 Smoker 
Tobacco consumption 137..00 Unknown 
Tobacco consumption unknown 137E.00 Unknown 
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Appendix III-j Codes for comorbidity 
 
Table j-i Codes for myocardial infarct 
Table j-ii Codes for Congestive heart failure 
Table j-iii Codes for Peripheral vascular disease 
Table j-iv Codes for Cerebrovascular disease 
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Table j-viii Codes for Ulcer disease 
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Table j-x Codes for Hemiplegia 
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Table j-xiii Codes for Any tumour 
Table j-xiv Codes for Leukaemia 
Table j-xv Codes for Lymphoma 
Table j-xvi Codes for Metastatic solid tumour 
Table j-xvii Codes for AIDS 
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Table j-i Codes for myocardial infarct 
description medcode 
H/O: myocardial infarct <60 14A3.00 
H/O: myocardial infarct >60 14A4.00 
H/O: angina pectoris 14A5.00 
H/O: heart disease NOS 14AA.00 
H/O: Myocardial infarction in last year 14AH.00 
H/O: Angina in last year 14AJ.00 
H/O: atrial fibrillation 14AN.00 
H/O: CVS disease NOS 14AZ.00 
Special CVS test abnormal 3154 
ECG: myocardial ischaemia 322..00 
ECG:shows myocardial ischaemia 3222 
ECG: myocardial ischaemia NOS 322Z.00 
ECG: myocardial infarction 323..00 
ECG: old myocardial infarction 3232 
ECG: antero-septal infarct. 3233 
ECG:posterior/inferior infarct 3234 
ECG: subendocardial infarct 3235 
ECG: lateral infarction 3236 
ECG: myocardial infarct NOS 323Z.00 
ECG: heart block 329..00 
Acute myocardial infarction G30..00 
Attack - heart G30..11 
Coronary thrombosis G30..12 
Cardiac rupture following myocardial infarction (MI) G30..13 
Heart attack G30..14 
MI - acute myocardial infarction G30..15 
Thrombosis - coronary G30..16 
Silent myocardial infarction G30..17 
Acute anterolateral infarction G300.00 
Other specified anterior myocardial infarction G301.00 
Acute anteroapical infarction G301000 
Acute anteroseptal infarction G301100 
Anterior myocardial infarction NOS G301z00 
Acute inferolateral infarction G302.00 
Acute inferoposterior infarction G303.00 
Posterior myocardial infarction NOS G304.00 
Lateral myocardial infarction NOS G305.00 
True posterior myocardial infarction G306.00 
Acute subendocardial infarction G307.00 
Acute non-Q wave infarction G307000 
Acute non-ST segment elevation myocardial infarction G307100 
Inferior myocardial infarction NOS G308.00 
Acute Q-wave infarct G309.00 
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Mural thrombosis G30A.00 
Acute posterolateral myocardial infarction G30B.00 
Acute transmural myocardial infarction of unspecif site G30X.00 
Acute ST segment elevation myocardial infarction G30X000 
Other acute myocardial infarction G30y.00 
Acute atrial infarction G30y000 
Acute papillary muscle infarction G30y100 
Acute septal infarction G30y200 
Other acute myocardial infarction NOS G30yz00 
Acute myocardial infarction NOS G30z.00 
Other acute and subacute ischaemic heart disease G31..00 
Postmyocardial infarction syndrome G310.00 
Dressler's syndrome G310.11 
Preinfarction syndrome G311.00 
Crescendo angina G311.11 
Impending infarction G311.12 
Unstable angina G311.13 
Angina at rest G311.14 
Unstable angina G311100 
Angina at rest G311200 
Refractory angina G311300 
Worsening angina G311400 
Acute coronary syndrome G311500 
Preinfarction syndrome NOS G311z00 
Coronary thrombosis not resulting in myocardial infarction G312.00 
Other acute and subacute ischaemic heart disease G31y.00 
Acute coronary insufficiency G31y000 
Microinfarction of heart G31y100 
Subendocardial ischaemia G31y200 
Transient myocardial ischaemia G31y300 
Other acute and subacute ischaemic heart disease NOS G31yz00 
Old myocardial infarction G32..00 
Healed myocardial infarction G32..11 
Personal history of myocardial infarction G32..12 
Angina pectoris G33..00 
Status anginosus G33z000 
Stenocardia G33z100 
Syncope anginosa G33z200 
Angina on effort G33z300 
Ischaemic chest pain G33z400 
Post infarct angina G33z500 
New onset angina G33z600 
Stable angina G33z700 
Angina pectoris NOS G33zz00 
Other chronic ischaemic heart disease G34..00 
Coronary atherosclerosis G340.00 
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Triple vessel disease of the heart G340.11 
Coronary artery disease G340.12 
Aneurysm of heart G341.00 
Cardiac aneurysm G341.11 
Atherosclerotic cardiovascular disease G342.00 
Ischaemic cardiomyopathy G343.00 
Silent myocardial ischaemia G344.00 
Other specified chronic ischaemic heart disease G34y.00 
Chronic coronary insufficiency G34y000 
Chronic myocardial ischaemia G34y100 
Other specified chronic ischaemic heart disease NOS G34yz00 
Other chronic ischaemic heart disease NOS G34z.00 
Subsequent myocardial infarction G35..00 
Subsequent myocardial infarction of anterior wall G350.00 
Subsequent myocardial infarction of inferior wall G351.00 
Subsequent myocardial infarction of other sites G353.00 
Subsequent myocardial infarction of unspecified site G35X.00 
Certain current complication follow acute myocardial infarct G36..00 
Haemopericardium/current comp folow acut myocard infarct G360.00 
Atrial septal defect/curr comp folow acut myocardal infarct G361.00 
Ventric septal defect/curr comp fol acut myocardal infarctn G362.00 
Ruptur cardiac wall w'out haemopericard/cur comp fol ac MI G363.00 
Ruptur chordae tendinae/curr comp fol acute myocard infarct G364.00 
Rupture papillary muscle/curr comp fol acute myocard infarct G365.00 
Thrombosis atrium,auric append&vent/curr comp foll acute MI G366.00 
Postoperative myocardial infarction G38..00 
Postoperative transmural myocardial infarction anterior wall G380.00 
Postoperative transmural myocardial infarction inferior wall G381.00 
Postoperative transmural myocardial infarction other sites G382.00 
Postoperative transmural myocardial infarction unspec site G383.00 
Postoperative subendocardial myocardial infarction G384.00 
Postoperative myocardial infarction, unspecified G38z.00 
Other specified ischaemic heart disease G3y..00 
Ischaemic heart disease NOS G3z..00 
Acute cor pulmonale G400.00 
Acute pericarditis in diseases EC G500.00 
Post infarction pericarditis G501.00 
Other and unspecified acute pericarditis G50z.00 
Rupture of papillary muscle G5y6.00 
[X]Other current complicatns following acute myocard infarct Gyu3100 
[X]Acute transmural myocardial infarction of unspecif site Gyu3400 
[X]Subsequent myocardial infarction of other sites Gyu3500 
[X]Subsequent myocardial infarction of unspecified site Gyu3600 
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description medcode 
Suspected heart failure 1J60.00 
Heart failure confirmed 1O1..00 
O/E - pulmonary oedema 23E1.00 
New York Heart Assoc classification heart failure symptoms 388D.00 
New York Heart Association classification - class I 662f.00 
New York Heart Association classification - class II 662g.00 
New York Heart Association classification - class III 662h.00 
New York Heart Association classification - class IV 662i.00 
Malignant hypertensive heart disease with CCF G210100 
Benign hypertensive heart disease with CCF G211100 
Hypertensive heart disease NOS with CCF G21z100 
Hypertensive heart&renal dis wth (congestive) heart failure G232.00 
Hyperten heart&renal dis+both(congestv)heart and renal fail G234.00 
Aneurysm of heart G341.00 
Congestive cardiomyopathy G554000 
Congestive obstructive cardiomyopathy G554011 
Heart failure G58..00 
Cardiac failure G58..11 
Congestive heart failure G580.00 
Congestive cardiac failure G580.11 
Right heart failure G580.12 
Right ventricular failure G580.13 
Biventricular failure G580.14 
Acute congestive heart failure G580000 
Chronic congestive heart failure G580100 
Left ventricular failure G581.00 
Pulmonary oedema - acute G581.12 
Acute heart failure G582.00 
Heart failure NOS G58z.00 
Cardiac failure NOS G58z.12 
Pulmonary oedema NOS H541z00 
Acute pulmonary oedema unspecified H584.00 
Acute oedema of lung, unspecified H584.11 
Acute pulmonary oedema NOS H584z00 
[D]Dropsy R023200 
Heart failure as a complication of care SP11111 
New York Heart Assoc classification heart failure symptoms ZRad.00 
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Table j-iii Codes for Peripheral vascular disease 
description medcode 
Diabetes mellitus with peripheral circulatory disorder C107.00 
Diabetes mellitus, juvenile +peripheral circulatory disorder C107000 
Diabetes mellitus, adult, + peripheral circulatory disorder C107100 
IDDM with peripheral circulatory disorder C107300 
NIDDM with peripheral circulatory disorder C107400 
Diabetes mellitus NOS with peripheral circulatory disorder C107z00 
Insulin dependent diab mell with peripheral angiopathy C108G00 
Type I diabetes mellitus with peripheral angiopathy C108G11 
Type 1 diabetes mellitus with peripheral angiopathy C108G12 
Non-insulin-dependent d m with peripheral angiopath C109F00 
Type II diabetes mellitus with peripheral angiopathy C109F11 
Type 2 diabetes mellitus with peripheral angiopathy C109F12 
Type 1 diabetes mellitus with peripheral angiopathy C10EG00 
Type I diabetes mellitus with peripheral angiopathy C10EG11 
Insulin dependent diab mell with peripheral angiopathy C10EG12 
Type 2 diabetes mellitus with peripheral angiopathy C10FF00 
Type II diabetes mellitus with peripheral angiopathy C10FF11 
Pulmonary arteritis G42y000 
Pulmonary vessel rupture G42y100 
Pulmonary vessel stricture G42y200 
Other specified pulmonary circulation disease NOS G42yz00 
Cardiovascular arteriosclerosis unspecified G5y2.00 
Arteriosclerosis G70..11 
Aorto-iliac disease G700.11 
Renal artery atherosclerosis G701.00 
Extremity artery atheroma G702.00 
Monckeberg's medial sclerosis G702000 
Other specified artery atheroma G70y.00 
Carotid artery atherosclerosis G70y000 
Arteriosclerotic vascular disease NOS G70z.00 
Other aneurysm G72..00 
Other peripheral vascular disease G73..00 
Peripheral ischaemic vascular disease G73..11 
Ischaemia of legs G73..12 
Peripheral ischaemia G73..13 
Buerger's disease G731000 
Peripheral gangrene G732.00 
Other specified peripheral vascular disease G73y.00 
Diabetic peripheral angiopathy G73y000 
Erythrocyanosis G73y700 
Spasm of peripheral artery G73z100 
Arterial embolism and thrombosis G74..00 
Arterial embolus and thrombosis G74..11 
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Thrombosis - arterial G74..12 
Arterial embolic and thrombotic occlusion G74..13 
Polyarteritis nodosa and allied conditions G75..00 
Polyarteritis nodosa G750.00 
Necrotising angiitis G750.11 
Wegener's granulomatosis G754.00 
Giant cell arteritis G755.00 
Cranial arteritis G755000 
Temporal arteritis G755100 
Horton's disease G755200 
Giant cell arteritis NOS G755z00 
Thrombotic microangiopathy G756.00 
Takayasu's disease G757.00 
Aortic arch arteritis G757.11 
Pulseless disease G757.12 
Churg-Strauss vasculitis G758.00 
Juvenile polyarteritis G759.00 
Necrotising vasculopathy, unspecified G75X.00 
Polyarteritis nodosa and allied conditions NOS G75z.00 
Other disorders of arteries and arterioles G76..00 
Acquired arteriovenous fistula G760.00 
Stricture of artery G761.00 
Rupture of artery G762.00 
Hyperplasia of renal artery G763.00 
Coeliac artery compression syndrome G764.00 
Marable's syndrome G764.11 
Necrosis of artery G765.00 
Arteritis unspecified G766.00 
Aortitis G766.11 
Aortitis - syphilitic G767.00 
Other disorders of arteries and arterioles G768.00 
Anterior spinal and vertebral artery compression syndromes G769.00 
Arterial insufficiency G76A.00 
Vasculitis G76B.00 
Disorders of arteries and arterioles NOS G76z.00 
Diseases of capillaries G77..00 
Other specified arterial, arteriole or capillary disease G7y..00 
Arterial, arteriole and capillary diseases NOS G7z..00 
Phlebosclerosis G8yy200 
[X]Atherosclerosis of other arteries Gyu7000 
[X]Other specified peripheral vascular diseases Gyu7400 
[X]Embolism and thrombosis of other arteries Gyu7500 
[X]Other specified disorders of arteries and arterioles Gyu7600 
[X]Other diseases of capillaries Gyu7700 
[X]Peripheral angiopathy in diseases classified elsewhere Gyu7A00 
[X]Oth disorders/arteries,arterioles+capillaries/diseases CE Gyu7B00 
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Vascular insufficiency of the intestine J42..00 
Acute intestinal vascular insufficiency J420.00 
Acute intestinal vascular insufficiency NOS J420z00 
Chronic intestinal vascular insufficiency J421.00 
Chronic intestinal vascular insufficiency NOS J421z00 
Intestinal vascular insufficiency NOS J42z.00 
Vascular disorders of intestine J577.00 
Gastric antral vascular ectasia J577100 
[X]Other vascular disorders of intestine Jyu5000 
Vascular disorders of kidney K138.00 
Renal vascular disorders K138.11 
Renal vascular disorders NOS K138z00 
Vascular disorders of penis K275.00 
Penile vascular disorder NOS K275z00 
Male genital organ vascular diseases K286.00 
Male genital vascular diseases NOS K286z00 
Giant cell arteritis with polymyalgia rheumatica N200.00 
[X]Other conditions related to polyarteritis nodosa Nyu4000 
[X]Other giant cell arteritis Nyu4100 
[X]Other specified necrotizing vasculopathies Nyu4200 
[X]Necrotising vasculopathy, unspecified Nyu4D00 
Other peripheral vascular system anomalies P76..00 
Peripheral arterio-venous aneurysm P766.00 
Peripheral arterio-venous malformation P766.11 
Congenital peripheral aneurysm P767.00 
Congenital anomaly of peripheral vascular system OS P76y.00 
Other congenital anomaly of peripheral vascular system NOS P76yz00 
Peripheral vascular system anomaly NOS P76z.00 
Cerebrovascular system anomaly NOS P7y0z00 
Other cardiovascular system anomaly NOS P7yz.00 
Other cardiovascular system anomaly NOS P7yzz00 
[D]Failure of peripheral circulation R055000 
[D]Peripheral circulatory failure R055011 
Peripheral vascular complications of care SP12.00 
Peripheral vascular complications of care NOS SP12z00 
 
  
331 
Table j-iv Codes for Cerebrovascular disease 
description medcode 
Diabetes mellitus with peripheral circulatory disorder C107.00 
Diabetes mellitus, juvenile +peripheral circulatory disorder C107000 
Diabetes mellitus, adult, + peripheral circulatory disorder C107100 
IDDM with peripheral circulatory disorder C107300 
NIDDM with peripheral circulatory disorder C107400 
Diabetes mellitus NOS with peripheral circulatory disorder C107z00 
Insulin dependent diab mell with peripheral angiopathy C108G00 
Type I diabetes mellitus with peripheral angiopathy C108G11 
Type 1 diabetes mellitus with peripheral angiopathy C108G12 
Non-insulin-dependent d m with peripheral angiopath C109F00 
Type II diabetes mellitus with peripheral angiopathy C109F11 
Type 2 diabetes mellitus with peripheral angiopathy C109F12 
Type 1 diabetes mellitus with peripheral angiopathy C10EG00 
Type I diabetes mellitus with peripheral angiopathy C10EG11 
Insulin dependent diab mell with peripheral angiopathy C10EG12 
Type 2 diabetes mellitus with peripheral angiopathy C10FF00 
Type II diabetes mellitus with peripheral angiopathy C10FF11 
Pulmonary arteritis G42y000 
Pulmonary vessel rupture G42y100 
Pulmonary vessel stricture G42y200 
Other specified pulmonary circulation disease NOS G42yz00 
Cardiovascular arteriosclerosis unspecified G5y2.00 
Arteriosclerosis G70..11 
Aorto-iliac disease G700.11 
Renal artery atherosclerosis G701.00 
Extremity artery atheroma G702.00 
Monckeberg's medial sclerosis G702000 
Other specified artery atheroma G70y.00 
Carotid artery atherosclerosis G70y000 
Arteriosclerotic vascular disease NOS G70z.00 
Other aneurysm G72..00 
Other peripheral vascular disease G73..00 
Peripheral ischaemic vascular disease G73..11 
Ischaemia of legs G73..12 
Peripheral ischaemia G73..13 
Buerger's disease G731000 
Peripheral gangrene G732.00 
Other specified peripheral vascular disease G73y.00 
Diabetic peripheral angiopathy G73y000 
Erythrocyanosis G73y700 
Spasm of peripheral artery G73z100 
Arterial embolism and thrombosis G74..00 
Arterial embolus and thrombosis G74..11 
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Thrombosis - arterial G74..12 
Arterial embolic and thrombotic occlusion G74..13 
Polyarteritis nodosa and allied conditions G75..00 
Polyarteritis nodosa G750.00 
Necrotising angiitis G750.11 
Wegener's granulomatosis G754.00 
Giant cell arteritis G755.00 
Cranial arteritis G755000 
Temporal arteritis G755100 
Horton's disease G755200 
Giant cell arteritis NOS G755z00 
Thrombotic microangiopathy G756.00 
Takayasu's disease G757.00 
Aortic arch arteritis G757.11 
Pulseless disease G757.12 
Churg-Strauss vasculitis G758.00 
Juvenile polyarteritis G759.00 
Necrotising vasculopathy, unspecified G75X.00 
Polyarteritis nodosa and allied conditions NOS G75z.00 
Other disorders of arteries and arterioles G76..00 
Acquired arteriovenous fistula G760.00 
Stricture of artery G761.00 
Rupture of artery G762.00 
Hyperplasia of renal artery G763.00 
Coeliac artery compression syndrome G764.00 
Marable's syndrome G764.11 
Necrosis of artery G765.00 
Arteritis unspecified G766.00 
Aortitis G766.11 
Aortitis - syphilitic G767.00 
Other disorders of arteries and arterioles G768.00 
Anterior spinal and vertebral artery compression syndromes G769.00 
Arterial insufficiency G76A.00 
Vasculitis G76B.00 
Disorders of arteries and arterioles NOS G76z.00 
Diseases of capillaries G77..00 
Other specified arterial, arteriole or capillary disease G7y..00 
Arterial, arteriole and capillary diseases NOS G7z..00 
Phlebosclerosis G8yy200 
[X]Atherosclerosis of other arteries Gyu7000 
[X]Other specified peripheral vascular diseases Gyu7400 
[X]Embolism and thrombosis of other arteries Gyu7500 
[X]Other specified disorders of arteries and arterioles Gyu7600 
[X]Other diseases of capillaries Gyu7700 
[X]Peripheral angiopathy in diseases classified elsewhere Gyu7A00 
[X]Oth disorders/arteries,arterioles+capillaries/diseases CE Gyu7B00 
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Vascular insufficiency of the intestine J42..00 
Acute intestinal vascular insufficiency J420.00 
Acute intestinal vascular insufficiency NOS J420z00 
Chronic intestinal vascular insufficiency J421.00 
Chronic intestinal vascular insufficiency NOS J421z00 
Intestinal vascular insufficiency NOS J42z.00 
Vascular disorders of intestine J577.00 
Gastric antral vascular ectasia J577100 
[X]Other vascular disorders of intestine Jyu5000 
Vascular disorders of kidney K138.00 
Renal vascular disorders K138.11 
Renal vascular disorders NOS K138z00 
Vascular disorders of penis K275.00 
Penile vascular disorder NOS K275z00 
Male genital organ vascular diseases K286.00 
Male genital vascular diseases NOS K286z00 
Giant cell arteritis with polymyalgia rheumatica N200.00 
[X]Other conditions related to polyarteritis nodosa Nyu4000 
[X]Other giant cell arteritis Nyu4100 
[X]Other specified necrotizing vasculopathies Nyu4200 
[X]Necrotising vasculopathy, unspecified Nyu4D00 
Other peripheral vascular system anomalies P76..00 
Peripheral arterio-venous aneurysm P766.00 
Peripheral arterio-venous malformation P766.11 
Congenital peripheral aneurysm P767.00 
Congenital anomaly of peripheral vascular system OS P76y.00 
Other congenital anomaly of peripheral vascular system NOS P76yz00 
Peripheral vascular system anomaly NOS P76z.00 
Cerebrovascular system anomaly NOS P7y0z00 
Other cardiovascular system anomaly NOS P7yz.00 
Other cardiovascular system anomaly NOS P7yzz00 
[D]Failure of peripheral circulation R055000 
[D]Peripheral circulatory failure R055011 
Peripheral vascular complications of care SP12.00 
Peripheral vascular complications of care NOS SP12z00 
 
  
334 
Table j-v Codes for Dementia 
description medcode 
H/O: dementia 1461 
Senile dementia E00..11 
Senile/presenile dementia E00..12 
Uncomplicated senile dementia E000.00 
Presenile dementia E001.00 
Uncomplicated presenile dementia E001000 
Presenile dementia with delirium E001100 
Presenile dementia with paranoia E001200 
Presenile dementia with depression E001300 
Presenile dementia NOS E001z00 
Senile dementia with depressive or paranoid features E002.00 
Senile dementia with paranoia E002000 
Senile dementia with depression E002100 
Senile dementia with depressive or paranoid features NOS E002z00 
Senile dementia with delirium E003.00 
Arteriosclerotic dementia E004.00 
Multi infarct dementia E004.11 
Uncomplicated arteriosclerotic dementia E004000 
Arteriosclerotic dementia with delirium E004100 
Arteriosclerotic dementia with paranoia E004200 
Arteriosclerotic dementia with depression E004300 
Arteriosclerotic dementia NOS E004z00 
Dementia in conditions EC E041.00 
Chronic confusional state E042.00 
[X]Dementia in Alzheimer's disease Eu00.00 
[X]Dementia in Alzheimer's disease with early onset Eu00000 
[X]Presenile dementia,Alzheimer's type Eu00011 
[X]Primary degen dementia, Alzheimer's type, presenile onset Eu00012 
[X]Alzheimer's disease type 2 Eu00013 
[X]Dementia in Alzheimer's disease with late onset Eu00100 
[X]Alzheimer's disease type 1 Eu00111 
[X]Senile dementia,Alzheimer's type Eu00112 
[X]Primary degen dementia of Alzheimer's type, senile onset Eu00113 
[X]Dementia in Alzheimer's dis, atypical or mixed type Eu00200 
[X]Dementia in Alzheimer's disease, unspecified Eu00z00 
[X]Alzheimer's dementia unspec Eu00z11 
[X]Vascular dementia Eu01.00 
[X]Arteriosclerotic dementia Eu01.11 
[X]Vascular dementia of acute onset Eu01000 
[X]Multi-infarct dementia Eu01100 
[X]Predominantly cortical dementia Eu01111 
[X]Subcortical vascular dementia Eu01200 
[X]Mixed cortical and subcortical vascular dementia Eu01300 
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[X]Other vascular dementia Eu01y00 
[X]Vascular dementia, unspecified Eu01z00 
[X]Dementia in other diseases classified elsewhere Eu02.00 
[X]Dementia in Pick's disease Eu02000 
[X]Dementia in Creutzfeldt-Jakob disease Eu02100 
[X]Dementia in Huntington's disease Eu02200 
[X]Dementia in Parkinson's disease Eu02300 
[X]Dementia in human immunodef virus [HIV] disease Eu02400 
[X]Dementia in other specified diseases classif elsewhere Eu02y00 
[X] Unspecified dementia Eu02z00 
[X] Presenile dementia NOS Eu02z11 
[X] Primary degenerative dementia NOS Eu02z13 
[X] Senile dementia NOS Eu02z14 
[X] Senile dementia, depressed or paranoid type Eu02z16 
[X]Delirium superimposed on dementia Eu04100 
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Table j-vi Codes for Chronic pulmonary disease 
description medcode 
Recurrent wheezy bronchitis H30..12 
Chronic bronchitis H31..00 
Chronic asthmatic bronchitis H312000 
Chronic wheezy bronchitis H312011 
Emphysematous bronchitis H312100 
Acute exacerbation of chronic obstructive airways disease H312200 
Bronchiolitis obliterans H312300 
Obstructive chronic bronchitis NOS H312z00 
Emphysema H32..00 
Chronic bullous emphysema H320.00 
Segmental bullous emphysema H320000 
Zonal bullous emphysema H320100 
Giant bullous emphysema H320200 
Bullous emphysema with collapse H320300 
Chronic bullous emphysema NOS H320z00 
Panlobular emphysema H321.00 
Centrilobular emphysema H322.00 
Other emphysema H32y.00 
Atrophic (senile) emphysema H32y100 
MacLeod's unilateral emphysema H32y200 
Other emphysema NOS H32yz00 
Emphysema NOS H32z.00 
Asthma H33..00 
Bronchial asthma H33..11 
Bronchiectasis H34..00 
Extrinsic allergic alveolitis H35..00 
Other allergic alveolitis H35y.00 
Other allergic alveolitis NOS H35yz00 
Allergic alveolitis and pneumonitis NOS H35z.00 
Allergic extrinsic alveolitis NOS H35z000 
Allergic alveolitis and pneumonitis NOS H35zz00 
Mild chronic obstructive pulmonary disease H36..00 
Moderate chronic obstructive pulmonary disease H37..00 
Severe chronic obstructive pulmonary disease H38..00 
Other specified chronic obstructive airways disease H3y..00 
Other specified chronic obstructive pulmonary disease H3y..11 
Chronic obstructive airways disease NOS H3z..00 
Chronic obstructive pulmonary disease NOS H3z..11 
Chronic emphysema due to chemical fumes H464000 
Obliterative bronchiolitis due to chemical fumes H464100 
Chronic pulmonary fibrosis due to chemical fumes H464200 
Chronic respiratory conditions due to chemical fumes NOS H464z00 
Idiopathic fibrosing alveolitis H563.00 
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Cryptogenic fibrosing alveolitis H563.12 
Idiopathic fibrosing alveolitis NOS H563z00 
Other lung disease NEC H58y.00 
Lung disease NOS H58z.00 
[X]Other emphysema Hyu3000 
[X]Other specified chronic obstructive pulmonary disease Hyu3100 
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Table j-vii Codes for Connective tissue disease 
description medcode 
Behcet's syndrome AD61.00 
Polyneuropathy in collagen vascular disease F371.00 
Polyneuropathy in disseminated lupus erythematosus F371000 
Polyneuropathy in polyarteritis nodosa F371100 
Polyneuropathy in collagen vascular disease NOS F371z00 
Muscular dystrophies and other myopathies F39..00 
Symptomatic inflammatory myopathy in disease EC F396.00 
Myopathy due to disseminated lupus erythematosus F396100 
Myopathy due to polyarteritis nodosa F396300 
Eyelid discoid lupus erythematosus F4D3300 
Arterial, arteriole and capillary disease G7...00 
Capillary disease G7...11 
Polyarteritis nodosa and allied conditions G75..00 
Polyarteritis nodosa G750.00 
Wegener's granulomatosis G754.00 
Juvenile polyarteritis G759.00 
Polyarteritis nodosa and allied conditions NOS G75z.00 
Lung disease with systemic lupus erythematosus H57y400 
Nephrotic syndrome in polyarteritis nodosa K01x300 
Lupus erythematosus M154.00 
Lupus erythematosus chronicus M154000 
Discoid lupus erythematosus M154100 
Lupus erythematosus migrans M154200 
Lupus erythematosus nodularis M154300 
Lupus erythematosus profundus M154400 
Lupus erythematosus tumidus M154500 
Lupus erythematosus unguium mutilans M154600 
Subacute cutaneous lupus erythematosus M154700 
Lupus erythematosus NOS M154z00 
[X]Other local lupus erythematosus Myu7800 
Musculoskeletal and connective tissue diseases N....00 
Connective tissue diseases N....11 
Arthropathies and related disorders N0...00 
Diffuse diseases of connective tissue N00..00 
Collagen diseases N00..11 
Systemic lupus erythematosus N000.00 
Disseminated lupus erythematosus N000000 
Drug-induced systemic lupus erythematosus N000200 
Systemic lupus erythematosus with organ or sys involv N000300 
Systemic lupus erythematosus with pericarditis N000400 
Systemic lupus erythematosus NOS N000z00 
Other specified diffuse collagen diseases N00y.00 
Collagen disease NOS N00z.00 
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Arthropathy in Behcet's syndrome N012.00 
Arthropathy in Behcet's syndrome of unspecified site N012000 
Behcet's syndrome arthropathy N012011 
Arthropathy in Behcet's syndrome of the shoulder region N012100 
Arthropathy in Behcet's syndrome of the upper arm N012200 
Arthropathy in Behcet's syndrome of the forearm N012300 
Arthropathy in Behcet's syndrome of the hand N012400 
Arthropathy in Behcet's syndrome of the pelvis/thigh N012500 
Arthropathy in Behcet's syndrome of the lower leg N012600 
Arthropathy in Behcet's syndrome of the ankle and foot N012700 
Arthropathy in Behcet's syndrome of multiple sites N012x00 
Arthropathy in Behcet's syndrome of other specified sites N012y00 
Arthropathy in Behcet's syndrome NOS N012z00 
Rheumatism, excluding the back N2...00 
Polymyalgia rheumatica N20..00 
Polymyalgia N20..11 
Giant cell arteritis with polymyalgia rheumatica N200.00 
Scoliosis in connective tissue anomalies N374D00 
Musculoskeletal or connective tissue diseases OS Ny...00 
[X]Addtnl musculskeletal+connectv tissue dis classfctn terms Nyu..00 
[X]Systemic connective tissue disorders Nyu4.00 
[X]Other conditions related to polyarteritis nodosa Nyu4000 
[X]Other forms of systemic lupus erythematosus Nyu4300 
[X]Other systemic diseases of connective tissue Nyu4700 
[X]Systemic disorders/connective tissue in other diseases CE Nyu4C00 
[X]Other disord musculoskeletal system and connective tissue NyuE.00 
Musculoskeletal and connective tissue diseases NOS Nz...00 
Unspecified anomaly of connective tissue PGz4.00 
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Table j-viii Codes for Ulcer disease 
description medcode 
Peptic ulcer symptoms 1956 
Oesophageal, stomach and duodenal diseases J1...00 
Duodenal diseases J1...11 
Ulcerative oesophagitis J101600 
Ulcer of oesophagus J102.00 
Peptic ulcer of oesophagus J102000 
Oesophageal ulcer due to aspirin J102200 
Oesophageal ulcer due to chemicals J102300 
Oesophageal ulcer due to medicines J102400 
Barrett's ulcer of oesophagus J102500 
Ulcer of oesophagus NOS J102z00 
Gastric ulcer - (GU) J11..00 
Prepyloric ulcer J11..11 
Pyloric ulcer J11..12 
Acute gastric ulcer J110.00 
Acute gastric ulcer without mention of complication J110000 
Acute gastric ulcer with haemorrhage J110100 
Bleeding acute gastric ulcer J110111 
Acute gastric ulcer with perforation J110200 
Acute gastric ulcer with haemorrhage and perforation J110300 
Acute gastric ulcer with obstruction J110400 
Acute gastric ulcer unspecified J110y00 
Acute gastric ulcer NOS J110z00 
Chronic gastric ulcer J111.00 
Chronic gastric ulcer without mention of complication J111000 
Chronic gastric ulcer with haemorrhage J111100 
Bleeding chronic gastric ulcer J111111 
Chronic gastric ulcer with perforation J111200 
Perforated chronic gastric ulcer J111211 
Chronic gastric ulcer with haemorrhage and perforation J111300 
Chronic gastric ulcer with obstruction J111400 
Chronic gastric ulcer unspecified J111y00 
Chronic gastric ulcer NOS J111z00 
Unspecified gastric ulcer J11y.00 
Unspecified gastric ulcer without mention of complication J11y000 
Unspecified gastric ulcer with haemorrhage J11y100 
Unspecified gastric ulcer with perforation J11y200 
Unspecified gastric ulcer with haemorrhage and perforation J11y300 
Unspecified gastric ulcer with obstruction J11y400 
Unspec gastric ulcer; unspec haemorrhage and/or perforation J11yy00 
Unspecified gastric ulcer NOS J11yz00 
Gastric ulcer NOS J11z.00 
Multiple gastric ulcers J11z.12 
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Duodenal ulcer - (DU) J12..00 
Acute duodenal ulcer J120.00 
Acute duodenal ulcer without mention of complication J120000 
Acute duodenal ulcer with haemorrhage J120100 
Acute duodenal ulcer with perforation J120200 
Acute duodenal ulcer with haemorrhage and perforation J120300 
Acute duodenal ulcer with obstruction J120400 
Acute duodenal ulcer unspecified J120y00 
Acute duodenal ulcer NOS J120z00 
Chronic duodenal ulcer J121.00 
Chronic duodenal ulcer without mention of complication J121000 
Chronic duodenal ulcer with haemorrhage J121100 
Bleeding chronic duodenal ulcer J121111 
Chronic duodenal ulcer with perforation J121200 
Perforated chronic duodenal ulcer J121211 
Chronic duodenal ulcer with haemorrhage and perforation J121300 
Chronic duodenal ulcer with obstruction J121400 
Chronic duodenal ulcer unspecified J121y00 
Chronic duodenal ulcer NOS J121z00 
Duodenal ulcer disease J122.00 
Recurrent duodenal ulcer J124.00 
Unspecified duodenal ulcer J12y.00 
Unspecified duodenal ulcer without mention of complication J12y000 
Unspecified duodenal ulcer with haemorrhage J12y100 
Unspecified duodenal ulcer with perforation J12y200 
Unspecified duodenal ulcer with haemorrhage and perforation J12y300 
Unspecified duodenal ulcer with obstruction J12y400 
Unspec duodenal ulcer; unspec haemorrhage and/or perforation J12yy00 
Unspecified duodenal ulcer NOS J12yz00 
Duodenal ulcer NOS J12z.00 
Peptic ulcer - (PU) site unspecified J13..00 
Stress ulcer NOS J13..11 
Acute peptic ulcer J130.00 
Acute peptic ulcer without mention of complication J130000 
Acute peptic ulcer with haemorrhage J130100 
Acute peptic ulcer with perforation J130200 
Acute peptic ulcer with haemorrhage and perforation J130300 
Acute peptic ulcer with obstruction J130400 
Acute peptic ulcer unspecified J130y00 
Acute peptic ulcer NOS J130z00 
Chronic peptic ulcer J131.00 
Chronic peptic ulcer without mention of complication J131000 
Chronic peptic ulcer with haemorrhage J131100 
Chronic peptic ulcer with perforation J131200 
Chronic peptic ulcer with haemorrhage and perforation J131300 
Chronic peptic ulcer with obstruction J131400 
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Chronic peptic ulcer unspecified J131y00 
Chronic peptic ulcer NOS J131z00 
Unspecified peptic ulcer J13y.00 
Unspecified peptic ulcer without mention of complication J13y000 
Unspecified peptic ulcer with haemorrhage J13y100 
Unspecified peptic ulcer with perforation J13y200 
Unspecified peptic ulcer with haemorrhage and perforation J13y300 
Unspecified peptic ulcer with obstruction J13y400 
Unspec peptic ulcer; unspec haemorrhage and/or perforation J13yy00 
Unspecified peptic ulcer NOS J13yz00 
Peptic ulcer NOS J13z.00 
Gastrojejunal ulcer (GJU) J14..00 
Gastrocolic ulcer J14..12 
Jejunal ulcer J14..13 
Marginal ulcer J14..14 
Stomal ulcer J14..15 
Acute gastrojejunal ulcer J140.00 
Acute gastrojejunal ulcer without mention of complication J140000 
Acute gastrojejunal ulcer with haemorrhage J140100 
Acute gastrojejunal ulcer with perforation J140200 
Acute gastrojejunal ulcer with haemorrhage and perforation J140300 
Acute gastrojejunal ulcer with obstruction J140400 
Acute gastrojejunal ulcer unspecified J140y00 
Acute gastrojejunal ulcer NOS J140z00 
Chronic gastrojejunal ulcer J141.00 
Chronic gastrojejunal ulcer without mention of complication J141000 
Chronic gastrojejunal ulcer with haemorrhage J141100 
Chronic gastrojejunal ulcer with perforation J141200 
Chronic gastrojejunal ulcer with haemorrhage and perforation J141300 
Chronic gastrojejunal ulcer with obstruction J141400 
Chronic gastrojejunal ulcer unspecified J141y00 
Chronic gastrojejunal ulcer NOS J141z00 
Unspecified gastrojejunal ulcer J14y.00 
Unspecified gastrojejunal ulcer without mention complication J14y000 
Unspecified gastrojejunal ulcer with haemorrhage J14y100 
Unspecified gastrojejunal ulcer with perforation J14y200 
Unspec gastrojejunal ulcer with haemorrhage and perforation J14y300 
Unspecified gastrojejunal ulcer with obstruction J14y400 
Unspec gastrojejunal ulcer; unspec haemorrhage/perforation J14yy00 
Unspecified gastrojejunal ulcer NOS J14yz00 
Gastrojejunal ulcer NOS J14z.00 
Other stomach and duodenal disorders J17..00 
Other stomach and duodenal disorders J17y.00 
Primary ulcer of intestine J57y800 
Ulceration of colon J57y900 
Ulceration of intestine NOS J57yA00 
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Table j-ix Codes for Diabetes (not specifying end organ damage) 
description medcode 
Initial diabetic assessment 66A1.00 
Follow-up diabetic assessment 66A2.00 
Diabetic on diet only 66A3.00 
Diabetic on oral treatment 66A4.00 
Diabetic on insulin 66A5.00 
Has seen dietician - diabetes 66A8.00 
Unstable diabetes 66AJ.11 
Diabetic - poor control NOS 66AJz00 
Diabetes: practice programme 66AP.00 
Diabetes: shared care programme 66AQ.00 
Diabetes care by hospital only 66AU.00 
Diabetic on insulin and oral treatment 66AV.00 
Diabetic monitoring NOS 66AZ.00 
Under care of diabetologist 9NN8.00 
Under care of diabetes specialist nurse 9NN9.00 
Diabetes mellitus C10..00 
Diabetes mellitus with no mention of complication C100.00 
Diabetes mellitus, juvenile type, no mention of complication C100000 
Insulin dependent diabetes mellitus C100011 
Diabetes mellitus, adult onset, no mention of complication C100100 
Maturity onset diabetes C100111 
Non-insulin dependent diabetes mellitus C100112 
Diabetes mellitus NOS with no mention of complication C100z00 
Insulin dependent diabetes mellitus C108.00 
IDDM-Insulin dependent diabetes mellitus C108.11 
Type 1 diabetes mellitus C108.12 
Type I diabetes mellitus C108.13 
Unstable insulin dependent diabetes mellitus C108400 
Unstable type I diabetes mellitus C108411 
Unstable type 1 diabetes mellitus C108412 
Insulin dependent diabetes mellitus - poor control C108800 
Type I diabetes mellitus - poor control C108811 
Type 1 diabetes mellitus - poor control C108812 
Insulin dependent diabetes maturity onset C108900 
Type I diabetes mellitus maturity onset C108911 
Type 1 diabetes mellitus maturity onset C108912 
Insulin-dependent diabetes without complication C108A00 
Type I diabetes mellitus without complication C108A11 
Type 1 diabetes mellitus without complication C108A12 
Non-insulin dependent diabetes mellitus C109.00 
NIDDM - Non-insulin dependent diabetes mellitus C109.11 
Type 2 diabetes mellitus C109.12 
344 
Type II diabetes mellitus C109.13 
Non-insulin dependent diabetes mellitus - poor control C109700 
Type II diabetes mellitus - poor control C109711 
Type 2 diabetes mellitus - poor control C109712 
Reaven's syndrome C109800 
Non-insulin-dependent diabetes mellitus without complication C109900 
Type II diabetes mellitus without complication C109911 
Type 2 diabetes mellitus without complication C109912 
Insulin treated Type 2 diabetes mellitus C109J00 
Insulin treated non-insulin dependent diabetes mellitus C109J11 
Insulin treated Type II diabetes mellitus C109J12 
Malnutrition-related diabetes mellitus C10A.00 
Diabetes mellitus induced by steroids C10B.00 
Steroid induced diabetes mellitus without complication C10B000 
Diabetes mellitus autosomal dominant C10C.00 
Maturity onset diabetes in youth C10C.11 
Maturity onset diabetes in youth type 1 C10C.12 
Diabetes mellitus autosomal dominant type 2 C10D.00 
Maturity onset diabetes in youth type 2 C10D.11 
Type 1 diabetes mellitus C10E.00 
Type I diabetes mellitus C10E.11 
Insulin dependent diabetes mellitus C10E.12 
Unstable type 1 diabetes mellitus C10E400 
Unstable type I diabetes mellitus C10E411 
Unstable insulin dependent diabetes mellitus C10E412 
Type 1 diabetes mellitus - poor control C10E800 
Type I diabetes mellitus - poor control C10E811 
Insulin dependent diabetes mellitus - poor control C10E812 
Type 1 diabetes mellitus maturity onset C10E900 
Type I diabetes mellitus maturity onset C10E911 
Insulin dependent diabetes maturity onset C10E912 
Type 1 diabetes mellitus without complication C10EA00 
Type I diabetes mellitus without complication C10EA11 
Insulin-dependent diabetes without complication C10EA12 
Type 2 diabetes mellitus C10F.00 
Type II diabetes mellitus C10F.11 
Type 2 diabetes mellitus - poor control C10F700 
Type II diabetes mellitus - poor control C10F711 
Reaven's syndrome C10F800 
Metabolic syndrome X C10F811 
Type 2 diabetes mellitus without complication C10F900 
Type II diabetes mellitus without complication C10F911 
Secondary pancreatic diabetes mellitus C10G.00 
Secondary pancreatic diabetes mellitus without complication C10G000 
Diabetes mellitus induced by non-steroid drugs C10H.00 
Insulin autoimmune syndrome C10J.00 
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Type A insulin resistance C10K.00 
Fibrocalculous pancreatopathy C10L.00 
Lipoatrophic diabetes mellitus C10M.00 
Lipoatrophic diabetes mellitus without complication C10M000 
Secondary diabetes mellitus C10N.00 
Secondary diabetes mellitus without complication C10N000 
Diabetes mellitus with other specified manifestation C10y.00 
Diabetes mellitus, juvenile, + other specified manifestation C10y000 
Diabetes mellitus, adult, + other specified manifestation C10y100 
Steroid induced diabetes C11y000 
[X]Diabetes mellitus Cyu2.00 
[X]Other specified diabetes mellitus Cyu2000 
Diabetes mellitus during pregnancy/childbirth/puerperium L180.00 
Diabetes mellitus - unspec whether in pregnancy/puerperium L180000 
Diabetes mellitus during pregnancy - baby delivered L180100 
Diabetes mellitus in puerperium - baby delivered L180200 
Diabetes mellitus during pregnancy - baby not yet delivered L180300 
Diabetes mellitus in pueperium - baby previously delivered L180400 
Pre-existing diabetes mellitus, insulin-dependent L180500 
Pre-existing diabetes mellitus, non-insulin-dependent L180600 
Pre-existing malnutrition-related diabetes mellitus L180700 
Diabetes mellitus arising in pregnancy L180800 
Gestational diabetes mellitus L180811 
Gestational diabetes mellitus L180900 
Pre-existing diabetes mellitus, unspecified L180X00 
Diabetes mellitus in pregnancy/childbirth/puerperium NOS L180z00 
Abnormal glucose tolerance test in pregnancy/childb/puerp L188.00 
GTT - glucose tolerance test abnormal in preg/childb/puerp L188.11 
[X]Pre-existing diabetes mellitus, unspecified Lyu2900 
[D]Drug induced hyperglycaemia R10C.00 
[D]Elevated blood glucose level R10D.00 
[D]Impaired glucose tolerance R10E.00 
Dietary advice for type I diabetes ZC2C900 
Diet advice for insulin-dependent diabetes ZC2C911 
Dietary advice for type II diabetes ZC2CA00 
Dietary advice non-insulin-dependent diabetes ZC2CA11 
Dietary advice for gestational diabetes ZC2CB00 
Referral to diabetes nurse ZL62500 
Referral to diabetic liaison nurse ZL62600 
[V]Dietary counselling in diabetes mellitus ZV65312 
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Table j-x Codes for Hemiplegia 
description medcode 
O/E - hemiplegia 2833 
Hemiplegia F22..00 
Flaccid hemiplegia F220.00 
Spastic hemiplegia F221.00 
Left hemiplegia F222.00 
Right hemiplegia F223.00 
Hemiplegia NOS F22z.00 
Paraplegia - congenital F230.11 
Congenital hemiplegia F231.00 
Infantile hemiplegia NOS F234.00 
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Table j-xi Codes for Moderate or severe renal disease 
description medcode 
Renal colic 1A52.00 
Renal colic, symptom 1A52.11 
Ureteric colic 1A54.00 
Dysuria 1A55.00 
Strangury 1A56.00 
O/E - kidney palpated 262..00 
O/E - renal palpation 262..11 
O/E - left kidney palpable 2622 
O/E - right kidney palpable 2623 
O/E - renal angle tenderness 2624 
O/E - kidney palpable NOS 262Z.00 
O/E - bladder palpated 263..00 
O/E - bladder palpable 263..11 
O/E: renal calculus 4G4..00 
O/E: kidney stone 4G4..11 
O/E: oxalate renal calculus 4G41.00 
Phosphate kidney stone 4G42.11 
O/E: uric acid renal calculus 4G43.00 
O/E: cystine renal calculus 4G44.00 
O/E: renal stone NOS 4G4Z.00 
O/E - ureteric calculus 4G6..00 
O/E - urethral calculus 4G7..00 
O/E - bladder calculus 4G8..00 
Dialysis for renal failure 7L1A.11 
Renal dialysis 7L1A000 
Thomas intravascular shunt for dialysis 7L1A011 
Peritoneal dialysis 7L1A100 
Haemodialysis NEC 7L1A200 
Other specified compensation for renal failure 7L1Ay00 
Compensation for renal failure NOS 7L1Az00 
Placement ambulatory apparatus compensation renal failure 7L1B.00 
Placement ambulatory dialysis apparatus - compens renal fail 7L1B.11 
Insertion of ambulatory peritoneal dialysis catheter 7L1B000 
Placement ambulatory apparatus- compensate renal failure OS 7L1By00 
Placement ambulatory apparatus- compensate renal failure NOS 7L1Bz00 
Placement other apparatus for compensation for renal failure 7L1C.00 
Insertion of temporary peritoneal dialysis catheter 7L1C000 
Placement other apparatus- compensate for renal failure OS 7L1Cy00 
Placement other apparatus- compensate for renal failure NOS 7L1Cz00 
Tuberculosis of kidney A160.00 
Renal tuberculosis A160.11 
Tuberculosis of bladder A161.00 
Tuberculosis of ureter A162.00 
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Tuberculosis of other urinary organs A163.00 
Tuberculosis of urinary tract A168.00 
Syphilis of kidney A954.00 
Renal syphilis A954.11 
Hypertensive renal disease G22..00 
Nephrosclerosis G22..11 
Malignant hypertensive renal disease G220.00 
Benign hypertensive renal disease G221.00 
Hypertensive renal disease with renal failure G222.00 
Hypertensive renal disease NOS G22z.00 
Renal hypertension G22z.11 
Hypertensive heart and renal disease G23..00 
Malignant hypertensive heart and renal disease G230.00 
Benign hypertensive heart and renal disease G231.00 
Hypertensive heart&renal dis wth (congestive) heart failure G232.00 
Hypertensive heart and renal disease with renal failure G233.00 
Hyperten heart&renal dis+both(congestv)heart and renal fail G234.00 
Hypertensive heart and renal disease NOS G23z.00 
Aneurysm of renal artery G721.00 
Hyperplasia of renal artery G763.00 
Embolism and thrombosis of the renal vein G823.00 
Acute glomerulonephritis K00..00 
Acute nephritis K00..11 
Bright's disease K00..12 
Nephrotic syndrome K01..00 
Chronic glomerulonephritis K02..00 
Nephritis - chronic K02..11 
Nephropathy - chronic K02..12 
Nephritis and nephropathy unspecified K03..00 
Nephritis and nephropathy unspecified K03..11 
Nephropathy, unspecified K03..12 
Proliferative nephritis unspecified K030.00 
Membranous nephritis unspecified K031.00 
Membranoproliferative nephritis unspecified K032.00 
Rapidly progressive nephritis unspecified K033.00 
Renal cortical necrosis unspecified K034.00 
Renal medullary necrosis unspecified K035.00 
Tubulo-interstit nephritis, not specif as acute or chron K03T.00 
Unspecif nephr synd, diff concentric glomerulonephritis K03U.00 
Unspecified nephritic syndrome, dense deposit disease K03V.00 
Unsp nephrit synd, diff endocap prolif glomerulonephritis K03W.00 
Unsp nephrit synd, diff mesang prolif glomerulonephritis K03X.00 
Other nephritis and nephrosis unspecified K03y.00 
Unspecified glomerulonephritis NOS K03z.00 
Acute renal failure K04..00 
Acute renal tubular necrosis K040.00 
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Acute renal cortical necrosis K041.00 
Acute renal medullary necrosis K042.00 
Necrotising renal papillitis K042.11 
Acute drug-induced renal failure K043.00 
Other acute renal failure K04y.00 
Acute renal failure NOS K04z.00 
Chronic renal failure K05..00 
Chronic uraemia K05..11 
End stage renal failure K05..12 
End stage renal failure K050.00 
Renal failure unspecified K06..00 
Uraemia NOS K06..11 
Renal impairment K060.00 
Impaired renal function K060.11 
Renal sclerosis unspecified K07..00 
Atrophy of kidney K070.00 
Renal fibrosis K071.00 
Glomerulosclerosis K072.00 
Renal sclerosis NOS K07z.00 
Impaired renal function disorder K08..00 
Renal osteodystrophy K080.00 
Phosphate-losing tubular disorders K080000 
Renal osteodystrophy NOS K080z00 
Nephrogenic diabetes insipidus K081.00 
Other impaired renal function disorder K08y.00 
Hypokalaemic nephropathy K08y000 
Lightwood - Albright syndrome K08y200 
Albright's renal tubular acidosis K08y211 
Renal function impairment with growth failure K08y300 
Renal tubular acidosis K08y400 
Renal tubular acidaemia K08y412 
Acute interstitial nephritis K08y500 
Other impaired renal function disorder NOS K08yz00 
Renal acidaemia K08yz11 
Renotubular acidaemia K08yz12 
Impaired renal function disorder NOS K08z.00 
Small kidney of unknown cause K09..00 
Glomerular disease K0A..00 
Renal tubulo-interstitial disorders in diseases EC K0B..00 
Ren tubulo-interstital disord infect and parasitic dis EC K0B0.00 
Renal tubulo-interstitial disorder/ neoplastic diseases K0B1.00 
Ren tub-interst disordr/blood dis+disordr inv immune mech K0B2.00 
Renal tubulo-interstitial disorders in metabolic diseases K0B3.00 
Ren tub-interstitl disordr/systemc connectv tiss disorder K0B4.00 
Renal tubulo-interstitial disorder in SLE K0B4000 
Renal tubulo-interstitial disordrs in transplant rejectn K0B5.00 
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Balkan nephropathy K0B6.00 
Drug/heavy-metal-induced tubulo-interstitial and tub conditn K0C..00 
End-stage renal disease K0D..00 
Other specified nephritis, nephrosis or nephrotic syndrome K0y..00 
Nephritis, nephrosis and nephrotic syndrome NOS K0z..00 
Infections of kidney K10..00 
Renal infections K10..11 
Chronic pyelonephritis K100.00 
Acute pyelonephritis K101.00 
Renal and perinephric abscess K102.00 
Renal abscess K102000 
Perinephric abscess K102100 
Renal carbuncle K102200 
Renal and perinephric abscess NOS K102z00 
Pyeloureteritis cystica K103.00 
Ureteritis cystica K103.11 
Infestation of renal pelvis with ureter K103.12 
Xanthogranulomatous pyelonephritis K104.00 
Pyelonephritis and pyonephrosis unspecified K10y.00 
Infection of kidney NOS K10z.00 
Hydronephrosis K11..00 
Hydrocalycosis K110.00 
Hydroureteronephrosis K111.00 
Hydronephrosis with renal and ureteral calculous obstruction K112.00 
Hydronephrosis with ureteropelvic junction obstruction K113.00 
Hydronephrosis with pelviureteric junction obstruction K113.11 
Hydronephrosis with ureteral stricture NEC K11X.00 
Hydronephrosis NOS K11z.00 
Calculus of kidney and ureter K12..00 
Kidney calculus K12..11 
Urinary calculus K12..12 
Calculus of kidney K120.00 
Nephrolithiasis NOS K120.11 
Renal calculus K120.12 
Renal stone K120.13 
Staghorn calculus K120000 
Renal calculus NOS K120z00 
Calculus of ureter K121.00 
Ureteric calculus K121.11 
Ureteric stone K121.12 
Ureterolithiasis K121.13 
Calculus of kidney with calculus of ureter K122.00 
Urinary calculus NOS K12z.00 
Other kidney and ureter disorders K13..00 
Other kidney disorders K13..11 
Other ureter disorders K13..12 
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Nephroptosis K130.00 
Floating kidney K130.11 
Mobile kidney K130.12 
Hypertrophy of kidney K131.00 
Acquired cyst of kidney K132.00 
Stricture of ureter K133.00 
Other ureteric obstruction K134.00 
Hydroureter K135.00 
Benign postural proteinuria K136.00 
Orthostatic proteinuria K136.11 
Vesicoureteric reflux K137.00 
Ureteric reflux K137.11 
Vascular disorders of kidney K138.00 
Renal vascular disorders K138.11 
Renal artery embolism K138000 
Renal artery embolus K138011 
Renal artery haemorrhage K138100 
Renal artery thrombosis K138200 
Intrarenal haematoma K138300 
Renal vascular disorders NOS K138z00 
Renal infarction K138z11 
Other kidney and ureteric disorders K13y.00 
Ureteric fistula K13y000 
Adhesions of kidney K13y100 
Adhesions of ureter K13y200 
Periureteritis K13y300 
Pyelectasia K13y400 
Polyp of ureter K13y500 
Ureterocele - acquired K13y600 
Idiopathic dilation of ureter K13y611 
Megaloureter - acquired K13y700 
Perirenal haematoma K13y800 
Ureteric neuromuscular incoordination K13y900 
Other kidney and ureteric disorders NOS K13yz00 
Salt-losing nephritis K13yz11 
Kidney and ureter disease NOS K13z.00 
Lower urinary tract calculus K14..00 
Cystitis K15..00 
Other disorders of bladder K16..00 
Urethritis due to non venereal causes K17..00 
Periurethritis K17..11 
Urethral stricture K18..00 
Pinhole meatus K18..11 
Other urethral and urinary tract disorders K19..00 
Other urethral disorders K19..11 
Urinary calculus in schistosomiasis K1A..00 
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Other specified diseases of urinary system K1y..00 
Other urinary system diseases NOS K1z..00 
[X]Glomerular diseases Kyu0.00 
[X]Renal tubulo-interstitial diseases Kyu1.00 
[X]Other chronic tubulo-interstitial nephritis Kyu1000 
[X]Other and unspecified hydronephrosis Kyu1100 
[X]Other obstructive and reflux uropathy Kyu1200 
[X]Obstructive and reflux uropathy, unspecified Kyu1300 
[X]Nephropathy induced by other drugs+biological substances Kyu1400 
[X]Toxic nephropathy, not elsewhere classified Kyu1500 
[X]Other specified renal tubulo-interstitial diseases Kyu1600 
[X]Renal tubulo-interstitial disordr/infect+parasitic dis CE Kyu1700 
[X]Renal tubulo-interstitial disordrs/neoplastic diseases CE Kyu1800 
[X]Renal tub-interstl disord/bld dis+disord invl imm mech CE Kyu1900 
[X]Renal tubulo-interstitial disorders/metabolic diseases CE Kyu1A00 
[X]Renal tubul-interstitl disordrs/connectv tissu disordr CE Kyu1B00 
[X]Renal tubulo-interstitial disorders/transplant rejection Kyu1C00 
[X]Renal tubulo-interstitial disorders in other diseases CE Kyu1D00 
[X]Tubulo-interstit nephritis, not specif as acute or chron Kyu1E00 
[X]Hydronephrosis with ureteral stricture NEC Kyu1F00 
[X]Renal failure Kyu2.00 
[X]Other acute renal failure Kyu2000 
[X]Other chronic renal failure Kyu2100 
[X]Urolithiasis Kyu3.00 
[X]Other disorders of kidney and ureter Kyu4.00 
[X]Other disorders resulting/impaired renal tubular function Kyu4000 
[X]Other specified disorders of kidney and ureter Kyu4100 
[X]Oth disordrs/kidney+ureter/infects+parasitic diseases CE Kyu4200 
[X]Other disorders of kidney+ureter in other diseases CE Kyu4300 
[X]Other diseases of urinary system Kyu5.00 
[X]Other disorders of genitourinary tract KyuA.00 
Incomplete spontaneous abortion with renal failure L041300 
Complete spontaneous abortion with renal failure L042300 
Unspecified legal abortion with renal failure L050300 
Incomplete legal abortion with renal failure L051300 
Complete legal abortion with renal failure L052300 
Unspecified illegal abortion with renal failure L060300 
Incomplete illegal abortion with renal failure L061300 
Complete illegal abortion with renal failure L062300 
Unspecified abortion with renal failure L070300 
Unspecified abortion with metabolic disorder L070400 
Unspecified abortion with shock L070500 
Unspecified abortion with embolism L070600 
Unspecified abortion with other specified complication L070w00 
Unspecified abortion with complication NOS L070x00 
Unspecified abortion with no mention of complication L070y00 
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Unspecified abortion NOS L070z00 
Unspecified incomplete abortion +genital tract/pelvic infect L071000 
Unspecified incomplete abortion + delayed/excess haemorrhage L071100 
Unspecified complete abortion with renal failure L072300 
Failed attempted abortion with renal failure L083.00 
Renal failure following abortive pregnancy L093.00 
Oliguria following abortive pregnancy L093000 
Acute renal failure following abortive pregnancy L093100 
Renal shutdown following abortive pregnancy L093200 
Renal tubular necrosis following abortive pregnancy L093300 
Uraemia following abortive pregnancy L093400 
Renal failure NOS following abortive pregnancy L093z00 
Renal hypertension in pregnancy/childbirth/puerperium L121.00 
Renal hypertension in pregnancy/childbirth/puerp unspecified L121000 
Renal hypertension in pregnancy/childbirth/puerp - delivered L121100 
Renal hypertension in preg/childb/puerp -deliv with p/n comp L121200 
Renal hypertension in preg/childbirth/puerp - not delivered L121300 
Renal hypertension in preg/childb/puerp + p/n complication L121400 
Renal hypertension in pregnancy/childbirth/puerperium NOS L121z00 
Other pre-existing hypertension in preg/childbirth/puerp L122.00 
Pre-exist hyperten heart renal dis comp preg chldbirth/puerp L128100 
Unspecified renal disease in pregnancy L162.00 
Unspecified renal disease in pregnancy unspecified L162000 
Unspecified renal disease in pregnancy - delivered L162100 
Unspecified renal disease in pregnancy - del with p/n comp L162200 
Unspecified renal disease in pregnancy - not delivered L162300 
Unspecified renal disease in pregnancy with p/n complication L162400 
Unspecified renal disease in pregnancy NOS L162z00 
Acute renal failure following labour and delivery L393.00 
Post-delivery acute renal failure unspecified L393000 
Post-delivery acute renal failure - delivered with p/n prob L393100 
Post-delivery acute renal failure with postnatal problem L393200 
Post-delivery acute renal failure NOS L393z00 
Renal agenesis and dysgenesis PD0..00 
Renal agenesis, unspecified PD00.00 
Bilateral renal agenesis PD00000 
Unilateral renal agenesis PD00100 
Renal agenesis, unspecified NOS PD00z00 
Congenital renal atrophy PD01.00 
Congenital absence of kidney PD02.00 
Hypoplasia of kidney PD03.00 
Bilateral renal hypoplasia PD03000 
Potter's syndrome PD03011 
Unilateral renal hypoplasia PD03100 
Dysplasia of kidney PD04.00 
Bilateral renal dysplasia PD04000 
354 
Bilateral renal dysgenesis PD04011 
Unilateral renal dysplasia PD04100 
Unilateral renal dysgenesis PD04111 
Dysplasia of kidney NOS PD04z00 
Renal agenesis or dysgenesis NOS PD0z.00 
Congenital cystic kidney disease PD1..00 
Congenital cystic renal disease PD1..11 
Fibrocystic kidney PD1..12 
Polycystic kidney PD1..13 
Sponge kidney PD1..14 
Congenital renal cyst, single PD10.00 
Polycystic kidney disease PD11.00 
Medullary cystic disease PD12.00 
Multicystic renal dysplasia PD13.00 
Multicystic kidney PD13.11 
Other specified congenital cystic kidney disease PD1y.00 
Fibrocystic kidney disease PD1y000 
Fibrocystic renal degeneration PD1y011 
Other congenital cystic kidney disease NOS PD1yz00 
Congenital cystic kidney disease NOS PD1z.00 
Renal pelvis and ureter obstructive defects PD2..00 
Atresia of ureter PD20.00 
Occlusion of ureter PD21.00 
Congenital ureteric valves PD21.11 
Congenital stricture of ureter PD22.00 
Congenital stenosis of ureter PD22.11 
Congenital hydronephrosis PD23.00 
Congenital dilated renal pelvis PD23.11 
Congenital dilatation of ureter PD24.00 
Hydroureter - congenital PD25.00 
Megaloureter - congenital PD26.00 
Ureterocele - congenital PD27.00 
Impervious ureter PD28.00 
Other specified obstructive defect of renal pelvis or ureter PD2y.00 
Obstructive defect of renal pelvis or ureter NOS PD2z.00 
Other specified renal anomaly PD3..00 
Accessory kidney PD30.00 
Duplication of kidney PD30.11 
Renal duplication NEC PD30.12 
Supernumerary kidney PD30.13 
Congenital calculus of kidney PD31.00 
Congenital displaced kidney PD32.00 
Discoid kidney PD33.00 
Double kidney with double pelvis PD34.00 
Duplex kidneys PD34.11 
Pyelon duplex PD34.12 
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Ectopic kidney PD35.00 
Pelvic kidney PD35.11 
Fusion of kidneys PD36.00 
Giant kidney PD37.00 
Horseshoe kidney PD38.00 
Hyperplasia of kidney PD39.00 
Lobulation of kidney PD3A.00 
Ren arcuatus PD3A.11 
Ren unguliformis PD3A.12 
Malrotation of kidney PD3B.00 
Triple kidney with triple pelvis PD3C.00 
Trifid kidney PD3C.11 
Pyelon triplex PD3C.12 
Enlarged kidney PD3D.00 
Other specified renal anomaly NOS PD3z.00 
Other specified ureter anomalies PD4..00 
Absent ureter PD40.00 
Accessory ureter PD41.00 
Deviation of ureter PD42.00 
Displaced ureteric orifice PD43.00 
Double ureter PD44.00 
Duplication of ureter PD44.11 
Ectopic ureter PD45.00 
Congenital displacement of opening of ureter PD45.11 
Ectopic insertion of ureter PD45.12 
Anomalous ureter implantation PD46.00 
Congenital vesico-uretero-renal reflux PD47.00 
Other specified ureter anomaly NOS PD4z.00 
Exstrophy of urinary bladder PD5..00 
Ectopia vesicae PD5..11 
Ectopic bladder PD5..12 
Urethra and bladder neck atresia and stenosis PD6..00 
Other specified bladder and urethral anomalies PDy..00 
Urinary system anomalies NOS PDz..00 
[D]Renal colic R080.00 
[D]Renal colic, unspecified R080000 
[D]Ureteric colic R080100 
[D]Renal colic NOS R080z00 
[D]Dysuria R081.00 
[D]Retention of urine R082.00 
[D]Incontinence of urine R083.00 
[D]Micturition frequency and polyuria R084.00 
[D]Oliguria and anuria R085.00 
[D]Other urination abnormality R086.00 
[D]Difficulty with micturition R086.11 
[D]Urethral discharge R087.00 
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[D]Extravasation of urine R088.00 
[D]Other urinary system symptom R08z.00 
[D]Urinary system symptoms NOS R08zz00 
[D]Bladder filling defect R135000 
[D]Kidney filling defect R135100 
[D]Ureter filling defect R135200 
[D]Renal scarring R135300 
[D]Genitourinary x-ray or scan abnormality NOS R135z00 
[D]Renal function test abnormal R144.00 
[D]Kidney function test abnormal R144.11 
Kidney injury without open wound into cavity, unspecified S760000 
Kidney haematoma without mention of open wound into cavity S760100 
Renal haematoma without mention of open wound into cavity S760111 
Kidney laceration without mention of open wound into cavity S760200 
Kidney parenchyma disruption without open wound to cavity S760300 
Kidney injury without mention of open wound into cavity NOS S760z00 
Kidney injury with open wound into cavity, unspecified S761000 
Kidney haematoma with open wound into cavity S761100 
Renal haematoma with open wound into cavity S761111 
Kidney laceration with open wound into cavity S761200 
Kidney parenchyma disruption with open wound into cavity S761300 
Kidney injury with open wound into cavity NOS S761z00 
Renal failure following crush syndrome SK05.00 
Renal failure after crushing SK05.11 
Traumatic anuria - crush syndrome SK05.12 
Oliguria as a complication of care SP15200 
Anuria as a complication of care SP15300 
Renal failure as a complication of care SP15400 
Kidney failure as a complication of care SP15411 
Post operative renal failure SP15412 
Uraemia - post operative SP15413 
Kidney transplant with complication, without blame TB00100 
Renal transplant with complication, without blame TB00111 
Kidney dialysis with complication, without blame TB11.00 
Renal dialysis with complication, without blame TB11.11 
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Table j-xii Codes for Diabetes with end organ damage 
description medcode 
Retinal abnormality - diabetes related 2BBF.00 
O/E - diabetic maculopathy present both eyes 2BBL.00 
O/E - diabetic maculopathy absent both eyes 2BBM.00 
O/E - right eye background diabetic retinopathy 2BBP.00 
O/E - left eye background diabetic retinopathy 2BBQ.00 
O/E - right eye preproliferative diabetic retinopathy 2BBR.00 
O/E - left eye preproliferative diabetic retinopathy 2BBS.00 
O/E - right eye proliferative diabetic retinopathy 2BBT.00 
O/E - left eye proliferative diabetic retinopathy 2BBV.00 
O/E - right eye diabetic maculopathy 2BBW.00 
O/E - left eye diabetic maculopathy 2BBX.00 
O/E - sight threatening diabetic retinopathy 2BBo.00 
Foot abnormality - diabetes related 2G51000 
O/E - Right diabetic foot at risk 2G5A.00 
O/E - Left diabetic foot at risk 2G5B.00 
Foot abnormality - diabetes related 2G5C.00 
O/E - Right diabetic foot at low risk 2G5E.00 
O/E - Right diabetic foot at moderate risk 2G5F.00 
O/E - Right diabetic foot at high risk 2G5G.00 
O/E - Right diabetic foot - ulcerated 2G5H.00 
O/E - Left diabetic foot at low risk 2G5I.00 
O/E - Left diabetic foot at moderate risk 2G5J.00 
O/E - Left diabetic foot at high risk 2G5K.00 
O/E - Left diabetic foot - ulcerated 2G5L.00 
O/E - right chronic diabetic foot ulcer 2G5V.00 
O/E - left chronic diabetic foot ulcer 2G5W.00 
Pan retinal photocoagulation for diabetes 7276 
Diabetes mellitus with ketoacidosis C101.00 
Diabetes mellitus, juvenile type, with ketoacidosis C101000 
Diabetes mellitus, adult onset, with ketoacidosis C101100 
Other specified diabetes mellitus with ketoacidosis C101y00 
Diabetes mellitus NOS with ketoacidosis C101z00 
Diabetes mellitus with hyperosmolar coma C102.00 
Diabetes mellitus, juvenile type, with hyperosmolar coma C102000 
Diabetes mellitus, adult onset, with hyperosmolar coma C102100 
Diabetes mellitus NOS with hyperosmolar coma C102z00 
Diabetes mellitus with ketoacidotic coma C103.00 
Diabetes mellitus, juvenile type, with ketoacidotic coma C103000 
Diabetes mellitus, adult onset, with ketoacidotic coma C103100 
Other specified diabetes mellitus with coma C103y00 
Diabetes mellitus NOS with ketoacidotic coma C103z00 
Diabetes mellitus with renal manifestation C104.00 
Diabetic nephropathy C104.11 
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Diabetes mellitus, juvenile type, with renal manifestation C104000 
Diabetes mellitus, adult onset, with renal manifestation C104100 
Other specified diabetes mellitus with renal complications C104y00 
Diabetes mellitis with nephropathy NOS C104z00 
Diabetes mellitus with ophthalmic manifestation C105.00 
Diabetes mellitus, juvenile type, + ophthalmic manifestation C105000 
Diabetes mellitus, adult onset, + ophthalmic manifestation C105100 
Other specified diabetes mellitus with ophthalmic complicatn C105y00 
Diabetes mellitus NOS with ophthalmic manifestation C105z00 
Diabetes mellitus with neurological manifestation C106.00 
Diabetic amyotrophy C106.11 
Diabetes mellitus with neuropathy C106.12 
Diabetes mellitus with polyneuropathy C106.13 
Diabetes mellitus, juvenile, + neurological manifestation C106000 
Diabetes mellitus, adult onset, + neurological manifestation C106100 
Other specified diabetes mellitus with neurological comps C106y00 
Diabetes mellitus NOS with neurological manifestation C106z00 
Diabetes mellitus with peripheral circulatory disorder C107.00 
Diabetes mellitus with gangrene C107.11 
Diabetes with gangrene C107.12 
Diabetes mellitus, juvenile +peripheral circulatory disorder C107000 
Diabetes mellitus, adult, + peripheral circulatory disorder C107100 
Diabetes mellitus, adult with gangrene C107200 
IDDM with peripheral circulatory disorder C107300 
NIDDM with peripheral circulatory disorder C107400 
Other specified diabetes mellitus with periph circ comps C107y00 
Insulin-dependent diabetes mellitus with renal complications C108000 
Type I diabetes mellitus with renal complications C108011 
Type 1 diabetes mellitus with renal complications C108012 
Insulin-dependent diabetes mellitus with ophthalmic comps C108100 
Type I diabetes mellitus with ophthalmic complications C108111 
Type 1 diabetes mellitus with ophthalmic complications C108112 
Insulin-dependent diabetes mellitus with neurological comps C108200 
Type I diabetes mellitus with neurological complications C108211 
Type 1 diabetes mellitus with neurological complications C108212 
Insulin dependent diabetes mellitus with multiple complicatn C108300 
Type I diabetes mellitus with multiple complications C108311 
Type 1 diabetes mellitus with multiple complications C108312 
Insulin dependent diabetes mellitus with ulcer C108500 
Type I diabetes mellitus with ulcer C108511 
Type 1 diabetes mellitus with ulcer C108512 
Insulin dependent diabetes mellitus with gangrene C108600 
Type I diabetes mellitus with gangrene C108611 
Type 1 diabetes mellitus with gangrene C108612 
Insulin dependent diabetes mellitus with retinopathy C108700 
Type I diabetes mellitus with retinopathy C108711 
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Type 1 diabetes mellitus with retinopathy C108712 
Insulin dependent diabetes mellitus with mononeuropathy C108B00 
Type I diabetes mellitus with mononeuropathy C108B11 
Type 1 diabetes mellitus with mononeuropathy C108B12 
Insulin dependent diabetes mellitus with polyneuropathy C108C00 
Type I diabetes mellitus with polyneuropathy C108C11 
Type 1 diabetes mellitus with polyneuropathy C108C12 
Insulin dependent diabetes mellitus with nephropathy C108D00 
Type I diabetes mellitus with nephropathy C108D11 
Type 1 diabetes mellitus with nephropathy C108D12 
Insulin dependent diabetes mellitus with hypoglycaemic coma C108E00 
Type I diabetes mellitus with hypoglycaemic coma C108E11 
Type 1 diabetes mellitus with hypoglycaemic coma C108E12 
Insulin dependent diabetes mellitus with diabetic cataract C108F00 
Type I diabetes mellitus with diabetic cataract C108F11 
Type 1 diabetes mellitus with diabetic cataract C108F12 
Insulin dependent diab mell with peripheral angiopathy C108G00 
Type I diabetes mellitus with peripheral angiopathy C108G11 
Type 1 diabetes mellitus with peripheral angiopathy C108G12 
Insulin dependent diabetes mellitus with arthropathy C108H00 
Type I diabetes mellitus with arthropathy C108H11 
Type 1 diabetes mellitus with arthropathy C108H12 
Insulin dependent diab mell with neuropathic arthropathy C108J00 
Type I diabetes mellitus with neuropathic arthropathy C108J11 
Type 1 diabetes mellitus with neuropathic arthropathy C108J12 
Other specified diabetes mellitus with multiple comps C108y00 
Unspecified diabetes mellitus with multiple complications C108z00 
Non-insulin-dependent diabetes mellitus with renal comps C109000 
Type II diabetes mellitus with renal complications C109011 
Type 2 diabetes mellitus with renal complications C109012 
Non-insulin-dependent diabetes mellitus with ophthalm comps C109100 
Type II diabetes mellitus with ophthalmic complications C109111 
Type 2 diabetes mellitus with ophthalmic complications C109112 
Non-insulin-dependent diabetes mellitus with neuro comps C109200 
Type II diabetes mellitus with neurological complications C109211 
Type 2 diabetes mellitus with neurological complications C109212 
Non-insulin-dependent diabetes mellitus with multiple comps C109300 
Type II diabetes mellitus with multiple complications C109311 
Type 2 diabetes mellitus with multiple complications C109312 
Non-insulin dependent diabetes mellitus with ulcer C109400 
Type II diabetes mellitus with ulcer C109411 
Type 2 diabetes mellitus with ulcer C109412 
Non-insulin dependent diabetes mellitus with gangrene C109500 
Type II diabetes mellitus with gangrene C109511 
Type 2 diabetes mellitus with gangrene C109512 
Non-insulin-dependent diabetes mellitus with retinopathy C109600 
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Type II diabetes mellitus with retinopathy C109611 
Type 2 diabetes mellitus with retinopathy C109612 
Non-insulin dependent diabetes mellitus with mononeuropathy C109A00 
Type II diabetes mellitus with mononeuropathy C109A11 
Type 2 diabetes mellitus with mononeuropathy C109A12 
Non-insulin dependent diabetes mellitus with polyneuropathy C109B00 
Type II diabetes mellitus with polyneuropathy C109B11 
Type 2 diabetes mellitus with polyneuropathy C109B12 
Non-insulin dependent diabetes mellitus with nephropathy C109C00 
Type II diabetes mellitus with nephropathy C109C11 
Type 2 diabetes mellitus with nephropathy C109C12 
Non-insulin dependent diabetes mellitus with hypoglyca coma C109D00 
Type II diabetes mellitus with hypoglycaemic coma C109D11 
Type 2 diabetes mellitus with hypoglycaemic coma C109D12 
Non-insulin depend diabetes mellitus with diabetic cataract C109E00 
Type II diabetes mellitus with diabetic cataract C109E11 
Type 2 diabetes mellitus with diabetic cataract C109E12 
Non-insulin-dependent d m with peripheral angiopath C109F00 
Type II diabetes mellitus with peripheral angiopathy C109F11 
Type 2 diabetes mellitus with peripheral angiopathy C109F12 
Non-insulin dependent diabetes mellitus with arthropathy C109G00 
Type II diabetes mellitus with arthropathy C109G11 
Type 2 diabetes mellitus with arthropathy C109G12 
Non-insulin dependent d m with neuropathic arthropathy C109H00 
Type II diabetes mellitus with neuropathic arthropathy C109H11 
Type 2 diabetes mellitus with neuropathic arthropathy C109H12 
Hyperosmolar non-ketotic state in type 2 diabetes mellitus C109K00 
Malnutrition-related diabetes mellitus with coma C10A000 
Malnutrition-related diabetes mellitus with ketoacidosis C10A100 
Malnutrition-related diabetes mellitus with renal complicatn C10A200 
Malnutrit-related diabetes mellitus wth ophthalmic complicat C10A300 
Malnutrition-related diabetes mellitus wth neuro complicatns C10A400 
Malnutritn-relat diabetes melitus wth periph circul complctn C10A500 
Malnutrition-related diabetes mellitus with multiple comps C10A600 
Malnutrition-related diabetes mellitus without complications C10A700 
Malnutrit-related diabetes mellitus with unspec complics C10AW00 
Malnutrit-relat diabetes mellitus with other spec comps C10AX00 
Type 1 diabetes mellitus with renal complications C10E000 
Type I diabetes mellitus with renal complications C10E011 
Insulin-dependent diabetes mellitus with renal complications C10E012 
Type 1 diabetes mellitus with ophthalmic complications C10E100 
Type I diabetes mellitus with ophthalmic complications C10E111 
Insulin-dependent diabetes mellitus with ophthalmic comps C10E112 
Type 1 diabetes mellitus with neurological complications C10E200 
Type I diabetes mellitus with neurological complications C10E211 
Insulin-dependent diabetes mellitus with neurological comps C10E212 
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Type 1 diabetes mellitus with multiple complications C10E300 
Type I diabetes mellitus with multiple complications C10E311 
Insulin dependent diabetes mellitus with multiple complicat C10E312 
Type 1 diabetes mellitus with ulcer C10E500 
Type I diabetes mellitus with ulcer C10E511 
Insulin dependent diabetes mellitus with ulcer C10E512 
Type 1 diabetes mellitus with gangrene C10E600 
Type I diabetes mellitus with gangrene C10E611 
Insulin dependent diabetes mellitus with gangrene C10E612 
Type 1 diabetes mellitus with retinopathy C10E700 
Type I diabetes mellitus with retinopathy C10E711 
Insulin dependent diabetes mellitus with retinopathy C10E712 
Type 1 diabetes mellitus with mononeuropathy C10EB00 
Type I diabetes mellitus with mononeuropathy C10EB11 
Insulin dependent diabetes mellitus with mononeuropathy C10EB12 
Type 1 diabetes mellitus with polyneuropathy C10EC00 
Type I diabetes mellitus with polyneuropathy C10EC11 
Insulin dependent diabetes mellitus with polyneuropathy C10EC12 
Type 1 diabetes mellitus with nephropathy C10ED00 
Type I diabetes mellitus with nephropathy C10ED11 
Insulin dependent diabetes mellitus with nephropathy C10ED12 
Type 1 diabetes mellitus with hypoglycaemic coma C10EE00 
Type I diabetes mellitus with hypoglycaemic coma C10EE11 
Insulin dependent diabetes mellitus with hypoglycaemic coma C10EE12 
Type 1 diabetes mellitus with diabetic cataract C10EF00 
Type I diabetes mellitus with diabetic cataract C10EF11 
Insulin dependent diabetes mellitus with diabetic cataract C10EF12 
Type 1 diabetes mellitus with peripheral angiopathy C10EG00 
Type I diabetes mellitus with peripheral angiopathy C10EG11 
Insulin dependent diab mell with peripheral angiopathy C10EG12 
Type 1 diabetes mellitus with arthropathy C10EH00 
Type I diabetes mellitus with arthropathy C10EH11 
Insulin dependent diabetes mellitus with arthropathy C10EH12 
Type 1 diabetes mellitus with neuropathic arthropathy C10EJ00 
Type I diabetes mellitus with neuropathic arthropathy C10EJ11 
Insulin dependent diab mell with neuropathic arthropathy C10EJ12 
Type 1 diabetes mellitus with persistent proteinuria C10EK00 
Type I diabetes mellitus with persistent proteinuria C10EK11 
Type 1 diabetes mellitus with persistent microalbuminuria C10EL00 
Type I diabetes mellitus with persistent microalbuminuria C10EL11 
Type 1 diabetes mellitus with ketoacidosis C10EM00 
Type I diabetes mellitus with ketoacidosis C10EM11 
Type 1 diabetes mellitus with ketoacidotic coma C10EN00 
Type I diabetes mellitus with ketoacidotic coma C10EN11 
Type 1 diabetes mellitus with exudative maculopathy C10EP00 
Type I diabetes mellitus with exudative maculopathy C10EP11 
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Type 2 diabetes mellitus with renal complications C10F000 
Type II diabetes mellitus with renal complications C10F011 
Type 2 diabetes mellitus with ophthalmic complications C10F100 
Type II diabetes mellitus with ophthalmic complications C10F111 
Type 2 diabetes mellitus with neurological complications C10F200 
Type II diabetes mellitus with neurological complications C10F211 
Type 2 diabetes mellitus with multiple complications C10F300 
Type II diabetes mellitus with multiple complications C10F311 
Type 2 diabetes mellitus with ulcer C10F400 
Type II diabetes mellitus with ulcer C10F411 
Type 2 diabetes mellitus with gangrene C10F500 
Type II diabetes mellitus with gangrene C10F511 
Type 2 diabetes mellitus with retinopathy C10F600 
Type II diabetes mellitus with retinopathy C10F611 
Type 2 diabetes mellitus with mononeuropathy C10FA00 
Type II diabetes mellitus with mononeuropathy C10FA11 
Type 2 diabetes mellitus with polyneuropathy C10FB00 
Type II diabetes mellitus with polyneuropathy C10FB11 
Type 2 diabetes mellitus with nephropathy C10FC00 
Type II diabetes mellitus with nephropathy C10FC11 
Type 2 diabetes mellitus with hypoglycaemic coma C10FD00 
Type II diabetes mellitus with hypoglycaemic coma C10FD11 
Type 2 diabetes mellitus with diabetic cataract C10FE00 
Type II diabetes mellitus with diabetic cataract C10FE11 
Type 2 diabetes mellitus with peripheral angiopathy C10FF00 
Type II diabetes mellitus with peripheral angiopathy C10FF11 
Type 2 diabetes mellitus with arthropathy C10FG00 
Type II diabetes mellitus with arthropathy C10FG11 
Type 2 diabetes mellitus with neuropathic arthropathy C10FH00 
Type II diabetes mellitus with neuropathic arthropathy C10FH11 
Hyperosmolar non-ketotic state in type 2 diabetes mellitus C10FK00 
Type 2 diabetes mellitus with persistent proteinuria C10FL00 
Type II diabetes mellitus with persistent proteinuria C10FL11 
Type 2 diabetes mellitus with persistent microalbuminuria C10FM00 
Type II diabetes mellitus with persistent microalbuminuria C10FM11 
Type 2 diabetes mellitus with ketoacidosis C10FN00 
Type II diabetes mellitus with ketoacidosis C10FN11 
Type 2 diabetes mellitus with ketoacidotic coma C10FP00 
Type II diabetes mellitus with ketoacidotic coma C10FP11 
Type 2 diabetes mellitus with exudative maculopathy C10FQ00 
Type II diabetes mellitus with exudative maculopathy C10FQ11 
Other specified diabetes mellitus with other spec comps C10yy00 
Diabetes mellitus NOS with other specified manifestation C10yz00 
Diabetes mellitus with unspecified complication C10z.00 
Diabetes mellitus, juvenile type, + unspecified complication C10z000 
Diabetes mellitus, adult onset, + unspecified complication C10z100 
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Other specified diabetes mellitus with unspecified comps C10zy00 
Diabetes mellitus NOS with unspecified complication C10zz00 
[X]Malnutrit-relat diabetes mellitus with other spec comps Cyu2100 
[X]Malnutrit-related diabetes mellitus with unspec complics Cyu2200 
[X]Unspecified diabetes mellitus with renal complications Cyu2300 
[X]Glomerular disorders in diabetes mellitus Kyu0300 
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Table j-xiii Codes for Any tumour 
description medcode 
Malignant neoplasm of eye B50..00 
Malignant neoplasm of brain B51..00 
Cerebral tumour - malignant B51..11 
Malig neop of other and unspecified parts of nervous system B52..00 
Malignant neoplasm of thyroid gland B53..00 
Malig neop of other endocrine glands and related structures B54..00 
Malignant neoplasm of other and ill-defined sites B55..00 
Malignant neoplasm of unspecified site B59..00 
Malignant neoplasm of other and unspecified site OS B5y..00 
Malignant neoplasm of other and unspecified site NOS B5z..00 
Malignant neoplasms of lymphoid and histiocytic tissue NOS B62z.00 
Benign neoplasm of parotid gland B702000 
Adenoma of parotid gland B702011 
Benign neoplasm of submandibular gland B702100 
Benign neoplasm of sublingual gland B702200 
Warthin's tumour B702300 
Benign neoplasm of major salivary gland NOS B702z00 
Benign islet cell tumour B717000 
Endocrine tumour of pancreas B717011 
Benign neoplasm of islets of Langerhans NOS B717z00 
Benign neoplasm of brain B7F0.00 
Cerebral tumour - benign B7F0.11 
Benign neoplasm of cranial nerves B7F1.00 
Benign neoplasm of cerebral meninges B7F2.00 
Benign neoplasm of spinal cord B7F3.00 
Benign neoplasm of spinal meninges B7F4.00 
Benign neoplasm of meninges, unspecified B7FX.00 
Benign neoplasm of other part of nervous system B7Fy.00 
Benign neoplasm of brain or other nervous system NOS B7Fz.00 
Haemangioma B7J0.00 
Glomus tumour B7J0.11 
Lymphangioma B7J1.00 
Congenital lymphangioma B7J1.11 
Naevus - lymphatic B7J1.12 
Haemangioma or lymphangioma NOS B7Jz.00 
Neoplasm of uncertain behaviour of parotid gland B900000 
Mixed parotid tumour B900011 
Neoplasm of uncertain behaviour of sublingual gland B900100 
Neoplasm of uncertain behaviour of submandibular gland B900200 
Neoplasm of uncertain behaviour of major salivary gland NOS B900z00 
Neop of uncertain behaviour of bone and articular cartilage B930.00 
Neop of uncertain behaviour connective and other soft tissue B931.00 
Neoplasm of uncertain behaviour of skin B932.00 
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Neoplasm of uncertain behaviour of breast B933.00 
Cystosarcoma phyllodes B933.11 
Neoplasm of uncertain behaviour of histiocytic and mast cell B935.00 
Histiocytic tumour NOS B935.11 
Mastocytoma NOS B935.12 
Neoplasm of uncertain behaviour of plasma cells B936.00 
Myeloma - solitary B936.11 
Plasmacytoma NOS B936.12 
Neop uncertain behaviour other lymphatic/haematopoietic tiss B937.00 
Neoplasm of uncertain behaviour of blood B937.11 
Neo/uncertn+unknwn behav/lymph,h'matopetc+rel tiss,unspcf B93X.00 
Neoplasm of uncertain behaviour of other specified sites B93y.00 
Neop uncertain behaviour other unspec site and tissue NOS B93z.00 
[M]Tumour morphology BB...11 
[M]Neoplasms NOS BB0..00 
[M]Neoplasm, benign BB00.00 
[M]Neoplasm, uncertain whether benign or malignant BB01.00 
[M]Neoplasm, malignant BB02.00 
[M]Neoplasm, metastatic BB03.00 
[M]Secondary neoplasm BB03.11 
[M]Neoplasm, malig, uncertain whether primary or metastatic BB04.00 
[M]Tumour cells, benign BB05.00 
[M]Tumour cells, uncertain whether benign or malignant BB06.00 
[M]Tumour cells, malignant BB07.00 
[M]Malignant tumour, small cell type BB08.00 
[M]Malignant tumour, giant cell type BB09.00 
[M]Malignant tumour, fusiform cell type BB0A.00 
[M]Unspecified tumour cell NOS BB0z.00 
[M]Epithelial neoplasms NOS BB1..00 
[M]Epithelial tumour, benign BB10.00 
[M]Carcinoma in situ NOS BB11.00 
[M]Intraepithelial carcinoma NOS BB11.11 
[M]Carcinoma NOS BB12.00 
[M]Carcinoma, metastatic, NOS BB13.00 
[M]Secondary carcinoma BB13.11 
[M]Carcinomatosis BB14.00 
[M]Epithelioma, benign BB15.00 
[M]Epithelioma, malignant BB16.00 
[M]Large cell carcinoma NOS BB17.00 
[M]Carcinoma, undifferentiated type, NOS BB18.00 
[M]Carcinoma, anaplastic type, NOS BB19.00 
[M]Pleomorphic carcinoma BB1A.00 
[M]Giant cell and spindle cell carcinoma BB1B.00 
[M]Giant cell carcinoma BB1C.00 
[M]Spindle cell carcinoma BB1D.00 
[M]Pseudosarcomatous carcinoma BB1E.00 
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[M]Polygonal cell carcinoma BB1F.00 
[M]Spheroidal cell carcinoma BB1G.00 
[M]Small cell carcinoma NOS BB1J.00 
[M]Reserve cell carcinoma BB1J.11 
[M]Round cell carcinoma BB1J.12 
[M]Oat cell carcinoma BB1K.00 
[M]Small cell carcinoma, fusiform cell type BB1L.00 
[M]Small cell carcinoma, intermediate cell BB1M.00 
[M]Small cell-large cell carcinoma BB1N.00 
[M]Unspecified epithelial neoplasm BB1z.00 
[M]Papillary and squamous cell neoplasms BB2..00 
[M]Papillary neoplasms BB2..11 
[M]Squamous cell neoplasms BB2..12 
[M]Basal cell neoplasms BB3..00 
[M]Basal cell tumour BB30.00 
[M]Basal cell carcinoma NOS BB31.00 
[M]Multicentric basal cell carcinoma BB32.00 
[M]Basal cell carcinoma, morphoea type BB33.00 
[M]Basal cell carcinoma, fibroepithelial type BB34.00 
[M]Basosquamous carcinoma BB35.00 
[M]Metatypical carcinoma BB36.00 
[M]Intraepidermal epithelioma of Jadassohn BB37.00 
[M]Trichoepithelioma BB38.00 
[M]Brooke's tumour BB38.11 
[M]Epithelioma adenoides cyst BB38.12 
[M]Trichofolliculoma BB39.00 
[M]Tricholemmoma BB3A.00 
[M]Pilomatrixoma BB3B.00 
[M]Malherbe's calcified epithelioma BB3B.11 
[M]Basal cell neoplasm NOS BB3z.00 
[M]Transitional cell papillomas and carcinomas BB4..00 
[M]Adenomas and adenocarcinomas BB5..00 
[M]Adenocarcinomas BB5..11 
[M]Adenomas BB5..12 
[M]Adenoma NOS BB50.00 
[M]Adenocarcinoma in situ BB51.00 
[M]Adenocarcinoma NOS BB52.00 
[M]Adenocarcinoma, metastatic, NOS BB53.00 
[M]Scirrhous adenocarcinoma BB54.00 
[M]Linitis plastica BB55.00 
[M]Superficial spreading adenocarcinoma BB56.00 
[M]Adenocarcinoma, intestinal type BB57.00 
[M]Carcinoma, diffuse type BB58.00 
[M]Monomorphic adenoma BB59.00 
[M]Basal cell adenoma BB5A.00 
[M]Pancreatic adenomas and carcinomas BB5B.00 
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[M]Islet cell adenoma BB5B000 
[M]Nesidioblastoma BB5B011 
[M]Islet cell carcinoma BB5B100 
[M]Insulinoma NOS BB5B200 
[M]Beta-cell adenoma BB5B211 
[M]Insulinoma, malignant BB5B300 
[M]Beta-cell tumour, malignant BB5B311 
[M]Glucagonoma NOS BB5B400 
[M]Alpha-cell adenoma BB5B411 
[M]Glucagonoma, malignant BB5B500 
[M]Alpha-cell tumour,malignant BB5B511 
[M]Mixed islet cell and exocrine adenocarcinoma BB5B600 
[M]Pancreatic adenoma or carcinoma NOS BB5Bz00 
[M]Gastrinoma and carcinomas BB5C.00 
[M]Gastrinoma NOS BB5C000 
[M]G cell tumour NOS BB5C011 
[M]Gastrinoma, malignant BB5C100 
[M]G cell tumour, malignant BB5C111 
[M]Gastrinoma or carcinoma NOS BB5Cz00 
[M]Hepatobiliary tract adenomas and carcinomas BB5D.00 
[M]Biliary tract adenomas and adenocarcinomas BB5D.11 
[M]Trabecular adenoma BB5E.00 
[M]Trabecular adenocarcinoma BB5F.00 
[M]Embryonal adenoma BB5G.00 
[M]Eccrine dermal cylindroma BB5H.00 
[M]Turban tumour BB5H.11 
[M]Adenoid cystic carcinoma BB5J.00 
[M]Cylindroid adenocarcinoma BB5J.11 
[M]Cylindroid bronchial adenoma BB5J.12 
[M]Cylindroma NOS BB5J.13 
[M]Cribriform carcinoma BB5K.00 
[M]Adenomatous and adenocarcinomatous polyps BB5L.00 
[M]Tubular adenomas and adenocarcinomas BB5M.00 
[M]Adenomatous and adenocarcinomatous polyps of colon BB5N.00 
[M]Adenoma or or adenocarcinoma in polyposis coli BB5N.11 
[M]Solid carcinoma NOS BB5P.00 
[M]Carcinoma simplex BB5Q.00 
[M]Carcinoid tumours BB5R.00 
[M]Carcinoid tumour NOS BB5R000 
[M]Carcinoid tumour, malignant BB5R100 
[M]Carcinoid bronchial adenoma BB5R111 
[M]Carcinoid tumour, argentaffin, NOS BB5R200 
[M]Argentaffinoma NOS BB5R211 
[M]Carcinoid tumour, argentaffin, malignant BB5R300 
[M]Carcinoid tumour, nonargentaffin, NOS BB5R400 
[M]Carcinoid tumour, nonargentaffin, malignant BB5R500 
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[M]Mucocarcinoid tumour, malignant BB5R600 
[M]Goblet cell tumour BB5R611 
[M]Composite carcinoid BB5R700 
[M]Adenocarcinoid tumour BB5R800 
[M]Neuroendocrine carcinoma BB5R900 
[M]Merkel cell carcinoma BB5RA00 
[M]Carcinoid tumours NOS BB5Rz00 
[M]Respiratory tract adenomas and adenocarcinomas BB5S.00 
[M]Papillary adenomas and adenocarcinomas BB5T.00 
[M]Villous adenomas and adenocarcinomas BB5U.00 
[M]Pituitary adenomas and carcinomas BB5V.00 
[M]Oxyphilic adenomas and adenocarcinomas BB5W.00 
[M]Clear cell adenomas and adenocarcinomas BB5X.00 
[M]Hypernephroid tumour BB5Y.00 
[M]Clear cell adenofibroma BB5Z.00 
[M]Renal adenoma and carcinoma BB5a.00 
[M]Renal cell carcinoma BB5a000 
[M]Grawitz tumour BB5a011 
[M]Hypernephroma BB5a012 
[M]Juxtaglomerular tumour BB5a100 
[M]Reninoma BB5a111 
[M]Renal adenoma or carcinoma NOS BB5az00 
[M]Granular cell carcinoma BB5b.00 
[M]Parathyroid adenomas and adenocarcinomas BB5c.00 
[M]Mixed cell adenoma and adenocarcinoma BB5d.00 
[M]Lipoadenoma BB5e.00 
[M]Thyroid adenoma and adenocarcinoma BB5f.00 
[M]Multiple endocrine adenomas BB5g.00 
[M]Adrenal cortical tumours BB5h.00 
[M]Adrenal cortical adenoma NOS BB5h000 
[M]Adrenal cortical carcinoma BB5h100 
[M]Adrenal cortical adenoma, compact cell type BB5h200 
[M]Adrenal cortical adenoma, heavily pigmented variant BB5h300 
[M]Black adenoma BB5h311 
[M]Adrenal cortical adenoma, clear cell type BB5h400 
[M]Adrenal cortical adenoma, glomerulosa cell type BB5h500 
[M]Adrenal cortical adenoma, mixed cell type BB5h600 
[M]Adrenal cortical tumours NOS BB5hz00 
[M]Endometrioid adenomas and carcinomas BB5j.00 
[M]Adenoma and adenocarcinoms OS BB5y.00 
[M]Basal cell adenocarcinoma BB5y000 
[M]Vipoma BB5y100 
[M]Klatskin's tumour BB5y200 
[M]Apudoma BB5y300 
[M]Prolactinoma BB5y400 
[M]Lipid-rich carcinoma BB5y500 
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[M]Glycogen-rich carcinoma BB5y600 
[M]Adenoma or adenocarcinoma NOS BB5z.00 
[M]Adnexal and skin appendage neoplasms BB6..00 
[M]Sweat gland adenoma BB61000 
[M]Hidradenoma NOS BB61011 
[M]Nodular hidradenoma BB61012 
[M]Syringadenoma NOS BB61013 
[M]Sweat gland tumour NOS BB61100 
[M]Sweat gland adenocarcinoma BB61200 
[M]Sweat gland adenoma or adenocarcinoma NOS BB61z00 
[M]Mucoepidermoid neoplasms BB7..00 
[M]Mucoepidermoid tumour BB70.00 
[M]Mucoepidermoid carcinoma BB71.00 
[M]Mucoepidermoid neoplasm NOS BB7z.00 
[M]Cystic, mucinous and serous neoplasms BB8..00 
[M]Cystadenoma and carcinoma BB80.00 
[M]Ovarian cystic, mucinous and serous neoplasms BB81.00 
[M]Ovarian cystadenoma or carcinoma BB81.11 
[M]Ovarian mucinous tumour BB81.12 
[M]Ovarian papillary tumour BB81.13 
[M]Ovarian serous tumour BB81.14 
[M]Serous cystadenoma NOS BB81000 
[M]Serous cystadenoma, borderline malignancy BB81100 
[M]Serous cystadenocarcinoma, NOS BB81200 
[M]Papillary cystadenoma NOS BB81300 
[M]Papillary cystadenoma, borderline malignancy BB81400 
[M]Papillary cystadenocarcinoma, NOS BB81500 
[M]Papillary serous cystadenoma NOS BB81600 
[M]Papillary serous cystadenoma, borderline malignancy BB81700 
[M]Papillary serous cystadenocarcinoma BB81800 
[M]Serous surface papilloma NOS BB81900 
[M]Serous surface papilloma, borderline malignancy BB81A00 
[M]Serous surface papillary carcinoma BB81B00 
[M]Mucinous cystadenoma NOS BB81C00 
[M]Pseudomucinous cystadenoma NOS BB81C11 
[M]Mucinous cystadenoma, borderline malignancy BB81D00 
[M]Mucinous cystadenocarcinoma NOS BB81E00 
[M]Pseudomucinous adenocarcinoma BB81E11 
[M]Papillary mucinous cystadenoma NOS BB81F00 
[M]Papillary mucinous cystadenoma, borderline malignancy BB81G00 
[M]Papillary mucinous cystadenocarcinoma BB81H00 
[M]Serous cystadenoma, borderline malignancy BB81J00 
[M]Papillary cystadenoma, borderline malignancy BB81K00 
[M]Papillary cystic tumour BB81L00 
[M]Papillary serous cystadenoma, borderline malignancy BB81M00 
[M]Ovarian cystic, mucinous or serous neoplasm NOS BB81z00 
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[M]Mucinous adenoma and adenocarcinoma BB82.00 
[M]Pseudomyxoma peritonei BB83.00 
[M]Mucin-producing adenocarcinoma BB84.00 
[M]Signet ring carcinoma BB85.00 
[M]Signet ring cell carcinoma BB85000 
[M]Metastatic signet ring cell carcinoma BB85100 
[M]Krukenberg tumour BB85111 
[M]Signet ring carcinoma NOS BB85z00 
[M]Cystic, mucinous or serous neoplasm NOS BB8z.00 
[M]Ductal, lobular and medullary neoplasms BB9..00 
[M]Acinar cell neoplasms BBA..00 
[M]Acinar cell adenoma BBA0.00 
[M]Acinar cell tumour BBA1.00 
[M]Acinar cell carcinoma BBA2.00 
[M]Acinar cell neoplasm NOS BBAz.00 
[M]Complex epithelial neoplasms BBB..00 
[M]Adenosquamous carcinoma BBB0.00 
[M]Adenolymphoma BBB1.00 
[M]Warthin's tumour BBB1.11 
[M]Adenocarcinoma with squamous metaplasia BBB2.00 
[M]Adenoacanthoma BBB2.11 
[M]Adenocarcinoma with cartilaginous and osseous metaplasia BBB3.00 
[M]Adenocarcinoma with spindle cell metaplasia BBB4.00 
[M]Adenocarcinoma with apocrine metaplasia BBB5.00 
[M]Thymoma BBB6.00 
[M]Epithelial-myoepithelial carcinoma BBB7.00 
[M]Complex epithelial neoplasm NOS BBBz.00 
[M]Specialised gonadal neoplasms BBC..00 
[M]Sex cord-stromal tumour BBC0.00 
[M]Gonadal stromal tumour BBC0.11 
[M]Ovarian stromal tumour BBC0.12 
[M]Testicular stromal tumour BBC0.13 
[M]Sex cord tumour with annular tubules BBC0000 
[M]Thecal cell neoplasms BBC1.00 
[M]Luteoma NOS BBC2.00 
[M]Luteinoma BBC2.11 
[M]Granulosa cell tumour NOS BBC3.00 
[M]Juvenile granulosa cell tumour BBC3000 
[M]Granulosa cell tumour, malignant BBC4.00 
[M]Granulosa cell-theca cell tumour BBC5.00 
[M]Androblastoma BBC6.00 
[M]Sertoli-Leydig cell tumour BBC7.00 
[M]Gynandroblastoma BBC8.00 
[M]Tubular androblastoma NOS BBC9.00 
[M]Pick's tubular adenoma BBC9.11 
[M]Sertoli cell adenoma BBC9.12 
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[M]Sertoli cell tumour BBC9.13 
[M]Testicular adenoma BBC9.14 
[M]Sertoli cell carcinoma BBCA.00 
[M]Tubular androblastoma with lipid storage BBCB.00 
[M]Sertoli cell tumour with lipid storage BBCB.11 
[M]Leydig cell tumour BBCC.00 
[M]Leydig cell tumour, benign BBCC000 
[M]Interstitial cell tumour, benign BBCC011 
[M]Leydig cell tumour, malignant BBCC100 
[M]Interstitial cell tumour, malignant BBCC111 
[M]Leydig cell tumour NOS BBCCz00 
[M]Interstitial cell tumour NOS BBCCz11 
[M]Hilar cell tumour BBCD.00 
[M]Lipid cell tumour of ovary BBCE.00 
[M]Masculinovoblastoma BBCE.11 
[M]Adrenal rest tumour BBCF.00 
[M]Sclerosing stromal tumour BBCG.00 
[M]Specialised gonadal neoplasm NOS BBCz.00 
[M]Paragangliomas and glomus tumours BBD..00 
[M]Paraganglioma NOS BBD0.00 
[M]Paraganglioma, malignant BBD1.00 
[M]Sympathetic paraganglioma BBD2.00 
[M]Parasympathetic paraganglioma BBD3.00 
[M]Glomus jugulare tumour BBD4.00 
[M]Jugular paraganglioma BBD4.11 
[M]Aortic body tumour BBD5.00 
[M]Carotid body tumour BBD6.00 
[M]Extra-adrenal paraganglioma, NOS BBD7.00 
[M]Chemodectoma BBD7.11 
[M]Extra-adrenal paraganglioma, malignant BBD8.00 
[M]Phaeochromocytoma NOS BBD9.00 
[M]Chromaffin paraganglioma BBD9.11 
[M]Chromaffin tumour BBD9.12 
[M]Chromaffinoma BBD9.13 
[M]Phaeochromocytoma, malignant BBDA.00 
[M]Phaeochromoblastoma BBDA.11 
[M]Glomangiosarcoma BBDB.00 
[M]Glomoid sarcoma BBDB.11 
[M]Glomus tumour BBDC.00 
[M]Glomangioma BBDD.00 
[M]Gangliocytic paraganglioma BBDE.00 
[M]Glomangiomyoma BBDF.00 
[M]Paraganglioma or glomus tumour NOS BBDz.00 
[M]Naevi and melanomas BBE..00 
[M]Soft tissue tumours and sarcomas NOS BBF..00 
[M]Soft tissue tumour, benign BBF0.00 
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[M]Sarcoma NOS BBF1.00 
[M]Sarcomatosis NOS BBF2.00 
[M]Spindle cell sarcoma BBF3.00 
[M]Giant cell sarcoma (except of bone) BBF4.00 
[M]Pleomorphic cell sarcoma BBF4.11 
[M]Small cell sarcoma BBF5.00 
[M]Round cell sarcoma BBF5.11 
[M]Epithelioid cell sarcoma BBF6.00 
[M]Soft tissue tumour or sarcoma NOS BBFz.00 
[M]Fibromatous neoplasms BBG..00 
[M]Myxomatous neoplasms BBH..00 
[M]Lipomatous neoplasms BBJ..00 
[M]Lipoma NOS BBJ0.00 
[M]Liposarcoma NOS BBJ1.00 
[M]Fibroliposarcoma BBJ1.11 
[M]Fibrolipoma BBJ2.00 
[M]Fibroma molle BBJ2.11 
[M]Soft fibroma BBJ2.12 
[M]Liposarcoma, well differentiated type BBJ3.00 
[M]Fibromyxolipoma BBJ4.00 
[M]Myxolipoma BBJ4.11 
[M]Myxoid liposarcoma BBJ5.00 
[M]Embryonal liposarcoma BBJ5.11 
[M]Myxoliposarcoma BBJ5.12 
[M]Round cell liposarcoma BBJ6.00 
[M]Pleomorphic liposarcoma BBJ7.00 
[M]Mixed type liposarcoma BBJ8.00 
[M]Intramuscular lipoma BBJ9.00 
[M]Infiltrating lipoma BBJ9.11 
[M]Spindle cell lipoma BBJA.00 
[M]Angiolipomatous neoplasms BBJB.00 
[M]Myelolipoma BBJC.00 
[M]Hibernoma BBJD.00 
[M]Brown fat tumour BBJD.11 
[M]Fetal fat cell lipoma BBJD.12 
[M]Lipoblastomatosis BBJE.00 
[M]Fetal lipoma NOS BBJE.11 
[M]Pleomorphic lipoma BBJF.00 
[M]Dedifferentiated liposarcoma BBJH.00 
[M]Lipomatous neoplasms NOS BBJz.00 
[M]Myomatous neoplasms BBK..00 
[M]Rhabdomyoma NOS BBK3000 
[M]Rhabdomyosarcoma NOS BBK3100 
[M]Pleomorphic rhabdomyosarcoma BBK3200 
[M]Mixed cell rhabdomyosarcoma BBK3300 
[M]Fetal rhabdomyoma BBK3400 
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[M]Adult rhabdomyoma BBK3500 
[M]Glycogenic rhabdomyoma BBK3511 
[M]Embryonal rhabdomyosarcoma BBK3600 
[M]Sarcoma botryoides BBK3611 
[M]Alveolar rhabdomyosarcoma BBK3700 
[M]Smooth muscle tumour NOS BBK3800 
[M]Rhabdomyomatous neoplasm NOS BBK3z00 
[M]Complex mixed and stromal neoplasms BBL..00 
[M]Endometrial stromal sarcoma BBL0.00 
[M]Endolymphatic stromal myosis BBL1.00 
[M]Stromal endometriosis BBL1.11 
[M]Adenomyoma BBL2.00 
[M]Pleomorphic adenoma BBL3.00 
[M]Chondroid syringoma BBL3.11 
[M]Mixed tumour NOS BBL3.12 
[M]Mixed tumour, malignant, NOS BBL4.00 
[M]Mullerian mixed tumour BBL5.00 
[M]Mesodermal mixed tumour BBL6.00 
[M]Mixed and stromal renal neoplasms BBL7.00 
[M]Nephromas and nephroblastomas BBL7.11 
[M]Mesoblastic nephroma BBL7000 
[M]Nephroblastoma NOS BBL7100 
[M]Adenosarcoma BBL7111 
[M]Wilms' tumour BBL7112 
[M]Epithelial nephroblastoma BBL7200 
[M]Mesenchymal nephroblastoma BBL7300 
[M]Mixed or stromal renal neoplasm NOS BBL7z00 
[M]Hepatoblastoma BBL8.00 
[M]Embryonal hepatoma BBL8.11 
[M]Carcinosarcoma NOS BBL9.00 
[M]Carcinosarcoma, embryonal type BBLA.00 
[M]Pneumoblastoma BBLA.11 
[M]Myoepithelioma BBLB.00 
[M]Mesenchymomas BBLC.00 
[M]Embryonal sarcoma BBLD.00 
[M]Adenosarcoma BBLE.00 
[M]Endometrial stromal nodule BBLF.00 
[M]Carcinoma in pleomorphic adenoma BBLG.00 
[M]Rhabdoid sarcoma BBLH.00 
[M]Clear cell sarcoma of kidney BBLJ.00 
[M]Pancreatoblastoma BBLK.00 
[M]Pulmonary blastoma BBLM.00 
[M]Complex mixed or stromal neoplasm NOS BBLz.00 
[M]Fibroepithelial neoplasms BBM..00 
[M]Brenner tumours BBM0.00 
[M]Brenner tumour, borderline malignancy BBM0000 
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[M]Brenner tumour, malignant BBM0100 
[M]Brenner tumour NOS BBM0z00 
[M]Fibroadenoma NOS BBM1.00 
[M]Intracanalicular fibroadenoma NOS BBM2.00 
[M]Pericanalicular fibroadenoma BBM3.00 
[M]Adenofibroma NOS BBM4.00 
[M]Cystadenofibroma NOS BBM4.11 
[M]Serous adenofibroma BBM5.00 
[M]Mucinous adenofibroma BBM6.00 
[M]Cellular intracanalicular fibroadenoma BBM7.00 
[M]Cystosarcoma phyllodes, benign BBM7.11 
[M]Fibroadenoma phyllodes BBM7.12 
[M]Giant fibroadenoma NOS BBM7.13 
[M]Giant intracanalicular fibroadedoma BBM7.14 
[M]Cystosarcoma phyllodes NOS BBM8.00 
[M]Cystosarcoma phyllodes, malignant BBM9.00 
[M]Juvenile fibroadenoma BBMA.00 
[M]Giant fibroadenoma BBMB.00 
[M]Fibroepithelial neoplasm NOS BBMz.00 
[M]Synovial neoplasms BBN..00 
[M]Mesothelial neoplasms BBP..00 
[M]Mesothelioma, benign BBP0.00 
[M]Mesothelioma, malignant BBP1.00 
[M]Fibrous mesothelioma, benign BBP2.00 
[M]Fibrous mesothelioma, malignant BBP3.00 
[M]Epithelioid mesothelioma, benign BBP4.00 
[M]Epithelioid mesothelioma, malignant BBP5.00 
[M]Mesothelioma, biphasic type, benign BBP6.00 
[M]Mesothelioma, biphasic type, malignant BBP7.00 
[M]Adenomatoid tumour NOS BBP8.00 
[M]Cystic mesothelioma BBP9.00 
[M]Mesothelioma, unspecified BBPX.00 
[M]Mesothelial neoplasm NOS BBPz.00 
[M]Germ cell neoplasms BBQ..00 
[M]Dysgerminoma BBQ0.00 
[M]Seminomas BBQ1.00 
[M]Germinoma BBQ2.00 
[M]Embryonal carcinoma NOS BBQ3.00 
[M]Endodermal sinus tumour BBQ4.00 
[M]Infantile embryonal carcinoma BBQ4.11 
[M]Orchioblastoma BBQ4.12 
[M]Polyvesicular vitelline tumour BBQ4.13 
[M]Yolk sac tumour BBQ4.14 
[M]Polyembryoma BBQ5.00 
[M]Polyembryonal embryonal carcinoma BBQ5.11 
[M]Gonadoblastoma BBQ6.00 
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[M]Gonocytoma BBQ6.11 
[M]Teratomas BBQ7.00 
[M]Dermoid cyst BBQ8.00 
[M]Dermoid NOS BBQ8.11 
[M]Dermoid cyst with malignant transformation BBQ9.00 
[M]Strumal neoplasms BBQA.00 
[M]Mixed germ cell tumour BBQB.00 
[M]Germ cell neoplasm NOS BBQz.00 
[M]Trophoblastic neoplasms BBR..00 
[M]Hydatidiform mole NOS BBR0.00 
[M]Hydatid mole BBR0.11 
[M]Invasive hydatidiform mole BBR1.00 
[M]Chorioadenoma BBR1.11 
[M]Chorioadenoma destruens BBR1.12 
[M]Invasive mole NOS BBR1.13 
[M]Choriocarcinoma BBR2.00 
[M]Chorioepithelioma BBR2.11 
[M]Choriocarcinoma combined with teratoma BBR3.00 
[M]Malignant teratoma, trophoblastic BBR4.00 
[M]Partial hydatidiform mole BBR5.00 
[M]Placental site trophoblastic tumour BBR6.00 
[M]Classical hydatidiform mole BBR7.00 
[M]Complete hydatidiform mole BBR8.00 
[M]Trophoblastic neoplasm NOS BBRz.00 
[M]Mesonephromas BBS..00 
[M]Mesonephroma, benign BBS0.00 
[M]Wolffian duct adenoma BBS0.11 
[M]Mesonephric tumour BBS1.00 
[M]Mesonephroma, malignant BBS2.00 
[M]Wolffian duct carcinoma BBS2.11 
[M]Endosalpingioma BBS3.00 
[M]Mesonephroma NOS BBSz.00 
[M]Blood vessel tumours BBT..00 
[M]Haemangiomatous tumours BBT..11 
[M]Haemangioma NOS BBT0.00 
[M]Angioma NOS BBT0.11 
[M]Chorioangioma BBT0.12 
[M]Haemangiosarcoma BBT1.00 
[M]Angiosarcoma BBT1.11 
[M]Cavernous haemangioma BBT2.00 
[M]Venous haemangioma BBT3.00 
[M]Racemose haemangioma BBT4.00 
[M]Arteriovenous haemangioma BBT4.11 
[M]Kupffer cell sarcoma BBT5.00 
[M]Haemangioendothelioma BBT7.00 
[M]Capillary haemangioma BBT8.00 
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[M]Haemangioma simplex BBT8.11 
[M]Infantile haemangioma BBT8.12 
[M]Juvenile haemangioma BBT8.13 
[M]Plexiform haemangioma BBT8.14 
[M]Intramuscular haemangioma BBT9.00 
[M]Kaposi's sarcoma BBTA.00 
[M]Multiple haemorrhagic sarcoma BBTA.11 
[M]Angiokeratoma BBTB.00 
[M]Verrucous keratotic haemangioma BBTC.00 
[M]Haemangiopericytic neoplasms BBTD.00 
[M]Angiofibroma NOS BBTE.00 
[M]Juvenile angiofibroma BBTE.11 
[M]Haemangioblastoma BBTF.00 
[M]Angioblastoma BBTF.11 
[M]Epithelioid haemangioma BBTG.00 
[M]Histiocytoid haemangioma BBTH.00 
[M]Epithelioid haemangioendothelioma NOS BBTJ.00 
[M]Epithelioid haemangioendothelioma, malignant BBTK.00 
[M]Intravascular bronchial alveolar tumour BBTL.00 
[M]Blood vessel tumour NOS BBTz.00 
[M]Lymphatic vessel tumours BBU..00 
[M]Lymphangiomatous tumours BBU..11 
[M]Lymphangioma NOS BBU0.00 
[M]Lymphangiosarcoma BBU1.00 
[M]Capillary lymphangioma BBU2.00 
[M]Cavernous lymphangioma BBU3.00 
[M]Cystic lymphangioma BBU4.00 
[M]Cystic hygroma BBU4.11 
[M]Hygroma BBU4.12 
[M]Lymphangiomyoma BBU5.00 
[M]Lymphangiomyomatosis BBU6.00 
[M]Haemolymphangioma BBU7.00 
[M]Lymphatic vessel tumour NOS BBUz.00 
[M]Osteomas and osteosarcomas BBV..00 
[M]Juxtacortical osteogenic sarcoma BBV..11 
[M]Parosteal osteosarcoma BBV..12 
[M]Periosteal osteogenic sarcoma BBV..13 
[M]Chondromatous neoplasms BBW..00 
[M]Osteochondroma BBW0.00 
[M]Cartilaginous exostosis BBW0.11 
[M]Ecchondroma BBW0.12 
[M]Osteocartilaginous exostosis BBW0.13 
[M]Osteochondromatosis NOS BBW1.00 
[M]Ecchondrosis BBW1.11 
[M]Chondroma NOS BBW2.00 
[M]Enchondroma BBW2.11 
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[M]Chondromatosis NOS BBW3.00 
[M]Chondrosarcoma NOS BBW4.00 
[M]Fibrochondrosarcoma BBW4.11 
[M]Juxtacortical chondroma BBW5.00 
[M]Periosteal chondroma BBW5.11 
[M]Juxtacortical chondrosarcoma BBW6.00 
[M]Chondroblastoma NOS BBW7.00 
[M]Chondromatous giant cell tumour BBW7.11 
[M]Codman's tumour BBW7.12 
[M]Chondroblastoma, malignant BBW8.00 
[M]Mesenchymal chondrosarcoma BBW9.00 
[M]Chondromyxoid fibroma BBWA.00 
[M]Chondromatous neoplasm NOS BBWz.00 
[M]Giant cell tumours BBX..00 
[M]Giant cell tumour of bone NOS BBX0.00 
[M]Osteoclastoma BBX0.11 
[M]Giant cell tumour of bone, malignant BBX1.00 
[M]Giant cell bone sarcoma BBX1.11 
[M]Osteoclastoma, malignant BBX1.12 
[M]Giant cell tumour of soft parts NOS BBX2.00 
[M]Malignant giant cell tumour of soft parts BBX3.00 
[M]Giant cell tumour NOS BBXz.00 
[M]Miscellaneous bone tumours BBY..00 
[M]Ewing's sarcoma BBY0.00 
[M]Endothelial bone sarcoma BBY0.11 
[M]Adamantinoma of long bones BBY1.00 
[M]Tibial adamantinoma BBY1.11 
[M]Ossifying fibroma BBY2.00 
[M]Ossifying fibroma BBY2.11 
[M]Osteofibroma BBY2.12 
[M]Miscellaneous bone tumour NOS BBYz.00 
[M]Odontogenic tumours BBZ..00 
[M]Odontogenic tumour, benign BBZ0.00 
[M]Odontogenic tumour NOS BBZ1.00 
[M]Odontogenic tumour, malignant BBZ2.00 
[M]Intraosseous carcinoma BBZ2.11 
[M]Dentinoma BBZ3.00 
[M]Cementoma NOS BBZ4.00 
[M]Cementoblastoma, benign BBZ5.00 
[M]Cementifying fibroma BBZ6.00 
[M]Gigantiform cementoma BBZ7.00 
[M]Odontoma NOS BBZ8.00 
[M]Compound odontoma BBZ9.00 
[M]Complex odontoma BBZA.00 
[M]Ameloblastic fibro-odontoma BBZB.00 
[M]Ameloblastic odontosarcoma BBZC.00 
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[M]Adenomatoid odontogenic tumour BBZD.00 
[M]Adenoameloblastoma BBZD.11 
[M]Calcifying odontogenic cyst BBZE.00 
[M]Ameloblastoma NOS BBZF.00 
[M]Adamantinoma NOS BBZF.11 
[M]Ameloblastoma, malignant BBZG.00 
[M]Adamantinoma, malignant BBZG.11 
[M]Odontoameloblastoma BBZH.00 
[M]Squamous odontogenic tumour BBZJ.00 
[M]Odontogenic myxoma BBZK.00 
[M]Odontogenic myxofibroma BBZK.11 
[M]Odontogenic fibroma NOS BBZL.00 
[M]Ameloblastic fibroma BBZM.00 
[M]Ameloblastic fibrosarcoma BBZN.00 
[M]Odontogenic fibrosarcoma BBZN.11 
[M]Calcifying epithelial odontogenic tumour BBZP.00 
[M]Odontogenic tumour NOS BBZz.00 
[M]Miscellaneous tumours BBa..00 
[M]Craniopharyngioma BBa0.00 
[M]Rathke's pouch tumour BBa0.11 
[M]Pinealoma BBa1.00 
[M]Pineocytoma BBa2.00 
[M]Pineoblastoma BBa3.00 
[M]Melanotic neuroectodermal tumour BBa4.00 
[M]Melanoameloblastoma BBa4.11 
[M]Melanotic progonoma BBa4.12 
[M]Retinal angle tumour BBa4.13 
[M]Chordoma BBa5.00 
[M]Miscellaneous tumour NOS BBaz.00 
[M]Gliomas BBb..00 
[M]Glioma, malignant BBb0.00 
[M]Glioma NOS BBb0.11 
[M]Gliosarcoma BBb0.12 
[M]Gliomatosis cerebri BBb1.00 
[M]Mixed glioma BBb2.00 
[M]Mixed glioma BBb2.11 
[M]Subependymal glioma BBb3.00 
[M]Subependymal astrocytoma NOS BBb3.11 
[M]Subependymal astrocytoma NOS BBb3.12 
[M]Subependymoma BBb3.13 
[M]Subependymal giant cell astrocytoma BBb4.00 
[M]Choroid plexus papilloma NOS BBb5.00 
[M]Choroid plexus papilloma, malignant BBb6.00 
[M]Ependymoma NOS BBb7.00 
[M]Ependymoma, anaplastic type BBb8.00 
[M]Ependymoblastoma BBb8.11 
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[M]Papillary ependymoma BBb9.00 
[M]Myxopapillary ependymoma BBbA.00 
[M]Astrocytoma NOS BBbB.00 
[M]Astrocytic glioma BBbB.11 
[M]Astroganglioma BBbB.12 
[M]Astrocytoma, anaplastic type BBbC.00 
[M]Protoplasmic astrocytoma BBbD.00 
[M]Gemistocytic astrocytoma BBbE.00 
[M]Gemistocytoma BBbE.11 
[M]Fibrillary astrocytoma BBbF.00 
[M]Pilocytic astrocytoma BBbG.00 
[M]Juvenile astrocytoma BBbG.11 
[M]Piloid astrocytoma BBbG.12 
[M]Spongioblastoma NOS BBbH.00 
[M]Spongioblastoma polare BBbJ.00 
[M]Astroblastoma BBbK.00 
[M]Glioblastoma NOS BBbL.00 
[M]Glioblastoma multiforme BBbL.11 
[M]Spongioblastoma multiforme BBbL.12 
[M]Giant cell glioblastoma BBbM.00 
[M]Glioblastoma with sarcomatous component BBbN.00 
[M]Primitive polar spongioblastoma BBbP.00 
[M]Oligodendroglioma NOS BBbQ.00 
[M]Oligodendroglioma, anaplastic type BBbR.00 
[M]Oligodendroblastoma BBbS.00 
[M]Medulloblastoma NOS BBbT.00 
[M]Desmoplastic medulloblastoma BBbU.00 
[M]Medullomyoblastoma BBbV.00 
[M]Cerebellar sarcoma NOS BBbW.00 
[M]Monstrocellular sarcoma BBbX.00 
[M]Pleomorphic xanthoastrocytoma BBbZ.00 
[M]Primitive neuroectodermal tumour BBba.00 
[M]Glioma NOS BBbz.00 
[M]Neuroepitheliomatous neoplasms BBc..00 
[M]Ganglioneuromatous neoplasms BBc0.00 
[M]Neuroblastoma NOS BBc1.00 
[M]Sympathicoblastoma BBc1.11 
[M]Sympathicogonioma BBc1.12 
[M]Sympathogonioma BBc1.13 
[M]Medulloepithelioma NOS BBc2.00 
[M]Diktyoma BBc2.11 
[M]Teratoid medulloepithelioma BBc3.00 
[M]Neuroepithelioma NOS BBc4.00 
[M]Spongioneuroblastoma BBc5.00 
[M]Ganglioglioma BBc6.00 
[M]Glioneuroma BBc6.11 
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[M]Neurocytoma BBc7.00 
[M]Neuroastrocytoma BBc7.11 
[M]Pacinian tumour BBc8.00 
[M]Retinoblastomas BBc9.00 
[M]Olfactory neurogenic tumour BBcA.00 
[M]Aesthesioneurocytoma BBcB.00 
[M]Aesthesioneuroblastoma BBcC.00 
[M]Olfactory neuroblastoma BBcC.11 
[M]Aesthesioneuroepithelioma BBcD.00 
[M]Olfactory neuroepithelioma BBcD.11 
[M]Neuroepitheliomatous neoplasm NOS BBcz.00 
[M]Meningiomas BBd..00 
[M]Nerve sheath tumour BBe..00 
[M]Neurofibromas BBe..11 
[M]Neurofibroma NOS BBe0.00 
[M]Neurofibromatosis NOS BBe1.00 
[M]Multiple neurofibromatosis BBe1.11 
[M]Von Recklinghausen's disease BBe1.12 
[M]Neurofibrosarcoma BBe2.00 
[M]Melanotic neurofibroma BBe3.00 
[M]Plexiform neurofibroma BBe4.00 
[M]Neurilemmoma NOS BBe5.00 
[M]Acoustic neuroma BBe5.11 
[M]Neurinoma BBe5.12 
[M]Schwannoma NOS BBe5.13 
[M]Neurinomatosis BBe6.00 
[M]Neurilemmoma, malignant BBe7.00 
[M]Schwannoma, malignant BBe7.11 
[M]Neuroma NOS BBe8.00 
[M]Triton tumour, malignant BBe9.00 
[M]Neurothekeoma BBeA.00 
[M]Nerve sheath tumour NOS BBez.00 
[M]Granular cell tumours and alveolar soft part sarcoma BBf..00 
[M]Granular cell tumour NOS BBf0.00 
[M]Granular cell tumour, malignant BBf1.00 
[M]Alveolar soft part sarcoma BBf2.00 
[M]Granular cell tumour or alveolar soft part sarcoma NOS BBfz.00 
Tumour of uterine body in pregnancy/childbirth/puerperium L241.00 
Uterine fibroids in pregnancy, childbirth and the puerperium L241.11 
Tumour of uterine body affecting obstetric care L241000 
Uterine fibroid affecting obstetric care L241011 
Tumour of uterine body - baby delivered L241100 
Uterine fibroid - baby delivered L241111 
Tumour of uterine body - baby delivered + p/n complication L241200 
Uterine fibroid - baby delivered + postpartum complication L241211 
Tumour of uterine body complicating a/n care, baby not deliv L241300 
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Uterine fibroid complicating a/n care, baby not delivered L241311 
Tumour of uterine body complic p/n care, baby prev delivered L241400 
Uterine fibroid complicating p/n care - baby delivered prev L241411 
Uterine body tumour in pregnancy/childbirth/puerperium NOS L241z00 
Uterine fibroid in pregnancy/childbirth/puerperium NOS L241z11 
Polyp of cervix in pregnancy, childbirth and the puerperium L246.11 
Pelvic soft tissue abnormality in pregnancy/childbirth/puerp L24z.00 
Monostotic fibrous dysplasia N332300 
Fibrous cortical defect N332400 
Brown tumour of hyperparathyroidism N332500 
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Table j-xiv Codes for Leukaemia 
description medcode 
H/O: * leukaemia 1429 
Suspected leukaemia 1J02.00 
Plasma cell leukaemia B631.00 
Lymphoid leukaemia B64..00 
Lymphatic leukaemia B64..11 
Acute lymphoid leukaemia B640.00 
Chronic lymphoid leukaemia B641.00 
Chronic lymphatic leukaemia B641.11 
Subacute lymphoid leukaemia B642.00 
Other lymphoid leukaemia B64y.00 
Aleukaemic lymphoid leukaemia B64y000 
Prolymphocytic leukaemia B64y100 
Adult T-cell leukaemia B64y200 
Other lymphoid leukaemia NOS B64yz00 
Lymphoid leukaemia NOS B64z.00 
Myeloid leukaemia B65..00 
Acute myeloid leukaemia B650.00 
Chronic myeloid leukaemia B651.00 
Chronic granulocytic leukaemia B651.11 
Chronic eosinophilic leukaemia B651000 
Chronic neutrophilic leukaemia B651200 
Chronic myeloid leukaemia NOS B651z00 
Subacute myeloid leukaemia B652.00 
Other myeloid leukaemia B65y.00 
Aleukaemic myeloid leukaemia B65y000 
Acute promyelocytic leukaemia B65y100 
Other myeloid leukaemia NOS B65yz00 
Myeloid leukaemia NOS B65z.00 
Monocytic leukaemia B66..00 
Histiocytic leukaemia B66..11 
Monoblastic leukaemia B66..12 
Acute monocytic leukaemia B660.00 
Chronic monocytic leukaemia B661.00 
Subacute monocytic leukaemia B662.00 
Other monocytic leukaemia B66y.00 
Aleukaemic monocytic leukaemia B66y000 
Other monocytic leukaemia NOS B66yz00 
Monocytic leukaemia NOS B66z.00 
Other specified leukaemia B67..00 
Acute erythraemia and erythroleukaemia B670.00 
Megakaryocytic leukaemia B672.00 
Thrombocytic leukaemia B672.11 
Mast cell leukaemia B673.00 
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Other and unspecified leukaemia B67y.00 
Lymphosarcoma cell leukaemia B67y000 
Other and unspecified leukaemia NOS B67yz00 
Other specified leukaemia NOS B67z.00 
Leukaemia of unspecified cell type B68..00 
Acute leukaemia NOS B680.00 
Chronic leukaemia NOS B681.00 
Subacute leukaemia NOS B682.00 
Other leukaemia of unspecified cell type B68y.00 
Leukaemia NOS B68z.00 
Myelomonocytic leukaemia B69..00 
Acute myelomonocytic leukaemia B690.00 
Chronic myelomonocytic leukaemia B691.00 
Subacute myelomonocytic leukaemia B692.00 
[M]Leukaemias BBr..00 
[M]Leukaemias unspecified BBr0.00 
[M]Leukaemia NOS BBr0000 
[M]Acute leukaemia NOS BBr0100 
[M]Blast cell leukaemia BBr0111 
[M]Blastic leukaemia BBr0112 
[M]Stem cell leukaemia BBr0113 
[M]Subacute leukaemia NOS BBr0200 
[M]Chronic leukaemia NOS BBr0300 
[M]Aleukaemic leukaemia NOS BBr0400 
[M]Leukaemia unspecified, NOS BBr0z00 
[M]Compound leukaemias BBr1.00 
[M]Compound leukaemia BBr1000 
[M]Mixed leukaemia BBr1011 
[M]Compound leukaemia NOS BBr1z00 
[M]Lymphoid leukaemias BBr2.00 
[M]Lymphoid leukaemia NOS BBr2000 
[M]Lymphatic leukaemia BBr2011 
[M]Acute lymphoid leukaemia BBr2100 
[M]Subacute lymphoid leukaemia BBr2200 
[M]Chronic lymphoid leukaemia BBr2300 
[M]Aleukaemic lymphoid leukaemia BBr2400 
[M]Prolymphocytic leukaemia BBr2500 
[M]Burkitt's cell leukaemia BBr2600 
[M]Adult T-cell leukaemia/lymphoma BBr2700 
[M]Other lymphoid leukaemia NOS BBr2z00 
[M]Plasma cell leukaemias BBr3.00 
[M]Plasma cell leukaemia BBr3000 
[M]Plasma cell leukaemia NOS BBr3z00 
[M]Erythroleukaemias BBr4.00 
[M]Erythroleukaemia BBr4000 
[M]Erythraemic myelosis BBr4011 
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[M]Di Guglielmo's disease BBr4111 
[M]Chronic erythraemia BBr4200 
[M]Erythroleukaemia NOS BBr4z00 
[M]Lymphosarcoma cell leukaemias BBr5.00 
[M]Lymphosarcoma cell leukaemia BBr5000 
[M]Lymphosarcoma cell leukaemia NOS BBr5z00 
[M]Myeloid leukaemias BBr6.00 
[M]Myeloid leukaemia NOS BBr6000 
[M]Granulocytic leukaemia NOS BBr6011 
[M]Acute myeloid leukaemia BBr6100 
[M]Subacute myeloid leukaemia BBr6200 
[M]Chronic myeloid leukaemia BBr6300 
[M]Naegeli-type monocytic leukaemia BBr6311 
[M]Aleukaemic myeloid leukaemia BBr6400 
[M]Neutrophilic leukaemia BBr6500 
[M]Acute promyelocytic leukaemia BBr6600 
[M]Acute myelomonocytic leukaemia BBr6700 
[M]Chronic myelomonocytic leukaemia BBr6800 
[M]Other myeloid leukaemia NOS BBr6z00 
[M]Basophilic leukaemias BBr7.00 
[M]Basophilic leukaemia BBr7000 
[M]Basophilic leukaemia NOS BBr7z00 
[M]Eosinophilic leukaemias BBr8.00 
[M]Eosinophilic leukaemia BBr8000 
[M]Eosinophilic leukaemia NOS BBr8z00 
[M]Monocytic leukaemias BBr9.00 
[M]Monocytic leukaemia NOS BBr9000 
[M]Histiocytic leukaemia BBr9011 
[M]Schilling-type monocytic leukaemia BBr9012 
[M]Acute monocytic leukaemia BBr9100 
[M]Subacute monocytic leukaemia BBr9200 
[M]Chronic monocytic leukaemia BBr9300 
[M]Aleukaemic monocytic leukaemia BBr9400 
[M]Other monocytic leukaemia NOS BBr9z00 
[M]Miscellaneous leukaemias BBrA.00 
[M]Mast cell leukaemia BBrA000 
[M]Megakaryocytic leukaemia BBrA100 
[M]Thrombocytic leukaemia BBrA111 
[M]Hairy cell leukaemia BBrA400 
[M]Leukaemic reticuloendotheliosis BBrA411 
[M]Acute megakaryoblastic leukaemia BBrA500 
[M]Leukaemic reticuloendotheliosis BBrA800 
[M]Miscellaneous leukaemia NOS BBrAz00 
[M]Leukaemia NOS BBrz.00 
[X]Other lymphoid leukaemia ByuD500 
[X]Other myeloid leukaemia ByuD600 
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[X]Other monocytic leukaemia ByuD700 
[X]Other specified leukaemias ByuD800 
[X]Other leukaemia of unspecified cell type ByuD900 
[V]Personal history of leukaemia ZV10600 
[V]Personal history of lymphoid leukaemia ZV10611 
[V]Personal history of monocytic leukaemia ZV10612 
[V]Personal history of myeloid leukaemia ZV10613 
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Table j-xv Codes for Lymphoma 
description medcode 
Lymphoma stage I 4M20.00 
Lymphoma stage II 4M21.00 
Lymphoma stage III 4M22.00 
Lymphoma stage IV 4M23.00 
HIV disease resulting in Burkitt's lymphoma A789600 
HIV dis resulting oth types of non-Hodgkin's lymphoma A789700 
[X]HIV disease resulting in other non-Hodgkin's lymphoma AyuC600 
Lymphosarcoma B601.00 
Burkitt's lymphoma B602.00 
Burkitt's lymphoma of unspecified site B602000 
Burkitt's lymphoma of lymph nodes of head, face and neck B602100 
Burkitt's lymphoma of intrathoracic lymph nodes B602200 
Burkitt's lymphoma of intra-abdominal lymph nodes B602300 
Burkitt's lymphoma of lymph nodes of axilla and upper limb B602400 
Burkitt's lymphoma of lymph nodes of inguinal region and leg B602500 
Burkitt's lymphoma of intrapelvic lymph nodes B602600 
Burkitt's lymphoma of spleen B602700 
Burkitt's lymphoma of lymph nodes of multiple sites B602800 
Burkitt's lymphoma NOS B602z00 
Other specified reticulosarcoma or lymphosarcoma B60y.00 
Reticulosarcoma or lymphosarcoma NOS B60z.00 
Nodular lymphoma (Brill - Symmers disease) B620.00 
Reticulosarcoma - follicular or nodular B620.11 
Nodular lymphoma of unspecified site B620000 
Nodular lymphoma of lymph nodes of head, face and neck B620100 
Nodular lymphoma of intrathoracic lymph nodes B620200 
Nodular lymphoma of intra-abdominal lymph nodes B620300 
Nodular lymphoma of lymph nodes of axilla and upper limb B620400 
Nodular lymphoma of lymph nodes of inguinal region and leg B620500 
Nodular lymphoma of intrapelvic lymph nodes B620600 
Nodular lymphoma of spleen B620700 
Nodular lymphoma of lymph nodes of multiple sites B620800 
Nodular lymphoma NOS B620z00 
Mycosis fungoides B621.00 
Sezary's disease B622.00 
Malignant histiocytosis B623.00 
Malignant histiocytosis of unspecified site B623000 
Malignant histiocytosis of lymph nodes head, face and neck B623100 
Malignant histiocytosis of intrathoracic lymph nodes B623200 
Malignant histiocytosis of intra-abdominal lymph nodes B623300 
Malignant histiocytosis of lymph nodes of axilla and arm B623400 
Malignant histiocytosis of lymph nodes inguinal and leg B623500 
Malignant histiocytosis of intrapelvic lymph nodes B623600 
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Malignant histiocytosis of spleen B623700 
Malignant histiocytosis of lymph nodes of multiple sites B623800 
Malignant histiocytosis NOS B623z00 
Leukaemic reticuloendotheliosis B624.00 
Leukaemic reticuloendotheliosis B624.11 
Letterer-Siwe disease B625.00 
Histiocytosis X (acute, progressive) B625.11 
Malignant mast cell tumours B626.00 
Mast cell malignancy of unspecified site B626000 
Mast cell malignancy of lymph nodes of head, face and neck B626100 
Mast cell malignancy of intrathoracic lymph nodes B626200 
Mast cell malignancy of intra-abdominal lymph nodes B626300 
Mast cell malignancy of lymph nodes of axilla and upper limb B626400 
Mast cell malignancy of lymph nodes inguinal region and leg B626500 
Mast cell malignancy of intrapelvic lymph nodes B626600 
Mast cell malignancy of spleen B626700 
Mast cell malignancy of lymph nodes of multiple sites B626800 
Malignant mast cell tumour NOS B626z00 
Non - Hodgkin's lymphoma B627.00 
Follicular non-Hodgkin's small cleaved cell lymphoma B627000 
Follicular non-Hodg mixed sml cleavd & lge cell lymphoma B627100 
Follicular non-Hodgkin's large cell lymphoma B627200 
Diffuse non-Hodgkin's small cell (diffuse) lymphoma B627300 
Diffuse non-Hodgkin's small cleaved cell (diffuse) lymphoma B627400 
Diffuse non-Hodgkin mixed sml & lge cell (diffuse) lymphoma B627500 
Diffuse non-Hodgkin's immunoblastic (diffuse) lymphoma B627600 
Diffuse non-Hodgkin's lymphoblastic (diffuse) lymphoma B627700 
Diffuse non-Hodgkin's lymphoma undifferentiated (diffuse) B627800 
Other types of follicular non-Hodgkin's lymphoma B627B00 
Follicular non-Hodgkin's lymphoma B627C00 
Follicular lymphoma NOS B627C11 
Diffuse non-Hodgkin's centroblastic lymphoma B627D00 
Unspecified B-cell non-Hodgkin's lymphoma B627W00 
Diffuse non-Hodgkin's lymphoma, unspecified B627X00 
Malignant lymphoma otherwise specified B62x.00 
T-zone lymphoma B62x000 
Lymphoepithelioid lymphoma B62x100 
Peripheral T-cell lymphoma B62x200 
Malignant reticuloendotheliosis B62x300 
Malignant reticulosis B62x400 
True histiocytic lymphoma B62x600 
Oth and unspecif peripheral & cutaneous T-cell lymphomas B62xX00 
Malignant lymphoma NOS B62y.00 
Malignant lymphoma NOS of unspecified site B62y000 
Malignant lymphoma NOS of lymph nodes of head, face and neck B62y100 
Malignant lymphoma NOS of intrathoracic lymph nodes B62y200 
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Malignant lymphoma NOS of intra-abdominal lymph nodes B62y300 
Malignant lymphoma NOS of lymph nodes of axilla and arm B62y400 
Malignant lymphoma NOS of lymph node inguinal region and leg B62y500 
Malignant lymphoma NOS of intrapelvic lymph nodes B62y600 
Malignant lymphoma NOS of spleen B62y700 
Malignant lymphoma NOS of lymph nodes of multiple sites B62y800 
Malignant lymphoma NOS B62yz00 
Malignant neoplasms of lymphoid and histiocytic tissue NOS B62z.00 
Chloroma B653000 
Neoplasm of uncertain behaviour of histiocytic and mast cell B935.00 
Histiocytic tumour NOS B935.11 
Mastocytoma NOS B935.12 
Neoplasm of uncertain behaviour of plasma cells B936.00 
Myeloma - solitary B936.11 
Plasmacytoma NOS B936.12 
Neop uncertain behaviour other lymphatic/haematopoietic tiss B937.00 
[M]Adenolymphoma BBB1.00 
[M]Lymphatic vessel tumours BBU..00 
[M]Lymphangiomatous tumours BBU..11 
[M]Lymphomas, NOS or diffuse BBg..00 
[M]Lymphomatous tumour, benign BBg0.00 
[M]Malignant lymphoma NOS BBg1.00 
[M]Lymphoma NOS BBg1.11 
[M]Malignant lymphoma, diffuse NOS BBg1000 
[M]Malignant lymphoma, non Hodgkin's type BBg2.00 
[M]Non Hodgkins lymphoma BBg2.11 
[M]Malignant lymphoma, undifferentiated cell type NOS BBg3.00 
[M]Malignant lymphoma, stem cell type BBg4.00 
[M]Malignant lymphoma, convoluted cell type NOS BBg5.00 
[M]Lymphosarcoma NOS BBg6.00 
[M]Malignant lymphoma, lymphoplasmacytoid type BBg7.00 
[M]Malignant lymphoma, immunoblastic type BBg8.00 
[M]Malignant lymphoma, mixed lymphocytic-histiocytic NOS BBg9.00 
[M]Reticulolymphosarcoma NOS BBg9.11 
[M]Reticulolymphosarcoma, diffuse BBg9.12 
[M]Malignant lymphoma, centroblastic-centrocytic, diffuse BBgA.00 
[M]Germinoblastoma, diffuse BBgA.11 
[M]Malignant lymphoma, follicular centre cell NOS BBgB.00 
[M]Malignant lymphoma, lymphocytic, well differentiated NOS BBgC.00 
[M]Lymphocytic lymphoma NOS BBgC.11 
[M]Lymphocytic lymphosarcoma NOS BBgC.12 
[M]Malig lymphoma, lymphocytic, intermediate different NOS BBgD.00 
[M]Malignant lymphoma, centrocytic BBgE.00 
[M]Malignant lymphoma, follicular centre cell, cleaved NOS BBgF.00 
[M]Malignant lymphoma, lymphocytic, poorly different NOS BBgG.00 
[M]Lymphoblastic lymphosarcoma NOS BBgG.11 
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[M]Lymphoblastic lymphoma NOS BBgG.12 
[M]Lymphoblastoma NOS BBgG.13 
[M]Prolymphocytic lymphosarcoma BBgH.00 
[M]Malignant lymphoma, centroblastic type NOS BBgJ.00 
[M]Germinoblastic sarcoma NOS BBgJ.11 
[M]Malig lymphoma, follicular centre cell, non-cleaved NOS BBgK.00 
[M]Malignant lymphoma, small lymphocytic NOS BBgL.00 
[M]Malignant lymphoma, small cleaved cell, diffuse BBgM.00 
[M]Malign lymphoma,lymphocytic,intermediate differn, diffuse BBgN.00 
[M]Malignant lymphoma, mixed small and large cell, diffuse BBgP.00 
[M]Malignant lymphomatous polyposis BBgQ.00 
[M]Malignant lymphoma, large cell, diffuse NOS BBgR.00 
[M]Malignant lymphoma, large cell, cleaved, diffuse BBgS.00 
[M]Malignant lymphoma, large cell, noncleaved, diffuse BBgT.00 
[M]Malignant lymphoma, small cell, noncleaved, diffuse BBgV.00 
[M]Lymphoma, diffuse or NOS BBgz.00 
[M]Reticulosarcomas BBh..00 
[M]Hodgkin's disease BBj..00 
[M]Lymphomas, nodular or follicular BBk..00 
[M]Malignant lymphoma, nodular NOS BBk0.00 
[M]Brill - Symmers' disease BBk0.11 
[M]Follicular lymphosarcoma NOS BBk0.12 
[M]Giant follicular lymphoma BBk0.13 
[M]Nodular lymphosarcoma NOS BBk0.14 
[M]Malig lymphoma, mixed lymphocytic-histiocytic, nodular BBk1.00 
[M]Reticulolymphosarcoma, follicular BBk1.11 
[M]Reticulolymphosarcoma, nodular BBk1.12 
[M]Malignant lymphoma, centroblastic-centrocytic, follicular BBk2.00 
[M]Germinoblastoma, follicular BBk2.11 
[M]Malig lymphoma, lymphocytic, well differentiated,nodular BBk3.00 
[M]Malig lymp, lymphocytic, intermediate different, nodular BBk4.00 
[M]Malig lymp, follicular centre cell, cleaved, follicular BBk5.00 
[M]Malig lymp, lymphocytic, poorly differentiated, nodular BBk6.00 
[M]Malignant lymphoma, centroblastic type, follicular BBk7.00 
[M]Germinoblastic sarcoma, follicular BBk7.11 
[M]Malig lymp,follicular centre cell,noncleaved,follicular BBk8.00 
[M]Lymphoma, nodular or follicular NOS BBkz.00 
[M]Mycosis fungoides BBl..00 
[M]Miscellaneous reticuloendothelial neoplasms BBm..00 
[M]Malignant histiocytosis BBm1.00 
[M]Letterer - Siwe disease BBm3.00 
[M]Acute progressive histiocytosis X BBm3.12 
[M]True histiocytic lymphoma BBm4.00 
[M] Peripheral T-cell lymphoma NOS BBm5.00 
[M] Monocytoid B-cell lymphoma BBm9.00 
[M] Cutaneous lymphoma BBmD.00 
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[M] Large cell lymphoma BBmH.00 
[M]Waldenstrom's macroglobulinaemia BBmK.00 
[M]Miscellaneous reticuloendothelial neoplasm NOS BBmz.00 
[M]Plasma cell tumours BBn..00 
[M]Plasma cell myeloma BBn0.00 
[M]Multiple myeloma BBn0.11 
[M]Myeloma NOS BBn0.12 
[M]Myelomatosis BBn0.13 
[M]Plasmacytic myeloma BBn0.14 
[M]Plasma cell tumour, benign BBn1.00 
[M]Plasmacytoma, benign BBn1.11 
[M]Plasmacytoma NOS BBn2.00 
[M]Monostotic myeloma BBn2.11 
[M]Solitary myeloma BBn2.12 
[M]Plasma cell tumour, malignant BBn3.00 
[M]Plasma cell tumour NOS BBnz.00 
[M]Mast cell tumours BBp..00 
[M]Mastocytoma NOS BBp0.00 
[M]Mast cell sarcoma BBp1.00 
[M]Malignant mastocytosis BBp2.00 
[M]Mast cell tumour NOS BBpz.00 
[M]Burkitt's tumours BBq..00 
[M]Burkitt's tumour BBq0.00 
[M]Burkitt's tumour NOS BBqz.00 
[M]Leukaemias BBr..00 
[M]Other lymphoid leukaemia NOS BBr2z00 
[M]Chloroma BBrA311 
[M]Misc myeloproliferative and lymphoproliferative disorders BBs..00 
[M]Monocytoid B-cell lymphoma BBv0.00 
[M]AngiocentricT-cell lymphoma BBv2.00 
[X]Other Hodgkin's disease ByuD000 
[X]Other types of follicular non-Hodgkin's lymphoma ByuD100 
[X]Other types of diffuse non-Hodgkin's lymphoma ByuD200 
[X]Other specified types of non-Hodgkin's lymphoma ByuD300 
[X]Other malignant immunoproliferative diseases ByuD400 
[X]Oth spcf mal neoplsm/lymphoid,haematopoietic+rltd tissue ByuDA00 
[X]Mal neoplasm/lymphoid,haematopoietic+related tissu,unspcf ByuDB00 
[X]Diffuse non-Hodgkin's lymphoma, unspecified ByuDC00 
[X]Oth and unspecif peripheral & cutaneous T-cell lymphomas ByuDD00 
[X]Unspecified B-cell non-Hodgkin's lymphoma ByuDE00 
[X]Non-Hodgkin's lymphoma, unspecified type ByuDF00 
[X]Non-Hodgkin's lymphoma NOS ByuDF11 
Histiocytosis X , chronic C37y500 
Histiocytosis X , unspecified C37y600 
Histiocytosis, unspecified C37y700 
Haemophagocytic lymphohistiocytosis C37y800 
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Langerhans' cell histiocytosis C37yB00 
Histiocytosis X (chronic) C37yz11 
Lipochrome histiocytosis - familial D401.12 
Familial erythrophagocytic lymph histiocytosis D401100 
FEL-Familial erythrophagocytic lymph histiocytosis D401111 
[X]Other histiocytosis syndromes Dyu4400 
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Table j-xvi Codes for Metastatic solid tumour 
description medcode 
Pain from metastases 1D18.00 
Secondary malignant neoplasm of liver B153.00 
Secondary and unspecified malignant neoplasm of lymph nodes B56..00 
Lymph node metastases B56..11 
Secondary and unspec malig neop lymph nodes head/face/neck B560.00 
Secondary and unspec malig neop of superficial parotid LN B560000 
Secondary and unspec malignant neoplasm mastoid lymph nodes B560100 
Secondary and unspec malig neop superficial cervical LN B560200 
Secondary and unspec malignant neoplasm occipital lymph node B560300 
Secondary and unspec malig neop deep parotid lymph nodes B560400 
Secondary and unspec malig neop submandibular lymph nodes B560500 
Secondary and unspec malig neop of facial lymph nodes B560600 
Secondary and unspec malig neop submental lymph nodes B560700 
Secondary and unspec malig neop anterior cervical LN B560800 
Secondary and unspec malig neop deep cervical LN B560900 
Secondary unspec malig neop lymph nodes head/face/neck NOS B560z00 
Secondary and unspec malig neop intrathoracic lymph nodes B561.00 
Secondary and unspec malig neop internal mammary lymph nodes B561000 
Secondary and unspec malig neop intercostal lymph nodes B561100 
Secondary and unspec malig neop diaphragmatic lymph nodes B561200 
Secondary and unspec malig neop ant mediastinal lymph nodes B561300 
Secondary and unspec malig neop post mediastinal lymph nodes B561400 
Secondary and unspec malig neop paratracheal lymph nodes B561500 
Secondary and unspec malig neop superfic tracheobronchial LN B561600 
Secondary and unspec malig neop inferior tracheobronchial LN B561700 
Secondary and unspec malig neop bronchopulmonary lymph nodes B561800 
Secondary and unspec malig neop pulmonary lymph nodes B561900 
Secondary and unspec malig neop intrathoracic LN NOS B561z00 
Secondary and unspec malig neop intra-abdominal lymph nodes B562.00 
Secondary and unspec malig neop coeliac lymph nodes B562000 
Secondary and unspec malig neop superficial mesenteric LN B562100 
Secondary and unspec malig neop inferior mesenteric LN B562200 
Secondary and unspec malig neop common iliac lymph nodes B562300 
Secondary and unspec malig neop external iliac lymph nodes B562400 
Secondary and unspec malig neop intra-abdominal LN NOS B562z00 
Secondary and unspec malig neop axilla and upper limb LN B563.00 
Secondary and unspec malig neop axillary lymph nodes B563000 
Secondary and unspec malig neop supratrochlear lymph nodes B563100 
Secondary and unspec malig neop infraclavicular lymph nodes B563200 
Secondary and unspec malig neop pectoral lymph nodes B563300 
Secondary and unspec malig neop axilla and upper limb LN NOS B563z00 
Secondary and unspec malig neop inguinal and lower limb LN B564.00 
Secondary and unspec malig neop superficial inguinal LN B564000 
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Secondary and unspec malig neop deep inguinal lymph nodes B564100 
Secondary and unspec malig neop popliteal lymph nodes B564200 
Secondary and unspec malig neop of inguinal and leg LN NOS B564z00 
Secondary and unspec malig neop intrapelvic lymph nodes B565.00 
Secondary and unspec malig neop internal iliac lymph nodes B565000 
Secondary and unspec malig neop inferior epigastric LN B565100 
Secondary and unspec malig neop circumflex iliac LN B565200 
Secondary and unspec malig neop sacral lymph nodes B565300 
Secondary and unspec malig neop obturator lymph nodes B565400 
Secondary and unspec malig neop intrapelvic LN NOS B565z00 
Secondary and unspec malig neop lymph nodes multiple sites B56y.00 
Secondary and unspec malig neop lymph nodes NOS B56z.00 
Secondary malig neop of respiratory and digestive systems B57..00 
Metastases of respiratory and/or digestive systems B57..11 
Secondary carcinoma of respiratory and/or digestive systems B57..12 
Secondary malignant neoplasm of lung B570.00 
Secondary malignant neoplasm of mediastinum B571.00 
Secondary malignant neoplasm of pleura B572.00 
Secondary malignant neoplasm of other respiratory organs B573.00 
Secondary malignant neoplasm of small intestine and duodenum B574.00 
Secondary malignant neoplasm of duodenum B574000 
Secondary malignant neoplasm of jejunum B574100 
Secondary malignant neoplasm of ileum B574200 
Secondary malig neop of small intestine or duodenum NOS B574z00 
Secondary malignant neoplasm of large intestine and rectum B575.00 
Secondary malignant neoplasm of colon B575000 
Secondary malignant neoplasm of rectum B575100 
Secondary malig neop of large intestine or rectum NOS B575z00 
Secondary malig neop of retroperitoneum and peritoneum B576.00 
Secondary malignant neoplasm of retroperitoneum B576000 
Secondary malignant neoplasm of peritoneum B576100 
Secondary malig neop of retroperitoneum or peritoneum NOS B576z00 
Secondary malignant neoplasm of liver B577.00 
Liver metastases B577.11 
Secondary malignant neoplasm of other digestive organ B57y.00 
Secondary malig neop of respiratory or digestive system NOS B57z.00 
Secondary malignant neoplasm of other specified sites B58..00 
Secondary carcinoma of other specified sites B58..11 
Secondary malignant neoplasm of kidney B580.00 
Secondary malignant neoplasm of other urinary organs B581.00 
Secondary malignant neoplasm of ureter B581000 
Secondary malignant neoplasm of bladder B581100 
Secondary malignant neoplasm of urethra B581200 
Secondary malignant neoplasm of other urinary organ NOS B581z00 
Secondary malignant neoplasm of skin B582.00 
Secondary malignant neoplasm of skin of head B582000 
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Secondary malignant neoplasm of skin of face B582100 
Secondary malignant neoplasm of skin of neck B582200 
Secondary malignant neoplasm of skin of trunk B582300 
Secondary malignant neoplasm of skin of shoulder and arm B582400 
Secondary malignant neoplasm of skin of hip and leg B582500 
Secondary malignant neoplasm of skin of breast B582600 
Secondary malignant neoplasm of skin NOS B582z00 
Secondary malignant neoplasm of brain and spinal cord B583.00 
Secondary malignant neoplasm of brain B583000 
Secondary malignant neoplasm of spinal cord B583100 
Cerebral metastasis B583200 
Secondary malignant neoplasm of brain or spinal cord NOS B583z00 
Secondary malignant neoplasm of other part of nervous system B584.00 
Secondary malignant neoplasm of bone and bone marrow B585.00 
Pathological fracture due to metastatic bone disease B585000 
Secondary malignant neoplasm of ovary B586.00 
Secondary malignant neoplasm of adrenal gland B587.00 
Secondary malignant neoplasm of other specified sites B58y.00 
Secondary malignant neoplasm of breast B58y000 
Secondary malignant neoplasm of uterus B58y100 
Secondary malignant neoplasm of cervix uteri B58y200 
Secondary cancer of the cervix B58y211 
Secondary malignant neoplasm of vagina B58y300 
Secondary malignant neoplasm of vulva B58y400 
Secondary cancer of the vulva B58y411 
Secondary malignant neoplasm of prostate B58y500 
Secondary malignant neoplasm of testis B58y600 
Secondary malignant neoplasm of penis B58y700 
Secondary malignant neoplasm of epididymis and vas deferens B58y800 
Secondary malignant neoplasm of tongue B58y900 
Secondary malignant neoplasm of other specified site NOS B58yz00 
Secondary malignant neoplasm of other specified site NOS B58z.00 
Secondary malignant neoplasm of unknown site B594.00 
[M]Neoplasm, metastatic BB03.00 
[M]Secondary neoplasm BB03.11 
[M]Neoplasm, malig, uncertain whether primary or metastatic BB04.00 
[M]Carcinoma, metastatic, NOS BB13.00 
[M]Secondary carcinoma BB13.11 
[M]Squamous cell carcinoma, metastatic NOS BB2B.00 
[M]Adenocarcinoma, metastatic, NOS BB53.00 
[M]Metastatic signet ring cell carcinoma BB85100 
[M]No microscopic confirmation tumour, clinically metastatic BBy2.00 
[X]Malignant neoplasm of ill-defined, secondary and unspeci ByuC.00 
[X]Secondary malignant neoplasm/oth+unspc respiratory organs ByuC300 
[X]Secondary malignant neoplasm/oth+unspcfd digestive organs ByuC400 
[X]Secondary malignant neoplasm of other specified sites ByuC700 
395 
 
Table j-xvii Codes for AIDS 
description medcode 
HIV positive 43C3.11 
AIDS carrier 65QA.00 
Notification of AIDS 65VE.00 
Acute human immunodeficiency virus infection A788000 
Asymptomatic human immunodeficiency virus infection A788100 
HIV infection with persistent generalised lymphadenopathy A788200 
Human immunodeficiency virus with constitutional disease A788300 
Human immunodeficiency virus with neurological disease A788400 
Human immunodeficiency virus with secondary infection A788500 
Human immunodeficiency virus with secondary cancers A788600 
HIV disease result/haematological+immunologic abnorms,NEC A788U00 
HIV disease resulting in multiple diseases CE A788V00 
HIV disease resulting in unspecified malignant neoplasm A788W00 
HIV disease resulting/unspcf infectious+parasitic disease A788X00 
Human immunodeficiency virus with other clinical findings A788y00 
Acquired human immunodeficiency virus infection syndrome NOS A788z00 
HIV disease resulting in mycobacterial infection A789000 
HIV disease resulting in cytomegaloviral disease A789100 
HIV disease resulting in candidiasis A789200 
HIV disease resulting in Pneumocystis carinii pneumonia A789300 
HIV disease resulting in multiple infections A789400 
HIV disease resulting in Kaposi's sarcoma A789500 
HIV disease resulting in Burkitt's lymphoma A789600 
HIV dis resulting oth types of non-Hodgkin's lymphoma A789700 
HIV disease resulting in multiple malignant neoplasms A789800 
HIV disease resulting in lymphoid interstitial pneumonitis A789900 
HIV disease resulting in wasting syndrome A789A00 
HIV dis reslt/oth mal neopl/lymph,h'matopoetc+reltd tissu A789X00 
[X]HIV disease resulting in other bacterial infections AyuC000 
[X]HIV disease resulting in other viral infections AyuC100 
[X]HIV disease resulting in other mycoses AyuC200 
[X]HIV disease resulting in multiple infections AyuC300 
[X]HIV disease resulting/other infectious+parasitic diseases AyuC400 
[X]HIV disease resulting/unspcf infectious+parasitic disease AyuC500 
[X]HIV disease resulting in other non-Hodgkin's lymphoma AyuC600 
[X]HIV dis reslt/oth mal neopl/lymph,h'matopoetc+reltd tissu AyuC700 
[X]HIV disease resulting in other malignant neoplasms AyuC800 
[X]HIV disease resulting in unspecified malignant neoplasm AyuC900 
[X]HIV disease resulting in multiple diseases CE AyuCA00 
[X]HIV disease result/haematological+immunologic abnorms,NEC AyuCB00 
[X]HIV disease resulting in other specified conditions AyuCC00 
[X]Unspecified human immunodeficiency virus [HIV] disease AyuCD00 
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[X]Dementia in human immunodef virus [HIV] disease Eu02400 
[D]Laboratory evidence of human immunodefiency virus [HIV] R109.00 
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Appendix III-k Codes for liver transplant 
Description medcode 
Transplantation of liver 7800 
Orthotopic transplantation of liver 7800000 
Heterotopic transplantation of liver 7800100 
Auxillary liver transplant 7800111 
Piggy back liver transplant 7800112 
Replacement of previous liver transplant 7800200 
Other specified transplantation of liver 7800y00 
Transplantation of liver NOS 7800z00 
TRANSPLANTATION LIVER K5005 
Liver transplant failure and rejection SP08600 
Liver transplant with complication, without blame TB00200 
[V]Liver transplanted ZV42700 
 
 
 
 
 
 
 
 
 
 
